id	sid	tid	token	lemma	pos
fnp-6762	1	1	multiple	multiple	ADJ
fnp-6762	1	2	sclerosis	sclerosis	NOUN
fnp-6762	1	3	:	:	PUNCT
fnp-6762	1	4	2024	2024	NUM
fnp-6762	1	5	update	update	NOUN
fnp-6762	1	6	feel	feel	VERB
fnp-6762	1	7	free	free	ADJ
fnp-6762	1	8	to	to	PART
fnp-6762	1	9	add	add	VERB
fnp-6762	1	10	comments	comment	NOUN
fnp-6762	1	11	by	by	ADP
fnp-6762	1	12	clicking	click	VERB
fnp-6762	1	13	these	these	DET
fnp-6762	1	14	icons	icon	NOUN
fnp-6762	1	15	on	on	ADP
fnp-6762	1	16	the	the	DET
fnp-6762	1	17	sidebar	sidebar	NOUN
fnp-6762	1	18	free	free	ADJ
fnp-6762	1	19	neuropathology	neuropathology	NOUN
fnp-6762	1	20	6:14	6:14	NUM
fnp-6762	1	21	(	(	PUNCT
fnp-6762	1	22	2025	2025	NUM
fnp-6762	1	23	)	)	PUNCT
fnp-6762	1	24	review	review	VERB
fnp-6762	1	25	multiple	multiple	ADJ
fnp-6762	1	26	sclerosis	sclerosis	NOUN
fnp-6762	1	27	:	:	PUNCT
fnp-6762	1	28	2024	2024	NUM
fnp-6762	1	29	update	update	NOUN
fnp-6762	1	30	luisa	luisa	PROPN
fnp-6762	1	31	klotz1	klotz1	PROPN
fnp-6762	1	32	,	,	PUNCT
fnp-6762	1	33	maija	maija	NOUN
fnp-6762	1	34	saraste2,3,4,5	saraste2,3,4,5	NOUN
fnp-6762	1	35	,	,	PUNCT
fnp-6762	1	36	laura	laura	NOUN
fnp-6762	1	37	airas2,3,4,5	airas2,3,4,5	VERB
fnp-6762	1	38	,	,	PUNCT
fnp-6762	1	39	tanja	tanja	NOUN
fnp-6762	1	40	kuhlmann6	kuhlmann6	PROPN
fnp-6762	1	41	department	department	PROPN
fnp-6762	1	42	of	of	ADP
fnp-6762	1	43	neurology	neurology	NOUN
fnp-6762	1	44	,	,	PUNCT
fnp-6762	1	45	university	university	NOUN
fnp-6762	1	46	hospital	hospital	NOUN
fnp-6762	1	47	münster	münster	NOUN
fnp-6762	1	48	,	,	PUNCT
fnp-6762	1	49	münster	münster	PROPN
fnp-6762	1	50	,	,	PUNCT
fnp-6762	1	51	germany	germany	PROPN
fnp-6762	1	52	turku	turku	PROPN
fnp-6762	1	53	pet	pet	PROPN
fnp-6762	1	54	centre	centre	PROPN
fnp-6762	1	55	,	,	PUNCT
fnp-6762	1	56	turku	turku	PROPN
fnp-6762	1	57	university	university	PROPN
fnp-6762	1	58	hospital	hospital	NOUN
fnp-6762	1	59	,	,	PUNCT
fnp-6762	1	60	turku	turku	PROPN
fnp-6762	1	61	,	,	PUNCT
fnp-6762	1	62	finland	finland	PROPN
fnp-6762	1	63	neurocenter	neurocenter	PROPN
fnp-6762	1	64	,	,	PUNCT
fnp-6762	1	65	turku	turku	PROPN
fnp-6762	1	66	university	university	PROPN
fnp-6762	1	67	hospital	hospital	NOUN
fnp-6762	1	68	,	,	PUNCT
fnp-6762	1	69	turku	turku	PROPN
fnp-6762	1	70	,	,	PUNCT
fnp-6762	1	71	finland	finland	PROPN
fnp-6762	1	72	clinical	clinical	ADJ
fnp-6762	1	73	neurosciences	neuroscience	NOUN
fnp-6762	1	74	,	,	PUNCT
fnp-6762	1	75	university	university	NOUN
fnp-6762	1	76	of	of	ADP
fnp-6762	1	77	turku	turku	PROPN
fnp-6762	1	78	,	,	PUNCT
fnp-6762	1	79	turku	turku	PROPN
fnp-6762	1	80	,	,	PUNCT
fnp-6762	1	81	finland	finland	PROPN
fnp-6762	1	82	inflames	inflame	VERB
fnp-6762	1	83	research	research	NOUN
fnp-6762	1	84	flagship	flagship	NOUN
fnp-6762	1	85	,	,	PUNCT
fnp-6762	1	86	university	university	NOUN
fnp-6762	1	87	of	of	ADP
fnp-6762	1	88	turku	turku	PROPN
fnp-6762	1	89	,	,	PUNCT
fnp-6762	1	90	turku	turku	PROPN
fnp-6762	1	91	,	,	PUNCT
fnp-6762	1	92	finland	finland	PROPN
fnp-6762	1	93	institute	institute	PROPN
fnp-6762	1	94	of	of	ADP
fnp-6762	1	95	neuropathology	neuropathology	NOUN
fnp-6762	1	96	,	,	PUNCT
fnp-6762	1	97	university	university	NOUN
fnp-6762	1	98	hospital	hospital	NOUN
fnp-6762	1	99	münster	münster	NOUN
fnp-6762	1	100	,	,	PUNCT
fnp-6762	1	101	münster	münster	PROPN
fnp-6762	1	102	,	,	PUNCT
fnp-6762	1	103	germany	germany	PROPN
fnp-6762	1	104	corresponding	corresponding	ADJ
fnp-6762	1	105	author	author	NOUN
fnp-6762	1	106	:	:	PUNCT
fnp-6762	1	107	tanja	tanja	PROPN
fnp-6762	1	108	kuhlmann	kuhlmann	PROPN
fnp-6762	1	109	·	·	PUNCT
fnp-6762	1	110	institute	institute	PROPN
fnp-6762	1	111	of	of	ADP
fnp-6762	1	112	neuropathology	neuropathology	PROPN
fnp-6762	1	113	·	·	PUNCT
fnp-6762	1	114	university	university	NOUN
fnp-6762	1	115	hospital	hospital	NOUN
fnp-6762	1	116	münster	münster	NOUN
fnp-6762	1	117	·	·	PUNCT
fnp-6762	1	118	pottkamp	pottkamp	NOUN
fnp-6762	1	119	2	2	NUM
fnp-6762	1	120	,	,	PUNCT
fnp-6762	1	121	48149	48149	NUM
fnp-6762	1	122	·	·	PUNCT
fnp-6762	1	123	münster	münster	NOUN
fnp-6762	1	124	·	·	PUNCT
fnp-6762	1	125	germany	germany	PROPN
fnp-6762	1	126	tanja.kuhlmann@ukmuenster.de	tanja.kuhlmann@ukmuenster.de	PROPN
fnp-6762	1	127	submitted	submit	VERB
fnp-6762	1	128	:	:	PUNCT
fnp-6762	1	129	11	11	NUM
fnp-6762	1	130	may	may	AUX
fnp-6762	1	131	2025	2025	NUM
fnp-6762	1	132	accepted	accept	VERB
fnp-6762	1	133	:	:	PUNCT
fnp-6762	1	134	24	24	NUM
fnp-6762	1	135	june	june	PROPN
fnp-6762	1	136	2025	2025	NUM
fnp-6762	1	137	copyedited	copyedit	VERB
fnp-6762	1	138	by	by	ADP
fnp-6762	1	139	:	:	PUNCT
fnp-6762	1	140	joão	joão	PROPN
fnp-6762	1	141	gama	gama	PROPN
fnp-6762	1	142	published	publish	VERB
fnp-6762	1	143	:	:	PUNCT
fnp-6762	1	144	08	08	NUM
fnp-6762	1	145	july	july	PROPN
fnp-6762	1	146	2025	2025	NUM
fnp-6762	1	147	https://doi.org/10.17879/freeneuropathology-2025-6762	https://doi.org/10.17879/freeneuropathology-2025-6762	NOUN
fnp-6762	1	148	keywords	keyword	NOUN
fnp-6762	1	149	:	:	PUNCT
fnp-6762	2	1	multiple	multiple	ADJ
fnp-6762	2	2	sclerosis	sclerosis	NOUN
fnp-6762	2	3	,	,	PUNCT
fnp-6762	2	4	genetics	genetic	NOUN
fnp-6762	2	5	,	,	PUNCT
fnp-6762	2	6	disease	disease	NOUN
fnp-6762	2	7	course	course	NOUN
fnp-6762	2	8	,	,	PUNCT
fnp-6762	2	9	diagnostic	diagnostic	ADJ
fnp-6762	2	10	criteria	criterion	NOUN
fnp-6762	2	11	,	,	PUNCT
fnp-6762	2	12	biomarkers	biomarker	NOUN
fnp-6762	2	13	,	,	PUNCT
fnp-6762	2	14	imaging	imaging	NOUN
fnp-6762	2	15	,	,	PUNCT
fnp-6762	2	16	treatment	treatment	NOUN
fnp-6762	2	17	abstract	abstract	ADJ
fnp-6762	2	18	multiple	multiple	ADJ
fnp-6762	2	19	sclerosis	sclerosis	NOUN
fnp-6762	2	20	(	(	PUNCT
fnp-6762	2	21	ms	ms	NOUN
fnp-6762	2	22	)	)	PUNCT
fnp-6762	2	23	is	be	AUX
fnp-6762	2	24	a	a	DET
fnp-6762	2	25	complex	complex	ADJ
fnp-6762	2	26	immune	immune	NOUN
fnp-6762	2	27	-	-	PUNCT
fnp-6762	2	28	mediated	mediate	VERB
fnp-6762	2	29	disease	disease	NOUN
fnp-6762	2	30	that	that	PRON
fnp-6762	2	31	leads	lead	VERB
fnp-6762	2	32	to	to	ADP
fnp-6762	2	33	neurological	neurological	ADJ
fnp-6762	2	34	disability	disability	NOUN
fnp-6762	2	35	,	,	PUNCT
fnp-6762	2	36	with	with	ADP
fnp-6762	2	37	ongoing	ongoing	ADJ
fnp-6762	2	38	challenges	challenge	NOUN
fnp-6762	2	39	in	in	ADP
fnp-6762	2	40	understanding	understand	VERB
fnp-6762	2	41	its	its	PRON
fnp-6762	2	42	initiation	initiation	NOUN
fnp-6762	2	43	,	,	PUNCT
fnp-6762	2	44	predicting	predict	VERB
fnp-6762	2	45	progression	progression	NOUN
fnp-6762	2	46	,	,	PUNCT
fnp-6762	2	47	and	and	CCONJ
fnp-6762	2	48	optimizing	optimize	VERB
fnp-6762	2	49	personalized	personalized	ADJ
fnp-6762	2	50	treatment	treatment	NOUN
fnp-6762	2	51	.	.	PUNCT
fnp-6762	3	1	this	this	DET
fnp-6762	3	2	review	review	NOUN
fnp-6762	3	3	article	article	NOUN
fnp-6762	3	4	summarizes	summarize	VERB
fnp-6762	3	5	key	key	ADJ
fnp-6762	3	6	research	research	NOUN
fnp-6762	3	7	findings	finding	NOUN
fnp-6762	3	8	from	from	ADP
fnp-6762	3	9	2024	2024	NUM
fnp-6762	3	10	,	,	PUNCT
fnp-6762	3	11	covering	cover	VERB
fnp-6762	3	12	advances	advance	NOUN
fnp-6762	3	13	in	in	ADP
fnp-6762	3	14	diagnostic	diagnostic	ADJ
fnp-6762	3	15	criteria	criterion	NOUN
fnp-6762	3	16	,	,	PUNCT
fnp-6762	3	17	understanding	understanding	NOUN
fnp-6762	3	18	of	of	ADP
fnp-6762	3	19	pathophysiology	pathophysiology	NOUN
fnp-6762	3	20	,	,	PUNCT
fnp-6762	3	21	and	and	CCONJ
fnp-6762	3	22	treatment	treatment	NOUN
fnp-6762	3	23	strategies	strategy	NOUN
fnp-6762	3	24	.	.	PUNCT
fnp-6762	4	1	new	new	ADJ
fnp-6762	4	2	studies	study	NOUN
fnp-6762	4	3	reinforce	reinforce	VERB
fnp-6762	4	4	the	the	DET
fnp-6762	4	5	strong	strong	ADJ
fnp-6762	4	6	link	link	NOUN
fnp-6762	4	7	between	between	ADP
fnp-6762	4	8	epstein	epstein	PROPN
fnp-6762	4	9	-	-	PUNCT
fnp-6762	4	10	barr	barr	PROPN
fnp-6762	4	11	virus	virus	PROPN
fnp-6762	4	12	(	(	PUNCT
fnp-6762	4	13	ebv	ebv	NOUN
fnp-6762	4	14	)	)	PUNCT
fnp-6762	4	15	and	and	CCONJ
fnp-6762	4	16	ms	ms	NOUN
fnp-6762	4	17	,	,	PUNCT
fnp-6762	4	18	while	while	SCONJ
fnp-6762	4	19	recent	recent	ADJ
fnp-6762	4	20	data	datum	NOUN
fnp-6762	4	21	point	point	NOUN
fnp-6762	4	22	towards	towards	ADP
fnp-6762	4	23	a	a	DET
fnp-6762	4	24	role	role	NOUN
fnp-6762	4	25	of	of	ADP
fnp-6762	4	26	genetics	genetic	NOUN
fnp-6762	4	27	in	in	ADP
fnp-6762	4	28	ms	ms	NOUN
fnp-6762	4	29	disease	disease	NOUN
fnp-6762	4	30	progression	progression	NOUN
fnp-6762	4	31	.	.	PUNCT
fnp-6762	5	1	the	the	DET
fnp-6762	5	2	2024	2024	NUM
fnp-6762	5	3	mcdonald	mcdonald	NOUN
fnp-6762	5	4	criteria	criterion	NOUN
fnp-6762	5	5	revision	revision	NOUN
fnp-6762	5	6	enhances	enhance	VERB
fnp-6762	5	7	diagnostic	diagnostic	ADJ
fnp-6762	5	8	specificity	specificity	NOUN
fnp-6762	5	9	and	and	CCONJ
fnp-6762	5	10	includes	include	VERB
fnp-6762	5	11	novel	novel	ADJ
fnp-6762	5	12	mri	mri	NOUN
fnp-6762	5	13	markers	marker	NOUN
fnp-6762	5	14	and	and	CCONJ
fnp-6762	5	15	facilitates	facilitate	VERB
fnp-6762	5	16	measurement	measurement	NOUN
fnp-6762	5	17	of	of	ADP
fnp-6762	5	18	cerebrospinal	cerebrospinal	ADJ
fnp-6762	5	19	fluid	fluid	ADJ
fnp-6762	5	20	biomarkers	biomarker	NOUN
fnp-6762	5	21	.	.	PUNCT
fnp-6762	6	1	additionally	additionally	ADV
fnp-6762	6	2	,	,	PUNCT
fnp-6762	6	3	recent	recent	ADJ
fnp-6762	6	4	genetic	genetic	ADJ
fnp-6762	6	5	discoveries	discovery	NOUN
fnp-6762	6	6	,	,	PUNCT
fnp-6762	6	7	advanced	advanced	ADJ
fnp-6762	6	8	imaging	imaging	NOUN
fnp-6762	6	9	techniques	technique	NOUN
fnp-6762	6	10	,	,	PUNCT
fnp-6762	6	11	and	and	CCONJ
fnp-6762	6	12	emerging	emerge	VERB
fnp-6762	6	13	biomarkers	biomarker	NOUN
fnp-6762	6	14	are	be	AUX
fnp-6762	6	15	refining	refine	VERB
fnp-6762	6	16	disease	disease	NOUN
fnp-6762	6	17	monitoring	monitoring	NOUN
fnp-6762	6	18	and	and	CCONJ
fnp-6762	6	19	prognosis	prognosis	NOUN
fnp-6762	6	20	.	.	PUNCT
fnp-6762	7	1	finally	finally	ADV
fnp-6762	7	2	,	,	PUNCT
fnp-6762	7	3	we	we	PRON
fnp-6762	7	4	highlight	highlight	VERB
fnp-6762	7	5	promising	promise	VERB
fnp-6762	7	6	therapeutic	therapeutic	ADJ
fnp-6762	7	7	developments	development	NOUN
fnp-6762	7	8	,	,	PUNCT
fnp-6762	7	9	including	include	VERB
fnp-6762	7	10	bruton	bruton	PROPN
fnp-6762	7	11	tyrosine	tyrosine	PROPN
fnp-6762	7	12	kinase	kinase	PROPN
fnp-6762	7	13	(	(	PUNCT
fnp-6762	7	14	btk	btk	NOUN
fnp-6762	7	15	)	)	PUNCT
fnp-6762	7	16	inhibitors	inhibitor	NOUN
fnp-6762	7	17	and	and	CCONJ
fnp-6762	7	18	car	car	NOUN
fnp-6762	7	19	t	t	NOUN
fnp-6762	7	20	-	-	PUNCT
fnp-6762	7	21	cell	cell	NOUN
fnp-6762	7	22	therapies	therapy	NOUN
fnp-6762	7	23	,	,	PUNCT
fnp-6762	7	24	with	with	ADP
fnp-6762	7	25	the	the	DET
fnp-6762	7	26	former	former	ADJ
fnp-6762	7	27	representing	represent	VERB
fnp-6762	7	28	a	a	DET
fnp-6762	7	29	paradigm	paradigm	NOUN
fnp-6762	7	30	shift	shift	NOUN
fnp-6762	7	31	in	in	ADP
fnp-6762	7	32	the	the	DET
fnp-6762	7	33	potential	potential	NOUN
fnp-6762	7	34	of	of	ADP
fnp-6762	7	35	targeting	target	VERB
fnp-6762	7	36	ms	ms	ADJ
fnp-6762	7	37	progression	progression	NOUN
fnp-6762	7	38	beyond	beyond	ADP
fnp-6762	7	39	focal	focal	ADJ
fnp-6762	7	40	inflammation	inflammation	NOUN
fnp-6762	7	41	.	.	PUNCT
fnp-6762	8	1	introduction	introduction	NOUN
fnp-6762	8	2	multiple	multiple	ADJ
fnp-6762	8	3	sclerosis	sclerosis	NOUN
fnp-6762	8	4	(	(	PUNCT
fnp-6762	8	5	ms	ms	NOUN
fnp-6762	8	6	)	)	PUNCT
fnp-6762	8	7	is	be	AUX
fnp-6762	8	8	a	a	DET
fnp-6762	8	9	complex	complex	ADJ
fnp-6762	8	10	immune	immune	NOUN
fnp-6762	8	11	-	-	PUNCT
fnp-6762	8	12	mediated	mediate	VERB
fnp-6762	8	13	disease	disease	NOUN
fnp-6762	8	14	of	of	ADP
fnp-6762	8	15	the	the	DET
fnp-6762	8	16	central	central	ADJ
fnp-6762	8	17	nervous	nervous	ADJ
fnp-6762	8	18	system	system	NOUN
fnp-6762	8	19	and	and	CCONJ
fnp-6762	8	20	a	a	DET
fnp-6762	8	21	leading	lead	VERB
fnp-6762	8	22	cause	cause	NOUN
fnp-6762	8	23	of	of	ADP
fnp-6762	8	24	permanent	permanent	ADJ
fnp-6762	8	25	neurological	neurological	ADJ
fnp-6762	8	26	disability	disability	NOUN
fnp-6762	8	27	in	in	ADP
fnp-6762	8	28	young	young	ADJ
fnp-6762	8	29	adults	adult	NOUN
fnp-6762	8	30	.	.	PUNCT
fnp-6762	9	1	despite	despite	SCONJ
fnp-6762	9	2	progress	progress	NOUN
fnp-6762	9	3	in	in	ADP
fnp-6762	9	4	reducing	reduce	VERB
fnp-6762	9	5	focal	focal	ADJ
fnp-6762	9	6	inflammatory	inflammatory	ADJ
fnp-6762	9	7	activity	activity	NOUN
fnp-6762	9	8	through	through	ADP
fnp-6762	9	9	high	high	ADJ
fnp-6762	9	10	-	-	PUNCT
fnp-6762	9	11	efficacy	efficacy	NOUN
fnp-6762	9	12	immunomodulatory	immunomodulatory	ADJ
fnp-6762	9	13	treatments	treatment	NOUN
fnp-6762	9	14	,	,	PUNCT
fnp-6762	9	15	major	major	ADJ
fnp-6762	9	16	challenges	challenge	NOUN
fnp-6762	9	17	remain	remain	VERB
fnp-6762	9	18	in	in	ADP
fnp-6762	9	19	ms	ms	ADJ
fnp-6762	9	20	research	research	NOUN
fnp-6762	9	21	.	.	PUNCT
fnp-6762	10	1	our	our	PRON
fnp-6762	10	2	incomplete	incomplete	ADJ
fnp-6762	10	3	understanding	understanding	NOUN
fnp-6762	10	4	of	of	ADP
fnp-6762	10	5	disease	disease	NOUN
fnp-6762	10	6	initiation	initiation	NOUN
fnp-6762	10	7	in	in	ADP
fnp-6762	10	8	susceptible	susceptible	ADJ
fnp-6762	10	9	individuals	individual	NOUN
fnp-6762	10	10	hinders	hinder	VERB
fnp-6762	10	11	the	the	DET
fnp-6762	10	12	development	development	NOUN
fnp-6762	10	13	of	of	ADP
fnp-6762	10	14	preventive	preventive	ADJ
fnp-6762	10	15	treatments	treatment	NOUN
fnp-6762	10	16	.	.	PUNCT
fnp-6762	11	1	additionally	additionally	ADV
fnp-6762	11	2	,	,	PUNCT
fnp-6762	11	3	the	the	DET
fnp-6762	11	4	variability	variability	NOUN
fnp-6762	11	5	in	in	ADP
fnp-6762	11	6	disease	disease	NOUN
fnp-6762	11	7	course	course	NOUN
fnp-6762	11	8	makes	make	VERB
fnp-6762	11	9	it	it	PRON
fnp-6762	11	10	difficult	difficult	ADJ
fnp-6762	11	11	to	to	PART
fnp-6762	11	12	predict	predict	VERB
fnp-6762	11	13	outcomes	outcome	NOUN
fnp-6762	11	14	and	and	CCONJ
fnp-6762	11	15	individualize	individualize	VERB
fnp-6762	11	16	therapy	therapy	NOUN
fnp-6762	11	17	for	for	ADP
fnp-6762	11	18	optimal	optimal	ADJ
fnp-6762	11	19	efficacy	efficacy	NOUN
fnp-6762	11	20	and	and	CCONJ
fnp-6762	11	21	minimal	minimal	ADJ
fnp-6762	11	22	side	side	NOUN
fnp-6762	11	23	effects	effect	NOUN
fnp-6762	11	24	(	(	PUNCT
fnp-6762	11	25	"	"	PUNCT
fnp-6762	11	26	treat	treat	VERB
fnp-6762	11	27	-	-	PUNCT
fnp-6762	11	28	to	to	ADP
fnp-6762	11	29	-	-	PUNCT
fnp-6762	11	30	target	target	VERB
fnp-6762	11	31	"	"	PUNCT
fnp-6762	11	32	)	)	PUNCT
fnp-6762	11	33	.	.	PUNCT
fnp-6762	12	1	effective	effective	ADJ
fnp-6762	12	2	monitoring	monitoring	NOUN
fnp-6762	12	3	of	of	ADP
fnp-6762	12	4	this	this	DET
fnp-6762	12	5	heterogeneous	heterogeneous	ADJ
fnp-6762	12	6	disease	disease	NOUN
fnp-6762	12	7	and	and	CCONJ
fnp-6762	12	8	its	its	PRON
fnp-6762	12	9	treatment	treatment	NOUN
fnp-6762	12	10	requires	require	VERB
fnp-6762	12	11	a	a	DET
fnp-6762	12	12	personalized	personalized	ADJ
fnp-6762	12	13	approach	approach	NOUN
fnp-6762	12	14	using	use	VERB
fnp-6762	12	15	reliable	reliable	ADJ
fnp-6762	12	16	imaging	imaging	NOUN
fnp-6762	12	17	and	and	CCONJ
fnp-6762	12	18	biomarkers	biomarker	NOUN
fnp-6762	12	19	that	that	PRON
fnp-6762	12	20	offer	offer	VERB
fnp-6762	12	21	insight	insight	NOUN
fnp-6762	12	22	into	into	ADP
fnp-6762	12	23	individual	individual	ADJ
fnp-6762	12	24	disease	disease	NOUN
fnp-6762	12	25	biology	biology	NOUN
fnp-6762	12	26	.	.	PUNCT
fnp-6762	13	1	furthermore	furthermore	ADV
fnp-6762	13	2	,	,	PUNCT
fnp-6762	13	3	recent	recent	ADJ
fnp-6762	13	4	discoveries	discovery	NOUN
fnp-6762	13	5	on	on	ADP
fnp-6762	13	6	myeloid	myeloid	NOUN
fnp-6762	13	7	and	and	CCONJ
fnp-6762	13	8	b	b	NOUN
fnp-6762	13	9	cells	cell	NOUN
fnp-6762	13	10	in	in	ADP
fnp-6762	13	11	disease	disease	NOUN
fnp-6762	13	12	progression	progression	NOUN
fnp-6762	13	13	have	have	AUX
fnp-6762	13	14	driven	drive	VERB
fnp-6762	13	15	the	the	DET
fnp-6762	13	16	development	development	NOUN
fnp-6762	13	17	of	of	ADP
fnp-6762	13	18	novel	novel	ADJ
fnp-6762	13	19	therapies	therapy	NOUN
fnp-6762	13	20	.	.	PUNCT
fnp-6762	14	1	based	base	VERB
fnp-6762	14	2	on	on	ADP
fnp-6762	14	3	these	these	DET
fnp-6762	14	4	considerations	consideration	NOUN
fnp-6762	14	5	,	,	PUNCT
fnp-6762	14	6	we	we	PRON
fnp-6762	14	7	have	have	AUX
fnp-6762	14	8	selected	select	VERB
fnp-6762	14	9	publications	publication	NOUN
fnp-6762	14	10	from	from	ADP
fnp-6762	14	11	2024	2024	NUM
fnp-6762	14	12	that	that	PRON
fnp-6762	14	13	provide	provide	VERB
fnp-6762	14	14	new	new	ADJ
fnp-6762	14	15	insights	insight	NOUN
fnp-6762	14	16	into	into	ADP
fnp-6762	14	17	ms	ms	PROPN
fnp-6762	14	18	pathophysiology	pathophysiology	NOUN
fnp-6762	14	19	,	,	PUNCT
fnp-6762	14	20	evolving	evolve	VERB
fnp-6762	14	21	diagnostics	diagnostic	NOUN
fnp-6762	14	22	,	,	PUNCT
fnp-6762	14	23	novel	novel	ADJ
fnp-6762	14	24	biomarkers	biomarker	NOUN
fnp-6762	14	25	,	,	PUNCT
fnp-6762	14	26	imaging	imaging	NOUN
fnp-6762	14	27	techniques	technique	NOUN
fnp-6762	14	28	,	,	PUNCT
fnp-6762	14	29	and	and	CCONJ
fnp-6762	14	30	emerging	emerge	VERB
fnp-6762	14	31	treatment	treatment	NOUN
fnp-6762	14	32	strategies	strategy	NOUN
fnp-6762	14	33	(	(	PUNCT
fnp-6762	14	34	fig	fig	NOUN
fnp-6762	14	35	.	.	PUNCT
fnp-6762	14	36	 	 	SPACE
fnp-6762	14	37	1	1	NUM
fnp-6762	14	38	)	)	PUNCT
fnp-6762	14	39	.	.	PUNCT
fnp-6762	15	1	monozygotic	monozygotic	ADJ
fnp-6762	15	2	twin	twin	ADJ
fnp-6762	15	3	studies	study	NOUN
fnp-6762	15	4	revealed	reveal	VERB
fnp-6762	15	5	a	a	DET
fnp-6762	15	6	heritability	heritability	NOUN
fnp-6762	15	7	risk	risk	NOUN
fnp-6762	15	8	of	of	ADP
fnp-6762	15	9	approximately	approximately	ADV
fnp-6762	15	10	25–30	25–30	NUM
fnp-6762	15	11	 	 	SPACE
fnp-6762	15	12	%	%	NOUN
fnp-6762	15	13	.	.	PUNCT
fnp-6762	16	1	so	so	ADV
fnp-6762	16	2	far	far	ADV
fnp-6762	16	3	,	,	PUNCT
fnp-6762	16	4	studies	study	NOUN
fnp-6762	16	5	have	have	AUX
fnp-6762	16	6	identified	identify	VERB
fnp-6762	16	7	up	up	ADP
fnp-6762	16	8	to	to	PART
fnp-6762	16	9	233	233	NUM
fnp-6762	16	10	genetic	genetic	ADJ
fnp-6762	16	11	variants	variant	NOUN
fnp-6762	16	12	linked	link	VERB
fnp-6762	16	13	to	to	ADP
fnp-6762	16	14	ms	ms	PROPN
fnp-6762	16	15	susceptibility	susceptibility	NOUN
fnp-6762	16	16	,	,	PUNCT
fnp-6762	16	17	most	most	ADV
fnp-6762	16	18	expressed	express	VERB
fnp-6762	16	19	in	in	ADP
fnp-6762	16	20	immune	immune	ADJ
fnp-6762	16	21	cells1	cells1	NOUN
fnp-6762	16	22	.	.	PUNCT
fnp-6762	17	1	in	in	ADP
fnp-6762	17	2	2023	2023	NUM
fnp-6762	17	3	,	,	PUNCT
fnp-6762	17	4	the	the	DET
fnp-6762	17	5	first	first	ADJ
fnp-6762	17	6	study	study	NOUN
fnp-6762	17	7	focused	focus	VERB
fnp-6762	17	8	on	on	ADP
fnp-6762	17	9	ms	ms	NOUN
fnp-6762	17	10	severity	severity	NOUN
fnp-6762	17	11	and	and	CCONJ
fnp-6762	17	12	identified	identify	VERB
fnp-6762	17	13	one	one	NUM
fnp-6762	17	14	significant	significant	ADJ
fnp-6762	17	15	risk	risk	NOUN
fnp-6762	17	16	allele	allele	NOUN
fnp-6762	17	17	and	and	CCONJ
fnp-6762	17	18	11	11	NUM
fnp-6762	17	19	suggestive	suggestive	ADJ
fnp-6762	17	20	loci	locus	NOUN
fnp-6762	17	21	,	,	PUNCT
fnp-6762	17	22	all	all	PRON
fnp-6762	17	23	encoding	encode	VERB
fnp-6762	17	24	for	for	ADP
fnp-6762	17	25	genes	gene	NOUN
fnp-6762	17	26	expressed	express	VERB
fnp-6762	17	27	in	in	ADP
fnp-6762	17	28	the	the	DET
fnp-6762	17	29	cns2	cns2	NOUN
fnp-6762	17	30	.	.	PUNCT
fnp-6762	18	1	further	further	ADJ
fnp-6762	18	2	2024	2024	NUM
fnp-6762	18	3	research	research	NOUN
fnp-6762	18	4	has	have	AUX
fnp-6762	18	5	explored	explore	VERB
fnp-6762	18	6	correlations	correlation	NOUN
fnp-6762	18	7	between	between	ADP
fnp-6762	18	8	these	these	DET
fnp-6762	18	9	snps	snps	PROPN
fnp-6762	18	10	and	and	CCONJ
fnp-6762	18	11	aspects	aspect	NOUN
fnp-6762	18	12	of	of	ADP
fnp-6762	18	13	disease	disease	NOUN
fnp-6762	18	14	severity	severity	NOUN
fnp-6762	18	15	.	.	PUNCT
fnp-6762	19	1	figure	figure	VERB
fnp-6762	19	2	1	1	NUM
fnp-6762	19	3	schematic	schematic	ADJ
fnp-6762	19	4	illustration	illustration	NOUN
fnp-6762	19	5	depicting	depict	VERB
fnp-6762	19	6	the	the	DET
fnp-6762	19	7	ms	ms	PROPN
fnp-6762	19	8	disease	disease	NOUN
fnp-6762	19	9	course	course	NOUN
fnp-6762	19	10	and	and	CCONJ
fnp-6762	19	11	established	establish	VERB
fnp-6762	19	12	and	and	CCONJ
fnp-6762	19	13	explorative	explorative	ADJ
fnp-6762	19	14	tools	tool	NOUN
fnp-6762	19	15	to	to	PART
fnp-6762	19	16	diagnose	diagnose	VERB
fnp-6762	19	17	ms	ms	NOUN
fnp-6762	19	18	and	and	CCONJ
fnp-6762	19	19	monitor	monitor	VERB
fnp-6762	19	20	or	or	CCONJ
fnp-6762	19	21	predict	predict	VERB
fnp-6762	19	22	the	the	DET
fnp-6762	19	23	disease	disease	NOUN
fnp-6762	19	24	course	course	NOUN
fnp-6762	19	25	.	.	PUNCT
fnp-6762	20	1	a	a	DET
fnp-6762	20	2	role	role	NOUN
fnp-6762	20	3	of	of	ADP
fnp-6762	20	4	ebv	ebv	NOUN
fnp-6762	20	5	in	in	ADP
fnp-6762	20	6	ms	ms	ADJ
fnp-6762	20	7	pathogenesis	pathogenesis	NOUN
fnp-6762	20	8	has	have	AUX
fnp-6762	20	9	long	long	ADV
fnp-6762	20	10	been	be	AUX
fnp-6762	20	11	suspected	suspect	VERB
fnp-6762	20	12	and	and	CCONJ
fnp-6762	20	13	several	several	ADJ
fnp-6762	20	14	studies	study	NOUN
fnp-6762	20	15	provide	provide	VERB
fnp-6762	20	16	compelling	compelling	ADJ
fnp-6762	20	17	evidence	evidence	NOUN
fnp-6762	20	18	supporting	support	VERB
fnp-6762	20	19	this	this	DET
fnp-6762	20	20	connection	connection	NOUN
fnp-6762	20	21	.	.	PUNCT
fnp-6762	21	1	nearly	nearly	ADV
fnp-6762	21	2	all	all	DET
fnp-6762	21	3	ms	ms	ADJ
fnp-6762	21	4	patients	patient	NOUN
fnp-6762	21	5	have	have	VERB
fnp-6762	21	6	prior	prior	ADJ
fnp-6762	21	7	ebv	ebv	NOUN
fnp-6762	21	8	infection	infection	NOUN
fnp-6762	21	9	,	,	PUNCT
fnp-6762	21	10	and	and	CCONJ
fnp-6762	21	11	a	a	DET
fnp-6762	21	12	landmark	landmark	NOUN
fnp-6762	21	13	study	study	NOUN
fnp-6762	21	14	showed	show	VERB
fnp-6762	21	15	ebv	ebv	NOUN
fnp-6762	21	16	increases	increase	NOUN
fnp-6762	21	17	ms	ms	ADJ
fnp-6762	21	18	risk	risk	NOUN
fnp-6762	21	19	more	more	ADJ
fnp-6762	21	20	than	than	ADP
fnp-6762	21	21	30	30	NUM
fnp-6762	21	22	-	-	PUNCT
fnp-6762	21	23	fold3	fold3	NOUN
fnp-6762	21	24	.	.	PUNCT
fnp-6762	22	1	in	in	ADP
fnp-6762	22	2	2024	2024	NUM
fnp-6762	22	3	,	,	PUNCT
fnp-6762	22	4	research	research	NOUN
fnp-6762	22	5	confirmed	confirm	VERB
fnp-6762	22	6	that	that	SCONJ
fnp-6762	22	7	pediatric	pediatric	NOUN
fnp-6762	22	8	-	-	PUNCT
fnp-6762	22	9	onset	onset	NOUN
fnp-6762	22	10	ms	ms	NOUN
fnp-6762	22	11	is	be	AUX
fnp-6762	22	12	strongly	strongly	ADV
fnp-6762	22	13	associated	associate	VERB
fnp-6762	22	14	with	with	ADP
fnp-6762	22	15	ebv	ebv	NOUN
fnp-6762	22	16	,	,	PUNCT
fnp-6762	22	17	differentiating	differentiate	VERB
fnp-6762	22	18	it	it	PRON
fnp-6762	22	19	from	from	ADP
fnp-6762	22	20	mog	mog	NOUN
fnp-6762	22	21	antibody	antibody	NOUN
fnp-6762	22	22	-	-	PUNCT
fnp-6762	22	23	associated	associate	VERB
fnp-6762	22	24	disease	disease	NOUN
fnp-6762	22	25	(	(	PUNCT
fnp-6762	22	26	mogad	mogad	PROPN
fnp-6762	22	27	)	)	PUNCT
fnp-6762	22	28	.	.	PUNCT
fnp-6762	23	1	ms	ms	PROPN
fnp-6762	23	2	patients	patient	NOUN
fnp-6762	23	3	exhibit	exhibit	VERB
fnp-6762	23	4	dysregulated	dysregulated	ADJ
fnp-6762	23	5	immune	immune	ADJ
fnp-6762	23	6	responses	response	NOUN
fnp-6762	23	7	to	to	ADP
fnp-6762	23	8	ebv	ebv	NOUN
fnp-6762	23	9	,	,	PUNCT
fnp-6762	23	10	suggesting	suggest	VERB
fnp-6762	23	11	impaired	impaired	ADJ
fnp-6762	23	12	control	control	NOUN
fnp-6762	23	13	of	of	ADP
fnp-6762	23	14	latent	latent	NOUN
fnp-6762	23	15	infection	infection	NOUN
fnp-6762	23	16	,	,	PUNCT
fnp-6762	23	17	raising	raise	VERB
fnp-6762	23	18	the	the	DET
fnp-6762	23	19	potential	potential	NOUN
fnp-6762	23	20	for	for	ADP
fnp-6762	23	21	antiviral	antiviral	ADJ
fnp-6762	23	22	therapies	therapy	NOUN
fnp-6762	23	23	.	.	PUNCT
fnp-6762	24	1	accurate	accurate	ADJ
fnp-6762	24	2	,	,	PUNCT
fnp-6762	24	3	early	early	ADV
fnp-6762	24	4	ms	ms	ADJ
fnp-6762	24	5	diagnosis	diagnosis	NOUN
fnp-6762	24	6	remains	remain	VERB
fnp-6762	24	7	crucial	crucial	ADJ
fnp-6762	24	8	for	for	ADP
fnp-6762	24	9	improved	improved	ADJ
fnp-6762	24	10	long	long	ADJ
fnp-6762	24	11	-	-	PUNCT
fnp-6762	24	12	term	term	NOUN
fnp-6762	24	13	treatment	treatment	NOUN
fnp-6762	24	14	outcomes	outcome	NOUN
fnp-6762	24	15	.	.	PUNCT
fnp-6762	25	1	the	the	DET
fnp-6762	25	2	2024	2024	NUM
fnp-6762	25	3	mcdonald	mcdonald	NOUN
fnp-6762	25	4	criteria	criterion	NOUN
fnp-6762	25	5	revision	revision	NOUN
fnp-6762	25	6	aims	aim	VERB
fnp-6762	25	7	at	at	ADP
fnp-6762	25	8	enhancing	enhance	VERB
fnp-6762	25	9	specificity	specificity	NOUN
fnp-6762	25	10	while	while	SCONJ
fnp-6762	25	11	maintaining	maintain	VERB
fnp-6762	25	12	sensitivity	sensitivity	NOUN
fnp-6762	25	13	.	.	PUNCT
fnp-6762	26	1	key	key	ADJ
fnp-6762	26	2	updates	update	NOUN
fnp-6762	26	3	include	include	VERB
fnp-6762	26	4	recognizing	recognize	VERB
fnp-6762	26	5	optic	optic	ADJ
fnp-6762	26	6	nerve	nerve	NOUN
fnp-6762	26	7	involvement	involvement	NOUN
fnp-6762	26	8	as	as	ADP
fnp-6762	26	9	part	part	NOUN
fnp-6762	26	10	of	of	ADP
fnp-6762	26	11	dissemination	dissemination	NOUN
fnp-6762	26	12	in	in	ADP
fnp-6762	26	13	space	space	NOUN
fnp-6762	26	14	(	(	PUNCT
fnp-6762	26	15	dis	dis	PROPN
fnp-6762	26	16	)	)	PUNCT
fnp-6762	26	17	,	,	PUNCT
fnp-6762	26	18	incorporating	incorporate	VERB
fnp-6762	26	19	mri	mri	NOUN
fnp-6762	26	20	markers	marker	NOUN
fnp-6762	26	21	like	like	ADP
fnp-6762	26	22	the	the	DET
fnp-6762	26	23	central	central	ADJ
fnp-6762	26	24	vein	vein	ADJ
fnp-6762	26	25	sign	sign	NOUN
fnp-6762	26	26	(	(	PUNCT
fnp-6762	26	27	cvs	cvs	PROPN
fnp-6762	26	28	)	)	PUNCT
fnp-6762	26	29	and	and	CCONJ
fnp-6762	26	30	paramagnetic	paramagnetic	ADJ
fnp-6762	26	31	rim	rim	NOUN
fnp-6762	26	32	lesions	lesion	NOUN
fnp-6762	26	33	(	(	PUNCT
fnp-6762	26	34	prl	prl	NOUN
fnp-6762	26	35	)	)	PUNCT
fnp-6762	26	36	,	,	PUNCT
fnp-6762	26	37	and	and	CCONJ
fnp-6762	26	38	using	use	VERB
fnp-6762	26	39	kappa	kappa	ADJ
fnp-6762	26	40	-	-	ADJ
fnp-6762	26	41	free	free	ADJ
fnp-6762	26	42	light	light	ADJ
fnp-6762	26	43	chains	chain	NOUN
fnp-6762	26	44	(	(	PUNCT
fnp-6762	26	45	kflc	kflc	PROPN
fnp-6762	26	46	)	)	PUNCT
fnp-6762	26	47	as	as	ADP
fnp-6762	26	48	an	an	DET
fnp-6762	26	49	alternative	alternative	NOUN
fnp-6762	26	50	to	to	ADP
fnp-6762	26	51	oligoclonal	oligoclonal	ADJ
fnp-6762	26	52	bands	band	NOUN
fnp-6762	26	53	(	(	PUNCT
fnp-6762	26	54	ocbs	ocbs	PROPN
fnp-6762	26	55	)	)	PUNCT
fnp-6762	26	56	in	in	ADP
fnp-6762	26	57	cerebrospinal	cerebrospinal	ADJ
fnp-6762	26	58	fluid	fluid	ADJ
fnp-6762	26	59	analysis	analysis	NOUN
fnp-6762	26	60	.	.	PUNCT
fnp-6762	27	1	furthermore	furthermore	ADV
fnp-6762	27	2	,	,	PUNCT
fnp-6762	27	3	accumulating	accumulate	VERB
fnp-6762	27	4	evidence	evidence	NOUN
fnp-6762	27	5	indicates	indicate	VERB
fnp-6762	27	6	that	that	SCONJ
fnp-6762	27	7	ms	ms	PROPN
fnp-6762	27	8	pathology	pathology	NOUN
fnp-6762	27	9	begins	begin	VERB
fnp-6762	27	10	long	long	ADV
fnp-6762	27	11	before	before	ADP
fnp-6762	27	12	clinical	clinical	ADJ
fnp-6762	27	13	onset	onset	NOUN
fnp-6762	27	14	.	.	PUNCT
fnp-6762	28	1	consequently	consequently	ADV
fnp-6762	28	2	,	,	PUNCT
fnp-6762	28	3	radiologically	radiologically	ADV
fnp-6762	28	4	isolated	isolate	VERB
fnp-6762	28	5	syndrome	syndrome	NOUN
fnp-6762	28	6	(	(	PUNCT
fnp-6762	28	7	ris	ris	PROPN
fnp-6762	28	8	)	)	PUNCT
fnp-6762	28	9	,	,	PUNCT
fnp-6762	28	10	identified	identify	VERB
fnp-6762	28	11	via	via	ADP
fnp-6762	28	12	incidental	incidental	ADJ
fnp-6762	28	13	mri	mri	NOUN
fnp-6762	28	14	findings	finding	NOUN
fnp-6762	28	15	,	,	PUNCT
fnp-6762	28	16	is	be	AUX
fnp-6762	28	17	now	now	ADV
fnp-6762	28	18	recognized	recognize	VERB
fnp-6762	28	19	as	as	ADP
fnp-6762	28	20	a	a	DET
fnp-6762	28	21	preclinical	preclinical	ADJ
fnp-6762	28	22	ms	ms	NOUN
fnp-6762	28	23	stage	stage	NOUN
fnp-6762	28	24	allowing	allow	VERB
fnp-6762	28	25	ms	ms	ADJ
fnp-6762	28	26	diagnosis	diagnosis	NOUN
fnp-6762	28	27	even	even	ADV
fnp-6762	28	28	in	in	ADP
fnp-6762	28	29	the	the	DET
fnp-6762	28	30	absence	absence	NOUN
fnp-6762	28	31	of	of	ADP
fnp-6762	28	32	clinical	clinical	ADJ
fnp-6762	28	33	manifestation	manifestation	NOUN
fnp-6762	28	34	,	,	PUNCT
fnp-6762	28	35	with	with	ADP
fnp-6762	28	36	disease	disease	NOUN
fnp-6762	28	37	-	-	PUNCT
fnp-6762	28	38	modifying	modify	VERB
fnp-6762	28	39	therapies	therapy	NOUN
fnp-6762	28	40	shown	show	VERB
fnp-6762	28	41	to	to	PART
fnp-6762	28	42	delay	delay	VERB
fnp-6762	28	43	conversion	conversion	NOUN
fnp-6762	28	44	to	to	ADP
fnp-6762	28	45	ms	ms	PROPN
fnp-6762	28	46	.	.	PROPN
fnp-6762	29	1	we	we	PRON
fnp-6762	29	2	also	also	ADV
fnp-6762	29	3	highlight	highlight	VERB
fnp-6762	29	4	recent	recent	ADJ
fnp-6762	29	5	findings	finding	NOUN
fnp-6762	29	6	on	on	ADP
fnp-6762	29	7	the	the	DET
fnp-6762	29	8	ms	ms	PROPN
fnp-6762	29	9	prodromal	prodromal	ADJ
fnp-6762	29	10	stage	stage	NOUN
fnp-6762	29	11	,	,	PUNCT
fnp-6762	29	12	characterized	characterize	VERB
fnp-6762	29	13	by	by	ADP
fnp-6762	29	14	early	early	ADJ
fnp-6762	29	15	nonspecific	nonspecific	ADJ
fnp-6762	29	16	symptoms	symptom	NOUN
fnp-6762	29	17	such	such	ADJ
fnp-6762	29	18	as	as	ADP
fnp-6762	29	19	fatigue	fatigue	NOUN
fnp-6762	29	20	,	,	PUNCT
fnp-6762	29	21	depression	depression	NOUN
fnp-6762	29	22	,	,	PUNCT
fnp-6762	29	23	and	and	CCONJ
fnp-6762	29	24	sleep	sleep	VERB
fnp-6762	29	25	disturbances	disturbance	NOUN
fnp-6762	29	26	.	.	PUNCT
fnp-6762	30	1	biomarkers	biomarker	NOUN
fnp-6762	30	2	are	be	AUX
fnp-6762	30	3	essential	essential	ADJ
fnp-6762	30	4	for	for	ADP
fnp-6762	30	5	individual	individual	ADJ
fnp-6762	30	6	disease	disease	NOUN
fnp-6762	30	7	prognosis	prognosis	NOUN
fnp-6762	30	8	and	and	CCONJ
fnp-6762	30	9	prediction	prediction	NOUN
fnp-6762	30	10	but	but	CCONJ
fnp-6762	30	11	remain	remain	VERB
fnp-6762	30	12	underutilized	underutilized	ADJ
fnp-6762	30	13	in	in	ADP
fnp-6762	30	14	ms	ms	PROPN
fnp-6762	30	15	.	.	PROPN
fnp-6762	30	16	serum	serum	PROPN
fnp-6762	30	17	neurofilament	neurofilament	PROPN
fnp-6762	30	18	light	light	NOUN
fnp-6762	30	19	(	(	PUNCT
fnp-6762	30	20	nfl	nfl	PROPN
fnp-6762	30	21	)	)	PUNCT
fnp-6762	30	22	is	be	AUX
fnp-6762	30	23	the	the	DET
fnp-6762	30	24	most	most	ADV
fnp-6762	30	25	advanced	advanced	ADJ
fnp-6762	30	26	biomarker	biomarker	NOUN
fnp-6762	30	27	,	,	PUNCT
fnp-6762	30	28	correlating	correlate	VERB
fnp-6762	30	29	with	with	ADP
fnp-6762	30	30	disease	disease	NOUN
fnp-6762	30	31	activity	activity	NOUN
fnp-6762	30	32	and	and	CCONJ
fnp-6762	30	33	long	long	ADJ
fnp-6762	30	34	-	-	PUNCT
fnp-6762	30	35	term	term	NOUN
fnp-6762	30	36	disability	disability	NOUN
fnp-6762	30	37	risk	risk	NOUN
fnp-6762	30	38	.	.	PUNCT
fnp-6762	31	1	glial	glial	ADJ
fnp-6762	31	2	fibrillary	fibrillary	ADJ
fnp-6762	31	3	acidic	acidic	ADJ
fnp-6762	31	4	protein	protein	NOUN
fnp-6762	31	5	(	(	PUNCT
fnp-6762	31	6	gfap	gfap	ADJ
fnp-6762	31	7	)	)	PUNCT
fnp-6762	31	8	has	have	AUX
fnp-6762	31	9	emerged	emerge	VERB
fnp-6762	31	10	as	as	ADP
fnp-6762	31	11	a	a	DET
fnp-6762	31	12	complementary	complementary	ADJ
fnp-6762	31	13	biomarker	biomarker	NOUN
fnp-6762	31	14	,	,	PUNCT
fnp-6762	31	15	and	and	CCONJ
fnp-6762	31	16	findings	finding	NOUN
fnp-6762	31	17	from	from	ADP
fnp-6762	31	18	2024	2024	NUM
fnp-6762	31	19	suggest	suggest	VERB
fnp-6762	31	20	their	their	PRON
fnp-6762	31	21	combination	combination	NOUN
fnp-6762	31	22	might	might	AUX
fnp-6762	31	23	help	help	VERB
fnp-6762	31	24	to	to	PART
fnp-6762	31	25	distinguish	distinguish	VERB
fnp-6762	31	26	inflammatory	inflammatory	ADJ
fnp-6762	31	27	damage	damage	NOUN
fnp-6762	31	28	from	from	ADP
fnp-6762	31	29	neurodegeneration	neurodegeneration	NOUN
fnp-6762	31	30	.	.	PUNCT
fnp-6762	32	1	furthermore	furthermore	ADV
fnp-6762	32	2	,	,	PUNCT
fnp-6762	32	3	promising	promise	VERB
fnp-6762	32	4	new	new	ADJ
fnp-6762	32	5	data	datum	NOUN
fnp-6762	32	6	point	point	NOUN
fnp-6762	32	7	towards	towards	ADP
fnp-6762	32	8	novel	novel	ADJ
fnp-6762	32	9	approaches	approach	NOUN
fnp-6762	32	10	to	to	PART
fnp-6762	32	11	improve	improve	VERB
fnp-6762	32	12	patient	patient	ADJ
fnp-6762	32	13	stratification	stratification	NOUN
fnp-6762	32	14	and	and	CCONJ
fnp-6762	32	15	predict	predict	VERB
fnp-6762	32	16	treatment	treatment	NOUN
fnp-6762	32	17	responses	response	NOUN
fnp-6762	32	18	.	.	PUNCT
fnp-6762	33	1	novel	novel	ADJ
fnp-6762	33	2	imaging	imaging	NOUN
fnp-6762	33	3	markers	marker	NOUN
fnp-6762	33	4	like	like	ADP
fnp-6762	33	5	cvs	cvs	PROPN
fnp-6762	33	6	and	and	CCONJ
fnp-6762	33	7	prl	prl	AUX
fnp-6762	33	8	enhance	enhance	VERB
fnp-6762	33	9	specificity	specificity	NOUN
fnp-6762	33	10	of	of	ADP
fnp-6762	33	11	ms	ms	NOUN
fnp-6762	33	12	diagnosis	diagnosis	NOUN
fnp-6762	33	13	,	,	PUNCT
fnp-6762	33	14	and	and	CCONJ
fnp-6762	33	15	in	in	ADP
fnp-6762	33	16	particular	particular	ADJ
fnp-6762	33	17	prls	prl	NOUN
fnp-6762	33	18	are	be	AUX
fnp-6762	33	19	considered	consider	VERB
fnp-6762	33	20	as	as	ADP
fnp-6762	33	21	novel	novel	ADJ
fnp-6762	33	22	biomarker	biomarker	NOUN
fnp-6762	33	23	of	of	ADP
fnp-6762	33	24	disease	disease	NOUN
fnp-6762	33	25	progression	progression	NOUN
fnp-6762	33	26	.	.	PUNCT
fnp-6762	34	1	besides	besides	SCONJ
fnp-6762	34	2	novel	novel	ADJ
fnp-6762	34	3	imaging	imaging	NOUN
fnp-6762	34	4	approaches	approach	NOUN
fnp-6762	34	5	,	,	PUNCT
fnp-6762	34	6	the	the	DET
fnp-6762	34	7	implementation	implementation	NOUN
fnp-6762	34	8	of	of	ADP
fnp-6762	34	9	ai	ai	ADJ
fnp-6762	34	10	-	-	PUNCT
fnp-6762	34	11	driven	drive	VERB
fnp-6762	34	12	analysis	analysis	NOUN
fnp-6762	34	13	of	of	ADP
fnp-6762	34	14	imaging	imaging	NOUN
fnp-6762	34	15	and	and	CCONJ
fnp-6762	34	16	clinical	clinical	ADJ
fnp-6762	34	17	data	datum	NOUN
fnp-6762	34	18	facilitates	facilitate	VERB
fnp-6762	34	19	both	both	DET
fnp-6762	34	20	diagnosis	diagnosis	NOUN
fnp-6762	34	21	and	and	CCONJ
fnp-6762	34	22	prognosis	prognosis	NOUN
fnp-6762	34	23	,	,	PUNCT
fnp-6762	34	24	potentially	potentially	ADV
fnp-6762	34	25	enabling	enable	VERB
fnp-6762	34	26	earlier	early	ADJ
fnp-6762	34	27	intervention	intervention	NOUN
fnp-6762	34	28	and	and	CCONJ
fnp-6762	34	29	personalized	personalized	ADJ
fnp-6762	34	30	therapy	therapy	NOUN
fnp-6762	34	31	in	in	ADP
fnp-6762	34	32	the	the	DET
fnp-6762	34	33	future	future	NOUN
fnp-6762	34	34	.	.	PUNCT
fnp-6762	35	1	recent	recent	ADJ
fnp-6762	35	2	findings	finding	NOUN
fnp-6762	35	3	challenge	challenge	VERB
fnp-6762	35	4	the	the	DET
fnp-6762	35	5	traditional	traditional	ADJ
fnp-6762	35	6	view	view	NOUN
fnp-6762	35	7	that	that	SCONJ
fnp-6762	35	8	ms	ms	PROPN
fnp-6762	35	9	disability	disability	NOUN
fnp-6762	35	10	is	be	AUX
fnp-6762	35	11	primarily	primarily	ADV
fnp-6762	35	12	relapse	relapse	NOUN
fnp-6762	35	13	-	-	PUNCT
fnp-6762	35	14	driven	drive	VERB
fnp-6762	35	15	,	,	PUNCT
fnp-6762	35	16	as	as	SCONJ
fnp-6762	35	17	progression	progression	NOUN
fnp-6762	35	18	independent	independent	ADJ
fnp-6762	35	19	of	of	ADP
fnp-6762	35	20	relapse	relapse	NOUN
fnp-6762	35	21	activity	activity	NOUN
fnp-6762	35	22	(	(	PUNCT
fnp-6762	35	23	pira	pira	PROPN
fnp-6762	35	24	)	)	PUNCT
fnp-6762	35	25	significantly	significantly	ADV
fnp-6762	35	26	contributes	contribute	VERB
fnp-6762	35	27	to	to	ADP
fnp-6762	35	28	long	long	ADJ
fnp-6762	35	29	-	-	PUNCT
fnp-6762	35	30	term	term	NOUN
fnp-6762	35	31	disability	disability	NOUN
fnp-6762	35	32	,	,	PUNCT
fnp-6762	35	33	even	even	ADV
fnp-6762	35	34	in	in	ADP
fnp-6762	35	35	early	early	ADJ
fnp-6762	35	36	ms	ms	NOUN
fnp-6762	35	37	.	.	PROPN
fnp-6762	35	38	reflecting	reflect	VERB
fnp-6762	35	39	this	this	DET
fnp-6762	35	40	conceptual	conceptual	ADJ
fnp-6762	35	41	shift	shift	NOUN
fnp-6762	35	42	,	,	PUNCT
fnp-6762	35	43	we	we	PRON
fnp-6762	35	44	discuss	discuss	VERB
fnp-6762	35	45	recent	recent	ADJ
fnp-6762	35	46	clinical	clinical	ADJ
fnp-6762	35	47	trial	trial	NOUN
fnp-6762	35	48	outcomes	outcome	NOUN
fnp-6762	35	49	on	on	ADP
fnp-6762	35	50	bruton	bruton	PROPN
fnp-6762	35	51	tyrosine	tyrosine	PROPN
fnp-6762	35	52	kinase	kinase	PROPN
fnp-6762	35	53	(	(	PUNCT
fnp-6762	35	54	btk	btk	PROPN
fnp-6762	35	55	)	)	PUNCT
fnp-6762	35	56	inhibitors	inhibitor	NOUN
fnp-6762	35	57	as	as	ADP
fnp-6762	35	58	the	the	DET
fnp-6762	35	59	most	most	ADV
fnp-6762	35	60	appreciated	appreciated	ADJ
fnp-6762	35	61	clinical	clinical	ADJ
fnp-6762	35	62	highlight	highlight	NOUN
fnp-6762	35	63	in	in	ADP
fnp-6762	35	64	ms	ms	PROPN
fnp-6762	35	65	research	research	NOUN
fnp-6762	35	66	in	in	ADP
fnp-6762	35	67	2024	2024	NUM
fnp-6762	35	68	.	.	PUNCT
fnp-6762	36	1	furthermore	furthermore	ADV
fnp-6762	36	2	,	,	PUNCT
fnp-6762	36	3	we	we	PRON
fnp-6762	36	4	discuss	discuss	VERB
fnp-6762	36	5	novel	novel	ADJ
fnp-6762	36	6	cellular	cellular	ADJ
fnp-6762	36	7	therapies	therapy	NOUN
fnp-6762	36	8	such	such	ADJ
fnp-6762	36	9	as	as	ADP
fnp-6762	36	10	car	car	NOUN
fnp-6762	36	11	t	t	NOUN
fnp-6762	36	12	cells	cell	NOUN
fnp-6762	36	13	,	,	PUNCT
fnp-6762	36	14	which	which	PRON
fnp-6762	36	15	target	target	VERB
fnp-6762	36	16	deep	deep	ADJ
fnp-6762	36	17	tissue	tissue	NOUN
fnp-6762	36	18	b	b	NOUN
fnp-6762	36	19	-	-	PUNCT
fnp-6762	36	20	cell	cell	NOUN
fnp-6762	36	21	depletion	depletion	NOUN
fnp-6762	36	22	,	,	PUNCT
fnp-6762	36	23	offering	offer	VERB
fnp-6762	36	24	a	a	DET
fnp-6762	36	25	new	new	ADJ
fnp-6762	36	26	frontier	frontier	NOUN
fnp-6762	36	27	in	in	ADP
fnp-6762	36	28	ms	ms	ADJ
fnp-6762	36	29	treatment	treatment	NOUN
fnp-6762	36	30	in	in	ADP
fnp-6762	36	31	the	the	DET
fnp-6762	36	32	future	future	NOUN
fnp-6762	36	33	.	.	PUNCT
fnp-6762	37	1	pathogenesis	pathogenesis	NOUN
fnp-6762	37	2	of	of	ADP
fnp-6762	37	3	ms	ms	PROPN
fnp-6762	37	4	ms	ms	PROPN
fnp-6762	37	5	and	and	CCONJ
fnp-6762	37	6	genetics	genetic	NOUN
fnp-6762	37	7	based	base	VERB
fnp-6762	37	8	on	on	ADP
fnp-6762	37	9	family	family	NOUN
fnp-6762	37	10	and	and	CCONJ
fnp-6762	37	11	twin	twin	ADJ
fnp-6762	37	12	studies	study	NOUN
fnp-6762	37	13	,	,	PUNCT
fnp-6762	37	14	the	the	DET
fnp-6762	37	15	heritability	heritability	NOUN
fnp-6762	37	16	of	of	ADP
fnp-6762	37	17	ms	ms	PROPN
fnp-6762	37	18	is	be	AUX
fnp-6762	37	19	estimated	estimate	VERB
fnp-6762	37	20	to	to	PART
fnp-6762	37	21	be	be	AUX
fnp-6762	37	22	approximately	approximately	ADV
fnp-6762	37	23	30	30	NUM
fnp-6762	37	24	 	 	SPACE
fnp-6762	37	25	%	%	NOUN
fnp-6762	37	26	4	4	NUM
fnp-6762	37	27	.	.	X
fnp-6762	37	28	hla	hla	PROPN
fnp-6762	37	29	-	-	PUNCT
fnp-6762	37	30	drb1	drb1	PROPN
fnp-6762	37	31	*	*	NOUN
fnp-6762	37	32	15:01	15:01	NUM
fnp-6762	37	33	is	be	AUX
fnp-6762	37	34	the	the	DET
fnp-6762	37	35	strongest	strong	ADJ
fnp-6762	37	36	ms	ms	ADJ
fnp-6762	37	37	risk	risk	NOUN
fnp-6762	37	38	factor	factor	NOUN
fnp-6762	37	39	,	,	PUNCT
fnp-6762	37	40	which	which	PRON
fnp-6762	37	41	increases	increase	VERB
fnp-6762	37	42	the	the	DET
fnp-6762	37	43	ms	ms	PROPN
fnp-6762	37	44	risk	risk	NOUN
fnp-6762	37	45	threefold	threefold	ADV
fnp-6762	37	46	in	in	ADP
fnp-6762	37	47	individuals	individual	NOUN
fnp-6762	37	48	carrying	carry	VERB
fnp-6762	37	49	at	at	ADP
fnp-6762	37	50	least	least	ADV
fnp-6762	37	51	one	one	NUM
fnp-6762	37	52	copy	copy	NOUN
fnp-6762	37	53	of	of	ADP
fnp-6762	37	54	the	the	DET
fnp-6762	37	55	allele4	allele4	PROPN
fnp-6762	37	56	.	.	PUNCT
fnp-6762	38	1	barrie	barrie	PROPN
fnp-6762	38	2	and	and	CCONJ
fnp-6762	38	3	colleagues	colleague	NOUN
fnp-6762	38	4	now	now	ADV
fnp-6762	38	5	demonstrated	demonstrate	VERB
fnp-6762	38	6	that	that	SCONJ
fnp-6762	38	7	the	the	DET
fnp-6762	38	8	genetic	genetic	ADJ
fnp-6762	38	9	risk	risk	NOUN
fnp-6762	38	10	of	of	ADP
fnp-6762	38	11	ms	ms	PROPN
fnp-6762	38	12	rose	rise	VERB
fnp-6762	38	13	among	among	ADP
fnp-6762	38	14	the	the	DET
fnp-6762	38	15	pastoralists	pastoralist	NOUN
fnp-6762	38	16	in	in	ADP
fnp-6762	38	17	the	the	DET
fnp-6762	38	18	pontic	pontic	ADJ
fnp-6762	38	19	steppe	steppe	NOUN
fnp-6762	38	20	and	and	CCONJ
fnp-6762	38	21	was	be	AUX
fnp-6762	38	22	brought	bring	VERB
fnp-6762	38	23	to	to	ADP
fnp-6762	38	24	europe	europe	PROPN
fnp-6762	38	25	by	by	ADP
fnp-6762	38	26	the	the	DET
fnp-6762	38	27	yamnaya	yamnaya	PROPN
fnp-6762	38	28	-	-	PUNCT
fnp-6762	38	29	related	relate	VERB
fnp-6762	38	30	migration	migration	NOUN
fnp-6762	38	31	approximately	approximately	ADV
fnp-6762	38	32	5000	5000	NUM
fnp-6762	38	33	years	year	NOUN
fnp-6762	38	34	ago	ago	ADV
fnp-6762	38	35	.	.	PUNCT
fnp-6762	39	1	the	the	DET
fnp-6762	39	2	authors	author	NOUN
fnp-6762	39	3	analyzed	analyze	VERB
fnp-6762	39	4	datasets	dataset	NOUN
fnp-6762	39	5	from	from	ADP
fnp-6762	39	6	the	the	DET
fnp-6762	39	7	mesolithic	mesolithic	ADJ
fnp-6762	39	8	,	,	PUNCT
fnp-6762	39	9	medieval	medieval	ADJ
fnp-6762	39	10	and	and	CCONJ
fnp-6762	39	11	post	post	ADJ
fnp-6762	39	12	-	-	ADJ
fnp-6762	39	13	medieval	medieval	ADJ
fnp-6762	39	14	periods	period	NOUN
fnp-6762	39	15	and	and	CCONJ
fnp-6762	39	16	found	find	VERB
fnp-6762	39	17	a	a	DET
fnp-6762	39	18	positive	positive	ADJ
fnp-6762	39	19	selection	selection	NOUN
fnp-6762	39	20	of	of	ADP
fnp-6762	39	21	ms	ms	PROPN
fnp-6762	39	22	associated	associate	VERB
fnp-6762	39	23	immunogenetic	immunogenetic	ADJ
fnp-6762	39	24	variant	variant	ADJ
fnp-6762	39	25	risk	risk	NOUN
fnp-6762	39	26	genes	gene	NOUN
fnp-6762	39	27	.	.	PUNCT
fnp-6762	40	1	interestingly	interestingly	ADV
fnp-6762	40	2	,	,	PUNCT
fnp-6762	40	3	most	most	ADJ
fnp-6762	40	4	of	of	ADP
fnp-6762	40	5	the	the	DET
fnp-6762	40	6	alleles	allele	NOUN
fnp-6762	40	7	under	under	ADP
fnp-6762	40	8	positive	positive	ADJ
fnp-6762	40	9	selection	selection	NOUN
fnp-6762	40	10	were	be	AUX
fnp-6762	40	11	associated	associate	VERB
fnp-6762	40	12	with	with	ADP
fnp-6762	40	13	protective	protective	ADJ
fnp-6762	40	14	effects	effect	NOUN
fnp-6762	40	15	against	against	ADP
fnp-6762	40	16	specific	specific	ADJ
fnp-6762	40	17	pathogens	pathogen	NOUN
fnp-6762	40	18	and/or	and/or	CCONJ
fnp-6762	40	19	infectious	infectious	ADJ
fnp-6762	40	20	diseases	disease	NOUN
fnp-6762	40	21	,	,	PUNCT
fnp-6762	40	22	suggesting	suggest	VERB
fnp-6762	40	23	that	that	SCONJ
fnp-6762	40	24	transmission	transmission	NOUN
fnp-6762	40	25	of	of	ADP
fnp-6762	40	26	pathogens	pathogen	NOUN
fnp-6762	40	27	drove	drive	VERB
fnp-6762	40	28	the	the	DET
fnp-6762	40	29	selection	selection	NOUN
fnp-6762	40	30	of	of	ADP
fnp-6762	40	31	immune	immune	ADJ
fnp-6762	40	32	gene	gene	NOUN
fnp-6762	40	33	variants	variant	NOUN
fnp-6762	40	34	,	,	PUNCT
fnp-6762	40	35	which	which	PRON
fnp-6762	40	36	are	be	AUX
fnp-6762	40	37	now	now	ADV
fnp-6762	40	38	associated	associate	VERB
fnp-6762	40	39	with	with	ADP
fnp-6762	40	40	an	an	DET
fnp-6762	40	41	increased	increase	VERB
fnp-6762	40	42	risk	risk	NOUN
fnp-6762	40	43	of	of	ADP
fnp-6762	40	44	autoimmune	autoimmune	ADJ
fnp-6762	40	45	diseases4	diseases4	NOUN
fnp-6762	40	46	.	.	PUNCT
fnp-6762	41	1	in	in	ADP
fnp-6762	41	2	2019	2019	NUM
fnp-6762	41	3	,	,	PUNCT
fnp-6762	41	4	the	the	DET
fnp-6762	41	5	international	international	ADJ
fnp-6762	41	6	ms	ms	PROPN
fnp-6762	41	7	genetic	genetic	PROPN
fnp-6762	41	8	consortium	consortium	NOUN
fnp-6762	41	9	provided	provide	VERB
fnp-6762	41	10	a	a	DET
fnp-6762	41	11	detailed	detailed	ADJ
fnp-6762	41	12	genetic	genetic	ADJ
fnp-6762	41	13	and	and	CCONJ
fnp-6762	41	14	genomic	genomic	ADJ
fnp-6762	41	15	map	map	NOUN
fnp-6762	41	16	of	of	ADP
fnp-6762	41	17	multiple	multiple	ADJ
fnp-6762	41	18	sclerosis1	sclerosis1	NOUN
fnp-6762	41	19	.	.	PUNCT
fnp-6762	42	1	this	this	DET
fnp-6762	42	2	study	study	NOUN
fnp-6762	42	3	identified	identify	VERB
fnp-6762	42	4	200	200	NUM
fnp-6762	42	5	autosomal	autosomal	ADJ
fnp-6762	42	6	susceptibility	susceptibility	NOUN
fnp-6762	42	7	variants	variant	NOUN
fnp-6762	42	8	outside	outside	ADP
fnp-6762	42	9	the	the	DET
fnp-6762	42	10	major	major	ADJ
fnp-6762	42	11	histocompatibility	histocompatibility	NOUN
fnp-6762	42	12	complex	complex	NOUN
fnp-6762	42	13	(	(	PUNCT
fnp-6762	42	14	mhc	mhc	PROPN
fnp-6762	42	15	)	)	PUNCT
fnp-6762	42	16	,	,	PUNCT
fnp-6762	42	17	one	one	NUM
fnp-6762	42	18	chromosome	chromosome	NOUN
fnp-6762	42	19	x	x	NOUN
fnp-6762	42	20	variant	variant	NOUN
fnp-6762	42	21	,	,	PUNCT
fnp-6762	42	22	and	and	CCONJ
fnp-6762	42	23	32	32	NUM
fnp-6762	42	24	within	within	ADP
fnp-6762	42	25	the	the	DET
fnp-6762	42	26	extended	extended	ADJ
fnp-6762	42	27	mhc	mhc	PROPN
fnp-6762	42	28	.	.	PUNCT
fnp-6762	43	1	these	these	DET
fnp-6762	43	2	genes	gene	NOUN
fnp-6762	43	3	associated	associate	VERB
fnp-6762	43	4	with	with	ADP
fnp-6762	43	5	ms	ms	PROPN
fnp-6762	43	6	susceptibility	susceptibility	NOUN
fnp-6762	43	7	are	be	AUX
fnp-6762	43	8	implicated	implicate	VERB
fnp-6762	43	9	in	in	ADP
fnp-6762	43	10	multiple	multiple	ADJ
fnp-6762	43	11	innate	innate	ADJ
fnp-6762	43	12	and	and	CCONJ
fnp-6762	43	13	adaptive	adaptive	ADJ
fnp-6762	43	14	pathways	pathway	NOUN
fnp-6762	43	15	(	(	PUNCT
fnp-6762	43	16	e.g.	e.g.	ADV
fnp-6762	43	17	tnfa	tnfa	ADJ
fnp-6762	43	18	,	,	PUNCT
fnp-6762	43	19	and	and	CCONJ
fnp-6762	43	20	type	type	NOUN
fnp-6762	43	21	1	1	NUM
fnp-6762	43	22	interferons	interferon	NOUN
fnp-6762	43	23	)	)	PUNCT
fnp-6762	43	24	and	and	CCONJ
fnp-6762	43	25	cells	cell	NOUN
fnp-6762	43	26	of	of	ADP
fnp-6762	43	27	the	the	DET
fnp-6762	43	28	immune	immune	ADJ
fnp-6762	43	29	system	system	NOUN
fnp-6762	43	30	including	include	VERB
fnp-6762	43	31	microglia	microglia	NOUN
fnp-6762	43	32	,	,	PUNCT
fnp-6762	43	33	thus	thus	ADV
fnp-6762	43	34	strongly	strongly	ADV
fnp-6762	43	35	supporting	support	VERB
fnp-6762	43	36	the	the	DET
fnp-6762	43	37	immune	immune	NOUN
fnp-6762	43	38	-	-	PUNCT
fnp-6762	43	39	driven	drive	VERB
fnp-6762	43	40	nature	nature	NOUN
fnp-6762	43	41	of	of	ADP
fnp-6762	43	42	disease	disease	NOUN
fnp-6762	43	43	onset	onset	VERB
fnp-6762	43	44	.	.	PUNCT
fnp-6762	44	1	the	the	DET
fnp-6762	44	2	authors	author	NOUN
fnp-6762	44	3	of	of	ADP
fnp-6762	44	4	these	these	DET
fnp-6762	44	5	studies	study	NOUN
fnp-6762	44	6	estimated	estimate	VERB
fnp-6762	44	7	that	that	SCONJ
fnp-6762	44	8	their	their	PRON
fnp-6762	44	9	results	result	NOUN
fnp-6762	44	10	could	could	AUX
fnp-6762	44	11	explain	explain	VERB
fnp-6762	44	12	48	48	NUM
fnp-6762	44	13	 	 	SPACE
fnp-6762	44	14	%	%	NOUN
fnp-6762	44	15	of	of	ADP
fnp-6762	44	16	ms	ms	PROPN
fnp-6762	44	17	heritability	heritability	NOUN
fnp-6762	44	18	.	.	PUNCT
fnp-6762	45	1	however	however	ADV
fnp-6762	45	2	,	,	PUNCT
fnp-6762	45	3	only	only	ADV
fnp-6762	45	4	in	in	ADP
fnp-6762	45	5	2023	2023	NUM
fnp-6762	45	6	,	,	PUNCT
fnp-6762	45	7	the	the	DET
fnp-6762	45	8	first	first	ADJ
fnp-6762	45	9	snp	snp	NOUN
fnp-6762	45	10	associated	associate	VERB
fnp-6762	45	11	with	with	ADP
fnp-6762	45	12	disease	disease	NOUN
fnp-6762	45	13	severity	severity	NOUN
fnp-6762	45	14	(	(	PUNCT
fnp-6762	45	15	reflected	reflect	VERB
fnp-6762	45	16	by	by	ADP
fnp-6762	45	17	the	the	DET
fnp-6762	45	18	age	age	NOUN
fnp-6762	45	19	-	-	PUNCT
fnp-6762	45	20	related	relate	VERB
fnp-6762	45	21	ms	ms	NOUN
fnp-6762	45	22	severity	severity	NOUN
fnp-6762	45	23	score	score	NOUN
fnp-6762	45	24	)	)	PUNCT
fnp-6762	45	25	was	be	AUX
fnp-6762	45	26	identified	identify	VERB
fnp-6762	45	27	in	in	ADP
fnp-6762	45	28	a	a	DET
fnp-6762	45	29	genome	genome	NOUN
fnp-6762	45	30	-	-	PUNCT
fnp-6762	45	31	wide	wide	ADJ
fnp-6762	45	32	association	association	NOUN
fnp-6762	45	33	study	study	NOUN
fnp-6762	45	34	including	include	VERB
fnp-6762	45	35	data	datum	NOUN
fnp-6762	45	36	from	from	ADP
fnp-6762	45	37	12,584	12,584	NUM
fnp-6762	45	38	cases	case	NOUN
fnp-6762	45	39	and	and	CCONJ
fnp-6762	45	40	replicated	replicate	VERB
fnp-6762	45	41	in	in	ADP
fnp-6762	45	42	an	an	DET
fnp-6762	45	43	additional	additional	ADJ
fnp-6762	45	44	study	study	NOUN
fnp-6762	45	45	comprising	comprise	VERB
fnp-6762	45	46	further	far	ADV
fnp-6762	45	47	9,805	9,805	NUM
fnp-6762	45	48	cases2	cases2	NOUN
fnp-6762	45	49	.	.	PUNCT
fnp-6762	46	1	the	the	DET
fnp-6762	46	2	authors	author	NOUN
fnp-6762	46	3	found	find	VERB
fnp-6762	46	4	a	a	DET
fnp-6762	46	5	significant	significant	ADJ
fnp-6762	46	6	association	association	NOUN
fnp-6762	46	7	with	with	ADP
fnp-6762	46	8	rs10191329	rs10191329	NOUN
fnp-6762	46	9	in	in	ADP
fnp-6762	46	10	the	the	DET
fnp-6762	46	11	dysf	dysf	PROPN
fnp-6762	46	12	–	–	PUNCT
fnp-6762	46	13	znf638	znf638	PROPN
fnp-6762	46	14	locus	locus	NOUN
fnp-6762	46	15	.	.	PUNCT
fnp-6762	47	1	dysf	dysf	PROPN
fnp-6762	47	2	is	be	AUX
fnp-6762	47	3	well	well	ADV
fnp-6762	47	4	known	known	ADJ
fnp-6762	47	5	for	for	ADP
fnp-6762	47	6	its	its	PRON
fnp-6762	47	7	function	function	NOUN
fnp-6762	47	8	in	in	ADP
fnp-6762	47	9	muscle	muscle	NOUN
fnp-6762	47	10	membrane	membrane	NOUN
fnp-6762	47	11	repair	repair	NOUN
fnp-6762	47	12	and	and	CCONJ
fnp-6762	47	13	calcium	calcium	NOUN
fnp-6762	47	14	dependent	dependent	ADJ
fnp-6762	47	15	membrane	membrane	NOUN
fnp-6762	47	16	fusion	fusion	NOUN
fnp-6762	47	17	,	,	PUNCT
fnp-6762	47	18	whereas	whereas	SCONJ
fnp-6762	47	19	znf638	znf638	PROPN
fnp-6762	47	20	is	be	AUX
fnp-6762	47	21	a	a	DET
fnp-6762	47	22	transcriptional	transcriptional	ADJ
fnp-6762	47	23	co	co	NOUN
fnp-6762	47	24	-	-	NOUN
fnp-6762	47	25	activator	activator	NOUN
fnp-6762	47	26	,	,	PUNCT
fnp-6762	47	27	which	which	PRON
fnp-6762	47	28	is	be	AUX
fnp-6762	47	29	involved	involve	VERB
fnp-6762	47	30	in	in	ADP
fnp-6762	47	31	cell	cell	NOUN
fnp-6762	47	32	differentiation	differentiation	NOUN
fnp-6762	47	33	and	and	CCONJ
fnp-6762	47	34	proliferation5	proliferation5	NOUN
fnp-6762	47	35	.	.	PUNCT
fnp-6762	48	1	both	both	DET
fnp-6762	48	2	genes	gene	NOUN
fnp-6762	48	3	are	be	AUX
fnp-6762	48	4	expressed	express	VERB
fnp-6762	48	5	by	by	ADP
fnp-6762	48	6	neurons	neuron	NOUN
fnp-6762	48	7	and	and	CCONJ
fnp-6762	48	8	glia	glia	NOUN
fnp-6762	48	9	cells	cell	NOUN
fnp-6762	48	10	,	,	PUNCT
fnp-6762	48	11	suggesting	suggest	VERB
fnp-6762	48	12	that	that	SCONJ
fnp-6762	48	13	disease	disease	NOUN
fnp-6762	48	14	severity	severity	NOUN
fnp-6762	48	15	may	may	AUX
fnp-6762	48	16	be	be	AUX
fnp-6762	48	17	influenced	influence	VERB
fnp-6762	48	18	by	by	ADP
fnp-6762	48	19	central	central	ADJ
fnp-6762	48	20	nervous	nervous	ADJ
fnp-6762	48	21	system	system	NOUN
fnp-6762	48	22	(	(	PUNCT
fnp-6762	48	23	cns	cns	NOUN
fnp-6762	48	24	)	)	PUNCT
fnp-6762	48	25	intrinsic	intrinsic	ADJ
fnp-6762	48	26	mechanisms	mechanism	NOUN
fnp-6762	48	27	.	.	PUNCT
fnp-6762	49	1	the	the	DET
fnp-6762	49	2	authors	author	NOUN
fnp-6762	49	3	could	could	AUX
fnp-6762	49	4	also	also	ADV
fnp-6762	49	5	show	show	VERB
fnp-6762	49	6	that	that	SCONJ
fnp-6762	49	7	rs10191329	rs10191329	PROPN
fnp-6762	49	8	was	be	AUX
fnp-6762	49	9	linked	link	VERB
fnp-6762	49	10	to	to	ADP
fnp-6762	49	11	higher	high	ADJ
fnp-6762	49	12	lesion	lesion	NOUN
fnp-6762	49	13	load	load	NOUN
fnp-6762	49	14	in	in	ADP
fnp-6762	49	15	brain	brain	NOUN
fnp-6762	49	16	stem	stem	NOUN
fnp-6762	49	17	and	and	CCONJ
fnp-6762	49	18	cortex	cortex	NOUN
fnp-6762	49	19	in	in	ADP
fnp-6762	49	20	a	a	DET
fnp-6762	49	21	large	large	ADJ
fnp-6762	49	22	ms	ms	ADJ
fnp-6762	49	23	autopsy	autopsy	ADJ
fnp-6762	49	24	cohort	cohort	NOUN
fnp-6762	49	25	,	,	PUNCT
fnp-6762	49	26	however	however	ADV
fnp-6762	49	27	the	the	DET
fnp-6762	49	28	molecular	molecular	ADJ
fnp-6762	49	29	pathways	pathway	NOUN
fnp-6762	49	30	and	and	CCONJ
fnp-6762	49	31	relevant	relevant	ADJ
fnp-6762	49	32	cell	cell	NOUN
fnp-6762	49	33	types	type	NOUN
fnp-6762	49	34	mediating	mediate	VERB
fnp-6762	49	35	this	this	DET
fnp-6762	49	36	phenotype	phenotype	NOUN
fnp-6762	49	37	are	be	AUX
fnp-6762	49	38	unknown2	unknown2	NOUN
fnp-6762	49	39	.	.	PUNCT
fnp-6762	50	1	maybe	maybe	ADV
fnp-6762	50	2	as	as	ADV
fnp-6762	50	3	important	important	ADJ
fnp-6762	50	4	than	than	ADP
fnp-6762	50	5	identifying	identify	VERB
fnp-6762	50	6	gene	gene	NOUN
fnp-6762	50	7	variants	variant	NOUN
fnp-6762	50	8	associated	associate	VERB
fnp-6762	50	9	with	with	ADP
fnp-6762	50	10	ms	ms	PROPN
fnp-6762	50	11	severity	severity	NOUN
fnp-6762	50	12	,	,	PUNCT
fnp-6762	50	13	the	the	DET
fnp-6762	50	14	authors	author	NOUN
fnp-6762	50	15	observed	observe	VERB
fnp-6762	50	16	a	a	DET
fnp-6762	50	17	significant	significant	ADJ
fnp-6762	50	18	heritability	heritability	NOUN
fnp-6762	50	19	enrichment	enrichment	NOUN
fnp-6762	50	20	in	in	ADP
fnp-6762	50	21	cns	cns	NOUN
fnp-6762	50	22	tissue	tissue	NOUN
fnp-6762	50	23	,	,	PUNCT
fnp-6762	50	24	further	far	ADV
fnp-6762	50	25	suggesting	suggest	VERB
fnp-6762	50	26	that	that	SCONJ
fnp-6762	50	27	cns	cns	PROPN
fnp-6762	50	28	resident	resident	ADJ
fnp-6762	50	29	cells	cell	NOUN
fnp-6762	50	30	determine	determine	VERB
fnp-6762	50	31	severity	severity	NOUN
fnp-6762	50	32	and	and	CCONJ
fnp-6762	50	33	outcome	outcome	NOUN
fnp-6762	50	34	of	of	ADP
fnp-6762	50	35	the	the	DET
fnp-6762	50	36	disease2	disease2	PROPN
fnp-6762	50	37	.	.	PROPN
fnp-6762	51	1	interestingly	interestingly	ADV
fnp-6762	51	2	,	,	PUNCT
fnp-6762	51	3	in	in	ADP
fnp-6762	51	4	2024	2024	NUM
fnp-6762	51	5	,	,	PUNCT
fnp-6762	51	6	an	an	DET
fnp-6762	51	7	independent	independent	ADJ
fnp-6762	51	8	imaging	imaging	NOUN
fnp-6762	51	9	study	study	NOUN
fnp-6762	51	10	including	include	VERB
fnp-6762	51	11	a	a	DET
fnp-6762	51	12	discovery	discovery	NOUN
fnp-6762	51	13	cohort	cohort	NOUN
fnp-6762	51	14	of	of	ADP
fnp-6762	51	15	748	748	NUM
fnp-6762	51	16	and	and	CCONJ
fnp-6762	51	17	a	a	DET
fnp-6762	51	18	replication	replication	NOUN
fnp-6762	51	19	study	study	NOUN
fnp-6762	51	20	of	of	ADP
fnp-6762	51	21	360	360	NUM
fnp-6762	51	22	people	people	NOUN
fnp-6762	51	23	with	with	ADP
fnp-6762	51	24	relapsing	relapse	VERB
fnp-6762	51	25	remitting	remit	VERB
fnp-6762	51	26	ms	ms	NOUN
fnp-6762	51	27	observed	observe	VERB
fnp-6762	51	28	an	an	DET
fnp-6762	51	29	association	association	NOUN
fnp-6762	51	30	with	with	ADP
fnp-6762	51	31	28	28	NUM
fnp-6762	51	32	 	 	SPACE
fnp-6762	51	33	%	%	NOUN
fnp-6762	51	34	more	more	ADJ
fnp-6762	51	35	brain	brain	NOUN
fnp-6762	51	36	atrophy	atrophy	NOUN
fnp-6762	51	37	per	per	ADP
fnp-6762	51	38	rs10191329*a	rs10191329*a	ADJ
fnp-6762	51	39	allele	allele	NOUN
fnp-6762	51	40	,	,	PUNCT
fnp-6762	51	41	further	far	ADV
fnp-6762	51	42	corroborating	corroborate	VERB
fnp-6762	51	43	its	its	PRON
fnp-6762	51	44	role	role	NOUN
fnp-6762	51	45	in	in	ADP
fnp-6762	51	46	pathophysiological	pathophysiological	ADJ
fnp-6762	51	47	processes	process	NOUN
fnp-6762	51	48	underlying	underlying	ADJ
fnp-6762	51	49	disease	disease	NOUN
fnp-6762	51	50	progression	progression	NOUN
fnp-6762	51	51	.	.	PUNCT
fnp-6762	52	1	the	the	DET
fnp-6762	52	2	authors	author	NOUN
fnp-6762	52	3	therefore	therefore	ADV
fnp-6762	52	4	encourage	encourage	VERB
fnp-6762	52	5	stratification	stratification	NOUN
fnp-6762	52	6	for	for	ADP
fnp-6762	52	7	rs10191329	rs10191329	NOUN
fnp-6762	52	8	in	in	ADP
fnp-6762	52	9	clinical	clinical	ADJ
fnp-6762	52	10	trials6	trials6	NOUN
fnp-6762	52	11	.	.	PUNCT
fnp-6762	53	1	in	in	ADP
fnp-6762	53	2	contrast	contrast	NOUN
fnp-6762	53	3	,	,	PUNCT
fnp-6762	53	4	other	other	ADJ
fnp-6762	53	5	studies	study	NOUN
fnp-6762	53	6	were	be	AUX
fnp-6762	53	7	not	not	PART
fnp-6762	53	8	able	able	ADJ
fnp-6762	53	9	to	to	PART
fnp-6762	53	10	detect	detect	VERB
fnp-6762	53	11	a	a	DET
fnp-6762	53	12	correlation	correlation	NOUN
fnp-6762	53	13	between	between	ADP
fnp-6762	53	14	rs10191329	rs10191329	PROPN
fnp-6762	53	15	and	and	CCONJ
fnp-6762	53	16	longitudinal	longitudinal	ADJ
fnp-6762	53	17	binary	binary	ADJ
fnp-6762	53	18	disease	disease	NOUN
fnp-6762	53	19	severity	severity	NOUN
fnp-6762	53	20	or	or	CCONJ
fnp-6762	53	21	other	other	ADJ
fnp-6762	53	22	clinically	clinically	ADV
fnp-6762	53	23	relevant	relevant	ADJ
fnp-6762	53	24	outcomes7,8	outcomes7,8	PROPN
fnp-6762	53	25	.	.	PUNCT
fnp-6762	54	1	however	however	ADV
fnp-6762	54	2	,	,	PUNCT
fnp-6762	54	3	the	the	DET
fnp-6762	54	4	sample	sample	NOUN
fnp-6762	54	5	size	size	NOUN
fnp-6762	54	6	of	of	ADP
fnp-6762	54	7	the	the	DET
fnp-6762	54	8	aforementioned	aforementioned	ADJ
fnp-6762	54	9	studies	study	NOUN
fnp-6762	54	10	was	be	AUX
fnp-6762	54	11	modest	modest	ADJ
fnp-6762	54	12	compared	compare	VERB
fnp-6762	54	13	to	to	ADP
fnp-6762	54	14	the	the	DET
fnp-6762	54	15	initial	initial	ADJ
fnp-6762	54	16	study	study	NOUN
fnp-6762	54	17	and	and	CCONJ
fnp-6762	54	18	the	the	DET
fnp-6762	54	19	estimated	estimate	VERB
fnp-6762	54	20	effect	effect	NOUN
fnp-6762	54	21	size	size	NOUN
fnp-6762	54	22	of	of	ADP
fnp-6762	54	23	rs10191329	rs10191329	NOUN
fnp-6762	54	24	rather	rather	ADV
fnp-6762	54	25	low	low	ADJ
fnp-6762	54	26	,	,	PUNCT
fnp-6762	54	27	further	far	ADV
fnp-6762	54	28	strengthen	strengthen	VERB
fnp-6762	54	29	the	the	DET
fnp-6762	54	30	necessity	necessity	NOUN
fnp-6762	54	31	for	for	ADP
fnp-6762	54	32	collaborative	collaborative	ADJ
fnp-6762	54	33	research	research	NOUN
fnp-6762	54	34	approaches	approach	NOUN
fnp-6762	54	35	to	to	PART
fnp-6762	54	36	maximize	maximize	VERB
fnp-6762	54	37	sample	sample	NOUN
fnp-6762	54	38	sizes	size	NOUN
fnp-6762	54	39	to	to	PART
fnp-6762	54	40	further	far	ADV
fnp-6762	54	41	disentangle	disentangle	VERB
fnp-6762	54	42	the	the	DET
fnp-6762	54	43	genetic	genetic	ADJ
fnp-6762	54	44	background	background	NOUN
fnp-6762	54	45	of	of	ADP
fnp-6762	54	46	ms	ms	PROPN
fnp-6762	54	47	.	.	PROPN
fnp-6762	54	48	ms	ms	PROPN
fnp-6762	54	49	and	and	CCONJ
fnp-6762	54	50	ebv	ebv	NOUN
fnp-6762	54	51	ebv	ebv	NOUN
fnp-6762	54	52	has	have	AUX
fnp-6762	54	53	been	be	AUX
fnp-6762	54	54	implicated	implicate	VERB
fnp-6762	54	55	in	in	ADP
fnp-6762	54	56	the	the	DET
fnp-6762	54	57	pathogenesis	pathogenesis	NOUN
fnp-6762	54	58	of	of	ADP
fnp-6762	54	59	ms	ms	NOUN
fnp-6762	54	60	for	for	ADP
fnp-6762	54	61	a	a	DET
fnp-6762	54	62	long	long	ADJ
fnp-6762	54	63	time	time	NOUN
fnp-6762	54	64	as	as	SCONJ
fnp-6762	54	65	reviewed	review	VERB
fnp-6762	54	66	and	and	CCONJ
fnp-6762	54	67	summarized	summarize	VERB
fnp-6762	54	68	in	in	ADP
fnp-6762	54	69	a	a	DET
fnp-6762	54	70	number	number	NOUN
fnp-6762	54	71	of	of	ADP
fnp-6762	54	72	well	well	ADV
fnp-6762	54	73	-	-	PUNCT
fnp-6762	54	74	written	write	VERB
fnp-6762	54	75	and	and	CCONJ
fnp-6762	54	76	informative	informative	ADJ
fnp-6762	54	77	reviews9,10	reviews9,10	NOUN
fnp-6762	54	78	.	.	PUNCT
fnp-6762	55	1	approximately	approximately	ADV
fnp-6762	55	2	90	90	NUM
fnp-6762	55	3	 	 	SPACE
fnp-6762	55	4	%	%	NOUN
fnp-6762	55	5	of	of	ADP
fnp-6762	55	6	the	the	DET
fnp-6762	55	7	population	population	NOUN
fnp-6762	55	8	are	be	AUX
fnp-6762	55	9	infected	infect	VERB
fnp-6762	55	10	by	by	ADP
fnp-6762	55	11	ebv	ebv	NOUN
fnp-6762	55	12	within	within	ADP
fnp-6762	55	13	the	the	DET
fnp-6762	55	14	first	first	ADJ
fnp-6762	55	15	two	two	NUM
fnp-6762	55	16	decades	decade	NOUN
fnp-6762	55	17	in	in	ADP
fnp-6762	55	18	life	life	NOUN
fnp-6762	55	19	;	;	PUNCT
fnp-6762	55	20	the	the	DET
fnp-6762	55	21	virus	virus	NOUN
fnp-6762	55	22	is	be	AUX
fnp-6762	55	23	transmitted	transmit	VERB
fnp-6762	55	24	by	by	ADP
fnp-6762	55	25	saliva	saliva	NOUN
fnp-6762	55	26	or	or	CCONJ
fnp-6762	55	27	infectious	infectious	ADJ
fnp-6762	55	28	b	b	NOUN
fnp-6762	55	29	cells	cell	NOUN
fnp-6762	55	30	.	.	PUNCT
fnp-6762	56	1	after	after	ADP
fnp-6762	56	2	infection	infection	NOUN
fnp-6762	56	3	,	,	PUNCT
fnp-6762	56	4	the	the	DET
fnp-6762	56	5	virus	virus	NOUN
fnp-6762	56	6	establishes	establish	VERB
fnp-6762	56	7	latency	latency	NOUN
fnp-6762	56	8	resulting	result	VERB
fnp-6762	56	9	in	in	ADP
fnp-6762	56	10	its	its	PRON
fnp-6762	56	11	lifelong	lifelong	ADJ
fnp-6762	56	12	persistence	persistence	NOUN
fnp-6762	56	13	.	.	PUNCT
fnp-6762	57	1	primary	primary	ADJ
fnp-6762	57	2	infection	infection	NOUN
fnp-6762	57	3	during	during	ADP
fnp-6762	57	4	childhood	childhood	NOUN
fnp-6762	57	5	is	be	AUX
fnp-6762	57	6	usually	usually	ADV
fnp-6762	57	7	asymptomatic	asymptomatic	ADJ
fnp-6762	57	8	,	,	PUNCT
fnp-6762	57	9	but	but	CCONJ
fnp-6762	57	10	the	the	DET
fnp-6762	57	11	majority	majority	NOUN
fnp-6762	57	12	of	of	ADP
fnp-6762	57	13	individuals	individual	NOUN
fnp-6762	57	14	infected	infect	VERB
fnp-6762	57	15	during	during	ADP
fnp-6762	57	16	adolescence	adolescence	NOUN
fnp-6762	57	17	or	or	CCONJ
fnp-6762	57	18	adulthood	adulthood	NOUN
fnp-6762	57	19	will	will	AUX
fnp-6762	57	20	develop	develop	VERB
fnp-6762	57	21	infectious	infectious	ADJ
fnp-6762	57	22	mononucleosis	mononucleosis	NOUN
fnp-6762	57	23	.	.	PUNCT
fnp-6762	58	1	a	a	DET
fnp-6762	58	2	seminal	seminal	ADJ
fnp-6762	58	3	longitudinal	longitudinal	ADJ
fnp-6762	58	4	study	study	NOUN
fnp-6762	58	5	published	publish	VERB
fnp-6762	58	6	in	in	ADP
fnp-6762	58	7	science	science	NOUN
fnp-6762	58	8	2022	2022	NUM
fnp-6762	58	9	studying	study	VERB
fnp-6762	58	10	a	a	DET
fnp-6762	58	11	cohort	cohort	NOUN
fnp-6762	58	12	of	of	ADP
fnp-6762	58	13	more	more	ADJ
fnp-6762	58	14	than	than	ADP
fnp-6762	58	15	10	10	NUM
fnp-6762	58	16	million	million	NUM
fnp-6762	58	17	young	young	ADJ
fnp-6762	58	18	adults	adult	NOUN
fnp-6762	58	19	on	on	ADP
fnp-6762	58	20	active	active	ADJ
fnp-6762	58	21	duty	duty	NOUN
fnp-6762	58	22	in	in	ADP
fnp-6762	58	23	the	the	DET
fnp-6762	58	24	us	us	PROPN
fnp-6762	58	25	military	military	NOUN
fnp-6762	58	26	,	,	PUNCT
fnp-6762	58	27	among	among	ADP
fnp-6762	58	28	them	they	PRON
fnp-6762	58	29	955	955	NUM
fnp-6762	58	30	who	who	PRON
fnp-6762	58	31	were	be	AUX
fnp-6762	58	32	diagnosed	diagnose	VERB
fnp-6762	58	33	with	with	ADP
fnp-6762	58	34	ms	ms	NOUN
fnp-6762	58	35	during	during	ADP
fnp-6762	58	36	their	their	PRON
fnp-6762	58	37	period	period	NOUN
fnp-6762	58	38	of	of	ADP
fnp-6762	58	39	service	service	NOUN
fnp-6762	58	40	,	,	PUNCT
fnp-6762	58	41	demonstrated	demonstrate	VERB
fnp-6762	58	42	that	that	SCONJ
fnp-6762	58	43	ebv	ebv	NOUN
fnp-6762	58	44	infection	infection	NOUN
fnp-6762	58	45	increases	increase	VERB
fnp-6762	58	46	the	the	DET
fnp-6762	58	47	risk	risk	NOUN
fnp-6762	58	48	to	to	PART
fnp-6762	58	49	develop	develop	VERB
fnp-6762	58	50	ms	ms	NOUN
fnp-6762	58	51	more	more	ADJ
fnp-6762	58	52	than	than	ADP
fnp-6762	58	53	30	30	NUM
fnp-6762	58	54	-	-	PUNCT
fnp-6762	58	55	fold3	fold3	NOUN
fnp-6762	58	56	.	.	PUNCT
fnp-6762	59	1	in	in	ADP
fnp-6762	59	2	contrast	contrast	NOUN
fnp-6762	59	3	,	,	PUNCT
fnp-6762	59	4	previous	previous	ADJ
fnp-6762	59	5	studies	study	NOUN
fnp-6762	59	6	reported	report	VERB
fnp-6762	59	7	lower	low	ADJ
fnp-6762	59	8	rates	rate	NOUN
fnp-6762	59	9	of	of	ADP
fnp-6762	59	10	ebv	ebv	NOUN
fnp-6762	59	11	infection	infection	NOUN
fnp-6762	59	12	among	among	ADP
fnp-6762	59	13	children	child	NOUN
fnp-6762	59	14	with	with	ADP
fnp-6762	59	15	pediatric	pediatric	ADJ
fnp-6762	59	16	onset	onset	NOUN
fnp-6762	59	17	of	of	ADP
fnp-6762	59	18	ms	ms	NOUN
fnp-6762	59	19	raising	raise	VERB
fnp-6762	59	20	questions	question	NOUN
fnp-6762	59	21	about	about	ADP
fnp-6762	59	22	whether	whether	SCONJ
fnp-6762	59	23	ebv	ebv	NOUN
fnp-6762	59	24	infection	infection	NOUN
fnp-6762	59	25	is	be	AUX
fnp-6762	59	26	indeed	indeed	ADV
fnp-6762	59	27	pre	pre	ADJ
fnp-6762	59	28	-	-	ADJ
fnp-6762	59	29	requisite	requisite	ADJ
fnp-6762	59	30	across	across	ADP
fnp-6762	59	31	the	the	DET
fnp-6762	59	32	age	age	NOUN
fnp-6762	59	33	spectrum11	spectrum11	NOUN
fnp-6762	59	34	.	.	PUNCT
fnp-6762	60	1	however	however	ADV
fnp-6762	60	2	,	,	PUNCT
fnp-6762	60	3	those	those	DET
fnp-6762	60	4	studies	study	NOUN
fnp-6762	60	5	were	be	AUX
fnp-6762	60	6	conducted	conduct	VERB
fnp-6762	60	7	before	before	SCONJ
fnp-6762	60	8	mog	mog	NOUN
fnp-6762	60	9	antibody	antibody	NOUN
fnp-6762	60	10	tests	test	NOUN
fnp-6762	60	11	were	be	AUX
fnp-6762	60	12	broadly	broadly	ADV
fnp-6762	60	13	available	available	ADJ
fnp-6762	60	14	and	and	CCONJ
fnp-6762	60	15	therefore	therefore	ADV
fnp-6762	60	16	these	these	DET
fnp-6762	60	17	studies	study	NOUN
fnp-6762	60	18	could	could	AUX
fnp-6762	60	19	not	not	PART
fnp-6762	60	20	differentiate	differentiate	VERB
fnp-6762	60	21	reliably	reliably	ADV
fnp-6762	60	22	between	between	ADP
fnp-6762	60	23	pediatric	pediatric	ADJ
fnp-6762	60	24	onset	onset	NOUN
fnp-6762	60	25	-	-	PUNCT
fnp-6762	60	26	ms	ms	NOUN
fnp-6762	60	27	and	and	CCONJ
fnp-6762	60	28	mog	mog	NOUN
fnp-6762	60	29	antibody	antibody	NOUN
fnp-6762	60	30	-	-	PUNCT
fnp-6762	60	31	associated	associate	VERB
fnp-6762	60	32	disease	disease	NOUN
fnp-6762	60	33	(	(	PUNCT
fnp-6762	60	34	mogad	mogad	PROPN
fnp-6762	60	35	)	)	PUNCT
fnp-6762	60	36	.	.	PUNCT
fnp-6762	61	1	in	in	ADP
fnp-6762	61	2	this	this	DET
fnp-6762	61	3	line	line	NOUN
fnp-6762	61	4	,	,	PUNCT
fnp-6762	61	5	a	a	DET
fnp-6762	61	6	recent	recent	ADJ
fnp-6762	61	7	study	study	NOUN
fnp-6762	61	8	differentiating	differentiate	VERB
fnp-6762	61	9	between	between	ADP
fnp-6762	61	10	mogad	mogad	NOUN
fnp-6762	61	11	and	and	CCONJ
fnp-6762	61	12	pediatric	pediatric	ADJ
fnp-6762	61	13	onset	onset	NOUN
fnp-6762	61	14	ms	ms	PROPN
fnp-6762	61	15	now	now	ADV
fnp-6762	61	16	demonstrated	demonstrate	VERB
fnp-6762	61	17	that	that	SCONJ
fnp-6762	61	18	96	96	NUM
fnp-6762	61	19	 	 	SPACE
fnp-6762	61	20	%	%	NOUN
fnp-6762	61	21	of	of	ADP
fnp-6762	61	22	the	the	DET
fnp-6762	61	23	children	child	NOUN
fnp-6762	61	24	with	with	ADP
fnp-6762	61	25	pediatric	pediatric	ADJ
fnp-6762	61	26	onset	onset	NOUN
fnp-6762	61	27	ms	ms	NOUN
fnp-6762	61	28	had	have	VERB
fnp-6762	61	29	antibodies	antibody	NOUN
fnp-6762	61	30	directed	direct	VERB
fnp-6762	61	31	against	against	ADP
fnp-6762	61	32	the	the	DET
fnp-6762	61	33	viral	viral	ADJ
fnp-6762	61	34	capsid	capsid	NOUN
fnp-6762	61	35	of	of	ADP
fnp-6762	61	36	ebv	ebv	NOUN
fnp-6762	61	37	and	and	CCONJ
fnp-6762	61	38	90	90	NUM
fnp-6762	61	39	 	 	SPACE
fnp-6762	61	40	%	%	NOUN
fnp-6762	61	41	had	have	VERB
fnp-6762	61	42	antibodies	antibody	NOUN
fnp-6762	61	43	directed	direct	VERB
fnp-6762	61	44	against	against	ADP
fnp-6762	61	45	ebna1	ebna1	PROPN
fnp-6762	61	46	(	(	PUNCT
fnp-6762	61	47	a	a	DET
fnp-6762	61	48	marker	marker	NOUN
fnp-6762	61	49	of	of	ADP
fnp-6762	61	50	a	a	DET
fnp-6762	61	51	remote	remote	ADJ
fnp-6762	61	52	ebv	ebv	NOUN
fnp-6762	61	53	infection	infection	NOUN
fnp-6762	61	54	)	)	PUNCT
fnp-6762	61	55	further	far	ADV
fnp-6762	61	56	supporting	support	VERB
fnp-6762	61	57	the	the	DET
fnp-6762	61	58	notion	notion	NOUN
fnp-6762	61	59	that	that	SCONJ
fnp-6762	61	60	ebv	ebv	NOUN
fnp-6762	61	61	infection	infection	NOUN
fnp-6762	61	62	is	be	AUX
fnp-6762	61	63	required	require	VERB
fnp-6762	61	64	to	to	PART
fnp-6762	61	65	trigger	trigger	VERB
fnp-6762	61	66	ms	ms	NOUN
fnp-6762	61	67	across	across	ADP
fnp-6762	61	68	the	the	DET
fnp-6762	61	69	whole	whole	ADJ
fnp-6762	61	70	age	age	NOUN
fnp-6762	61	71	spectrum12	spectrum12	NOUN
fnp-6762	61	72	.	.	PUNCT
fnp-6762	62	1	interestingly	interestingly	ADV
fnp-6762	62	2	,	,	PUNCT
fnp-6762	62	3	children	child	NOUN
fnp-6762	62	4	with	with	ADP
fnp-6762	62	5	mogad	mogad	PROPN
fnp-6762	62	6	had	have	VERB
fnp-6762	62	7	similar	similar	ADJ
fnp-6762	62	8	rates	rate	NOUN
fnp-6762	62	9	of	of	ADP
fnp-6762	62	10	ebv	ebv	NOUN
fnp-6762	62	11	seropositivity	seropositivity	NOUN
fnp-6762	62	12	as	as	ADP
fnp-6762	62	13	healthy	healthy	ADJ
fnp-6762	62	14	children	child	NOUN
fnp-6762	62	15	,	,	PUNCT
fnp-6762	62	16	indicating	indicate	VERB
fnp-6762	62	17	that	that	SCONJ
fnp-6762	62	18	ebv	ebv	NOUN
fnp-6762	62	19	infection	infection	NOUN
fnp-6762	62	20	is	be	AUX
fnp-6762	62	21	not	not	PART
fnp-6762	62	22	a	a	DET
fnp-6762	62	23	risk	risk	NOUN
fnp-6762	62	24	factor	factor	NOUN
fnp-6762	62	25	for	for	ADP
fnp-6762	62	26	mogad	mogad	NOUN
fnp-6762	62	27	.	.	PUNCT
fnp-6762	63	1	the	the	DET
fnp-6762	63	2	mechanisms	mechanism	NOUN
fnp-6762	63	3	underlying	underlie	VERB
fnp-6762	63	4	the	the	DET
fnp-6762	63	5	increased	increase	VERB
fnp-6762	63	6	ms	ms	NOUN
fnp-6762	63	7	risk	risk	NOUN
fnp-6762	63	8	associated	associate	VERB
fnp-6762	63	9	with	with	ADP
fnp-6762	63	10	ebv	ebv	NOUN
fnp-6762	63	11	infection	infection	NOUN
fnp-6762	63	12	are	be	AUX
fnp-6762	63	13	still	still	ADV
fnp-6762	63	14	poorly	poorly	ADV
fnp-6762	63	15	understood	understand	VERB
fnp-6762	63	16	.	.	PUNCT
fnp-6762	64	1	results	result	NOUN
fnp-6762	64	2	from	from	ADP
fnp-6762	64	3	previous	previous	ADJ
fnp-6762	64	4	studies	study	NOUN
fnp-6762	64	5	suggest	suggest	VERB
fnp-6762	64	6	that	that	SCONJ
fnp-6762	64	7	the	the	DET
fnp-6762	64	8	ebv	ebv	NOUN
fnp-6762	64	9	infection	infection	NOUN
fnp-6762	64	10	is	be	AUX
fnp-6762	64	11	less	less	ADV
fnp-6762	64	12	well	well	ADV
fnp-6762	64	13	controlled	control	VERB
fnp-6762	64	14	in	in	ADP
fnp-6762	64	15	people	people	NOUN
fnp-6762	64	16	with	with	ADP
fnp-6762	64	17	ms13,14	ms13,14	PROPN
fnp-6762	64	18	.	.	PUNCT
fnp-6762	65	1	this	this	DET
fnp-6762	65	2	concept	concept	NOUN
fnp-6762	65	3	is	be	AUX
fnp-6762	65	4	further	far	ADV
fnp-6762	65	5	supported	support	VERB
fnp-6762	65	6	by	by	ADP
fnp-6762	65	7	a	a	DET
fnp-6762	65	8	number	number	NOUN
fnp-6762	65	9	of	of	ADP
fnp-6762	65	10	findings	finding	NOUN
fnp-6762	65	11	published	publish	VERB
fnp-6762	65	12	during	during	ADP
fnp-6762	65	13	the	the	DET
fnp-6762	65	14	last	last	ADJ
fnp-6762	65	15	year	year	NOUN
fnp-6762	65	16	:	:	PUNCT
fnp-6762	65	17	1	1	NUM
fnp-6762	65	18	.	.	PUNCT
fnp-6762	65	19	)	)	PUNCT
fnp-6762	66	1	the	the	DET
fnp-6762	66	2	ebv	ebv	NOUN
fnp-6762	66	3	antibody	antibody	NOUN
fnp-6762	66	4	response	response	NOUN
fnp-6762	66	5	is	be	AUX
fnp-6762	66	6	not	not	PART
fnp-6762	66	7	limited	limit	VERB
fnp-6762	66	8	to	to	ADP
fnp-6762	66	9	ebna1	ebna1	PROPN
fnp-6762	66	10	,	,	PUNCT
fnp-6762	66	11	suggesting	suggest	VERB
fnp-6762	66	12	a	a	DET
fnp-6762	66	13	larger	large	ADJ
fnp-6762	66	14	dysregulation	dysregulation	NOUN
fnp-6762	66	15	of	of	ADP
fnp-6762	66	16	ebv	ebv	NOUN
fnp-6762	66	17	-	-	PUNCT
fnp-6762	66	18	specific	specific	ADJ
fnp-6762	66	19	antibody	antibody	NOUN
fnp-6762	66	20	responses	response	NOUN
fnp-6762	66	21	than	than	SCONJ
fnp-6762	66	22	previously	previously	ADV
fnp-6762	66	23	recognized	recognize	VERB
fnp-6762	66	24	in	in	ADP
fnp-6762	66	25	pwms15	pwms15	NOUN
fnp-6762	66	26	.	.	PUNCT
fnp-6762	67	1	2	2	NUM
fnp-6762	67	2	.	.	NUM
fnp-6762	67	3	)	)	PUNCT
fnp-6762	67	4	pwms	pwms	PROPN
fnp-6762	67	5	,	,	PUNCT
fnp-6762	67	6	but	but	CCONJ
fnp-6762	67	7	not	not	PART
fnp-6762	67	8	individuals	individual	NOUN
fnp-6762	67	9	with	with	ADP
fnp-6762	67	10	other	other	ADJ
fnp-6762	67	11	neuroinflammatory	neuroinflammatory	ADJ
fnp-6762	67	12	diseases	disease	NOUN
fnp-6762	67	13	including	include	VERB
fnp-6762	67	14	neuromyelitis	neuromyelitis	PROPN
fnp-6762	67	15	optica	optica	PROPN
fnp-6762	67	16	,	,	PUNCT
fnp-6762	67	17	mogad	mogad	VERB
fnp-6762	67	18	or	or	CCONJ
fnp-6762	67	19	susac	susac	NOUN
fnp-6762	67	20	’s	’s	PART
fnp-6762	67	21	syndrome	syndrome	NOUN
fnp-6762	67	22	display	display	VERB
fnp-6762	67	23	an	an	DET
fnp-6762	67	24	aberrant	aberrant	ADJ
fnp-6762	67	25	mhc	mhc	PROPN
fnp-6762	67	26	-	-	PUNCT
fnp-6762	67	27	i	i	PRON
fnp-6762	67	28	-	-	PUNCT
fnp-6762	67	29	restricted	restrict	VERB
fnp-6762	67	30	t	t	NOUN
fnp-6762	67	31	cell	cell	NOUN
fnp-6762	67	32	response	response	NOUN
fnp-6762	67	33	directed	direct	VERB
fnp-6762	67	34	against	against	ADP
fnp-6762	67	35	ebv16	ebv16	NOUN
fnp-6762	67	36	and	and	CCONJ
fnp-6762	67	37	3	3	NUM
fnp-6762	67	38	.	.	PUNCT
fnp-6762	67	39	)	)	PUNCT
fnp-6762	68	1	the	the	DET
fnp-6762	68	2	frequencies	frequency	NOUN
fnp-6762	68	3	of	of	ADP
fnp-6762	68	4	cxcr3	cxcr3	NOUN
fnp-6762	68	5	+	+	SYM
fnp-6762	68	6	memory	memory	NOUN
fnp-6762	68	7	b	b	PROPN
fnp-6762	68	8	cells	cell	NOUN
fnp-6762	68	9	are	be	AUX
fnp-6762	68	10	reduced	reduce	VERB
fnp-6762	68	11	in	in	ADP
fnp-6762	68	12	the	the	DET
fnp-6762	68	13	blood	blood	NOUN
fnp-6762	68	14	of	of	ADP
fnp-6762	68	15	genetically	genetically	ADV
fnp-6762	68	16	identical	identical	ADJ
fnp-6762	68	17	twins	twin	NOUN
fnp-6762	68	18	with	with	ADP
fnp-6762	68	19	ms	ms	NOUN
fnp-6762	68	20	compared	compare	VERB
fnp-6762	68	21	to	to	ADP
fnp-6762	68	22	their	their	PRON
fnp-6762	68	23	unaffected	unaffected	ADJ
fnp-6762	68	24	siblings	sibling	NOUN
fnp-6762	68	25	.	.	PUNCT
fnp-6762	69	1	based	base	VERB
fnp-6762	69	2	on	on	ADP
fnp-6762	69	3	the	the	DET
fnp-6762	69	4	latter	latter	ADJ
fnp-6762	69	5	finding	finding	NOUN
fnp-6762	69	6	,	,	PUNCT
fnp-6762	69	7	the	the	DET
fnp-6762	69	8	authors	author	NOUN
fnp-6762	69	9	propose	propose	VERB
fnp-6762	69	10	that	that	SCONJ
fnp-6762	69	11	these	these	DET
fnp-6762	69	12	memory	memory	NOUN
fnp-6762	69	13	b	b	PROPN
fnp-6762	69	14	cells	cell	NOUN
fnp-6762	69	15	migrate	migrate	VERB
fnp-6762	69	16	into	into	ADP
fnp-6762	69	17	the	the	DET
fnp-6762	69	18	cns	cns	NOUN
fnp-6762	69	19	,	,	PUNCT
fnp-6762	69	20	mature	mature	VERB
fnp-6762	69	21	into	into	ADP
fnp-6762	69	22	antibody	antibody	NOUN
fnp-6762	69	23	secreting	secrete	VERB
fnp-6762	69	24	cells	cell	NOUN
fnp-6762	69	25	in	in	ADP
fnp-6762	69	26	the	the	DET
fnp-6762	69	27	cns	cns	NOUN
fnp-6762	69	28	and	and	CCONJ
fnp-6762	69	29	drive	drive	VERB
fnp-6762	69	30	the	the	DET
fnp-6762	69	31	disease17	disease17	NOUN
fnp-6762	69	32	.	.	PUNCT
fnp-6762	70	1	4	4	NUM
fnp-6762	70	2	.	.	PUNCT
fnp-6762	70	3	)	)	PUNCT
fnp-6762	71	1	spontaneous	spontaneous	ADJ
fnp-6762	71	2	lymphoblastoid	lymphoblastoid	NOUN
fnp-6762	71	3	cell	cell	NOUN
fnp-6762	71	4	lines	line	NOUN
fnp-6762	71	5	(	(	PUNCT
fnp-6762	71	6	slcls	slcls	NOUN
fnp-6762	71	7	)	)	PUNCT
fnp-6762	71	8	isolated	isolate	VERB
fnp-6762	71	9	from	from	ADP
fnp-6762	71	10	pwms	pwm	NOUN
fnp-6762	71	11	with	with	ADP
fnp-6762	71	12	active	active	ADJ
fnp-6762	71	13	disease	disease	NOUN
fnp-6762	71	14	had	have	VERB
fnp-6762	71	15	higher	high	ADJ
fnp-6762	71	16	ebv	ebv	NOUN
fnp-6762	71	17	lytic	lytic	ADJ
fnp-6762	71	18	gene	gene	NOUN
fnp-6762	71	19	expression	expression	NOUN
fnp-6762	71	20	than	than	ADP
fnp-6762	71	21	slcls	slcls	NOUN
fnp-6762	71	22	from	from	ADP
fnp-6762	71	23	ms	ms	PROPN
fnp-6762	71	24	patients	patient	NOUN
fnp-6762	71	25	with	with	ADP
fnp-6762	71	26	stable	stable	ADJ
fnp-6762	71	27	disease	disease	NOUN
fnp-6762	71	28	or	or	CCONJ
fnp-6762	71	29	hcs	hcs	PROPN
fnp-6762	71	30	.	.	PUNCT
fnp-6762	72	1	furthermore	furthermore	ADV
fnp-6762	72	2	,	,	PUNCT
fnp-6762	72	3	lcls	lcls	NOUN
fnp-6762	72	4	from	from	ADP
fnp-6762	72	5	patients	patient	NOUN
fnp-6762	72	6	with	with	ADP
fnp-6762	72	7	active	active	ADJ
fnp-6762	72	8	disease	disease	NOUN
fnp-6762	72	9	displayed	display	VERB
fnp-6762	72	10	activation	activation	NOUN
fnp-6762	72	11	of	of	ADP
fnp-6762	72	12	selected	select	VERB
fnp-6762	72	13	inflammatory	inflammatory	ADJ
fnp-6762	72	14	pathways	pathway	NOUN
fnp-6762	72	15	and	and	CCONJ
fnp-6762	72	16	of	of	ADP
fnp-6762	72	17	genes	gene	NOUN
fnp-6762	72	18	associated	associate	VERB
fnp-6762	72	19	with	with	ADP
fnp-6762	72	20	the	the	DET
fnp-6762	72	21	lytic	lytic	ADJ
fnp-6762	72	22	gene	gene	NOUN
fnp-6762	72	23	expression	expression	NOUN
fnp-6762	72	24	of	of	ADP
fnp-6762	72	25	ebv	ebv	NOUN
fnp-6762	72	26	indicating	indicate	VERB
fnp-6762	72	27	that	that	SCONJ
fnp-6762	72	28	dysregulation	dysregulation	NOUN
fnp-6762	72	29	of	of	ADP
fnp-6762	72	30	ebv	ebv	NOUN
fnp-6762	72	31	gene	gene	NOUN
fnp-6762	72	32	expression	expression	NOUN
fnp-6762	72	33	by	by	ADP
fnp-6762	72	34	b	b	PROPN
fnp-6762	72	35	cells	cell	NOUN
fnp-6762	72	36	drives	drive	VERB
fnp-6762	72	37	a	a	DET
fnp-6762	72	38	pro	pro	ADJ
fnp-6762	72	39	-	-	ADJ
fnp-6762	72	40	inflammatory	inflammatory	ADJ
fnp-6762	72	41	,	,	PUNCT
fnp-6762	72	42	pathogenic	pathogenic	ADJ
fnp-6762	72	43	b	b	NOUN
fnp-6762	72	44	cell	cell	NOUN
fnp-6762	72	45	phenotype18	phenotype18	NOUN
fnp-6762	72	46	.	.	PUNCT
fnp-6762	73	1	interestingly	interestingly	ADV
fnp-6762	73	2	,	,	PUNCT
fnp-6762	73	3	the	the	DET
fnp-6762	73	4	authors	author	NOUN
fnp-6762	73	5	provide	provide	VERB
fnp-6762	73	6	also	also	ADV
fnp-6762	73	7	evidence	evidence	NOUN
fnp-6762	73	8	that	that	SCONJ
fnp-6762	73	9	antiviral	antiviral	ADJ
fnp-6762	73	10	approaches	approach	NOUN
fnp-6762	73	11	targeting	target	VERB
fnp-6762	73	12	ebv	ebv	NOUN
fnp-6762	73	13	replication	replication	NOUN
fnp-6762	73	14	decreased	decrease	VERB
fnp-6762	73	15	cytokine	cytokine	ADJ
fnp-6762	73	16	production	production	NOUN
fnp-6762	73	17	and	and	CCONJ
fnp-6762	73	18	autologous	autologous	ADJ
fnp-6762	73	19	cd4	cd4	PROPN
fnp-6762	73	20	+	+	PROPN
fnp-6762	73	21	t	t	NOUN
fnp-6762	73	22	cell	cell	NOUN
fnp-6762	73	23	responses	response	NOUN
fnp-6762	73	24	.	.	PUNCT
fnp-6762	74	1	the	the	DET
fnp-6762	74	2	identification	identification	NOUN
fnp-6762	74	3	of	of	ADP
fnp-6762	74	4	ebv	ebv	NOUN
fnp-6762	74	5	as	as	ADP
fnp-6762	74	6	an	an	DET
fnp-6762	74	7	important	important	ADJ
fnp-6762	74	8	contributing	contribute	VERB
fnp-6762	74	9	factor	factor	NOUN
fnp-6762	74	10	of	of	ADP
fnp-6762	74	11	ms	ms	PROPN
fnp-6762	74	12	raises	raise	VERB
fnp-6762	74	13	the	the	DET
fnp-6762	74	14	questions	question	NOUN
fnp-6762	74	15	whether	whether	SCONJ
fnp-6762	74	16	anti	anti	ADJ
fnp-6762	74	17	-	-	ADJ
fnp-6762	74	18	viral	viral	ADJ
fnp-6762	74	19	treatment	treatment	NOUN
fnp-6762	74	20	approaches	approach	NOUN
fnp-6762	74	21	could	could	AUX
fnp-6762	74	22	either	either	CCONJ
fnp-6762	74	23	prevent	prevent	VERB
fnp-6762	74	24	or	or	CCONJ
fnp-6762	74	25	slow	slow	VERB
fnp-6762	74	26	down	down	ADP
fnp-6762	74	27	ms	ms	NOUN
fnp-6762	74	28	disease	disease	NOUN
fnp-6762	74	29	progression	progression	NOUN
fnp-6762	74	30	and	and	CCONJ
fnp-6762	74	31	first	first	ADJ
fnp-6762	74	32	clinical	clinical	ADJ
fnp-6762	74	33	trials	trial	NOUN
fnp-6762	74	34	are	be	AUX
fnp-6762	74	35	currently	currently	ADV
fnp-6762	74	36	under	under	ADP
fnp-6762	74	37	way10,19	way10,19	PROPN
fnp-6762	74	38	.	.	PUNCT
fnp-6762	75	1	novel	novel	PROPN
fnp-6762	75	2	insight	insight	NOUN
fnp-6762	75	3	into	into	ADP
fnp-6762	75	4	ms	ms	NOUN
fnp-6762	75	5	pathophysiology	pathophysiology	NOUN
fnp-6762	75	6	using	use	VERB
fnp-6762	75	7	new	new	ADJ
fnp-6762	75	8	technologies	technology	NOUN
fnp-6762	75	9	there	there	PRON
fnp-6762	75	10	are	be	VERB
fnp-6762	75	11	ongoing	ongoing	ADJ
fnp-6762	75	12	efforts	effort	NOUN
fnp-6762	75	13	to	to	PART
fnp-6762	75	14	characterize	characterize	VERB
fnp-6762	75	15	molecular	molecular	ADJ
fnp-6762	75	16	signatures	signature	NOUN
fnp-6762	75	17	associated	associate	VERB
fnp-6762	75	18	with	with	ADP
fnp-6762	75	19	ms	ms	NOUN
fnp-6762	75	20	lesion	lesion	NOUN
fnp-6762	75	21	types	type	NOUN
fnp-6762	75	22	,	,	PUNCT
fnp-6762	75	23	remyelination	remyelination	NOUN
fnp-6762	75	24	failure	failure	NOUN
fnp-6762	75	25	or	or	CCONJ
fnp-6762	75	26	neurodegeneration	neurodegeneration	NOUN
fnp-6762	75	27	using	use	VERB
fnp-6762	75	28	modern	modern	ADJ
fnp-6762	75	29	sequencing	sequencing	NOUN
fnp-6762	75	30	technologies	technology	NOUN
fnp-6762	75	31	,	,	PUNCT
fnp-6762	75	32	such	such	ADJ
fnp-6762	75	33	as	as	ADP
fnp-6762	75	34	sc	sc	PROPN
fnp-6762	75	35	/	/	SYM
fnp-6762	75	36	snrna	snrna	ADJ
fnp-6762	75	37	sequencing	sequencing	NOUN
fnp-6762	75	38	or	or	CCONJ
fnp-6762	75	39	spatial	spatial	ADJ
fnp-6762	75	40	transcriptomics	transcriptomic	NOUN
fnp-6762	75	41	(	(	PUNCT
fnp-6762	75	42	st	st	NOUN
fnp-6762	75	43	)	)	PUNCT
fnp-6762	75	44	to	to	PART
fnp-6762	75	45	identify	identify	VERB
fnp-6762	75	46	new	new	ADJ
fnp-6762	75	47	pharmacological	pharmacological	ADJ
fnp-6762	75	48	treatment	treatment	NOUN
fnp-6762	75	49	targets20–22	targets20–22	NOUN
fnp-6762	75	50	.	.	PUNCT
fnp-6762	76	1	spatial	spatial	ADJ
fnp-6762	76	2	transcriptomics	transcriptomic	NOUN
fnp-6762	76	3	enables	enable	VERB
fnp-6762	76	4	spatially	spatially	ADV
fnp-6762	76	5	resolved	resolve	VERB
fnp-6762	76	6	analysis	analysis	NOUN
fnp-6762	76	7	of	of	ADP
fnp-6762	76	8	gene	gene	NOUN
fnp-6762	76	9	expression	expression	NOUN
fnp-6762	76	10	within	within	ADP
fnp-6762	76	11	intact	intact	ADJ
fnp-6762	76	12	tissue	tissue	NOUN
fnp-6762	76	13	sections	section	NOUN
fnp-6762	76	14	in	in	ADP
fnp-6762	76	15	contrast	contrast	NOUN
fnp-6762	76	16	to	to	ADP
fnp-6762	76	17	bulk	bulk	ADJ
fnp-6762	76	18	or	or	CCONJ
fnp-6762	76	19	single	single	ADJ
fnp-6762	76	20	-	-	PUNCT
fnp-6762	76	21	cell	cell	NOUN
fnp-6762	76	22	rna	rna	NOUN
fnp-6762	76	23	sequencing	sequence	VERB
fnp-6762	76	24	(	(	PUNCT
fnp-6762	76	25	scrna	scrna	NOUN
fnp-6762	76	26	-	-	PUNCT
fnp-6762	76	27	seq	seq	NOUN
fnp-6762	76	28	)	)	PUNCT
fnp-6762	76	29	,	,	PUNCT
fnp-6762	76	30	which	which	PRON
fnp-6762	76	31	requires	require	VERB
fnp-6762	76	32	the	the	DET
fnp-6762	76	33	dissociation	dissociation	NOUN
fnp-6762	76	34	of	of	ADP
fnp-6762	76	35	tissues	tissue	NOUN
fnp-6762	76	36	and	and	CCONJ
fnp-6762	76	37	loses	lose	VERB
fnp-6762	76	38	spatial	spatial	ADJ
fnp-6762	76	39	context	context	NOUN
fnp-6762	76	40	.	.	PUNCT
fnp-6762	77	1	lerma	lerma	PROPN
fnp-6762	77	2	-	-	PUNCT
fnp-6762	77	3	martin	martin	PROPN
fnp-6762	77	4	and	and	CCONJ
fnp-6762	77	5	colleagues	colleague	NOUN
fnp-6762	77	6	analyzed	analyze	VERB
fnp-6762	77	7	12	12	NUM
fnp-6762	77	8	subcortical	subcortical	ADJ
fnp-6762	77	9	ms	ms	ADJ
fnp-6762	77	10	lesions	lesion	NOUN
fnp-6762	77	11	from	from	ADP
fnp-6762	77	12	six	six	NUM
fnp-6762	77	13	donors	donor	NOUN
fnp-6762	77	14	and	and	CCONJ
fnp-6762	77	15	seven	seven	NUM
fnp-6762	77	16	controls	control	NOUN
fnp-6762	77	17	by	by	ADP
fnp-6762	77	18	combining	combine	VERB
fnp-6762	77	19	spatial	spatial	ADJ
fnp-6762	77	20	transcriptomics	transcriptomic	NOUN
fnp-6762	77	21	(	(	PUNCT
fnp-6762	77	22	10x	10x	X
fnp-6762	77	23	genomics	genomics	PROPN
fnp-6762	77	24	visium	visium	PROPN
fnp-6762	77	25	spatial	spatial	ADJ
fnp-6762	77	26	gene	gene	NOUN
fnp-6762	77	27	expression	expression	NOUN
fnp-6762	77	28	platform	platform	NOUN
fnp-6762	77	29	)	)	PUNCT
fnp-6762	77	30	with	with	ADP
fnp-6762	77	31	snrna	snrna	ADJ
fnp-6762	77	32	sequencing	sequencing	NOUN
fnp-6762	77	33	.	.	PUNCT
fnp-6762	78	1	the	the	DET
fnp-6762	78	2	comparison	comparison	NOUN
fnp-6762	78	3	between	between	ADP
fnp-6762	78	4	histologically	histologically	ADV
fnp-6762	78	5	annotated	annotate	VERB
fnp-6762	78	6	areas	area	NOUN
fnp-6762	78	7	and	and	CCONJ
fnp-6762	78	8	unsupervised	unsupervised	ADJ
fnp-6762	78	9	molecularly	molecularly	ADV
fnp-6762	78	10	defined	define	VERB
fnp-6762	78	11	niches	niche	NOUN
fnp-6762	78	12	revealed	reveal	VERB
fnp-6762	78	13	a	a	DET
fnp-6762	78	14	significant	significant	ADJ
fnp-6762	78	15	overlap	overlap	NOUN
fnp-6762	78	16	both	both	CCONJ
fnp-6762	78	17	at	at	ADP
fnp-6762	78	18	the	the	DET
fnp-6762	78	19	cluster	cluster	NOUN
fnp-6762	78	20	and	and	CCONJ
fnp-6762	78	21	tissue	tissue	NOUN
fnp-6762	78	22	section	section	NOUN
fnp-6762	78	23	level	level	NOUN
fnp-6762	78	24	validating	validate	VERB
fnp-6762	78	25	the	the	DET
fnp-6762	78	26	reliability	reliability	NOUN
fnp-6762	78	27	of	of	ADP
fnp-6762	78	28	the	the	DET
fnp-6762	78	29	method20	method20	NOUN
fnp-6762	78	30	.	.	PUNCT
fnp-6762	79	1	alemsa	alemsa	NOUN
fnp-6762	79	2	and	and	CCONJ
fnp-6762	79	3	colleagues	colleague	NOUN
fnp-6762	79	4	performed	perform	VERB
fnp-6762	79	5	a	a	DET
fnp-6762	79	6	similar	similar	ADJ
fnp-6762	79	7	study	study	NOUN
fnp-6762	79	8	using	use	VERB
fnp-6762	79	9	two	two	NUM
fnp-6762	79	10	different	different	ADJ
fnp-6762	79	11	spatial	spatial	ADJ
fnp-6762	79	12	transcriptomic	transcriptomic	ADJ
fnp-6762	79	13	platforms	platform	NOUN
fnp-6762	79	14	(	(	PUNCT
fnp-6762	79	15	10x	10x	X
fnp-6762	79	16	genomics	genomics	PROPN
fnp-6762	79	17	visium	visium	PROPN
fnp-6762	79	18	spatial	spatial	ADJ
fnp-6762	79	19	gene	gene	NOUN
fnp-6762	79	20	expression	expression	NOUN
fnp-6762	79	21	platform	platform	NOUN
fnp-6762	79	22	,	,	PUNCT
fnp-6762	79	23	nanostring	nanostre	VERB
fnp-6762	79	24	geomx	geomx	NOUN
fnp-6762	79	25	)	)	PUNCT
fnp-6762	79	26	21	21	NUM
fnp-6762	79	27	.	.	PUNCT
fnp-6762	80	1	both	both	DET
fnp-6762	80	2	publications	publication	NOUN
fnp-6762	80	3	provide	provide	VERB
fnp-6762	80	4	further	further	ADJ
fnp-6762	80	5	insights	insight	NOUN
fnp-6762	80	6	into	into	ADP
fnp-6762	80	7	potential	potential	ADJ
fnp-6762	80	8	cell	cell	NOUN
fnp-6762	80	9	-	-	PUNCT
fnp-6762	80	10	cell	cell	NOUN
fnp-6762	80	11	communication	communication	NOUN
fnp-6762	80	12	via	via	ADP
fnp-6762	80	13	receptor	receptor	NOUN
fnp-6762	80	14	ligand	ligand	NOUN
fnp-6762	80	15	interactions	interaction	NOUN
fnp-6762	80	16	,	,	PUNCT
fnp-6762	80	17	which	which	PRON
fnp-6762	80	18	will	will	AUX
fnp-6762	80	19	contribute	contribute	VERB
fnp-6762	80	20	to	to	ADP
fnp-6762	80	21	the	the	DET
fnp-6762	80	22	disentanglement	disentanglement	NOUN
fnp-6762	80	23	of	of	ADP
fnp-6762	80	24	the	the	DET
fnp-6762	80	25	dynamic	dynamic	ADJ
fnp-6762	80	26	cellular	cellular	ADJ
fnp-6762	80	27	and	and	CCONJ
fnp-6762	80	28	molecular	molecular	ADJ
fnp-6762	80	29	changes	change	NOUN
fnp-6762	80	30	occurring	occur	VERB
fnp-6762	80	31	in	in	ADP
fnp-6762	80	32	ms	ms	ADJ
fnp-6762	80	33	lesions	lesion	NOUN
fnp-6762	80	34	.	.	PUNCT
fnp-6762	81	1	furthermore	furthermore	ADV
fnp-6762	81	2	,	,	PUNCT
fnp-6762	81	3	they	they	PRON
fnp-6762	81	4	compared	compare	VERB
fnp-6762	81	5	the	the	DET
fnp-6762	81	6	transcriptional	transcriptional	ADJ
fnp-6762	81	7	profiles	profile	NOUN
fnp-6762	81	8	in	in	ADP
fnp-6762	81	9	perilesional	perilesional	PROPN
fnp-6762	81	10	wm	wm	PROPN
fnp-6762	81	11	and	and	CCONJ
fnp-6762	81	12	nawm	nawm	PROPN
fnp-6762	81	13	and	and	CCONJ
fnp-6762	81	14	observed	observed	ADJ
fnp-6762	81	15	lesion	lesion	NOUN
fnp-6762	81	16	-	-	PUNCT
fnp-6762	81	17	type	type	NOUN
fnp-6762	81	18	dependent	dependent	ADJ
fnp-6762	81	19	alterations	alteration	NOUN
fnp-6762	81	20	,	,	PUNCT
fnp-6762	81	21	further	far	ADV
fnp-6762	81	22	supporting	support	VERB
fnp-6762	81	23	the	the	DET
fnp-6762	81	24	notion	notion	NOUN
fnp-6762	81	25	that	that	SCONJ
fnp-6762	81	26	perilesional	perilesional	ADJ
fnp-6762	81	27	white	white	NOUN
fnp-6762	81	28	matter	matter	NOUN
fnp-6762	81	29	directly	directly	ADV
fnp-6762	81	30	adjacent	adjacent	ADJ
fnp-6762	81	31	to	to	ADP
fnp-6762	81	32	a	a	DET
fnp-6762	81	33	lesion	lesion	NOUN
fnp-6762	81	34	differs	differ	VERB
fnp-6762	81	35	from	from	ADP
fnp-6762	81	36	nawm	nawm	PROPN
fnp-6762	81	37	,	,	PUNCT
fnp-6762	81	38	which	which	PRON
fnp-6762	81	39	is	be	AUX
fnp-6762	81	40	in	in	ADP
fnp-6762	81	41	line	line	NOUN
fnp-6762	81	42	with	with	ADP
fnp-6762	81	43	observations	observation	NOUN
fnp-6762	81	44	from	from	ADP
fnp-6762	81	45	histopathology	histopathology	NOUN
fnp-6762	81	46	and	and	CCONJ
fnp-6762	81	47	imaging23–25	imaging23–25	CCONJ
fnp-6762	81	48	.	.	PUNCT
fnp-6762	82	1	together	together	ADV
fnp-6762	82	2	,	,	PUNCT
fnp-6762	82	3	these	these	DET
fnp-6762	82	4	data	datum	NOUN
fnp-6762	82	5	suggest	suggest	VERB
fnp-6762	82	6	,	,	PUNCT
fnp-6762	82	7	that	that	SCONJ
fnp-6762	82	8	the	the	DET
fnp-6762	82	9	inflammatory	inflammatory	ADJ
fnp-6762	82	10	infiltrates	infiltrate	NOUN
fnp-6762	82	11	in	in	ADP
fnp-6762	82	12	active	active	ADJ
fnp-6762	82	13	and	and	CCONJ
fnp-6762	82	14	mixed	mixed	ADJ
fnp-6762	82	15	active	active	ADJ
fnp-6762	82	16	/	/	SYM
fnp-6762	82	17	inactive	inactive	ADJ
fnp-6762	82	18	lesions	lesion	NOUN
fnp-6762	82	19	affect	affect	VERB
fnp-6762	82	20	the	the	DET
fnp-6762	82	21	perilesional	perilesional	ADJ
fnp-6762	82	22	tissue	tissue	NOUN
fnp-6762	82	23	environment	environment	NOUN
fnp-6762	82	24	.	.	PUNCT
fnp-6762	83	1	however	however	ADV
fnp-6762	83	2	,	,	PUNCT
fnp-6762	83	3	although	although	SCONJ
fnp-6762	83	4	spatial	spatial	ADJ
fnp-6762	83	5	transcriptomics	transcriptomic	NOUN
fnp-6762	83	6	is	be	AUX
fnp-6762	83	7	a	a	DET
fnp-6762	83	8	valuable	valuable	ADJ
fnp-6762	83	9	new	new	ADJ
fnp-6762	83	10	tool	tool	NOUN
fnp-6762	83	11	for	for	ADP
fnp-6762	83	12	the	the	DET
fnp-6762	83	13	identification	identification	NOUN
fnp-6762	83	14	of	of	ADP
fnp-6762	83	15	disease	disease	NOUN
fnp-6762	83	16	associated	associate	VERB
fnp-6762	83	17	molecular	molecular	ADJ
fnp-6762	83	18	pathways	pathway	NOUN
fnp-6762	83	19	in	in	ADP
fnp-6762	83	20	ms	ms	PROPN
fnp-6762	83	21	,	,	PUNCT
fnp-6762	83	22	the	the	DET
fnp-6762	83	23	techniques	technique	NOUN
fnp-6762	83	24	used	use	VERB
fnp-6762	83	25	in	in	ADP
fnp-6762	83	26	the	the	DET
fnp-6762	83	27	above	above	ADJ
fnp-6762	83	28	mentioned	mention	VERB
fnp-6762	83	29	manuscript	manuscript	NOUN
fnp-6762	83	30	do	do	AUX
fnp-6762	83	31	not	not	PART
fnp-6762	83	32	reach	reach	VERB
fnp-6762	83	33	single	single	ADJ
fnp-6762	83	34	cell	cell	NOUN
fnp-6762	83	35	resolution	resolution	NOUN
fnp-6762	83	36	.	.	PUNCT
fnp-6762	84	1	a	a	DET
fnp-6762	84	2	new	new	ADJ
fnp-6762	84	3	method	method	NOUN
fnp-6762	84	4	,	,	PUNCT
fnp-6762	84	5	named	name	VERB
fnp-6762	84	6	in	in	ADP
fnp-6762	84	7	situ	situ	ADJ
fnp-6762	84	8	sequencing	sequencing	NOUN
fnp-6762	84	9	allows	allow	VERB
fnp-6762	84	10	the	the	DET
fnp-6762	84	11	identification	identification	NOUN
fnp-6762	84	12	of	of	ADP
fnp-6762	84	13	transcriptomic	transcriptomic	ADJ
fnp-6762	84	14	patterns	pattern	NOUN
fnp-6762	84	15	with	with	ADP
fnp-6762	84	16	single	single	ADJ
fnp-6762	84	17	cell	cell	NOUN
fnp-6762	84	18	resolution	resolution	NOUN
fnp-6762	84	19	.	.	PUNCT
fnp-6762	85	1	kukanja	kukanja	NOUN
fnp-6762	85	2	and	and	CCONJ
fnp-6762	85	3	colleagues	colleague	NOUN
fnp-6762	85	4	used	use	VERB
fnp-6762	85	5	this	this	DET
fnp-6762	85	6	method	method	NOUN
fnp-6762	85	7	to	to	PART
fnp-6762	85	8	disentangle	disentangle	VERB
fnp-6762	85	9	molecular	molecular	ADJ
fnp-6762	85	10	mechanisms	mechanism	NOUN
fnp-6762	85	11	underlying	underlie	VERB
fnp-6762	85	12	lesion	lesion	NOUN
fnp-6762	85	13	formation	formation	NOUN
fnp-6762	85	14	in	in	ADP
fnp-6762	85	15	experimental	experimental	ADJ
fnp-6762	85	16	autoimmune	autoimmune	ADJ
fnp-6762	85	17	encephalitis	encephalitis	NOUN
fnp-6762	85	18	,	,	PUNCT
fnp-6762	85	19	an	an	DET
fnp-6762	85	20	animal	animal	NOUN
fnp-6762	85	21	model	model	NOUN
fnp-6762	85	22	of	of	ADP
fnp-6762	85	23	ms26	ms26	PROPN
fnp-6762	85	24	.	.	PUNCT
fnp-6762	86	1	they	they	PRON
fnp-6762	86	2	also	also	ADV
fnp-6762	86	3	identified	identify	VERB
fnp-6762	86	4	disease	disease	NOUN
fnp-6762	86	5	-	-	PUNCT
fnp-6762	86	6	associated	associate	VERB
fnp-6762	86	7	glia	glia	NOUN
fnp-6762	86	8	cells	cell	NOUN
fnp-6762	86	9	,	,	PUNCT
fnp-6762	86	10	which	which	PRON
fnp-6762	86	11	were	be	AUX
fnp-6762	86	12	detected	detect	VERB
fnp-6762	86	13	outside	outside	ADV
fnp-6762	86	14	of	of	ADP
fnp-6762	86	15	eae	eae	PROPN
fnp-6762	86	16	lesions	lesion	NOUN
fnp-6762	86	17	,	,	PUNCT
fnp-6762	86	18	and	and	CCONJ
fnp-6762	86	19	which	which	PRON
fnp-6762	86	20	were	be	AUX
fnp-6762	86	21	dynamically	dynamically	ADV
fnp-6762	86	22	induced	induce	VERB
fnp-6762	86	23	and	and	CCONJ
fnp-6762	86	24	resolved	resolve	VERB
fnp-6762	86	25	during	during	ADP
fnp-6762	86	26	the	the	DET
fnp-6762	86	27	eae	eae	PROPN
fnp-6762	86	28	course	course	NOUN
fnp-6762	86	29	in	in	ADP
fnp-6762	86	30	line	line	NOUN
fnp-6762	86	31	with	with	ADP
fnp-6762	86	32	the	the	DET
fnp-6762	86	33	observation	observation	NOUN
fnp-6762	86	34	of	of	ADP
fnp-6762	86	35	disease	disease	NOUN
fnp-6762	86	36	associated	associate	VERB
fnp-6762	86	37	changes	change	NOUN
fnp-6762	86	38	also	also	ADV
fnp-6762	86	39	outside	outside	ADP
fnp-6762	86	40	of	of	ADP
fnp-6762	86	41	ms	ms	NOUN
fnp-6762	86	42	lesions	lesion	NOUN
fnp-6762	86	43	.	.	PUNCT
fnp-6762	87	1	the	the	DET
fnp-6762	87	2	authors	author	NOUN
fnp-6762	87	3	could	could	AUX
fnp-6762	87	4	also	also	ADV
fnp-6762	87	5	provide	provide	VERB
fnp-6762	87	6	evidence	evidence	NOUN
fnp-6762	87	7	that	that	SCONJ
fnp-6762	87	8	the	the	DET
fnp-6762	87	9	method	method	NOUN
fnp-6762	87	10	is	be	AUX
fnp-6762	87	11	suitable	suitable	ADJ
fnp-6762	87	12	to	to	PART
fnp-6762	87	13	analyze	analyze	VERB
fnp-6762	87	14	human	human	ADJ
fnp-6762	87	15	ms	ms	NOUN
fnp-6762	87	16	tissue	tissue	NOUN
fnp-6762	87	17	samples	sample	NOUN
fnp-6762	87	18	.	.	PUNCT
fnp-6762	88	1	a	a	DET
fnp-6762	88	2	limitation	limitation	NOUN
fnp-6762	88	3	of	of	ADP
fnp-6762	88	4	these	these	DET
fnp-6762	88	5	techniques	technique	NOUN
fnp-6762	88	6	are	be	AUX
fnp-6762	88	7	the	the	DET
fnp-6762	88	8	limited	limited	ADJ
fnp-6762	88	9	number	number	NOUN
fnp-6762	88	10	of	of	ADP
fnp-6762	88	11	genes	gene	NOUN
fnp-6762	88	12	that	that	PRON
fnp-6762	88	13	can	can	AUX
fnp-6762	88	14	be	be	AUX
fnp-6762	88	15	analyzed	analyze	VERB
fnp-6762	88	16	(	(	PUNCT
fnp-6762	88	17	in	in	ADP
fnp-6762	88	18	this	this	DET
fnp-6762	88	19	study	study	NOUN
fnp-6762	88	20	239	239	NUM
fnp-6762	88	21	and	and	CCONJ
fnp-6762	88	22	266	266	NUM
fnp-6762	88	23	genes	gene	NOUN
fnp-6762	88	24	in	in	ADP
fnp-6762	88	25	mouse	mouse	NOUN
fnp-6762	88	26	and	and	CCONJ
fnp-6762	88	27	human	human	ADJ
fnp-6762	88	28	samples	sample	NOUN
fnp-6762	88	29	,	,	PUNCT
fnp-6762	88	30	respectively	respectively	ADV
fnp-6762	88	31	)	)	PUNCT
fnp-6762	88	32	;	;	PUNCT
fnp-6762	88	33	however	however	ADV
fnp-6762	88	34	there	there	PRON
fnp-6762	88	35	are	be	VERB
fnp-6762	88	36	ongoing	ongoing	ADJ
fnp-6762	88	37	efforts	effort	NOUN
fnp-6762	88	38	to	to	PART
fnp-6762	88	39	enable	enable	VERB
fnp-6762	88	40	whole	whole	ADJ
fnp-6762	88	41	transcriptome	transcriptome	ADJ
fnp-6762	88	42	single	single	ADJ
fnp-6762	88	43	cell	cell	NOUN
fnp-6762	88	44	scale	scale	NOUN
fnp-6762	88	45	analysis	analysis	NOUN
fnp-6762	88	46	in	in	ADP
fnp-6762	88	47	in	in	ADP
fnp-6762	88	48	formalin	formalin	NOUN
fnp-6762	88	49	fixed	fix	VERB
fnp-6762	88	50	paraffin	paraffin	NOUN
fnp-6762	88	51	embedded	embed	VERB
fnp-6762	88	52	tissue	tissue	NOUN
fnp-6762	88	53	sections27	sections27	NOUN
fnp-6762	88	54	.	.	PUNCT
fnp-6762	89	1	preclinical	preclinical	ADJ
fnp-6762	89	2	stages	stage	NOUN
fnp-6762	89	3	of	of	ADP
fnp-6762	89	4	ms	ms	NOUN
fnp-6762	89	5	–	–	PUNCT
fnp-6762	89	6	expanding	expand	VERB
fnp-6762	89	7	the	the	DET
fnp-6762	89	8	ms	ms	PROPN
fnp-6762	89	9	disease	disease	NOUN
fnp-6762	89	10	continuume	continuume	NOUN
fnp-6762	89	11	historically	historically	ADV
fnp-6762	89	12	,	,	PUNCT
fnp-6762	89	13	ms	ms	ADJ
fnp-6762	89	14	diagnosis	diagnosis	NOUN
fnp-6762	89	15	required	require	VERB
fnp-6762	89	16	a	a	DET
fnp-6762	89	17	clinically	clinically	ADV
fnp-6762	89	18	defined	define	VERB
fnp-6762	89	19	event	event	NOUN
fnp-6762	89	20	,	,	PUNCT
fnp-6762	89	21	but	but	CCONJ
fnp-6762	89	22	recent	recent	ADJ
fnp-6762	89	23	evidence	evidence	NOUN
fnp-6762	89	24	indicates	indicate	VERB
fnp-6762	89	25	that	that	SCONJ
fnp-6762	89	26	disease	disease	NOUN
fnp-6762	89	27	processes	process	NOUN
fnp-6762	89	28	begin	begin	VERB
fnp-6762	89	29	well	well	ADV
fnp-6762	89	30	before	before	SCONJ
fnp-6762	89	31	symptoms	symptom	NOUN
fnp-6762	89	32	emerge	emerge	VERB
fnp-6762	89	33	.	.	PUNCT
fnp-6762	90	1	mri	mri	NOUN
fnp-6762	90	2	studies	study	NOUN
fnp-6762	90	3	have	have	AUX
fnp-6762	90	4	shown	show	VERB
fnp-6762	90	5	that	that	SCONJ
fnp-6762	90	6	asymptomatic	asymptomatic	ADJ
fnp-6762	90	7	individuals	individual	NOUN
fnp-6762	90	8	can	can	AUX
fnp-6762	90	9	have	have	VERB
fnp-6762	90	10	lesions	lesion	NOUN
fnp-6762	90	11	suggestive	suggestive	ADJ
fnp-6762	90	12	of	of	ADP
fnp-6762	90	13	inflammatory	inflammatory	ADJ
fnp-6762	90	14	demyelination	demyelination	NOUN
fnp-6762	90	15	,	,	PUNCT
fnp-6762	90	16	with	with	ADP
fnp-6762	90	17	some	some	DET
fnp-6762	90	18	later	later	ADV
fnp-6762	90	19	developing	develop	VERB
fnp-6762	90	20	clinical	clinical	ADJ
fnp-6762	90	21	ms	ms	NOUN
fnp-6762	90	22	–	–	PUNCT
fnp-6762	90	23	a	a	DET
fnp-6762	90	24	condition	condition	NOUN
fnp-6762	90	25	termed	term	VERB
fnp-6762	90	26	radiologically	radiologically	ADV
fnp-6762	90	27	isolated	isolate	VERB
fnp-6762	90	28	syndrome	syndrome	NOUN
fnp-6762	90	29	(	(	PUNCT
fnp-6762	90	30	ris	ris	PROPN
fnp-6762	90	31	)	)	PUNCT
fnp-6762	90	32	,	,	PUNCT
fnp-6762	90	33	first	first	ADV
fnp-6762	90	34	described	describe	VERB
fnp-6762	90	35	by	by	ADP
fnp-6762	90	36	okuda	okuda	NOUN
fnp-6762	90	37	et	et	PROPN
fnp-6762	90	38	al	al	PROPN
fnp-6762	90	39	.	.	PROPN
fnp-6762	91	1	in	in	ADP
fnp-6762	91	2	200928	200928	NUM
fnp-6762	91	3	.	.	PUNCT
fnp-6762	92	1	ris	ris	PROPN
fnp-6762	92	2	is	be	AUX
fnp-6762	92	3	a	a	DET
fnp-6762	92	4	condition	condition	NOUN
fnp-6762	92	5	in	in	ADP
fnp-6762	92	6	which	which	PRON
fnp-6762	92	7	asymptomatic	asymptomatic	ADJ
fnp-6762	92	8	individuals	individual	NOUN
fnp-6762	92	9	exhibit	exhibit	VERB
fnp-6762	92	10	mri	mri	NOUN
fnp-6762	92	11	lesions	lesion	NOUN
fnp-6762	92	12	in	in	ADP
fnp-6762	92	13	characteristic	characteristic	ADJ
fnp-6762	92	14	locations	location	NOUN
fnp-6762	92	15	that	that	PRON
fnp-6762	92	16	are	be	AUX
fnp-6762	92	17	highly	highly	ADV
fnp-6762	92	18	suggestive	suggestive	ADJ
fnp-6762	92	19	for	for	ADP
fnp-6762	92	20	ms	ms	PROPN
fnp-6762	92	21	.	.	PROPN
fnp-6762	92	22	in	in	ADP
fnp-6762	92	23	2023	2023	NUM
fnp-6762	92	24	,	,	PUNCT
fnp-6762	92	25	the	the	DET
fnp-6762	92	26	ris	ris	PROPN
fnp-6762	92	27	consortium	consortium	PROPN
fnp-6762	92	28	refined	refine	VERB
fnp-6762	92	29	the	the	DET
fnp-6762	92	30	diagnostic	diagnostic	ADJ
fnp-6762	92	31	criteria	criterion	NOUN
fnp-6762	92	32	for	for	ADP
fnp-6762	92	33	ris	ris	PROPN
fnp-6762	92	34	:	:	PUNCT
fnp-6762	92	35	individuals	individual	NOUN
fnp-6762	92	36	with	with	ADP
fnp-6762	92	37	lesions	lesion	NOUN
fnp-6762	92	38	in	in	ADP
fnp-6762	92	39	at	at	ADV
fnp-6762	92	40	least	least	ADV
fnp-6762	92	41	three	three	NUM
fnp-6762	92	42	key	key	ADJ
fnp-6762	92	43	cns	cns	NOUN
fnp-6762	92	44	locations	location	NOUN
fnp-6762	92	45	(	(	PUNCT
fnp-6762	92	46	periventricular	periventricular	ADJ
fnp-6762	92	47	,	,	PUNCT
fnp-6762	92	48	juxtacortical	juxtacortical	ADJ
fnp-6762	92	49	,	,	PUNCT
fnp-6762	92	50	infratentorial	infratentorial	ADJ
fnp-6762	92	51	,	,	PUNCT
fnp-6762	92	52	or	or	CCONJ
fnp-6762	92	53	spinal	spinal	ADJ
fnp-6762	92	54	cord	cord	NOUN
fnp-6762	92	55	)	)	PUNCT
fnp-6762	92	56	fulfill	fulfill	NOUN
fnp-6762	92	57	ris	ris	PROPN
fnp-6762	92	58	imaging	image	VERB
fnp-6762	92	59	criteria.29	criteria.29	PROPN
fnp-6762	92	60	alternatively	alternatively	ADV
fnp-6762	92	61	,	,	PUNCT
fnp-6762	92	62	those	those	PRON
fnp-6762	92	63	having	have	VERB
fnp-6762	92	64	lesions	lesion	NOUN
fnp-6762	92	65	in	in	ADP
fnp-6762	92	66	only	only	ADV
fnp-6762	92	67	one	one	NUM
fnp-6762	92	68	or	or	CCONJ
fnp-6762	92	69	two	two	NUM
fnp-6762	92	70	of	of	ADP
fnp-6762	92	71	these	these	DET
fnp-6762	92	72	areas	area	NOUN
fnp-6762	92	73	but	but	CCONJ
fnp-6762	92	74	additionally	additionally	ADV
fnp-6762	92	75	exhibiting	exhibit	VERB
fnp-6762	92	76	with	with	ADP
fnp-6762	92	77	two	two	NUM
fnp-6762	92	78	of	of	ADP
fnp-6762	92	79	the	the	DET
fnp-6762	92	80	following	follow	VERB
fnp-6762	92	81	criteria	criterion	NOUN
fnp-6762	92	82	–	–	PUNCT
fnp-6762	92	83	spinal	spinal	ADJ
fnp-6762	92	84	cord	cord	NOUN
fnp-6762	92	85	lesion	lesion	NOUN
fnp-6762	92	86	,	,	PUNCT
fnp-6762	92	87	csf	csf	NOUN
fnp-6762	92	88	-	-	PUNCT
fnp-6762	92	89	restricted	restricted	ADJ
fnp-6762	92	90	oligoclonal	oligoclonal	ADJ
fnp-6762	92	91	bands	band	NOUN
fnp-6762	92	92	,	,	PUNCT
fnp-6762	92	93	or	or	CCONJ
fnp-6762	92	94	new	new	ADJ
fnp-6762	92	95	demyelinating	demyelinate	VERB
fnp-6762	92	96	lesions	lesion	NOUN
fnp-6762	92	97	on	on	ADP
fnp-6762	92	98	follow	follow	NOUN
fnp-6762	92	99	-	-	PUNCT
fnp-6762	92	100	up	up	ADP
fnp-6762	92	101	mri	mri	NOUN
fnp-6762	92	102	–	–	PUNCT
fnp-6762	92	103	fulfill	fulfill	VERB
fnp-6762	92	104	the	the	DET
fnp-6762	92	105	ris	ris	PROPN
fnp-6762	92	106	definition	definition	NOUN
fnp-6762	92	107	.	.	PUNCT
fnp-6762	93	1	this	this	DET
fnp-6762	93	2	revision	revision	NOUN
fnp-6762	93	3	improves	improve	VERB
fnp-6762	93	4	prognostic	prognostic	ADJ
fnp-6762	93	5	stratification	stratification	NOUN
fnp-6762	93	6	,	,	PUNCT
fnp-6762	93	7	as	as	SCONJ
fnp-6762	93	8	studies	study	NOUN
fnp-6762	93	9	report	report	VERB
fnp-6762	93	10	conversion	conversion	NOUN
fnp-6762	93	11	rates	rate	NOUN
fnp-6762	93	12	to	to	ADP
fnp-6762	93	13	clinical	clinical	ADJ
fnp-6762	93	14	ms	ms	NOUN
fnp-6762	93	15	of	of	ADP
fnp-6762	93	16	34	34	NUM
fnp-6762	93	17	 	 	SPACE
fnp-6762	93	18	%	%	NOUN
fnp-6762	93	19	at	at	ADP
fnp-6762	93	20	five	five	NUM
fnp-6762	93	21	years	year	NOUN
fnp-6762	93	22	and	and	CCONJ
fnp-6762	93	23	51	51	NUM
fnp-6762	93	24	 	 	SPACE
fnp-6762	93	25	%	%	NOUN
fnp-6762	93	26	at	at	ADP
fnp-6762	93	27	ten	ten	NUM
fnp-6762	93	28	years	year	NOUN
fnp-6762	93	29	.	.	PUNCT
fnp-6762	94	1	additional	additional	ADJ
fnp-6762	94	2	risk	risk	NOUN
fnp-6762	94	3	factors	factor	NOUN
fnp-6762	94	4	for	for	ADP
fnp-6762	94	5	conversion	conversion	NOUN
fnp-6762	94	6	into	into	ADP
fnp-6762	94	7	ms	ms	NOUN
fnp-6762	94	8	include	include	VERB
fnp-6762	94	9	younger	young	ADJ
fnp-6762	94	10	age	age	NOUN
fnp-6762	94	11	(	(	PUNCT
fnp-6762	94	12	30	30	NUM
fnp-6762	94	13	based	base	VERB
fnp-6762	94	14	on	on	ADP
fnp-6762	94	15	these	these	DET
fnp-6762	94	16	considerations	consideration	NOUN
fnp-6762	94	17	,	,	PUNCT
fnp-6762	94	18	some	some	DET
fnp-6762	94	19	ris	ris	PROPN
fnp-6762	94	20	constellations	constellation	NOUN
fnp-6762	94	21	now	now	ADV
fnp-6762	94	22	fulfill	fulfill	VERB
fnp-6762	94	23	the	the	DET
fnp-6762	94	24	new	new	ADJ
fnp-6762	94	25	diagnostic	diagnostic	ADJ
fnp-6762	94	26	criteria	criterion	NOUN
fnp-6762	94	27	of	of	ADP
fnp-6762	94	28	ms	ms	PROPN
fnp-6762	94	29	,	,	PUNCT
fnp-6762	94	30	which	which	PRON
fnp-6762	94	31	are	be	AUX
fnp-6762	94	32	discussed	discuss	VERB
fnp-6762	94	33	below	below	ADV
fnp-6762	94	34	,	,	PUNCT
fnp-6762	94	35	which	which	PRON
fnp-6762	94	36	illustrates	illustrate	VERB
fnp-6762	94	37	that	that	SCONJ
fnp-6762	94	38	biological	biological	NOUN
fnp-6762	94	39	rather	rather	ADV
fnp-6762	94	40	than	than	ADP
fnp-6762	94	41	purely	purely	ADV
fnp-6762	94	42	clinical	clinical	ADJ
fnp-6762	94	43	considerations	consideration	NOUN
fnp-6762	94	44	are	be	AUX
fnp-6762	94	45	now	now	ADV
fnp-6762	94	46	implemented	implement	VERB
fnp-6762	94	47	in	in	ADP
fnp-6762	94	48	our	our	PRON
fnp-6762	94	49	current	current	ADJ
fnp-6762	94	50	concept	concept	NOUN
fnp-6762	94	51	of	of	ADP
fnp-6762	94	52	ms	ms	ADJ
fnp-6762	94	53	diagnosis	diagnosis	NOUN
fnp-6762	94	54	.	.	PUNCT
fnp-6762	95	1	beyond	beyond	ADP
fnp-6762	95	2	imaging	imaging	NOUN
fnp-6762	95	3	,	,	PUNCT
fnp-6762	95	4	a	a	DET
fnp-6762	95	5	range	range	NOUN
fnp-6762	95	6	of	of	ADP
fnp-6762	95	7	nonspecific	nonspecific	ADJ
fnp-6762	95	8	clinical	clinical	ADJ
fnp-6762	95	9	symptoms	symptom	NOUN
fnp-6762	95	10	–	–	PUNCT
fnp-6762	95	11	including	include	VERB
fnp-6762	95	12	depression	depression	NOUN
fnp-6762	95	13	,	,	PUNCT
fnp-6762	95	14	anxiety	anxiety	NOUN
fnp-6762	95	15	,	,	PUNCT
fnp-6762	95	16	fatigue	fatigue	NOUN
fnp-6762	95	17	,	,	PUNCT
fnp-6762	95	18	sleep	sleep	NOUN
fnp-6762	95	19	disturbances	disturbance	NOUN
fnp-6762	95	20	,	,	PUNCT
fnp-6762	95	21	and	and	CCONJ
fnp-6762	95	22	headache	headache	NOUN
fnp-6762	95	23	–	–	PUNCT
fnp-6762	95	24	have	have	AUX
fnp-6762	95	25	been	be	AUX
fnp-6762	95	26	identified	identify	VERB
fnp-6762	95	27	as	as	ADP
fnp-6762	95	28	part	part	NOUN
fnp-6762	95	29	of	of	ADP
fnp-6762	95	30	the	the	DET
fnp-6762	95	31	so	so	ADV
fnp-6762	95	32	-	-	PUNCT
fnp-6762	95	33	called	call	VERB
fnp-6762	95	34	ms	ms	PROPN
fnp-6762	95	35	prodrome31	prodrome31	NOUN
fnp-6762	95	36	.	.	PUNCT
fnp-6762	96	1	recently	recently	ADV
fnp-6762	96	2	,	,	PUNCT
fnp-6762	96	3	studies	study	NOUN
fnp-6762	96	4	in	in	ADP
fnp-6762	96	5	both	both	DET
fnp-6762	96	6	children	child	NOUN
fnp-6762	96	7	and	and	CCONJ
fnp-6762	96	8	adults	adult	NOUN
fnp-6762	96	9	confirm	confirm	VERB
fnp-6762	96	10	that	that	SCONJ
fnp-6762	96	11	these	these	DET
fnp-6762	96	12	early	early	ADJ
fnp-6762	96	13	signs	sign	NOUN
fnp-6762	96	14	,	,	PUNCT
fnp-6762	96	15	along	along	ADP
fnp-6762	96	16	with	with	ADP
fnp-6762	96	17	elevated	elevated	ADJ
fnp-6762	96	18	serum	serum	NOUN
fnp-6762	96	19	neurofilament	neurofilament	PROPN
fnp-6762	96	20	light	light	ADJ
fnp-6762	96	21	chain	chain	NOUN
fnp-6762	96	22	levels	level	NOUN
fnp-6762	96	23	up	up	ADP
fnp-6762	96	24	to	to	PART
fnp-6762	96	25	nine	nine	NUM
fnp-6762	96	26	years	year	NOUN
fnp-6762	96	27	before	before	ADP
fnp-6762	96	28	clinical	clinical	ADJ
fnp-6762	96	29	onset	onset	NOUN
fnp-6762	96	30	,	,	PUNCT
fnp-6762	96	31	support	support	VERB
fnp-6762	96	32	the	the	DET
fnp-6762	96	33	concept	concept	NOUN
fnp-6762	96	34	that	that	SCONJ
fnp-6762	96	35	ms	ms	PROPN
fnp-6762	96	36	pathophysiology	pathophysiology	NOUN
fnp-6762	96	37	initiates	initiate	VERB
fnp-6762	96	38	long	long	ADV
fnp-6762	96	39	before	before	ADP
fnp-6762	96	40	overt	overt	ADJ
fnp-6762	96	41	clinical	clinical	ADJ
fnp-6762	96	42	symptoms32–34	symptoms32–34	PROPN
fnp-6762	96	43	.	.	PUNCT
fnp-6762	97	1	however	however	ADV
fnp-6762	97	2	,	,	PUNCT
fnp-6762	97	3	due	due	ADP
fnp-6762	97	4	to	to	ADP
fnp-6762	97	5	the	the	DET
fnp-6762	97	6	unspecific	unspecific	ADJ
fnp-6762	97	7	nature	nature	NOUN
fnp-6762	97	8	of	of	ADP
fnp-6762	97	9	these	these	DET
fnp-6762	97	10	symptoms	symptom	NOUN
fnp-6762	97	11	and	and	CCONJ
fnp-6762	97	12	a	a	DET
fnp-6762	97	13	high	high	ADJ
fnp-6762	97	14	overlap	overlap	NOUN
fnp-6762	97	15	with	with	ADP
fnp-6762	97	16	other	other	ADJ
fnp-6762	97	17	immune	immune	NOUN
fnp-6762	97	18	-	-	PUNCT
fnp-6762	97	19	mediated	mediate	VERB
fnp-6762	97	20	diseases	disease	NOUN
fnp-6762	97	21	,	,	PUNCT
fnp-6762	97	22	it	it	PRON
fnp-6762	97	23	is	be	AUX
fnp-6762	97	24	currently	currently	ADV
fnp-6762	97	25	not	not	PART
fnp-6762	97	26	possible	possible	ADJ
fnp-6762	97	27	to	to	PART
fnp-6762	97	28	provide	provide	VERB
fnp-6762	97	29	a	a	DET
fnp-6762	97	30	clear	clear	ADJ
fnp-6762	97	31	ms	ms	NOUN
fnp-6762	97	32	prodrome	prodrome	NOUN
fnp-6762	97	33	definition	definition	NOUN
fnp-6762	97	34	that	that	PRON
fnp-6762	97	35	may	may	AUX
fnp-6762	97	36	guide	guide	VERB
fnp-6762	97	37	further	far	ADV
fnp-6762	97	38	diagnostic	diagnostic	ADJ
fnp-6762	97	39	workup	workup	NOUN
fnp-6762	97	40	to	to	PART
fnp-6762	97	41	facilitate	facilitate	VERB
fnp-6762	97	42	early	early	ADV
fnp-6762	97	43	ms	ms	ADJ
fnp-6762	97	44	diagnosis	diagnosis	NOUN
fnp-6762	97	45	.	.	PUNCT
fnp-6762	98	1	new	new	ADJ
fnp-6762	98	2	diagnostic	diagnostic	ADJ
fnp-6762	98	3	framework	framework	NOUN
fnp-6762	98	4	of	of	ADP
fnp-6762	98	5	ms	ms	ADJ
fnp-6762	98	6	diagnosis	diagnosis	NOUN
fnp-6762	98	7	of	of	ADP
fnp-6762	98	8	ms	ms	NOUN
fnp-6762	98	9	–	–	PUNCT
fnp-6762	98	10	the	the	DET
fnp-6762	98	11	2024	2024	NUM
fnp-6762	98	12	update	update	NOUN
fnp-6762	98	13	of	of	ADP
fnp-6762	98	14	the	the	DET
fnp-6762	98	15	mcdonald	mcdonald	PROPN
fnp-6762	98	16	criteria	criterion	NOUN
fnp-6762	98	17	diagnosing	diagnose	VERB
fnp-6762	98	18	multiple	multiple	ADJ
fnp-6762	98	19	sclerosis	sclerosis	NOUN
fnp-6762	98	20	requires	require	VERB
fnp-6762	98	21	balancing	balance	VERB
fnp-6762	98	22	early	early	ADJ
fnp-6762	98	23	detection	detection	NOUN
fnp-6762	98	24	with	with	ADP
fnp-6762	98	25	minimizing	minimize	VERB
fnp-6762	98	26	misdiagnosis	misdiagnosis	NOUN
fnp-6762	98	27	.	.	PUNCT
fnp-6762	99	1	over	over	ADP
fnp-6762	99	2	two	two	NUM
fnp-6762	99	3	decades	decade	NOUN
fnp-6762	99	4	,	,	PUNCT
fnp-6762	99	5	diagnostic	diagnostic	ADJ
fnp-6762	99	6	criteria	criterion	NOUN
fnp-6762	99	7	have	have	AUX
fnp-6762	99	8	evolved	evolve	VERB
fnp-6762	99	9	with	with	ADP
fnp-6762	99	10	mri	mri	NOUN
fnp-6762	99	11	and	and	CCONJ
fnp-6762	99	12	csf	csf	ADJ
fnp-6762	99	13	biomarkers	biomarker	NOUN
fnp-6762	99	14	,	,	PUNCT
fnp-6762	99	15	enabling	enable	VERB
fnp-6762	99	16	earlier	early	ADV
fnp-6762	99	17	and	and	CCONJ
fnp-6762	99	18	more	more	ADV
fnp-6762	99	19	accurate	accurate	ADJ
fnp-6762	99	20	diagnosis	diagnosis	NOUN
fnp-6762	99	21	.	.	PUNCT
fnp-6762	100	1	after	after	ADP
fnp-6762	100	2	the	the	DET
fnp-6762	100	3	last	last	ADJ
fnp-6762	100	4	revision	revision	NOUN
fnp-6762	100	5	of	of	ADP
fnp-6762	100	6	diagnostic	diagnostic	ADJ
fnp-6762	100	7	criteria	criterion	NOUN
fnp-6762	100	8	in	in	ADP
fnp-6762	100	9	201735	201735	NUM
fnp-6762	100	10	,	,	PUNCT
fnp-6762	100	11	another	another	DET
fnp-6762	100	12	update	update	NOUN
fnp-6762	100	13	has	have	AUX
fnp-6762	100	14	been	be	AUX
fnp-6762	100	15	proposed	propose	VERB
fnp-6762	100	16	in	in	ADP
fnp-6762	100	17	2024	2024	NUM
fnp-6762	100	18	.	.	PUNCT
fnp-6762	101	1	this	this	DET
fnp-6762	101	2	update	update	NOUN
fnp-6762	101	3	is	be	AUX
fnp-6762	101	4	based	base	VERB
fnp-6762	101	5	on	on	ADP
fnp-6762	101	6	novel	novel	ADJ
fnp-6762	101	7	data	datum	NOUN
fnp-6762	101	8	highlighting	highlight	VERB
fnp-6762	101	9	the	the	DET
fnp-6762	101	10	role	role	NOUN
fnp-6762	101	11	of	of	ADP
fnp-6762	101	12	the	the	DET
fnp-6762	101	13	optic	optic	NOUN
fnp-6762	101	14	nerve	nerve	NOUN
fnp-6762	101	15	,	,	PUNCT
fnp-6762	101	16	the	the	DET
fnp-6762	101	17	relevance	relevance	NOUN
fnp-6762	101	18	of	of	ADP
fnp-6762	101	19	ris	ris	PROPN
fnp-6762	101	20	,	,	PUNCT
fnp-6762	101	21	the	the	DET
fnp-6762	101	22	necessity	necessity	NOUN
fnp-6762	101	23	to	to	PART
fnp-6762	101	24	differentiate	differentiate	VERB
fnp-6762	101	25	ms	ms	NOUN
fnp-6762	101	26	from	from	ADP
fnp-6762	101	27	other	other	ADJ
fnp-6762	101	28	autoimmune	autoimmune	ADJ
fnp-6762	101	29	conditions	condition	NOUN
fnp-6762	101	30	like	like	ADP
fnp-6762	101	31	nmosd	nmosd	ADV
fnp-6762	101	32	and	and	CCONJ
fnp-6762	101	33	mogad	mogad	NOUN
fnp-6762	101	34	,	,	PUNCT
fnp-6762	101	35	acknowledgement	acknowledgement	NOUN
fnp-6762	101	36	of	of	ADP
fnp-6762	101	37	the	the	DET
fnp-6762	101	38	concept	concept	NOUN
fnp-6762	101	39	that	that	SCONJ
fnp-6762	101	40	disease	disease	NOUN
fnp-6762	101	41	progression	progression	NOUN
fnp-6762	101	42	is	be	AUX
fnp-6762	101	43	a	a	DET
fnp-6762	101	44	key	key	ADJ
fnp-6762	101	45	feature	feature	NOUN
fnp-6762	101	46	of	of	ADP
fnp-6762	101	47	relapsing	relapse	VERB
fnp-6762	101	48	ms	ms	NOUN
fnp-6762	101	49	,	,	PUNCT
fnp-6762	101	50	and	and	CCONJ
fnp-6762	101	51	finally	finally	ADV
fnp-6762	101	52	,	,	PUNCT
fnp-6762	101	53	the	the	DET
fnp-6762	101	54	diagnostic	diagnostic	ADJ
fnp-6762	101	55	challenge	challenge	NOUN
fnp-6762	101	56	of	of	ADP
fnp-6762	101	57	ms	ms	NOUN
fnp-6762	101	58	in	in	ADP
fnp-6762	101	59	older	old	ADJ
fnp-6762	101	60	individuals	individual	NOUN
fnp-6762	101	61	and	and	CCONJ
fnp-6762	101	62	those	those	PRON
fnp-6762	101	63	with	with	ADP
fnp-6762	101	64	comorbidities	comorbiditie	NOUN
fnp-6762	101	65	.	.	PUNCT
fnp-6762	102	1	based	base	VERB
fnp-6762	102	2	on	on	ADP
fnp-6762	102	3	these	these	DET
fnp-6762	102	4	emerging	emerge	VERB
fnp-6762	102	5	concepts	concept	NOUN
fnp-6762	102	6	,	,	PUNCT
fnp-6762	102	7	the	the	DET
fnp-6762	102	8	following	follow	VERB
fnp-6762	102	9	changes	change	NOUN
fnp-6762	102	10	have	have	AUX
fnp-6762	102	11	been	be	AUX
fnp-6762	102	12	presented	present	VERB
fnp-6762	102	13	at	at	ADP
fnp-6762	102	14	the	the	DET
fnp-6762	102	15	ectrims	ectrims	ADJ
fnp-6762	102	16	congress	congress	PROPN
fnp-6762	102	17	in	in	ADP
fnp-6762	102	18	2024	2024	NUM
fnp-6762	102	19	by	by	ADP
fnp-6762	102	20	x.	x.	PROPN
fnp-6762	102	21	montalban	montalban	PROPN
fnp-6762	102	22	on	on	ADP
fnp-6762	102	23	behalf	behalf	NOUN
fnp-6762	102	24	of	of	ADP
fnp-6762	102	25	the	the	DET
fnp-6762	102	26	international	international	ADJ
fnp-6762	102	27	advisory	advisory	ADJ
fnp-6762	102	28	committee	committee	NOUN
fnp-6762	102	29	on	on	ADP
fnp-6762	102	30	clinical	clinical	ADJ
fnp-6762	102	31	trials	trial	NOUN
fnp-6762	102	32	in	in	ADP
fnp-6762	102	33	ms36,37	ms36,37	ADV
fnp-6762	102	34	,	,	PUNCT
fnp-6762	102	35	however	however	ADV
fnp-6762	102	36	the	the	DET
fnp-6762	102	37	diagnostic	diagnostic	ADJ
fnp-6762	102	38	criteria	criterion	NOUN
fnp-6762	102	39	have	have	AUX
fnp-6762	102	40	not	not	PART
fnp-6762	102	41	been	be	AUX
fnp-6762	102	42	published	publish	VERB
fnp-6762	102	43	yet	yet	ADV
fnp-6762	102	44	.	.	PUNCT
fnp-6762	103	1	first	first	ADV
fnp-6762	103	2	,	,	PUNCT
fnp-6762	103	3	the	the	DET
fnp-6762	103	4	optic	optic	ADJ
fnp-6762	103	5	nerve	nerve	NOUN
fnp-6762	103	6	is	be	AUX
fnp-6762	103	7	now	now	ADV
fnp-6762	103	8	included	include	VERB
fnp-6762	103	9	as	as	ADP
fnp-6762	103	10	a	a	DET
fnp-6762	103	11	diagnostic	diagnostic	ADJ
fnp-6762	103	12	region	region	NOUN
fnp-6762	103	13	providing	provide	VERB
fnp-6762	103	14	evidence	evidence	NOUN
fnp-6762	103	15	for	for	ADP
fnp-6762	103	16	the	the	DET
fnp-6762	103	17	dissemination	dissemination	NOUN
fnp-6762	103	18	in	in	ADP
fnp-6762	103	19	space	space	NOUN
fnp-6762	103	20	(	(	PUNCT
fnp-6762	103	21	dis	dis	PROPN
fnp-6762	103	22	)	)	PUNCT
fnp-6762	103	23	,	,	PUNCT
fnp-6762	103	24	and	and	CCONJ
fnp-6762	103	25	besides	besides	SCONJ
fnp-6762	103	26	clinical	clinical	ADJ
fnp-6762	103	27	manifestation	manifestation	NOUN
fnp-6762	103	28	as	as	ADP
fnp-6762	103	29	optic	optic	ADJ
fnp-6762	103	30	neuritis	neuritis	NOUN
fnp-6762	103	31	,	,	PUNCT
fnp-6762	103	32	optic	optic	ADJ
fnp-6762	103	33	nerve	nerve	NOUN
fnp-6762	103	34	involvement	involvement	NOUN
fnp-6762	103	35	can	can	AUX
fnp-6762	103	36	be	be	AUX
fnp-6762	103	37	illustrated	illustrate	VERB
fnp-6762	103	38	by	by	ADP
fnp-6762	103	39	optical	optical	ADJ
fnp-6762	103	40	coherence	coherence	NOUN
fnp-6762	103	41	tomography	tomography	NOUN
fnp-6762	103	42	,	,	PUNCT
fnp-6762	103	43	visual	visual	ADJ
fnp-6762	103	44	evoked	evoke	VERB
fnp-6762	103	45	potential	potential	NOUN
fnp-6762	103	46	and	and	CCONJ
fnp-6762	103	47	mri	mri	NOUN
fnp-6762	103	48	.	.	PUNCT
fnp-6762	104	1	second	second	ADJ
fnp-6762	104	2	,	,	PUNCT
fnp-6762	104	3	ms	ms	ADJ
fnp-6762	104	4	diagnosis	diagnosis	NOUN
fnp-6762	104	5	requires	require	VERB
fnp-6762	104	6	documentation	documentation	NOUN
fnp-6762	104	7	of	of	ADP
fnp-6762	104	8	dis	dis	PROPN
fnp-6762	104	9	in	in	ADP
fnp-6762	104	10	at	at	ADV
fnp-6762	104	11	least	least	ADV
fnp-6762	104	12	two	two	NUM
fnp-6762	104	13	of	of	ADP
fnp-6762	104	14	five	five	NUM
fnp-6762	104	15	cns	cns	NOUN
fnp-6762	104	16	regions	region	NOUN
fnp-6762	104	17	(	(	PUNCT
fnp-6762	104	18	optic	optic	NOUN
fnp-6762	104	19	nerve	nerve	NOUN
fnp-6762	104	20	,	,	PUNCT
fnp-6762	104	21	cortical	cortical	ADJ
fnp-6762	104	22	/	/	SYM
fnp-6762	104	23	juxtacortical	juxtacortical	ADJ
fnp-6762	104	24	,	,	PUNCT
fnp-6762	104	25	periventricular	periventricular	ADJ
fnp-6762	104	26	,	,	PUNCT
fnp-6762	104	27	infratentorial	infratentorial	ADJ
fnp-6762	104	28	,	,	PUNCT
fnp-6762	104	29	spinal	spinal	ADJ
fnp-6762	104	30	cord	cord	NOUN
fnp-6762	104	31	)	)	PUNCT
fnp-6762	104	32	,	,	PUNCT
fnp-6762	104	33	if	if	SCONJ
fnp-6762	104	34	this	this	PRON
fnp-6762	104	35	is	be	AUX
fnp-6762	104	36	supplemented	supplement	VERB
fnp-6762	104	37	with	with	ADP
fnp-6762	104	38	either	either	DET
fnp-6762	104	39	dissemination	dissemination	NOUN
fnp-6762	104	40	in	in	ADP
fnp-6762	104	41	time	time	NOUN
fnp-6762	104	42	,	,	PUNCT
fnp-6762	104	43	or	or	CCONJ
fnp-6762	104	44	detection	detection	NOUN
fnp-6762	104	45	of	of	ADP
fnp-6762	104	46	oligoclonal	oligoclonal	ADJ
fnp-6762	104	47	bands	band	NOUN
fnp-6762	104	48	or	or	CCONJ
fnp-6762	104	49	kappa	kappa	ADJ
fnp-6762	104	50	free	free	ADJ
fnp-6762	104	51	light	light	ADJ
fnp-6762	104	52	chains	chain	NOUN
fnp-6762	104	53	in	in	ADP
fnp-6762	104	54	the	the	DET
fnp-6762	104	55	csf	csf	PROPN
fnp-6762	104	56	.	.	PROPN
fnp-6762	105	1	notably	notably	ADV
fnp-6762	105	2	,	,	PUNCT
fnp-6762	105	3	the	the	DET
fnp-6762	105	4	dissemination	dissemination	NOUN
fnp-6762	105	5	in	in	ADP
fnp-6762	105	6	time	time	NOUN
fnp-6762	105	7	(	(	PUNCT
fnp-6762	105	8	dit	dit	NOUN
fnp-6762	105	9	)	)	PUNCT
fnp-6762	105	10	is	be	AUX
fnp-6762	105	11	no	no	PRON
fnp-6762	105	12	longer	long	ADV
fnp-6762	105	13	mandatory	mandatory	ADJ
fnp-6762	105	14	for	for	ADP
fnp-6762	105	15	diagnosis	diagnosis	NOUN
fnp-6762	105	16	,	,	PUNCT
fnp-6762	105	17	as	as	SCONJ
fnp-6762	105	18	this	this	PRON
fnp-6762	105	19	is	be	AUX
fnp-6762	105	20	not	not	PART
fnp-6762	105	21	exclusive	exclusive	ADJ
fnp-6762	105	22	to	to	ADP
fnp-6762	105	23	ms	ms	NOUN
fnp-6762	105	24	and	and	CCONJ
fnp-6762	105	25	imaging	imaging	NOUN
fnp-6762	105	26	variability	variability	NOUN
fnp-6762	105	27	can	can	AUX
fnp-6762	105	28	affect	affect	VERB
fnp-6762	105	29	its	its	PRON
fnp-6762	105	30	interpretation	interpretation	NOUN
fnp-6762	105	31	.	.	PUNCT
fnp-6762	106	1	with	with	ADP
fnp-6762	106	2	regard	regard	NOUN
fnp-6762	106	3	to	to	ADP
fnp-6762	106	4	imaging	imaging	NOUN
fnp-6762	106	5	,	,	PUNCT
fnp-6762	106	6	two	two	NUM
fnp-6762	106	7	new	new	ADJ
fnp-6762	106	8	imaging	imaging	NOUN
fnp-6762	106	9	criteria	criterion	NOUN
fnp-6762	106	10	have	have	AUX
fnp-6762	106	11	newly	newly	ADV
fnp-6762	106	12	been	be	AUX
fnp-6762	106	13	implemented	implement	VERB
fnp-6762	106	14	that	that	PRON
fnp-6762	106	15	are	be	AUX
fnp-6762	106	16	not	not	PART
fnp-6762	106	17	mandatory	mandatory	ADJ
fnp-6762	106	18	but	but	CCONJ
fnp-6762	106	19	may	may	AUX
fnp-6762	106	20	facilitate	facilitate	VERB
fnp-6762	106	21	diagnosis	diagnosis	NOUN
fnp-6762	106	22	based	base	VERB
fnp-6762	106	23	on	on	ADP
fnp-6762	106	24	their	their	PRON
fnp-6762	106	25	high	high	ADJ
fnp-6762	106	26	specificity	specificity	NOUN
fnp-6762	106	27	for	for	ADP
fnp-6762	106	28	ms	ms	NOUN
fnp-6762	106	29	:	:	PUNCT
fnp-6762	106	30	the	the	DET
fnp-6762	106	31	central	central	ADJ
fnp-6762	106	32	vein	vein	ADJ
fnp-6762	106	33	sign	sign	NOUN
fnp-6762	106	34	(	(	PUNCT
fnp-6762	106	35	cvs	cvs	PROPN
fnp-6762	106	36	)	)	PUNCT
fnp-6762	106	37	,	,	PUNCT
fnp-6762	106	38	caused	cause	VERB
fnp-6762	106	39	by	by	ADP
fnp-6762	106	40	inflammatory	inflammatory	ADJ
fnp-6762	106	41	lesions	lesion	NOUN
fnp-6762	106	42	forming	form	VERB
fnp-6762	106	43	around	around	ADP
fnp-6762	106	44	central	central	ADJ
fnp-6762	106	45	veins	vein	NOUN
fnp-6762	106	46	,	,	PUNCT
fnp-6762	106	47	can	can	AUX
fnp-6762	106	48	be	be	AUX
fnp-6762	106	49	visualized	visualize	VERB
fnp-6762	106	50	by	by	ADP
fnp-6762	106	51	t2	t2	PROPN
fnp-6762	106	52	*	*	PUNCT
fnp-6762	106	53	mr	mr	PROPN
fnp-6762	106	54	imaging	imaging	PROPN
fnp-6762	106	55	,	,	PUNCT
fnp-6762	106	56	and	and	CCONJ
fnp-6762	106	57	detection	detection	NOUN
fnp-6762	106	58	of	of	ADP
fnp-6762	106	59	at	at	ADV
fnp-6762	106	60	least	least	ADV
fnp-6762	106	61	6	6	NUM
fnp-6762	106	62	cvs	cvs	NOUN
fnp-6762	106	63	can	can	AUX
fnp-6762	106	64	confirm	confirm	VERB
fnp-6762	106	65	ms	ms	NOUN
fnp-6762	106	66	in	in	ADP
fnp-6762	106	67	a	a	DET
fnp-6762	106	68	situation	situation	NOUN
fnp-6762	106	69	when	when	SCONJ
fnp-6762	106	70	only	only	ADV
fnp-6762	106	71	two	two	NUM
fnp-6762	106	72	topographies	topography	NOUN
fnp-6762	106	73	are	be	AUX
fnp-6762	106	74	affected38	affected38	NOUN
fnp-6762	106	75	.	.	PUNCT
fnp-6762	107	1	paramagnetic	paramagnetic	ADJ
fnp-6762	107	2	rim	rim	PROPN
fnp-6762	107	3	lesions	lesion	NOUN
fnp-6762	107	4	(	(	PUNCT
fnp-6762	107	5	prl	prl	X
fnp-6762	107	6	)	)	PUNCT
fnp-6762	107	7	indicate	indicate	VERB
fnp-6762	107	8	chronic	chronic	ADJ
fnp-6762	107	9	active	active	ADJ
fnp-6762	107	10	ms	ms	NOUN
fnp-6762	107	11	lesions	lesion	NOUN
fnp-6762	107	12	and	and	CCONJ
fnp-6762	107	13	can	can	AUX
fnp-6762	107	14	be	be	AUX
fnp-6762	107	15	detected	detect	VERB
fnp-6762	107	16	by	by	ADP
fnp-6762	107	17	susceptibility	susceptibility	NOUN
fnp-6762	107	18	-	-	PUNCT
fnp-6762	107	19	weighted	weight	VERB
fnp-6762	107	20	mri	mri	NOUN
fnp-6762	107	21	sequences	sequence	NOUN
fnp-6762	107	22	,	,	PUNCT
fnp-6762	107	23	which	which	PRON
fnp-6762	107	24	are	be	AUX
fnp-6762	107	25	sensitive	sensitive	ADJ
fnp-6762	107	26	for	for	ADP
fnp-6762	107	27	detection	detection	NOUN
fnp-6762	107	28	of	of	ADP
fnp-6762	107	29	iron	iron	NOUN
fnp-6762	107	30	accumulation	accumulation	NOUN
fnp-6762	107	31	in	in	ADP
fnp-6762	107	32	a	a	DET
fnp-6762	107	33	rim	rim	NOUN
fnp-6762	107	34	of	of	ADP
fnp-6762	107	35	myeloid	myeloid	ADJ
fnp-6762	107	36	cells	cell	NOUN
fnp-6762	107	37	around	around	ADP
fnp-6762	107	38	chronic	chronic	ADJ
fnp-6762	107	39	ms	ms	PROPN
fnp-6762	107	40	lesions38	lesions38	PROPN
fnp-6762	107	41	.	.	PUNCT
fnp-6762	108	1	these	these	DET
fnp-6762	108	2	prls	prl	NOUN
fnp-6762	108	3	are	be	AUX
fnp-6762	108	4	not	not	PART
fnp-6762	108	5	exclusively	exclusively	ADV
fnp-6762	108	6	found	find	VERB
fnp-6762	108	7	in	in	ADP
fnp-6762	108	8	ms	ms	NOUN
fnp-6762	108	9	but	but	CCONJ
fnp-6762	108	10	display	display	VERB
fnp-6762	108	11	high	high	ADJ
fnp-6762	108	12	specificity	specificity	NOUN
fnp-6762	108	13	;	;	PUNCT
fnp-6762	108	14	therefore	therefore	ADV
fnp-6762	108	15	,	,	PUNCT
fnp-6762	108	16	detection	detection	NOUN
fnp-6762	108	17	of	of	ADP
fnp-6762	108	18	at	at	ADV
fnp-6762	108	19	least	least	ADV
fnp-6762	108	20	one	one	NUM
fnp-6762	108	21	prl	prl	NOUN
fnp-6762	108	22	in	in	ADP
fnp-6762	108	23	the	the	DET
fnp-6762	108	24	presence	presence	NOUN
fnp-6762	108	25	of	of	ADP
fnp-6762	108	26	either	either	CCONJ
fnp-6762	108	27	dit	dit	PROPN
fnp-6762	108	28	or	or	CCONJ
fnp-6762	108	29	csf	csf	ADJ
fnp-6762	108	30	positivity	positivity	NOUN
fnp-6762	108	31	can	can	AUX
fnp-6762	108	32	now	now	ADV
fnp-6762	108	33	confirm	confirm	VERB
fnp-6762	108	34	ms	ms	NOUN
fnp-6762	108	35	in	in	ADP
fnp-6762	108	36	cases	case	NOUN
fnp-6762	108	37	with	with	ADP
fnp-6762	108	38	so	so	ADV
fnp-6762	108	39	far	far	ADV
fnp-6762	108	40	only	only	ADV
fnp-6762	108	41	one	one	NUM
fnp-6762	108	42	topography	topography	NOUN
fnp-6762	108	43	affected	affect	VERB
fnp-6762	108	44	.	.	PUNCT
fnp-6762	109	1	for	for	ADP
fnp-6762	109	2	csf	csf	ADJ
fnp-6762	109	3	analysis	analysis	NOUN
fnp-6762	109	4	in	in	ADP
fnp-6762	109	5	the	the	DET
fnp-6762	109	6	context	context	NOUN
fnp-6762	109	7	of	of	ADP
fnp-6762	109	8	ms	ms	PROPN
fnp-6762	109	9	workup	workup	PROPN
fnp-6762	109	10	,	,	PUNCT
fnp-6762	109	11	the	the	DET
fnp-6762	109	12	kappa	kappa	ADJ
fnp-6762	109	13	-	-	ADJ
fnp-6762	109	14	free	free	ADJ
fnp-6762	109	15	light	light	NOUN
fnp-6762	109	16	chain	chain	NOUN
fnp-6762	109	17	(	(	PUNCT
fnp-6762	109	18	kflc	kflc	PROPN
fnp-6762	109	19	)	)	PUNCT
fnp-6762	109	20	index	index	NOUN
fnp-6762	109	21	can	can	AUX
fnp-6762	109	22	now	now	ADV
fnp-6762	109	23	replace	replace	VERB
fnp-6762	109	24	ocb	ocb	PROPN
fnp-6762	109	25	detection	detection	NOUN
fnp-6762	109	26	,	,	PUNCT
fnp-6762	109	27	both	both	PRON
fnp-6762	109	28	reflecting	reflect	VERB
fnp-6762	109	29	intrathecal	intrathecal	ADJ
fnp-6762	109	30	immunoglobulin	immunoglobulin	NOUN
fnp-6762	109	31	production39	production39	NOUN
fnp-6762	109	32	.	.	PUNCT
fnp-6762	110	1	this	this	PRON
fnp-6762	110	2	may	may	AUX
fnp-6762	110	3	facilitate	facilitate	VERB
fnp-6762	110	4	diagnostic	diagnostic	ADJ
fnp-6762	110	5	procedures	procedure	NOUN
fnp-6762	110	6	as	as	SCONJ
fnp-6762	110	7	this	this	PRON
fnp-6762	110	8	is	be	AUX
fnp-6762	110	9	a	a	DET
fnp-6762	110	10	cost	cost	NOUN
fnp-6762	110	11	-	-	PUNCT
fnp-6762	110	12	effective	effective	ADJ
fnp-6762	110	13	and	and	CCONJ
fnp-6762	110	14	rater	rater	NOUN
fnp-6762	110	15	-	-	PUNCT
fnp-6762	110	16	independent	independent	ADJ
fnp-6762	110	17	method	method	NOUN
fnp-6762	110	18	based	base	VERB
fnp-6762	110	19	on	on	ADP
fnp-6762	110	20	nephelometry	nephelometry	NOUN
fnp-6762	110	21	or	or	CCONJ
fnp-6762	110	22	turbidimetry	turbidimetry	NOUN
fnp-6762	110	23	.	.	PUNCT
fnp-6762	111	1	furthermore	furthermore	ADV
fnp-6762	111	2	,	,	PUNCT
fnp-6762	111	3	as	as	SCONJ
fnp-6762	111	4	described	describe	VERB
fnp-6762	111	5	in	in	ADP
fnp-6762	111	6	the	the	DET
fnp-6762	111	7	previous	previous	ADJ
fnp-6762	111	8	section	section	NOUN
fnp-6762	111	9	,	,	PUNCT
fnp-6762	111	10	evidence	evidence	NOUN
fnp-6762	111	11	supports	support	VERB
fnp-6762	111	12	ris	ris	PROPN
fnp-6762	111	13	as	as	ADP
fnp-6762	111	14	part	part	NOUN
fnp-6762	111	15	of	of	ADP
fnp-6762	111	16	the	the	DET
fnp-6762	111	17	ms	ms	PROPN
fnp-6762	111	18	continuum	continuum	PROPN
fnp-6762	111	19	,	,	PUNCT
fnp-6762	111	20	with	with	ADP
fnp-6762	111	21	over	over	ADP
fnp-6762	111	22	half	half	NOUN
fnp-6762	111	23	of	of	ADP
fnp-6762	111	24	ris	ris	PROPN
fnp-6762	111	25	cases	case	NOUN
fnp-6762	111	26	developing	develop	VERB
fnp-6762	111	27	clinical	clinical	ADJ
fnp-6762	111	28	ms	ms	NOUN
fnp-6762	111	29	within	within	ADP
fnp-6762	111	30	10	10	NUM
fnp-6762	111	31	years40	years40	NOUN
fnp-6762	111	32	.	.	PUNCT
fnp-6762	112	1	therefore	therefore	ADV
fnp-6762	112	2	,	,	PUNCT
fnp-6762	112	3	the	the	DET
fnp-6762	112	4	diagnostic	diagnostic	ADJ
fnp-6762	112	5	criteria	criterion	NOUN
fnp-6762	112	6	now	now	ADV
fnp-6762	112	7	allow	allow	VERB
fnp-6762	112	8	for	for	ADP
fnp-6762	112	9	ms	ms	ADJ
fnp-6762	112	10	diagnosis	diagnosis	NOUN
fnp-6762	112	11	in	in	ADP
fnp-6762	112	12	those	those	DET
fnp-6762	112	13	ris	ris	PROPN
fnp-6762	112	14	patients	patient	NOUN
fnp-6762	112	15	exhibiting	exhibit	VERB
fnp-6762	112	16	lesions	lesion	NOUN
fnp-6762	112	17	in	in	ADP
fnp-6762	112	18	at	at	ADV
fnp-6762	112	19	least	least	ADV
fnp-6762	112	20	two	two	NUM
fnp-6762	112	21	topographies	topography	NOUN
fnp-6762	112	22	plus	plus	CCONJ
fnp-6762	112	23	dit	dit	NOUN
fnp-6762	112	24	or	or	CCONJ
fnp-6762	112	25	csf	csf	ADJ
fnp-6762	112	26	positivity	positivity	NOUN
fnp-6762	112	27	.	.	PUNCT
fnp-6762	113	1	this	this	PRON
fnp-6762	113	2	represents	represent	VERB
fnp-6762	113	3	a	a	DET
fnp-6762	113	4	real	real	ADJ
fnp-6762	113	5	conceptual	conceptual	ADJ
fnp-6762	113	6	change	change	NOUN
fnp-6762	113	7	as	as	SCONJ
fnp-6762	113	8	this	this	PRON
fnp-6762	113	9	accepts	accept	VERB
fnp-6762	113	10	ms	ms	NOUN
fnp-6762	113	11	as	as	ADP
fnp-6762	113	12	a	a	DET
fnp-6762	113	13	biological	biological	ADJ
fnp-6762	113	14	diagnosis	diagnosis	NOUN
fnp-6762	113	15	even	even	ADV
fnp-6762	113	16	in	in	ADP
fnp-6762	113	17	the	the	DET
fnp-6762	113	18	absence	absence	NOUN
fnp-6762	113	19	of	of	ADP
fnp-6762	113	20	any	any	DET
fnp-6762	113	21	clinical	clinical	ADJ
fnp-6762	113	22	manifestation	manifestation	NOUN
fnp-6762	113	23	.	.	PUNCT
fnp-6762	114	1	regarding	regard	VERB
fnp-6762	114	2	the	the	DET
fnp-6762	114	3	former	former	ADJ
fnp-6762	114	4	separation	separation	NOUN
fnp-6762	114	5	of	of	ADP
fnp-6762	114	6	diagnostic	diagnostic	ADJ
fnp-6762	114	7	criteria	criterion	NOUN
fnp-6762	114	8	for	for	ADP
fnp-6762	114	9	relapsing	relapse	VERB
fnp-6762	114	10	versus	versus	ADP
fnp-6762	114	11	progressive	progressive	ADJ
fnp-6762	114	12	ms	ms	PROPN
fnp-6762	114	13	,	,	PUNCT
fnp-6762	114	14	the	the	DET
fnp-6762	114	15	common	common	ADJ
fnp-6762	114	16	biological	biological	ADJ
fnp-6762	114	17	mechanisms	mechanism	NOUN
fnp-6762	114	18	of	of	ADP
fnp-6762	114	19	these	these	DET
fnp-6762	114	20	disease	disease	NOUN
fnp-6762	114	21	courses	course	NOUN
fnp-6762	114	22	have	have	AUX
fnp-6762	114	23	been	be	AUX
fnp-6762	114	24	acknowledged	acknowledge	VERB
fnp-6762	114	25	,	,	PUNCT
fnp-6762	114	26	and	and	CCONJ
fnp-6762	114	27	therefore	therefore	ADV
fnp-6762	114	28	,	,	PUNCT
fnp-6762	114	29	the	the	DET
fnp-6762	114	30	newly	newly	ADV
fnp-6762	114	31	revised	revise	VERB
fnp-6762	114	32	diagnostic	diagnostic	ADJ
fnp-6762	114	33	criteria	criterion	NOUN
fnp-6762	114	34	can	can	AUX
fnp-6762	114	35	be	be	AUX
fnp-6762	114	36	applied	apply	VERB
fnp-6762	114	37	to	to	ADP
fnp-6762	114	38	both	both	DET
fnp-6762	114	39	disease	disease	NOUN
fnp-6762	114	40	courses	course	NOUN
fnp-6762	114	41	.	.	PUNCT
fnp-6762	115	1	finally	finally	ADV
fnp-6762	115	2	,	,	PUNCT
fnp-6762	115	3	criteria	criterion	NOUN
fnp-6762	115	4	have	have	AUX
fnp-6762	115	5	been	be	AUX
fnp-6762	115	6	adapted	adapt	VERB
fnp-6762	115	7	in	in	ADP
fnp-6762	115	8	individuals	individual	NOUN
fnp-6762	115	9	over	over	ADP
fnp-6762	115	10	50	50	NUM
fnp-6762	115	11	or	or	CCONJ
fnp-6762	115	12	with	with	ADP
fnp-6762	115	13	comorbidities	comorbiditie	NOUN
fnp-6762	115	14	acknowledging	acknowledge	VERB
fnp-6762	115	15	the	the	DET
fnp-6762	115	16	increased	increase	VERB
fnp-6762	115	17	risk	risk	NOUN
fnp-6762	115	18	of	of	ADP
fnp-6762	115	19	ms	ms	NOUN
fnp-6762	115	20	misdiagnosis	misdiagnosis	NOUN
fnp-6762	115	21	in	in	ADP
fnp-6762	115	22	these	these	DET
fnp-6762	115	23	conditions	condition	NOUN
fnp-6762	115	24	due	due	ADP
fnp-6762	115	25	to	to	ADP
fnp-6762	115	26	small	small	ADJ
fnp-6762	115	27	vessel	vessel	NOUN
fnp-6762	115	28	disease	disease	NOUN
fnp-6762	115	29	,	,	PUNCT
fnp-6762	115	30	migraine	migraine	NOUN
fnp-6762	115	31	or	or	CCONJ
fnp-6762	115	32	other	other	ADJ
fnp-6762	115	33	inflammatory	inflammatory	ADJ
fnp-6762	115	34	disorders	disorder	NOUN
fnp-6762	115	35	,	,	PUNCT
fnp-6762	115	36	which	which	PRON
fnp-6762	115	37	can	can	AUX
fnp-6762	115	38	also	also	ADV
fnp-6762	115	39	present	present	VERB
fnp-6762	115	40	with	with	ADP
fnp-6762	115	41	t2	t2	NOUN
fnp-6762	115	42	lesions	lesion	NOUN
fnp-6762	115	43	.	.	PUNCT
fnp-6762	116	1	in	in	ADP
fnp-6762	116	2	these	these	DET
fnp-6762	116	3	cases	case	NOUN
fnp-6762	116	4	,	,	PUNCT
fnp-6762	116	5	additional	additional	ADJ
fnp-6762	116	6	criteria	criterion	NOUN
fnp-6762	116	7	should	should	AUX
fnp-6762	116	8	be	be	AUX
fnp-6762	116	9	fulfilled	fulfil	VERB
fnp-6762	116	10	,	,	PUNCT
fnp-6762	116	11	such	such	ADJ
fnp-6762	116	12	as	as	ADP
fnp-6762	116	13	detection	detection	NOUN
fnp-6762	116	14	of	of	ADP
fnp-6762	116	15	at	at	ADV
fnp-6762	116	16	least	least	ADV
fnp-6762	116	17	one	one	NUM
fnp-6762	116	18	spinal	spinal	ADJ
fnp-6762	116	19	cord	cord	NOUN
fnp-6762	116	20	lesion	lesion	NOUN
fnp-6762	116	21	,	,	PUNCT
fnp-6762	116	22	positive	positive	ADJ
fnp-6762	116	23	csf	csf	NOUN
fnp-6762	116	24	and/or	and/or	CCONJ
fnp-6762	116	25	detection	detection	NOUN
fnp-6762	116	26	of	of	ADP
fnp-6762	116	27	cvs	cvs	PROPN
fnp-6762	116	28	.	.	PUNCT
fnp-6762	117	1	together	together	ADV
fnp-6762	117	2	,	,	PUNCT
fnp-6762	117	3	this	this	DET
fnp-6762	117	4	2024	2024	NUM
fnp-6762	117	5	revision	revision	NOUN
fnp-6762	117	6	of	of	ADP
fnp-6762	117	7	the	the	DET
fnp-6762	117	8	ms	ms	PROPN
fnp-6762	117	9	diagnostic	diagnostic	ADJ
fnp-6762	117	10	criteria	criterion	NOUN
fnp-6762	117	11	aims	aim	VERB
fnp-6762	117	12	to	to	PART
fnp-6762	117	13	facilitate	facilitate	VERB
fnp-6762	117	14	the	the	DET
fnp-6762	117	15	diagnosis	diagnosis	NOUN
fnp-6762	117	16	of	of	ADP
fnp-6762	117	17	ms	ms	NOUN
fnp-6762	117	18	in	in	ADP
fnp-6762	117	19	individuals	individual	NOUN
fnp-6762	117	20	based	base	VERB
fnp-6762	117	21	on	on	ADP
fnp-6762	117	22	biological	biological	ADJ
fnp-6762	117	23	considerations	consideration	NOUN
fnp-6762	117	24	without	without	ADP
fnp-6762	117	25	compromising	compromise	VERB
fnp-6762	117	26	specificity	specificity	NOUN
fnp-6762	117	27	,	,	PUNCT
fnp-6762	117	28	which	which	PRON
fnp-6762	117	29	will	will	AUX
fnp-6762	117	30	ultimately	ultimately	ADV
fnp-6762	117	31	improve	improve	VERB
fnp-6762	117	32	clinical	clinical	ADJ
fnp-6762	117	33	outcomes	outcome	NOUN
fnp-6762	117	34	of	of	ADP
fnp-6762	117	35	people	people	NOUN
fnp-6762	117	36	with	with	ADP
fnp-6762	117	37	ms	ms	NOUN
fnp-6762	117	38	globally	globally	ADV
fnp-6762	117	39	.	.	PUNCT
fnp-6762	118	1	monitoring	monitoring	NOUN
fnp-6762	118	2	of	of	ADP
fnp-6762	118	3	disease	disease	NOUN
fnp-6762	118	4	activity	activity	NOUN
fnp-6762	118	5	biomarkers	biomarker	NOUN
fnp-6762	118	6	and	and	CCONJ
fnp-6762	118	7	their	their	PRON
fnp-6762	118	8	use	use	NOUN
fnp-6762	118	9	for	for	ADP
fnp-6762	118	10	personalized	personalized	ADJ
fnp-6762	118	11	medicine	medicine	NOUN
fnp-6762	118	12	–	–	PUNCT
fnp-6762	118	13	where	where	SCONJ
fnp-6762	118	14	do	do	AUX
fnp-6762	118	15	we	we	PRON
fnp-6762	118	16	stand	stand	VERB
fnp-6762	118	17	?	?	PUNCT
fnp-6762	119	1	biomarkers	biomarker	NOUN
fnp-6762	119	2	are	be	AUX
fnp-6762	119	3	key	key	ADJ
fnp-6762	119	4	to	to	ADP
fnp-6762	119	5	advancing	advance	VERB
fnp-6762	119	6	personalized	personalized	ADJ
fnp-6762	119	7	medicine	medicine	NOUN
fnp-6762	119	8	by	by	ADP
fnp-6762	119	9	enabling	enable	VERB
fnp-6762	119	10	precise	precise	ADJ
fnp-6762	119	11	diagnosis	diagnosis	NOUN
fnp-6762	119	12	,	,	PUNCT
fnp-6762	119	13	risk	risk	NOUN
fnp-6762	119	14	stratification	stratification	NOUN
fnp-6762	119	15	,	,	PUNCT
fnp-6762	119	16	and	and	CCONJ
fnp-6762	119	17	guidance	guidance	NOUN
fnp-6762	119	18	in	in	ADP
fnp-6762	119	19	treatment	treatment	NOUN
fnp-6762	119	20	responses	response	NOUN
fnp-6762	119	21	.	.	PUNCT
fnp-6762	120	1	in	in	ADP
fnp-6762	120	2	oncology	oncology	NOUN
fnp-6762	120	3	,	,	PUNCT
fnp-6762	120	4	the	the	DET
fnp-6762	120	5	use	use	NOUN
fnp-6762	120	6	of	of	ADP
fnp-6762	120	7	biomarkers	biomarker	NOUN
fnp-6762	120	8	for	for	ADP
fnp-6762	120	9	personalized	personalized	ADJ
fnp-6762	120	10	medicine	medicine	NOUN
fnp-6762	120	11	approaches	approach	NOUN
fnp-6762	120	12	is	be	AUX
fnp-6762	120	13	already	already	ADV
fnp-6762	120	14	firmly	firmly	ADV
fnp-6762	120	15	established	establish	VERB
fnp-6762	120	16	due	due	ADP
fnp-6762	120	17	to	to	ADP
fnp-6762	120	18	the	the	DET
fnp-6762	120	19	unique	unique	ADJ
fnp-6762	120	20	genetic	genetic	ADJ
fnp-6762	120	21	and	and	CCONJ
fnp-6762	120	22	molecular	molecular	ADJ
fnp-6762	120	23	profiles	profile	NOUN
fnp-6762	120	24	of	of	ADP
fnp-6762	120	25	a	a	DET
fnp-6762	120	26	patient	patient	NOUN
fnp-6762	120	27	’s	’s	PART
fnp-6762	120	28	tumor	tumor	NOUN
fnp-6762	120	29	.	.	PUNCT
fnp-6762	121	1	in	in	ADP
fnp-6762	121	2	autoimmune	autoimmune	ADJ
fnp-6762	121	3	diseases	disease	NOUN
fnp-6762	121	4	,	,	PUNCT
fnp-6762	121	5	personalized	personalized	ADJ
fnp-6762	121	6	medicine	medicine	NOUN
fnp-6762	121	7	based	base	VERB
fnp-6762	121	8	on	on	ADP
fnp-6762	121	9	biomarkers	biomarker	NOUN
fnp-6762	121	10	is	be	AUX
fnp-6762	121	11	still	still	ADV
fnp-6762	121	12	in	in	ADP
fnp-6762	121	13	its	its	PRON
fnp-6762	121	14	infancy	infancy	NOUN
fnp-6762	121	15	,	,	PUNCT
fnp-6762	121	16	primarily	primarily	ADV
fnp-6762	121	17	due	due	ADP
fnp-6762	121	18	to	to	ADP
fnp-6762	121	19	the	the	DET
fnp-6762	121	20	complexity	complexity	NOUN
fnp-6762	121	21	of	of	ADP
fnp-6762	121	22	their	their	PRON
fnp-6762	121	23	pathophysiology	pathophysiology	NOUN
fnp-6762	121	24	and	and	CCONJ
fnp-6762	121	25	the	the	DET
fnp-6762	121	26	heterogeneity	heterogeneity	NOUN
fnp-6762	121	27	in	in	ADP
fnp-6762	121	28	clinical	clinical	ADJ
fnp-6762	121	29	presentation	presentation	NOUN
fnp-6762	121	30	.	.	PUNCT
fnp-6762	122	1	in	in	ADP
fnp-6762	122	2	the	the	DET
fnp-6762	122	3	field	field	NOUN
fnp-6762	122	4	of	of	ADP
fnp-6762	122	5	ms	ms	PROPN
fnp-6762	122	6	,	,	PUNCT
fnp-6762	122	7	recent	recent	ADJ
fnp-6762	122	8	publications	publication	NOUN
fnp-6762	122	9	illustrate	illustrate	VERB
fnp-6762	122	10	both	both	CCONJ
fnp-6762	122	11	advances	advance	NOUN
fnp-6762	122	12	and	and	CCONJ
fnp-6762	122	13	limitations	limitation	NOUN
fnp-6762	122	14	in	in	ADP
fnp-6762	122	15	this	this	DET
fnp-6762	122	16	area	area	NOUN
fnp-6762	122	17	of	of	ADP
fnp-6762	122	18	research	research	NOUN
fnp-6762	122	19	.	.	PUNCT
fnp-6762	123	1	besides	besides	SCONJ
fnp-6762	123	2	mri	mri	NOUN
fnp-6762	123	3	,	,	PUNCT
fnp-6762	123	4	serum	serum	NOUN
fnp-6762	123	5	neurofilament	neurofilament	ADJ
fnp-6762	123	6	light	light	NOUN
fnp-6762	123	7	chain	chain	NOUN
fnp-6762	123	8	(	(	PUNCT
fnp-6762	123	9	nfl	nfl	PROPN
fnp-6762	123	10	)	)	PUNCT
fnp-6762	123	11	levels	level	NOUN
fnp-6762	123	12	represent	represent	VERB
fnp-6762	123	13	the	the	DET
fnp-6762	123	14	most	most	ADV
fnp-6762	123	15	advanced	advanced	ADJ
fnp-6762	123	16	biomarker	biomarker	NOUN
fnp-6762	123	17	for	for	ADP
fnp-6762	123	18	facilitating	facilitate	VERB
fnp-6762	123	19	the	the	DET
fnp-6762	123	20	assessment	assessment	NOUN
fnp-6762	123	21	of	of	ADP
fnp-6762	123	22	a	a	DET
fnp-6762	123	23	patient	patient	NOUN
fnp-6762	123	24	’s	’s	PART
fnp-6762	123	25	individual	individual	ADJ
fnp-6762	123	26	prognosis41	prognosis41	NOUN
fnp-6762	123	27	.	.	PUNCT
fnp-6762	124	1	although	although	SCONJ
fnp-6762	124	2	nfl	nfl	PROPN
fnp-6762	124	3	is	be	AUX
fnp-6762	124	4	a	a	DET
fnp-6762	124	5	non	non	ADJ
fnp-6762	124	6	-	-	ADJ
fnp-6762	124	7	specific	specific	ADJ
fnp-6762	124	8	marker	marker	NOUN
fnp-6762	124	9	of	of	ADP
fnp-6762	124	10	neuronal	neuronal	ADJ
fnp-6762	124	11	injury	injury	NOUN
fnp-6762	124	12	and	and	CCONJ
fnp-6762	124	13	therefore	therefore	ADV
fnp-6762	124	14	not	not	PART
fnp-6762	124	15	limited	limit	VERB
fnp-6762	124	16	to	to	ADP
fnp-6762	124	17	ms	ms	PROPN
fnp-6762	124	18	,	,	PUNCT
fnp-6762	124	19	elevated	elevated	ADJ
fnp-6762	124	20	serum	serum	PROPN
fnp-6762	124	21	nfl	nfl	PROPN
fnp-6762	124	22	(	(	PUNCT
fnp-6762	124	23	snfl	snfl	PROPN
fnp-6762	124	24	)	)	PUNCT
fnp-6762	124	25	levels	level	NOUN
fnp-6762	124	26	have	have	AUX
fnp-6762	124	27	been	be	AUX
fnp-6762	124	28	associated	associate	VERB
fnp-6762	124	29	with	with	ADP
fnp-6762	124	30	acute	acute	ADJ
fnp-6762	124	31	relapse	relapse	NOUN
fnp-6762	124	32	activity	activity	NOUN
fnp-6762	124	33	and	and	CCONJ
fnp-6762	124	34	responses	response	NOUN
fnp-6762	124	35	to	to	ADP
fnp-6762	124	36	highly	highly	ADV
fnp-6762	124	37	active	active	ADJ
fnp-6762	124	38	treatments42	treatments42	NOUN
fnp-6762	124	39	.	.	PUNCT
fnp-6762	125	1	recently	recently	ADV
fnp-6762	125	2	,	,	PUNCT
fnp-6762	125	3	the	the	DET
fnp-6762	125	4	relevance	relevance	NOUN
fnp-6762	125	5	of	of	ADP
fnp-6762	125	6	nfl	nfl	PROPN
fnp-6762	125	7	in	in	ADP
fnp-6762	125	8	predicting	predict	VERB
fnp-6762	125	9	disability	disability	NOUN
fnp-6762	125	10	accumulation	accumulation	NOUN
fnp-6762	125	11	has	have	AUX
fnp-6762	125	12	been	be	AUX
fnp-6762	125	13	further	far	ADV
fnp-6762	125	14	explored	explore	VERB
fnp-6762	125	15	,	,	PUNCT
fnp-6762	125	16	demonstrating	demonstrate	VERB
fnp-6762	125	17	that	that	SCONJ
fnp-6762	125	18	elevated	elevated	ADJ
fnp-6762	125	19	snfl	snfl	NOUN
fnp-6762	125	20	levels	level	NOUN
fnp-6762	125	21	after	after	SCONJ
fnp-6762	125	22	a	a	DET
fnp-6762	125	23	first	first	ADJ
fnp-6762	125	24	demyelinating	demyelinate	VERB
fnp-6762	125	25	event	event	NOUN
fnp-6762	125	26	are	be	AUX
fnp-6762	125	27	associated	associate	VERB
fnp-6762	125	28	with	with	ADP
fnp-6762	125	29	an	an	DET
fnp-6762	125	30	increased	increase	VERB
fnp-6762	125	31	risk	risk	NOUN
fnp-6762	125	32	of	of	ADP
fnp-6762	125	33	future	future	ADJ
fnp-6762	125	34	disability	disability	NOUN
fnp-6762	125	35	accumulation43	accumulation43	NOUN
fnp-6762	125	36	.	.	PUNCT
fnp-6762	126	1	furthermore	furthermore	ADV
fnp-6762	126	2	,	,	PUNCT
fnp-6762	126	3	glial	glial	ADJ
fnp-6762	126	4	fibrillary	fibrillary	ADJ
fnp-6762	126	5	acidic	acidic	ADJ
fnp-6762	126	6	protein	protein	NOUN
fnp-6762	126	7	(	(	PUNCT
fnp-6762	126	8	gfap	gfap	ADJ
fnp-6762	126	9	)	)	PUNCT
fnp-6762	126	10	has	have	AUX
fnp-6762	126	11	emerged	emerge	VERB
fnp-6762	126	12	as	as	ADP
fnp-6762	126	13	another	another	DET
fnp-6762	126	14	serum	serum	NOUN
fnp-6762	126	15	biomarker	biomarker	NOUN
fnp-6762	126	16	in	in	ADP
fnp-6762	126	17	ms	ms	PROPN
fnp-6762	126	18	.	.	PROPN
fnp-6762	126	19	one	one	NUM
fnp-6762	126	20	study	study	NOUN
fnp-6762	126	21	proposed	propose	VERB
fnp-6762	126	22	that	that	SCONJ
fnp-6762	126	23	the	the	DET
fnp-6762	126	24	combined	combined	ADJ
fnp-6762	126	25	assessment	assessment	NOUN
fnp-6762	126	26	of	of	ADP
fnp-6762	126	27	gfap	gfap	NOUN
fnp-6762	126	28	and	and	CCONJ
fnp-6762	126	29	nfl	nfl	PROPN
fnp-6762	126	30	may	may	AUX
fnp-6762	126	31	help	help	VERB
fnp-6762	126	32	distinguish	distinguish	VERB
fnp-6762	126	33	between	between	ADP
fnp-6762	126	34	acute	acute	ADJ
fnp-6762	126	35	focal	focal	ADJ
fnp-6762	126	36	inflammatory	inflammatory	ADJ
fnp-6762	126	37	damage	damage	NOUN
fnp-6762	126	38	–	–	PUNCT
fnp-6762	126	39	reflected	reflect	VERB
fnp-6762	126	40	by	by	ADP
fnp-6762	126	41	nfl	nfl	PROPN
fnp-6762	126	42	elevation	elevation	NOUN
fnp-6762	126	43	–	–	PUNCT
fnp-6762	126	44	and	and	CCONJ
fnp-6762	126	45	relapse	relapse	NOUN
fnp-6762	126	46	-	-	PUNCT
fnp-6762	126	47	independent	independent	ADJ
fnp-6762	126	48	progression	progression	NOUN
fnp-6762	126	49	,	,	PUNCT
fnp-6762	126	50	as	as	SCONJ
fnp-6762	126	51	indicated	indicate	VERB
fnp-6762	126	52	by	by	ADP
fnp-6762	126	53	gfap	gfap	ADJ
fnp-6762	126	54	elevation44	elevation44	NOUN
fnp-6762	126	55	.	.	PUNCT
fnp-6762	127	1	in	in	ADP
fnp-6762	127	2	contrast	contrast	NOUN
fnp-6762	127	3	,	,	PUNCT
fnp-6762	127	4	a	a	DET
fnp-6762	127	5	more	more	ADV
fnp-6762	127	6	recent	recent	ADJ
fnp-6762	127	7	study	study	NOUN
fnp-6762	127	8	by	by	ADP
fnp-6762	127	9	monreal	monreal	NOUN
fnp-6762	127	10	and	and	CCONJ
fnp-6762	127	11	colleagues	colleague	NOUN
fnp-6762	127	12	suggested	suggest	VERB
fnp-6762	127	13	that	that	SCONJ
fnp-6762	127	14	higher	high	ADJ
fnp-6762	127	15	nfl	nfl	PROPN
fnp-6762	127	16	levels	level	NOUN
fnp-6762	127	17	were	be	AUX
fnp-6762	127	18	associated	associate	VERB
fnp-6762	127	19	with	with	ADP
fnp-6762	127	20	an	an	DET
fnp-6762	127	21	increased	increase	VERB
fnp-6762	127	22	risk	risk	NOUN
fnp-6762	127	23	of	of	ADP
fnp-6762	127	24	both	both	DET
fnp-6762	127	25	relapse	relapse	NOUN
fnp-6762	127	26	-	-	PUNCT
fnp-6762	127	27	associated	associate	VERB
fnp-6762	127	28	worsening	worsen	VERB
fnp-6762	127	29	(	(	PUNCT
fnp-6762	127	30	raw	raw	ADJ
fnp-6762	127	31	)	)	PUNCT
fnp-6762	127	32	and	and	CCONJ
fnp-6762	127	33	pira	pira	PROPN
fnp-6762	127	34	,	,	PUNCT
fnp-6762	127	35	confirming	confirm	VERB
fnp-6762	127	36	its	its	PRON
fnp-6762	127	37	prognostic	prognostic	ADJ
fnp-6762	127	38	value	value	NOUN
fnp-6762	127	39	at	at	ADP
fnp-6762	127	40	disease	disease	NOUN
fnp-6762	127	41	onset	onset	VERB
fnp-6762	127	42	.	.	PUNCT
fnp-6762	128	1	higher	high	ADJ
fnp-6762	128	2	gfap	gfap	ADJ
fnp-6762	128	3	levels	level	NOUN
fnp-6762	128	4	were	be	AUX
fnp-6762	128	5	linked	link	VERB
fnp-6762	128	6	only	only	ADV
fnp-6762	128	7	to	to	ADP
fnp-6762	128	8	a	a	DET
fnp-6762	128	9	higher	high	ADJ
fnp-6762	128	10	risk	risk	NOUN
fnp-6762	128	11	of	of	ADP
fnp-6762	128	12	reaching	reach	VERB
fnp-6762	128	13	an	an	DET
fnp-6762	128	14	edss	edss	ADJ
fnp-6762	128	15	score	score	NOUN
fnp-6762	128	16	of	of	ADP
fnp-6762	128	17	3	3	NUM
fnp-6762	128	18	,	,	PUNCT
fnp-6762	128	19	but	but	CCONJ
fnp-6762	128	20	not	not	PART
fnp-6762	128	21	to	to	PART
fnp-6762	128	22	raw	raw	ADJ
fnp-6762	128	23	or	or	CCONJ
fnp-6762	128	24	pira	pira	NOUN
fnp-6762	128	25	.	.	PUNCT
fnp-6762	129	1	however	however	ADV
fnp-6762	129	2	,	,	PUNCT
fnp-6762	129	3	in	in	ADP
fnp-6762	129	4	a	a	DET
fnp-6762	129	5	subset	subset	NOUN
fnp-6762	129	6	of	of	ADP
fnp-6762	129	7	patients	patient	NOUN
fnp-6762	129	8	with	with	ADP
fnp-6762	129	9	low	low	PROPN
fnp-6762	129	10	nfl	nfl	PROPN
fnp-6762	129	11	levels	level	NOUN
fnp-6762	129	12	,	,	PUNCT
fnp-6762	129	13	gfap	gfap	NOUN
fnp-6762	129	14	was	be	AUX
fnp-6762	129	15	also	also	ADV
fnp-6762	129	16	associated	associate	VERB
fnp-6762	129	17	with	with	ADP
fnp-6762	129	18	pira	pira	PROPN
fnp-6762	129	19	.	.	PUNCT
fnp-6762	130	1	in	in	ADP
fnp-6762	130	2	individuals	individual	NOUN
fnp-6762	130	3	with	with	ADP
fnp-6762	130	4	low	low	ADJ
fnp-6762	130	5	levels	level	NOUN
fnp-6762	130	6	of	of	ADP
fnp-6762	130	7	both	both	DET
fnp-6762	130	8	markers	marker	NOUN
fnp-6762	130	9	,	,	PUNCT
fnp-6762	130	10	the	the	DET
fnp-6762	130	11	risk	risk	NOUN
fnp-6762	130	12	for	for	ADP
fnp-6762	130	13	all	all	DET
fnp-6762	130	14	outcomes	outcome	NOUN
fnp-6762	130	15	was	be	AUX
fnp-6762	130	16	lowest	low	ADJ
fnp-6762	130	17	.	.	PUNCT
fnp-6762	131	1	these	these	DET
fnp-6762	131	2	findings	finding	NOUN
fnp-6762	131	3	suggest	suggest	VERB
fnp-6762	131	4	that	that	SCONJ
fnp-6762	131	5	gfap	gfap	NOUN
fnp-6762	131	6	may	may	AUX
fnp-6762	131	7	indicate	indicate	VERB
fnp-6762	131	8	progression	progression	NOUN
fnp-6762	131	9	only	only	ADV
fnp-6762	131	10	in	in	ADP
fnp-6762	131	11	a	a	DET
fnp-6762	131	12	subset	subset	NOUN
fnp-6762	131	13	of	of	ADP
fnp-6762	131	14	patients	patient	NOUN
fnp-6762	131	15	,	,	PUNCT
fnp-6762	131	16	potentially	potentially	ADV
fnp-6762	131	17	driven	drive	VERB
fnp-6762	131	18	by	by	ADP
fnp-6762	131	19	a	a	DET
fnp-6762	131	20	distinct	distinct	ADJ
fnp-6762	131	21	pathophysiology	pathophysiology	NOUN
fnp-6762	131	22	,	,	PUNCT
fnp-6762	131	23	and	and	CCONJ
fnp-6762	131	24	that	that	SCONJ
fnp-6762	131	25	combining	combine	VERB
fnp-6762	131	26	both	both	DET
fnp-6762	131	27	markers	marker	NOUN
fnp-6762	131	28	may	may	AUX
fnp-6762	131	29	enhance	enhance	VERB
fnp-6762	131	30	prediction	prediction	NOUN
fnp-6762	131	31	accuracy45	accuracy45	NOUN
fnp-6762	131	32	.	.	PUNCT
fnp-6762	132	1	additional	additional	ADJ
fnp-6762	132	2	experimental	experimental	ADJ
fnp-6762	132	3	approaches	approach	NOUN
fnp-6762	132	4	have	have	AUX
fnp-6762	132	5	been	be	AUX
fnp-6762	132	6	published	publish	VERB
fnp-6762	132	7	,	,	PUNCT
fnp-6762	132	8	highlighting	highlight	VERB
fnp-6762	132	9	the	the	DET
fnp-6762	132	10	potential	potential	NOUN
fnp-6762	132	11	of	of	ADP
fnp-6762	132	12	more	more	ADJ
fnp-6762	132	13	pathophysiology	pathophysiology	NOUN
fnp-6762	132	14	-	-	PUNCT
fnp-6762	132	15	driven	drive	VERB
fnp-6762	132	16	biomarkers	biomarker	NOUN
fnp-6762	132	17	to	to	PART
fnp-6762	132	18	improve	improve	VERB
fnp-6762	132	19	patient	patient	ADJ
fnp-6762	132	20	stratification	stratification	NOUN
fnp-6762	132	21	in	in	ADP
fnp-6762	132	22	ms	ms	PROPN
fnp-6762	132	23	.	.	PROPN
fnp-6762	132	24	one	one	NUM
fnp-6762	132	25	study	study	NOUN
fnp-6762	132	26	,	,	PUNCT
fnp-6762	132	27	based	base	VERB
fnp-6762	132	28	on	on	ADP
fnp-6762	132	29	the	the	DET
fnp-6762	132	30	concept	concept	NOUN
fnp-6762	132	31	that	that	SCONJ
fnp-6762	132	32	ms	ms	PROPN
fnp-6762	132	33	has	have	AUX
fnp-6762	132	34	a	a	DET
fnp-6762	132	35	strong	strong	ADJ
fnp-6762	132	36	genetic	genetic	ADJ
fnp-6762	132	37	component	component	NOUN
fnp-6762	132	38	,	,	PUNCT
fnp-6762	132	39	used	use	VERB
fnp-6762	132	40	a	a	DET
fnp-6762	132	41	genetic	genetic	ADJ
fnp-6762	132	42	risk	risk	NOUN
fnp-6762	132	43	score	score	NOUN
fnp-6762	132	44	(	(	PUNCT
fnp-6762	132	45	grs	grs	PROPN
fnp-6762	132	46	)	)	PUNCT
fnp-6762	132	47	in	in	ADP
fnp-6762	132	48	individuals	individual	NOUN
fnp-6762	132	49	with	with	ADP
fnp-6762	132	50	optic	optic	ADJ
fnp-6762	132	51	neuritis	neuritis	NOUN
fnp-6762	132	52	(	(	PUNCT
fnp-6762	132	53	on	on	ADP
fnp-6762	132	54	)	)	PUNCT
fnp-6762	132	55	to	to	PART
fnp-6762	132	56	predict	predict	VERB
fnp-6762	132	57	the	the	DET
fnp-6762	132	58	future	future	ADJ
fnp-6762	132	59	development	development	NOUN
fnp-6762	132	60	of	of	ADP
fnp-6762	132	61	ms46	ms46	PROPN
fnp-6762	132	62	.	.	PUNCT
fnp-6762	133	1	the	the	DET
fnp-6762	133	2	study	study	NOUN
fnp-6762	133	3	demonstrated	demonstrate	VERB
fnp-6762	133	4	that	that	SCONJ
fnp-6762	133	5	combining	combine	VERB
fnp-6762	133	6	genetic	genetic	ADJ
fnp-6762	133	7	data	datum	NOUN
fnp-6762	133	8	with	with	ADP
fnp-6762	133	9	demographic	demographic	ADJ
fnp-6762	133	10	factors	factor	NOUN
fnp-6762	133	11	significantly	significantly	ADV
fnp-6762	133	12	improved	improve	VERB
fnp-6762	133	13	the	the	DET
fnp-6762	133	14	prediction	prediction	NOUN
fnp-6762	133	15	of	of	ADP
fnp-6762	133	16	ms	ms	NOUN
fnp-6762	133	17	in	in	ADP
fnp-6762	133	18	individuals	individual	NOUN
fnp-6762	133	19	with	with	ADP
fnp-6762	133	20	undifferentiated	undifferentiated	ADJ
fnp-6762	133	21	on	on	ADP
fnp-6762	133	22	,	,	PUNCT
fnp-6762	133	23	with	with	ADP
fnp-6762	133	24	results	result	NOUN
fnp-6762	133	25	replicated	replicate	VERB
fnp-6762	133	26	in	in	ADP
fnp-6762	133	27	an	an	DET
fnp-6762	133	28	independent	independent	ADJ
fnp-6762	133	29	cohort	cohort	NOUN
fnp-6762	133	30	.	.	PUNCT
fnp-6762	134	1	another	another	DET
fnp-6762	134	2	study	study	NOUN
fnp-6762	134	3	analyzed	analyze	VERB
fnp-6762	134	4	whole	whole	ADJ
fnp-6762	134	5	-	-	PUNCT
fnp-6762	134	6	proteome	proteome	ADJ
fnp-6762	134	7	autoantibody	autoantibody	ADJ
fnp-6762	134	8	profiles	profile	NOUN
fnp-6762	134	9	in	in	ADP
fnp-6762	134	10	individuals	individual	NOUN
fnp-6762	134	11	both	both	CCONJ
fnp-6762	134	12	before	before	ADP
fnp-6762	134	13	and	and	CCONJ
fnp-6762	134	14	after	after	ADP
fnp-6762	134	15	ms	ms	PROPN
fnp-6762	134	16	onset	onset	NOUN
fnp-6762	134	17	.	.	PUNCT
fnp-6762	135	1	notably	notably	ADV
fnp-6762	135	2	,	,	PUNCT
fnp-6762	135	3	around	around	ADV
fnp-6762	135	4	10	10	NUM
fnp-6762	135	5	 	 	SPACE
fnp-6762	135	6	%	%	NOUN
fnp-6762	135	7	of	of	ADP
fnp-6762	135	8	ms	ms	NOUN
fnp-6762	135	9	patients	patient	NOUN
fnp-6762	135	10	displayed	display	VERB
fnp-6762	135	11	a	a	DET
fnp-6762	135	12	unique	unique	ADJ
fnp-6762	135	13	signature	signature	NOUN
fnp-6762	135	14	that	that	PRON
fnp-6762	135	15	could	could	AUX
fnp-6762	135	16	already	already	ADV
fnp-6762	135	17	be	be	AUX
fnp-6762	135	18	detected	detect	VERB
fnp-6762	135	19	several	several	ADJ
fnp-6762	135	20	years	year	NOUN
fnp-6762	135	21	before	before	ADP
fnp-6762	135	22	disease	disease	NOUN
fnp-6762	135	23	onset47	onset47	NOUN
fnp-6762	135	24	.	.	PUNCT
fnp-6762	136	1	in	in	ADP
fnp-6762	136	2	line	line	NOUN
fnp-6762	136	3	with	with	ADP
fnp-6762	136	4	other	other	ADJ
fnp-6762	136	5	evidence	evidence	NOUN
fnp-6762	136	6	pointing	point	VERB
fnp-6762	136	7	toward	toward	ADP
fnp-6762	136	8	the	the	DET
fnp-6762	136	9	relevance	relevance	NOUN
fnp-6762	136	10	of	of	ADP
fnp-6762	136	11	certain	certain	ADJ
fnp-6762	136	12	virus	virus	NOUN
fnp-6762	136	13	-	-	PUNCT
fnp-6762	136	14	immune	immune	ADJ
fnp-6762	136	15	interactions	interaction	NOUN
fnp-6762	136	16	as	as	ADP
fnp-6762	136	17	prerequisites	prerequisite	NOUN
fnp-6762	136	18	for	for	ADP
fnp-6762	136	19	ms	ms	PROPN
fnp-6762	136	20	development	development	NOUN
fnp-6762	136	21	in	in	ADP
fnp-6762	136	22	susceptible	susceptible	ADJ
fnp-6762	136	23	individuals	individual	NOUN
fnp-6762	136	24	,	,	PUNCT
fnp-6762	136	25	this	this	DET
fnp-6762	136	26	antibody	antibody	NOUN
fnp-6762	136	27	signature	signature	NOUN
fnp-6762	136	28	included	include	VERB
fnp-6762	136	29	a	a	DET
fnp-6762	136	30	common	common	ADJ
fnp-6762	136	31	motif	motif	NOUN
fnp-6762	136	32	observed	observe	VERB
fnp-6762	136	33	in	in	ADP
fnp-6762	136	34	several	several	ADJ
fnp-6762	136	35	human	human	ADJ
fnp-6762	136	36	infectious	infectious	ADJ
fnp-6762	136	37	pathogens	pathogen	NOUN
fnp-6762	136	38	,	,	PUNCT
fnp-6762	136	39	including	include	VERB
fnp-6762	136	40	ebv	ebv	NOUN
fnp-6762	136	41	.	.	PUNCT
fnp-6762	137	1	although	although	SCONJ
fnp-6762	137	2	present	present	ADJ
fnp-6762	137	3	in	in	ADP
fnp-6762	137	4	only	only	ADV
fnp-6762	137	5	a	a	DET
fnp-6762	137	6	smaller	small	ADJ
fnp-6762	137	7	subset	subset	NOUN
fnp-6762	137	8	of	of	ADP
fnp-6762	137	9	ms	ms	NOUN
fnp-6762	137	10	patients	patient	NOUN
fnp-6762	137	11	,	,	PUNCT
fnp-6762	137	12	these	these	DET
fnp-6762	137	13	findings	finding	NOUN
fnp-6762	137	14	raise	raise	VERB
fnp-6762	137	15	the	the	DET
fnp-6762	137	16	possibility	possibility	NOUN
fnp-6762	137	17	that	that	SCONJ
fnp-6762	137	18	at	at	ADV
fnp-6762	137	19	least	least	ADJ
fnp-6762	137	20	a	a	DET
fnp-6762	137	21	fraction	fraction	NOUN
fnp-6762	137	22	of	of	ADP
fnp-6762	137	23	individuals	individual	NOUN
fnp-6762	137	24	at	at	ADP
fnp-6762	137	25	high	high	ADJ
fnp-6762	137	26	risk	risk	NOUN
fnp-6762	137	27	of	of	ADP
fnp-6762	137	28	developing	develop	VERB
fnp-6762	137	29	ms	ms	NOUN
fnp-6762	137	30	could	could	AUX
fnp-6762	137	31	be	be	AUX
fnp-6762	137	32	identified	identify	VERB
fnp-6762	137	33	before	before	ADP
fnp-6762	137	34	clinical	clinical	ADJ
fnp-6762	137	35	disease	disease	NOUN
fnp-6762	137	36	onset	onset	VERB
fnp-6762	137	37	,	,	PUNCT
fnp-6762	137	38	potentially	potentially	ADV
fnp-6762	137	39	facilitating	facilitate	VERB
fnp-6762	137	40	the	the	DET
fnp-6762	137	41	implementation	implementation	NOUN
fnp-6762	137	42	of	of	ADP
fnp-6762	137	43	preventive	preventive	ADJ
fnp-6762	137	44	strategies	strategy	NOUN
fnp-6762	137	45	in	in	ADP
fnp-6762	137	46	the	the	DET
fnp-6762	137	47	future	future	NOUN
fnp-6762	137	48	.	.	PUNCT
fnp-6762	138	1	a	a	DET
fnp-6762	138	2	german	german	ADJ
fnp-6762	138	3	study	study	NOUN
fnp-6762	138	4	employed	employ	VERB
fnp-6762	138	5	high	high	ADJ
fnp-6762	138	6	-	-	PUNCT
fnp-6762	138	7	dimensional	dimensional	ADJ
fnp-6762	138	8	immunological	immunological	ADJ
fnp-6762	138	9	profiling	profiling	NOUN
fnp-6762	138	10	of	of	ADP
fnp-6762	138	11	peripheral	peripheral	ADJ
fnp-6762	138	12	blood	blood	NOUN
fnp-6762	138	13	in	in	ADP
fnp-6762	138	14	untreated	untreated	ADJ
fnp-6762	138	15	early	early	ADV
fnp-6762	138	16	ms	ms	ADJ
fnp-6762	138	17	patients	patient	NOUN
fnp-6762	138	18	to	to	PART
fnp-6762	138	19	identify	identify	VERB
fnp-6762	138	20	subgroups	subgroup	NOUN
fnp-6762	138	21	based	base	VERB
fnp-6762	138	22	on	on	ADP
fnp-6762	138	23	distinct	distinct	ADJ
fnp-6762	138	24	immunological	immunological	ADJ
fnp-6762	138	25	characteristics47	characteristics47	NOUN
fnp-6762	138	26	.	.	PUNCT
fnp-6762	139	1	this	this	DET
fnp-6762	139	2	approach	approach	NOUN
fnp-6762	139	3	enabled	enable	VERB
fnp-6762	139	4	the	the	DET
fnp-6762	139	5	identification	identification	NOUN
fnp-6762	139	6	of	of	ADP
fnp-6762	139	7	three	three	NUM
fnp-6762	139	8	distinct	distinct	ADJ
fnp-6762	139	9	subgroups	subgroup	NOUN
fnp-6762	139	10	with	with	ADP
fnp-6762	139	11	unique	unique	ADJ
fnp-6762	139	12	immune	immune	ADJ
fnp-6762	139	13	patterns	pattern	NOUN
fnp-6762	139	14	–	–	PUNCT
fnp-6762	139	15	one	one	NUM
fnp-6762	139	16	associated	associate	VERB
fnp-6762	139	17	with	with	ADP
fnp-6762	139	18	high	high	ADJ
fnp-6762	139	19	inflammatory	inflammatory	ADJ
fnp-6762	139	20	activity	activity	NOUN
fnp-6762	139	21	based	base	VERB
fnp-6762	139	22	on	on	ADP
fnp-6762	139	23	clinical	clinical	ADJ
fnp-6762	139	24	and	and	CCONJ
fnp-6762	139	25	imaging	imaging	NOUN
fnp-6762	139	26	measures	measure	NOUN
fnp-6762	139	27	,	,	PUNCT
fnp-6762	139	28	and	and	CCONJ
fnp-6762	139	29	another	another	PRON
fnp-6762	139	30	characterized	characterize	VERB
fnp-6762	139	31	by	by	ADP
fnp-6762	139	32	early	early	ADJ
fnp-6762	139	33	signs	sign	NOUN
fnp-6762	139	34	of	of	ADP
fnp-6762	139	35	tissue	tissue	NOUN
fnp-6762	139	36	destruction	destruction	NOUN
fnp-6762	139	37	and	and	CCONJ
fnp-6762	139	38	neurodegeneration	neurodegeneration	NOUN
fnp-6762	139	39	.	.	PUNCT
fnp-6762	140	1	notably	notably	ADV
fnp-6762	140	2	,	,	PUNCT
fnp-6762	140	3	these	these	DET
fnp-6762	140	4	subgroups	subgroup	NOUN
fnp-6762	140	5	not	not	PART
fnp-6762	140	6	only	only	ADV
fnp-6762	140	7	exhibited	exhibit	VERB
fnp-6762	140	8	differences	difference	NOUN
fnp-6762	140	9	in	in	ADP
fnp-6762	140	10	clinical	clinical	ADJ
fnp-6762	140	11	disease	disease	NOUN
fnp-6762	140	12	trajectories	trajectory	NOUN
fnp-6762	140	13	but	but	CCONJ
fnp-6762	140	14	also	also	ADV
fnp-6762	140	15	in	in	ADP
fnp-6762	140	16	response	response	NOUN
fnp-6762	140	17	to	to	ADP
fnp-6762	140	18	immune	immune	ADJ
fnp-6762	140	19	treatments	treatment	NOUN
fnp-6762	140	20	,	,	PUNCT
fnp-6762	140	21	highlighting	highlight	VERB
fnp-6762	140	22	that	that	SCONJ
fnp-6762	140	23	a	a	DET
fnp-6762	140	24	better	well	ADJ
fnp-6762	140	25	characterization	characterization	NOUN
fnp-6762	140	26	of	of	ADP
fnp-6762	140	27	distinct	distinct	ADJ
fnp-6762	140	28	immunobiological	immunobiological	ADJ
fnp-6762	140	29	patterns	pattern	NOUN
fnp-6762	140	30	may	may	AUX
fnp-6762	140	31	help	help	VERB
fnp-6762	140	32	predict	predict	VERB
fnp-6762	140	33	individual	individual	ADJ
fnp-6762	140	34	treatment	treatment	NOUN
fnp-6762	140	35	responses	response	NOUN
fnp-6762	140	36	in	in	ADP
fnp-6762	140	37	the	the	DET
fnp-6762	140	38	future	future	NOUN
fnp-6762	140	39	.	.	PUNCT
fnp-6762	141	1	similarly	similarly	ADV
fnp-6762	141	2	,	,	PUNCT
fnp-6762	141	3	analyzing	analyze	VERB
fnp-6762	141	4	the	the	DET
fnp-6762	141	5	so	so	ADV
fnp-6762	141	6	far	far	ADV
fnp-6762	141	7	largest	large	ADJ
fnp-6762	141	8	ms	ms	ADJ
fnp-6762	141	9	brain	brain	NOUN
fnp-6762	141	10	tissue	tissue	NOUN
fnp-6762	141	11	collection	collection	NOUN
fnp-6762	141	12	comprising	comprise	VERB
fnp-6762	141	13	normal	normal	ADJ
fnp-6762	141	14	appearing	appear	VERB
fnp-6762	141	15	white	white	ADJ
fnp-6762	141	16	matter	matter	NOUN
fnp-6762	141	17	as	as	ADV
fnp-6762	141	18	well	well	ADV
fnp-6762	141	19	as	as	ADP
fnp-6762	141	20	grey	grey	ADJ
fnp-6762	141	21	and	and	CCONJ
fnp-6762	141	22	white	white	ADJ
fnp-6762	141	23	matter	matter	NOUN
fnp-6762	141	24	lesions	lesion	NOUN
fnp-6762	141	25	revealed	reveal	VERB
fnp-6762	141	26	different	different	ADJ
fnp-6762	141	27	cellular	cellular	ADJ
fnp-6762	141	28	compositions	composition	NOUN
fnp-6762	141	29	between	between	ADP
fnp-6762	141	30	the	the	DET
fnp-6762	141	31	lesions	lesion	NOUN
fnp-6762	141	32	but	but	CCONJ
fnp-6762	141	33	surprisingly	surprisingly	ADV
fnp-6762	141	34	similar	similar	ADJ
fnp-6762	141	35	cell	cell	NOUN
fnp-6762	141	36	-	-	PUNCT
fnp-6762	141	37	type	type	NOUN
fnp-6762	141	38	gene	gene	NOUN
fnp-6762	141	39	expression	expression	NOUN
fnp-6762	141	40	patterns	pattern	NOUN
fnp-6762	141	41	both	both	CCONJ
fnp-6762	141	42	within	within	ADP
fnp-6762	141	43	and	and	CCONJ
fnp-6762	141	44	across	across	ADP
fnp-6762	141	45	patients	patient	NOUN
fnp-6762	141	46	,	,	PUNCT
fnp-6762	141	47	suggesting	suggest	VERB
fnp-6762	141	48	patient	patient	NOUN
fnp-6762	141	49	-	-	PUNCT
fnp-6762	141	50	dependent	dependent	ADJ
fnp-6762	141	51	global	global	ADJ
fnp-6762	141	52	changes	change	NOUN
fnp-6762	141	53	.	.	PUNCT
fnp-6762	142	1	based	base	VERB
fnp-6762	142	2	on	on	ADP
fnp-6762	142	3	these	these	DET
fnp-6762	142	4	observations	observation	NOUN
fnp-6762	142	5	,	,	PUNCT
fnp-6762	142	6	the	the	DET
fnp-6762	142	7	authors	author	NOUN
fnp-6762	142	8	stratified	stratify	VERB
fnp-6762	142	9	the	the	DET
fnp-6762	142	10	patients	patient	NOUN
fnp-6762	142	11	into	into	ADP
fnp-6762	142	12	different	different	ADJ
fnp-6762	142	13	molecular	molecular	ADJ
fnp-6762	142	14	subgroups	subgroup	NOUN
fnp-6762	142	15	suggesting	suggest	VERB
fnp-6762	142	16	that	that	SCONJ
fnp-6762	142	17	different	different	ADJ
fnp-6762	142	18	molecular	molecular	ADJ
fnp-6762	142	19	mechanisms	mechanism	NOUN
fnp-6762	142	20	may	may	AUX
fnp-6762	142	21	drive	drive	VERB
fnp-6762	142	22	pathophysiology	pathophysiology	NOUN
fnp-6762	142	23	and	and	CCONJ
fnp-6762	142	24	predict	predict	VERB
fnp-6762	142	25	response	response	NOUN
fnp-6762	142	26	to	to	ADP
fnp-6762	142	27	treatments	treatment	NOUN
fnp-6762	142	28	targeting	target	VERB
fnp-6762	142	29	cns	cns	NOUN
fnp-6762	142	30	intrinsic	intrinsic	ADJ
fnp-6762	142	31	disease	disease	NOUN
fnp-6762	142	32	mechanism	mechanism	NOUN
fnp-6762	142	33	.	.	PUNCT
fnp-6762	143	1	however	however	ADV
fnp-6762	143	2	,	,	PUNCT
fnp-6762	143	3	the	the	DET
fnp-6762	143	4	correlation	correlation	NOUN
fnp-6762	143	5	of	of	ADP
fnp-6762	143	6	these	these	DET
fnp-6762	143	7	molecular	molecular	ADJ
fnp-6762	143	8	subtypes	subtype	NOUN
fnp-6762	143	9	with	with	ADP
fnp-6762	143	10	pathological	pathological	ADJ
fnp-6762	143	11	or	or	CCONJ
fnp-6762	143	12	clinical	clinical	ADJ
fnp-6762	143	13	disease	disease	NOUN
fnp-6762	143	14	trajectories	trajectory	NOUN
fnp-6762	143	15	has	have	AUX
fnp-6762	143	16	not	not	PART
fnp-6762	143	17	yet	yet	ADV
fnp-6762	143	18	been	be	AUX
fnp-6762	143	19	established22	established22	NOUN
fnp-6762	143	20	.	.	PUNCT
fnp-6762	144	1	novel	novel	NOUN
fnp-6762	144	2	advances	advance	NOUN
fnp-6762	144	3	in	in	ADP
fnp-6762	144	4	imaging	imaging	NOUN
fnp-6762	144	5	to	to	PART
fnp-6762	144	6	detect	detect	VERB
fnp-6762	144	7	disease	disease	NOUN
fnp-6762	144	8	progression	progression	NOUN
fnp-6762	144	9	conventional	conventional	ADJ
fnp-6762	144	10	mri	mri	NOUN
fnp-6762	144	11	detects	detect	NOUN
fnp-6762	144	12	focal	focal	ADJ
fnp-6762	144	13	lesions	lesion	NOUN
fnp-6762	144	14	with	with	ADP
fnp-6762	144	15	great	great	ADJ
fnp-6762	144	16	sensitivity	sensitivity	NOUN
fnp-6762	144	17	,	,	PUNCT
fnp-6762	144	18	but	but	CCONJ
fnp-6762	144	19	it	it	PRON
fnp-6762	144	20	does	do	AUX
fnp-6762	144	21	not	not	PART
fnp-6762	144	22	perform	perform	VERB
fnp-6762	144	23	well	well	ADV
fnp-6762	144	24	in	in	ADP
fnp-6762	144	25	detecting	detect	VERB
fnp-6762	144	26	the	the	DET
fnp-6762	144	27	diffuse	diffuse	ADJ
fnp-6762	144	28	pathology	pathology	NOUN
fnp-6762	144	29	responsible	responsible	ADJ
fnp-6762	144	30	for	for	ADP
fnp-6762	144	31	pira	pira	NOUN
fnp-6762	144	32	.	.	PUNCT
fnp-6762	145	1	the	the	DET
fnp-6762	145	2	imminent	imminent	ADJ
fnp-6762	145	3	need	need	NOUN
fnp-6762	145	4	of	of	ADP
fnp-6762	145	5	treatments	treatment	NOUN
fnp-6762	145	6	for	for	ADP
fnp-6762	145	7	slowing	slow	VERB
fnp-6762	145	8	down	down	ADP
fnp-6762	145	9	disease	disease	NOUN
fnp-6762	145	10	progression	progression	NOUN
fnp-6762	145	11	in	in	ADP
fnp-6762	145	12	ms	ms	PROPN
fnp-6762	145	13	has	have	AUX
fnp-6762	145	14	prompted	prompt	VERB
fnp-6762	145	15	wide	wide	ADJ
fnp-6762	145	16	interest	interest	NOUN
fnp-6762	145	17	in	in	ADP
fnp-6762	145	18	the	the	DET
fnp-6762	145	19	application	application	NOUN
fnp-6762	145	20	of	of	ADP
fnp-6762	145	21	advanced	advanced	ADJ
fnp-6762	145	22	imaging	imaging	NOUN
fnp-6762	145	23	methods	method	NOUN
fnp-6762	145	24	to	to	PART
fnp-6762	145	25	better	well	ADV
fnp-6762	145	26	understand	understand	VERB
fnp-6762	145	27	and	and	CCONJ
fnp-6762	145	28	assess	assess	VERB
fnp-6762	145	29	the	the	DET
fnp-6762	145	30	progression	progression	NOUN
fnp-6762	145	31	-	-	PUNCT
fnp-6762	145	32	promoting	promote	VERB
fnp-6762	145	33	pathological	pathological	ADJ
fnp-6762	145	34	processes	process	NOUN
fnp-6762	145	35	within	within	ADP
fnp-6762	145	36	the	the	DET
fnp-6762	145	37	cns	cns	NOUN
fnp-6762	145	38	.	.	PUNCT
fnp-6762	146	1	a	a	DET
fnp-6762	146	2	number	number	NOUN
fnp-6762	146	3	of	of	ADP
fnp-6762	146	4	comprehensive	comprehensive	ADJ
fnp-6762	146	5	review	review	NOUN
fnp-6762	146	6	articles	article	NOUN
fnp-6762	146	7	on	on	ADP
fnp-6762	146	8	imaging	imaging	NOUN
fnp-6762	146	9	of	of	ADP
fnp-6762	146	10	focal	focal	ADJ
fnp-6762	146	11	and	and	CCONJ
fnp-6762	146	12	diffuse	diffuse	VERB
fnp-6762	146	13	compartmentalized	compartmentalized	ADJ
fnp-6762	146	14	inflammatory	inflammatory	ADJ
fnp-6762	146	15	and	and	CCONJ
fnp-6762	146	16	neurodegenerative	neurodegenerative	ADJ
fnp-6762	146	17	processes	process	NOUN
fnp-6762	146	18	were	be	AUX
fnp-6762	146	19	published	publish	VERB
fnp-6762	146	20	in	in	ADP
fnp-6762	146	21	202448–53	202448–53	NUM
fnp-6762	146	22	.	.	PUNCT
fnp-6762	147	1	potential	potential	ADJ
fnp-6762	147	2	imaging	imaging	NOUN
fnp-6762	147	3	biomarkers	biomarker	NOUN
fnp-6762	147	4	of	of	ADP
fnp-6762	147	5	ms	ms	NOUN
fnp-6762	147	6	progression	progression	NOUN
fnp-6762	147	7	include	include	VERB
fnp-6762	147	8	detection	detection	NOUN
fnp-6762	147	9	of	of	ADP
fnp-6762	147	10	paramagnetic	paramagnetic	ADJ
fnp-6762	147	11	lesions	lesion	NOUN
fnp-6762	147	12	(	(	PUNCT
fnp-6762	147	13	prls	prl	NOUN
fnp-6762	147	14	)	)	PUNCT
fnp-6762	147	15	using	use	VERB
fnp-6762	147	16	iron	iron	NOUN
fnp-6762	147	17	-	-	PUNCT
fnp-6762	147	18	sensitive	sensitive	ADJ
fnp-6762	147	19	mri	mri	NOUN
fnp-6762	147	20	sequences	sequence	NOUN
fnp-6762	147	21	,	,	PUNCT
fnp-6762	147	22	identification	identification	NOUN
fnp-6762	147	23	of	of	ADP
fnp-6762	147	24	cortical	cortical	ADJ
fnp-6762	147	25	lesions	lesion	NOUN
fnp-6762	147	26	using	use	VERB
fnp-6762	147	27	double	double	ADJ
fnp-6762	147	28	inversion	inversion	NOUN
fnp-6762	147	29	recovery	recovery	NOUN
fnp-6762	147	30	(	(	PUNCT
fnp-6762	147	31	dir	dir	PROPN
fnp-6762	147	32	)	)	PUNCT
fnp-6762	147	33	,	,	PUNCT
fnp-6762	147	34	assessment	assessment	NOUN
fnp-6762	147	35	of	of	ADP
fnp-6762	147	36	grey	grey	PROPN
fnp-6762	147	37	matter	matter	NOUN
fnp-6762	147	38	damage	damage	NOUN
fnp-6762	147	39	,	,	PUNCT
fnp-6762	147	40	and	and	CCONJ
fnp-6762	147	41	measurement	measurement	NOUN
fnp-6762	147	42	of	of	ADP
fnp-6762	147	43	choroid	choroid	NOUN
fnp-6762	147	44	plexus	plexus	NOUN
fnp-6762	147	45	volume	volume	NOUN
fnp-6762	147	46	.	.	PUNCT
fnp-6762	148	1	in	in	ADP
fnp-6762	148	2	advanced	advanced	ADJ
fnp-6762	148	3	clinical	clinical	ADJ
fnp-6762	148	4	imaging	imaging	NOUN
fnp-6762	148	5	,	,	PUNCT
fnp-6762	148	6	prls	prl	NOUN
fnp-6762	148	7	,	,	PUNCT
fnp-6762	148	8	slowly	slowly	ADV
fnp-6762	148	9	expanding	expand	VERB
fnp-6762	148	10	lesions	lesion	NOUN
fnp-6762	148	11	(	(	PUNCT
fnp-6762	148	12	sels	sel	NOUN
fnp-6762	148	13	)	)	PUNCT
fnp-6762	148	14	and	and	CCONJ
fnp-6762	148	15	tspo	tspo	NOUN
fnp-6762	148	16	-	-	PUNCT
fnp-6762	148	17	rim	rim	NOUN
fnp-6762	148	18	-	-	PUNCT
fnp-6762	148	19	active	active	ADJ
fnp-6762	148	20	lesions	lesion	NOUN
fnp-6762	148	21	are	be	AUX
fnp-6762	148	22	considered	consider	VERB
fnp-6762	148	23	to	to	PART
fnp-6762	148	24	represent	represent	VERB
fnp-6762	148	25	chronic	chronic	ADJ
fnp-6762	148	26	active	active	ADJ
fnp-6762	148	27	lesions	lesion	NOUN
fnp-6762	148	28	(	(	PUNCT
fnp-6762	148	29	cals	cal	NOUN
fnp-6762	148	30	)	)	PUNCT
fnp-6762	148	31	(	(	PUNCT
fnp-6762	148	32	also	also	ADV
fnp-6762	148	33	termed	term	VERB
fnp-6762	148	34	mixed	mixed	ADJ
fnp-6762	148	35	active	active	ADJ
fnp-6762	148	36	/	/	SYM
fnp-6762	148	37	inactive	inactive	ADJ
fnp-6762	148	38	lesions)50	lesions)50	PROPN
fnp-6762	148	39	,	,	PUNCT
fnp-6762	148	40	which	which	PRON
fnp-6762	148	41	are	be	AUX
fnp-6762	148	42	characterized	characterize	VERB
fnp-6762	148	43	by	by	ADP
fnp-6762	148	44	a	a	DET
fnp-6762	148	45	hypocellular	hypocellular	ADJ
fnp-6762	148	46	lesion	lesion	NOUN
fnp-6762	148	47	center	center	NOUN
fnp-6762	148	48	and	and	CCONJ
fnp-6762	148	49	a	a	DET
fnp-6762	148	50	rim	rim	NOUN
fnp-6762	148	51	of	of	ADP
fnp-6762	148	52	macrophages	macrophage	NOUN
fnp-6762	148	53	/	/	SYM
fnp-6762	148	54	microglia	microglia	ADJ
fnp-6762	148	55	(	(	PUNCT
fnp-6762	148	56	fig	fig	NOUN
fnp-6762	148	57	.	.	PUNCT
fnp-6762	148	58	 	 	SPACE
fnp-6762	148	59	2	2	NUM
fnp-6762	148	60	)	)	PUNCT
fnp-6762	148	61	.	.	PUNCT
fnp-6762	149	1	however	however	ADV
fnp-6762	149	2	,	,	PUNCT
fnp-6762	149	3	which	which	PRON
fnp-6762	149	4	of	of	ADP
fnp-6762	149	5	these	these	DET
fnp-6762	149	6	different	different	ADJ
fnp-6762	149	7	methods	method	NOUN
fnp-6762	149	8	is	be	AUX
fnp-6762	149	9	the	the	DET
fnp-6762	149	10	best	good	ADJ
fnp-6762	149	11	predictor	predictor	NOUN
fnp-6762	149	12	of	of	ADP
fnp-6762	149	13	disease	disease	NOUN
fnp-6762	149	14	progression	progression	NOUN
fnp-6762	149	15	has	have	VERB
fnp-6762	149	16	yet	yet	ADV
fnp-6762	149	17	to	to	PART
fnp-6762	149	18	be	be	AUX
fnp-6762	149	19	determined	determine	VERB
fnp-6762	149	20	.	.	PUNCT
fnp-6762	150	1	notably	notably	ADV
fnp-6762	150	2	,	,	PUNCT
fnp-6762	150	3	recent	recent	ADJ
fnp-6762	150	4	work	work	NOUN
fnp-6762	150	5	suggests	suggest	VERB
fnp-6762	150	6	that	that	SCONJ
fnp-6762	150	7	there	there	PRON
fnp-6762	150	8	is	be	VERB
fnp-6762	150	9	only	only	ADV
fnp-6762	150	10	partial	partial	ADJ
fnp-6762	150	11	overlap	overlap	NOUN
fnp-6762	150	12	in	in	ADP
fnp-6762	150	13	cal	cal	ADJ
fnp-6762	150	14	-	-	PUNCT
fnp-6762	150	15	detection	detection	NOUN
fnp-6762	150	16	using	use	VERB
fnp-6762	150	17	these	these	DET
fnp-6762	150	18	imaging	imaging	NOUN
fnp-6762	150	19	methods	method	NOUN
fnp-6762	150	20	.	.	PUNCT
fnp-6762	151	1	here	here	ADV
fnp-6762	151	2	,	,	PUNCT
fnp-6762	151	3	numbers	number	NOUN
fnp-6762	151	4	of	of	ADP
fnp-6762	151	5	sels	sel	NOUN
fnp-6762	151	6	were	be	AUX
fnp-6762	151	7	shown	show	VERB
fnp-6762	151	8	to	to	PART
fnp-6762	151	9	be	be	AUX
fnp-6762	151	10	higher	high	ADJ
fnp-6762	151	11	than	than	ADP
fnp-6762	151	12	those	those	PRON
fnp-6762	151	13	of	of	ADP
fnp-6762	151	14	prls	prl	NOUN
fnp-6762	151	15	(	(	PUNCT
fnp-6762	151	16	616	616	NUM
fnp-6762	151	17	vs	vs	ADP
fnp-6762	151	18	80	80	NUM
fnp-6762	151	19	)	)	PUNCT
fnp-6762	151	20	,	,	PUNCT
fnp-6762	151	21	and	and	CCONJ
fnp-6762	151	22	the	the	DET
fnp-6762	151	23	correlation	correlation	NOUN
fnp-6762	151	24	between	between	ADP
fnp-6762	151	25	lesion	lesion	NOUN
fnp-6762	151	26	counts	count	NOUN
fnp-6762	151	27	was	be	AUX
fnp-6762	151	28	quite	quite	ADV
fnp-6762	151	29	moderate	moderate	ADJ
fnp-6762	151	30	(	(	PUNCT
fnp-6762	151	31	ρ	ρ	NOUN
fnp-6762	151	32	 	 	SPACE
fnp-6762	151	33	=	=	NOUN
fnp-6762	151	34	 	 	SPACE
fnp-6762	151	35	0.28	0.28	NUM
fnp-6762	151	36	,	,	PUNCT
fnp-6762	151	37	p	p	X
fnp-6762	151	38	 	 	SPACE
fnp-6762	151	39	=	=	NOUN
fnp-6762	151	40	 	 	SPACE
fnp-6762	151	41	0.03)54	0.03)54	NOUN
fnp-6762	151	42	.	.	PUNCT
fnp-6762	152	1	this	this	PRON
fnp-6762	152	2	suggests	suggest	VERB
fnp-6762	152	3	that	that	SCONJ
fnp-6762	152	4	sel	sel	PROPN
fnp-6762	152	5	and	and	CCONJ
fnp-6762	152	6	prl	prl	PROPN
fnp-6762	152	7	may	may	AUX
fnp-6762	152	8	capture	capture	VERB
fnp-6762	152	9	distinct	distinct	ADJ
fnp-6762	152	10	pathophysiological	pathophysiological	ADJ
fnp-6762	152	11	features	feature	NOUN
fnp-6762	152	12	of	of	ADP
fnp-6762	152	13	chronic	chronic	ADJ
fnp-6762	152	14	active	active	ADJ
fnp-6762	152	15	lesions	lesion	NOUN
fnp-6762	152	16	.	.	PUNCT
fnp-6762	153	1	similarly	similarly	ADV
fnp-6762	153	2	,	,	PUNCT
fnp-6762	153	3	based	base	VERB
fnp-6762	153	4	on	on	ADP
fnp-6762	153	5	a	a	DET
fnp-6762	153	6	recent	recent	ADJ
fnp-6762	153	7	publication	publication	NOUN
fnp-6762	153	8	,	,	PUNCT
fnp-6762	153	9	tspo	tspo	NOUN
fnp-6762	153	10	-	-	PUNCT
fnp-6762	153	11	pet	pet	NOUN
fnp-6762	153	12	has	have	VERB
fnp-6762	153	13	a	a	DET
fnp-6762	153	14	higher	high	ADJ
fnp-6762	153	15	sensitivity	sensitivity	NOUN
fnp-6762	153	16	to	to	PART
fnp-6762	153	17	detect	detect	VERB
fnp-6762	153	18	more	more	ADJ
fnp-6762	153	19	cals	cal	NOUN
fnp-6762	153	20	compared	compare	VERB
fnp-6762	153	21	to	to	ADP
fnp-6762	153	22	susceptibility	susceptibility	NOUN
fnp-6762	153	23	weighted	weight	VERB
fnp-6762	153	24	mri	mri	NOUN
fnp-6762	153	25	,	,	PUNCT
fnp-6762	153	26	although	although	SCONJ
fnp-6762	153	27	there	there	PRON
fnp-6762	153	28	was	be	VERB
fnp-6762	153	29	a	a	DET
fnp-6762	153	30	correlation	correlation	NOUN
fnp-6762	153	31	between	between	ADP
fnp-6762	153	32	the	the	DET
fnp-6762	153	33	number	number	NOUN
fnp-6762	153	34	of	of	ADP
fnp-6762	153	35	11c	11c	NOUN
fnp-6762	153	36	-	-	PUNCT
fnp-6762	153	37	pbr28	pbr28	NOUN
fnp-6762	153	38	active	active	ADJ
fnp-6762	153	39	lesions	lesion	NOUN
fnp-6762	153	40	and	and	CCONJ
fnp-6762	153	41	prls	prl	NOUN
fnp-6762	153	42	in	in	ADP
fnp-6762	153	43	7	7	NUM
fnp-6762	153	44	t	t	NOUN
fnp-6762	153	45	phase	phase	NOUN
fnp-6762	153	46	images55	images55	NOUN
fnp-6762	153	47	.	.	PUNCT
fnp-6762	154	1	moreover	moreover	ADV
fnp-6762	154	2	,	,	PUNCT
fnp-6762	154	3	this	this	DET
fnp-6762	154	4	study	study	NOUN
fnp-6762	154	5	found	find	VERB
fnp-6762	154	6	that	that	SCONJ
fnp-6762	154	7	tspo	tspo	NOUN
fnp-6762	154	8	-	-	PUNCT
fnp-6762	154	9	pet	pet	NOUN
fnp-6762	154	10	whole	whole	ADJ
fnp-6762	154	11	active	active	ADJ
fnp-6762	154	12	lesion	lesion	NOUN
fnp-6762	154	13	volume	volume	NOUN
fnp-6762	154	14	had	have	VERB
fnp-6762	154	15	the	the	DET
fnp-6762	154	16	strongest	strong	ADJ
fnp-6762	154	17	association	association	NOUN
fnp-6762	154	18	with	with	ADP
fnp-6762	154	19	the	the	DET
fnp-6762	154	20	edss	edss	ADJ
fnp-6762	154	21	score	score	NOUN
fnp-6762	154	22	in	in	ADP
fnp-6762	154	23	a	a	DET
fnp-6762	154	24	cohort	cohort	NOUN
fnp-6762	154	25	of	of	ADP
fnp-6762	154	26	30	30	NUM
fnp-6762	154	27	study	study	NOUN
fnp-6762	154	28	patients	patient	NOUN
fnp-6762	154	29	including	include	VERB
fnp-6762	154	30	equal	equal	ADJ
fnp-6762	154	31	numbers	number	NOUN
fnp-6762	154	32	of	of	ADP
fnp-6762	154	33	patients	patient	NOUN
fnp-6762	154	34	with	with	ADP
fnp-6762	154	35	rrms	rrm	NOUN
fnp-6762	154	36	and	and	CCONJ
fnp-6762	154	37	spms55	spms55	NOUN
fnp-6762	154	38	.	.	PUNCT
fnp-6762	155	1	prls	prl	NOUN
fnp-6762	155	2	have	have	AUX
fnp-6762	155	3	been	be	AUX
fnp-6762	155	4	particularly	particularly	ADV
fnp-6762	155	5	widely	widely	ADV
fnp-6762	155	6	studied	study	VERB
fnp-6762	155	7	during	during	ADP
fnp-6762	155	8	the	the	DET
fnp-6762	155	9	past	past	ADJ
fnp-6762	155	10	years	year	NOUN
fnp-6762	155	11	and	and	CCONJ
fnp-6762	155	12	are	be	AUX
fnp-6762	155	13	now	now	ADV
fnp-6762	155	14	considered	consider	VERB
fnp-6762	155	15	a	a	DET
fnp-6762	155	16	predictive	predictive	ADJ
fnp-6762	155	17	imaging	imaging	NOUN
fnp-6762	155	18	biomarker	biomarker	NOUN
fnp-6762	155	19	for	for	ADP
fnp-6762	155	20	greater	great	ADJ
fnp-6762	155	21	disease	disease	NOUN
fnp-6762	155	22	severity	severity	NOUN
fnp-6762	155	23	and	and	CCONJ
fnp-6762	155	24	progression	progression	NOUN
fnp-6762	155	25	and	and	CCONJ
fnp-6762	155	26	correlates	correlate	VERB
fnp-6762	155	27	with	with	ADP
fnp-6762	155	28	brain	brain	NOUN
fnp-6762	155	29	and	and	CCONJ
fnp-6762	155	30	spinal	spinal	ADJ
fnp-6762	155	31	cord	cord	NOUN
fnp-6762	155	32	atrophy53	atrophy53	NOUN
fnp-6762	155	33	.	.	PUNCT
fnp-6762	156	1	a	a	DET
fnp-6762	156	2	consensus	consensus	NOUN
fnp-6762	156	3	statement	statement	NOUN
fnp-6762	156	4	developed	develop	VERB
fnp-6762	156	5	by	by	ADP
fnp-6762	156	6	the	the	DET
fnp-6762	156	7	north	north	ADJ
fnp-6762	156	8	american	american	ADJ
fnp-6762	156	9	imaging	imaging	NOUN
fnp-6762	156	10	in	in	ADP
fnp-6762	156	11	multiple	multiple	ADJ
fnp-6762	156	12	sclerosis	sclerosis	NOUN
fnp-6762	156	13	(	(	PUNCT
fnp-6762	156	14	naims	naims	PROPN
fnp-6762	156	15	)	)	PUNCT
fnp-6762	156	16	cooperative	cooperative	NOUN
fnp-6762	156	17	published	publish	VERB
fnp-6762	156	18	in	in	ADP
fnp-6762	156	19	2024	2024	NUM
fnp-6762	156	20	provides	provide	VERB
fnp-6762	156	21	guidance	guidance	NOUN
fnp-6762	156	22	for	for	ADP
fnp-6762	156	23	the	the	DET
fnp-6762	156	24	definition	definition	NOUN
fnp-6762	156	25	and	and	CCONJ
fnp-6762	156	26	measurement	measurement	NOUN
fnp-6762	156	27	of	of	ADP
fnp-6762	156	28	prls	prl	NOUN
fnp-6762	156	29	to	to	PART
fnp-6762	156	30	promote	promote	VERB
fnp-6762	156	31	their	their	PRON
fnp-6762	156	32	clinical	clinical	ADJ
fnp-6762	156	33	translation51	translation51	NOUN
fnp-6762	156	34	.	.	PUNCT
fnp-6762	157	1	this	this	PRON
fnp-6762	157	2	also	also	ADV
fnp-6762	157	3	prompted	prompt	VERB
fnp-6762	157	4	their	their	PRON
fnp-6762	157	5	inclusion	inclusion	NOUN
fnp-6762	157	6	in	in	ADP
fnp-6762	157	7	the	the	DET
fnp-6762	157	8	new	new	ADJ
fnp-6762	157	9	diagnostic	diagnostic	ADJ
fnp-6762	157	10	criteria	criterion	NOUN
fnp-6762	157	11	for	for	ADP
fnp-6762	157	12	ms	ms	NOUN
fnp-6762	157	13	as	as	SCONJ
fnp-6762	157	14	described	describe	VERB
fnp-6762	157	15	above	above	ADV
fnp-6762	157	16	.	.	PUNCT
fnp-6762	158	1	figure	figure	NOUN
fnp-6762	158	2	 	 	SPACE
fnp-6762	158	3	2	2	NUM
fnp-6762	158	4	:	:	PUNCT
fnp-6762	158	5	histological	histological	ADJ
fnp-6762	158	6	and	and	CCONJ
fnp-6762	158	7	imaging	imaging	NOUN
fnp-6762	158	8	detection	detection	NOUN
fnp-6762	158	9	of	of	ADP
fnp-6762	158	10	chronic	chronic	ADJ
fnp-6762	158	11	active	active	ADJ
fnp-6762	158	12	lesions	lesion	NOUN
fnp-6762	158	13	.	.	PUNCT
fnp-6762	159	1	histological	histological	ADJ
fnp-6762	159	2	characterization	characterization	NOUN
fnp-6762	159	3	of	of	ADP
fnp-6762	159	4	a	a	DET
fnp-6762	159	5	chronic	chronic	ADJ
fnp-6762	159	6	active	active	ADJ
fnp-6762	159	7	lesions	lesion	NOUN
fnp-6762	159	8	(=	(=	ADV
fnp-6762	159	9	mixed	mix	VERB
fnp-6762	159	10	active	active	ADJ
fnp-6762	159	11	/	/	SYM
fnp-6762	159	12	inactive	inactive	ADJ
fnp-6762	159	13	lesions	lesion	NOUN
fnp-6762	159	14	)	)	PUNCT
fnp-6762	159	15	(	(	PUNCT
fnp-6762	159	16	a	a	DET
fnp-6762	159	17	to	to	PART
fnp-6762	159	18	d	d	NOUN
fnp-6762	159	19	)	)	PUNCT
fnp-6762	159	20	.	.	PUNCT
fnp-6762	160	1	the	the	DET
fnp-6762	160	2	lesion	lesion	NOUN
fnp-6762	160	3	is	be	AUX
fnp-6762	160	4	completely	completely	ADV
fnp-6762	160	5	demyelinated	demyelinated	ADJ
fnp-6762	160	6	and	and	CCONJ
fnp-6762	160	7	has	have	VERB
fnp-6762	160	8	a	a	DET
fnp-6762	160	9	sharp	sharp	ADJ
fnp-6762	160	10	border	border	NOUN
fnp-6762	160	11	to	to	ADP
fnp-6762	160	12	the	the	DET
fnp-6762	160	13	adjacent	adjacent	ADJ
fnp-6762	160	14	normal	normal	ADJ
fnp-6762	160	15	appearing	appearing	ADJ
fnp-6762	160	16	white	white	ADJ
fnp-6762	160	17	matter	matter	NOUN
fnp-6762	160	18	(	(	PUNCT
fnp-6762	160	19	luxol	luxol	NOUN
fnp-6762	160	20	-	-	PUNCT
fnp-6762	160	21	fast	fast	ADV
fnp-6762	160	22	blue	blue	ADJ
fnp-6762	160	23	staining	staining	NOUN
fnp-6762	160	24	)	)	PUNCT
fnp-6762	160	25	(	(	PUNCT
fnp-6762	160	26	a	a	X
fnp-6762	160	27	)	)	PUNCT
fnp-6762	160	28	.	.	PUNCT
fnp-6762	161	1	chronic	chronic	ADJ
fnp-6762	161	2	active	active	ADJ
fnp-6762	161	3	lesions	lesion	NOUN
fnp-6762	161	4	are	be	AUX
fnp-6762	161	5	characterized	characterize	VERB
fnp-6762	161	6	by	by	ADP
fnp-6762	161	7	a	a	DET
fnp-6762	161	8	rim	rim	NOUN
fnp-6762	161	9	of	of	ADP
fnp-6762	161	10	myeloid	myeloid	ADJ
fnp-6762	161	11	cells	cell	NOUN
fnp-6762	161	12	expressing	express	VERB
fnp-6762	161	13	cd68	cd68	PROPN
fnp-6762	161	14	and	and	CCONJ
fnp-6762	161	15	tspo	tspo	NOUN
fnp-6762	161	16	(	(	PUNCT
fnp-6762	161	17	b	b	PROPN
fnp-6762	161	18	and	and	CCONJ
fnp-6762	161	19	c	c	NOUN
fnp-6762	161	20	)	)	PUNCT
fnp-6762	161	21	.	.	PUNCT
fnp-6762	162	1	a	a	DET
fnp-6762	162	2	subset	subset	NOUN
fnp-6762	162	3	of	of	ADP
fnp-6762	162	4	chronic	chronic	ADJ
fnp-6762	162	5	active	active	ADJ
fnp-6762	162	6	lesions	lesion	NOUN
fnp-6762	162	7	displays	display	VERB
fnp-6762	162	8	a	a	DET
fnp-6762	162	9	dense	dense	ADJ
fnp-6762	162	10	rim	rim	NOUN
fnp-6762	162	11	of	of	ADP
fnp-6762	162	12	myeloid	myeloid	ADJ
fnp-6762	162	13	cells	cell	NOUN
fnp-6762	162	14	with	with	ADP
fnp-6762	162	15	cytoplasmic	cytoplasmic	ADJ
fnp-6762	162	16	iron	iron	NOUN
fnp-6762	162	17	depositions	deposition	NOUN
fnp-6762	162	18	(	(	PUNCT
fnp-6762	162	19	turnbull	turnbull	PROPN
fnp-6762	162	20	staining	stain	VERB
fnp-6762	162	21	)	)	PUNCT
fnp-6762	162	22	(	(	PUNCT
fnp-6762	162	23	d	d	NOUN
fnp-6762	162	24	)	)	PUNCT
fnp-6762	162	25	.	.	PUNCT
fnp-6762	163	1	different	different	ADJ
fnp-6762	163	2	imaging	imaging	NOUN
fnp-6762	163	3	techniques	technique	NOUN
fnp-6762	163	4	,	,	PUNCT
fnp-6762	163	5	such	such	ADJ
fnp-6762	163	6	as	as	ADP
fnp-6762	163	7	tspo	tspo	NOUN
fnp-6762	163	8	-	-	PUNCT
fnp-6762	163	9	pet	pet	NOUN
fnp-6762	163	10	and	and	CCONJ
fnp-6762	163	11	quantitative	quantitative	ADJ
fnp-6762	163	12	susceptibility	susceptibility	NOUN
fnp-6762	163	13	mapping	mapping	NOUN
fnp-6762	163	14	(	(	PUNCT
fnp-6762	163	15	qsm	qsm	PROPN
fnp-6762	163	16	)	)	PUNCT
fnp-6762	163	17	are	be	AUX
fnp-6762	163	18	currently	currently	ADV
fnp-6762	163	19	used	use	VERB
fnp-6762	163	20	to	to	PART
fnp-6762	163	21	identify	identify	VERB
fnp-6762	163	22	this	this	DET
fnp-6762	163	23	lesion	lesion	NOUN
fnp-6762	163	24	type	type	NOUN
fnp-6762	163	25	in	in	ADP
fnp-6762	163	26	individuals	individual	NOUN
fnp-6762	163	27	with	with	ADP
fnp-6762	163	28	ms	ms	PROPN
fnp-6762	163	29	(	(	PUNCT
fnp-6762	163	30	e	e	NOUN
fnp-6762	163	31	to	to	ADP
fnp-6762	163	32	g	g	PROPN
fnp-6762	163	33	)	)	PUNCT
fnp-6762	163	34	.	.	PUNCT
fnp-6762	164	1	the	the	DET
fnp-6762	164	2	red	red	ADJ
fnp-6762	164	3	circle	circle	PROPN
fnp-6762	164	4	in	in	ADP
fnp-6762	164	5	indicates	indicate	VERB
fnp-6762	164	6	a	a	DET
fnp-6762	164	7	hypointense	hypointense	NOUN
fnp-6762	164	8	t1	t1	NOUN
fnp-6762	164	9	lesions	lesion	NOUN
fnp-6762	164	10	(	(	PUNCT
fnp-6762	164	11	e	e	NOUN
fnp-6762	164	12	)	)	PUNCT
fnp-6762	164	13	,	,	PUNCT
fnp-6762	164	14	that	that	PRON
fnp-6762	164	15	displays	display	VERB
fnp-6762	164	16	a	a	DET
fnp-6762	164	17	tspo	tspo	NOUN
fnp-6762	164	18	positive	positive	ADJ
fnp-6762	164	19	rim	rim	NOUN
fnp-6762	164	20	in	in	ADP
fnp-6762	164	21	tspo	tspo	PROPN
fnp-6762	164	22	pet	pet	NOUN
fnp-6762	164	23	(	(	PUNCT
fnp-6762	164	24	ral	ral	ADJ
fnp-6762	164	25	:	:	PUNCT
fnp-6762	164	26	rim	rim	VERB
fnp-6762	164	27	active	active	ADJ
fnp-6762	164	28	lesion	lesion	NOUN
fnp-6762	164	29	)	)	PUNCT
fnp-6762	164	30	(	(	PUNCT
fnp-6762	164	31	f	f	X
fnp-6762	164	32	)	)	PUNCT
fnp-6762	164	33	and	and	CCONJ
fnp-6762	164	34	a	a	DET
fnp-6762	164	35	paramagnetic	paramagnetic	ADJ
fnp-6762	164	36	rim	rim	NOUN
fnp-6762	164	37	in	in	ADP
fnp-6762	164	38	qsm	qsm	PROPN
fnp-6762	164	39	(	(	PUNCT
fnp-6762	164	40	prl	prl	NOUN
fnp-6762	164	41	:	:	PUNCT
fnp-6762	164	42	paramagnetic	paramagnetic	ADJ
fnp-6762	164	43	rim	rim	NOUN
fnp-6762	164	44	lesion	lesion	NOUN
fnp-6762	164	45	)	)	PUNCT
fnp-6762	164	46	(	(	PUNCT
fnp-6762	164	47	g	g	NOUN
fnp-6762	164	48	)	)	PUNCT
fnp-6762	164	49	.	.	PUNCT
fnp-6762	165	1	following	follow	VERB
fnp-6762	165	2	this	this	DET
fnp-6762	165	3	line	line	NOUN
fnp-6762	165	4	,	,	PUNCT
fnp-6762	165	5	several	several	ADJ
fnp-6762	165	6	articles	article	NOUN
fnp-6762	165	7	published	publish	VERB
fnp-6762	165	8	in	in	ADP
fnp-6762	165	9	2024	2024	NUM
fnp-6762	165	10	provided	provide	VERB
fnp-6762	165	11	further	further	ADJ
fnp-6762	165	12	evidence	evidence	NOUN
fnp-6762	165	13	regarding	regard	VERB
fnp-6762	165	14	the	the	DET
fnp-6762	165	15	association	association	NOUN
fnp-6762	165	16	of	of	ADP
fnp-6762	165	17	prls	prl	NOUN
fnp-6762	165	18	with	with	ADP
fnp-6762	165	19	disease	disease	NOUN
fnp-6762	165	20	progression	progression	NOUN
fnp-6762	165	21	:	:	PUNCT
fnp-6762	165	22	.1	.1	X
fnp-6762	165	23	)	)	PUNCT
fnp-6762	165	24	patients	patient	NOUN
fnp-6762	165	25	with	with	ADP
fnp-6762	165	26	pira	pira	PROPN
fnp-6762	165	27	had	have	VERB
fnp-6762	165	28	significantly	significantly	ADV
fnp-6762	165	29	more	more	ADJ
fnp-6762	165	30	prls	prl	NOUN
fnp-6762	165	31	,	,	PUNCT
fnp-6762	165	32	also	also	ADV
fnp-6762	165	33	when	when	SCONJ
fnp-6762	165	34	analysis	analysis	NOUN
fnp-6762	165	35	was	be	AUX
fnp-6762	165	36	restricted	restrict	VERB
fnp-6762	165	37	to	to	ADP
fnp-6762	165	38	patients	patient	NOUN
fnp-6762	165	39	with	with	ADP
fnp-6762	165	40	rrms56	rrms56	PROPN
fnp-6762	165	41	.	.	PUNCT
fnp-6762	166	1	2	2	X
fnp-6762	166	2	)	)	PUNCT
fnp-6762	166	3	prls	prl	NOUN
fnp-6762	166	4	associated	associate	VERB
fnp-6762	166	5	with	with	ADP
fnp-6762	166	6	pira	pira	PROPN
fnp-6762	166	7	over	over	ADP
fnp-6762	166	8	the	the	DET
fnp-6762	166	9	2	2	NUM
fnp-6762	166	10	years	year	NOUN
fnp-6762	166	11	after	after	ADP
fnp-6762	166	12	study	study	NOUN
fnp-6762	166	13	entry	entry	NOUN
fnp-6762	166	14	demonstrating	demonstrate	VERB
fnp-6762	166	15	their	their	PRON
fnp-6762	166	16	predictive	predictive	ADJ
fnp-6762	166	17	power	power	NOUN
fnp-6762	166	18	for	for	ADP
fnp-6762	166	19	pira	pira	NOUN
fnp-6762	166	20	38	38	NUM
fnp-6762	166	21	.	.	PUNCT
fnp-6762	167	1	3	3	X
fnp-6762	167	2	)	)	PUNCT
fnp-6762	167	3	a	a	DET
fnp-6762	167	4	longitudinal	longitudinal	ADJ
fnp-6762	167	5	study	study	NOUN
fnp-6762	167	6	with	with	ADP
fnp-6762	167	7	median	median	ADJ
fnp-6762	167	8	follow	follow	VERB
fnp-6762	167	9	-	-	PUNCT
fnp-6762	167	10	up	up	NOUN
fnp-6762	167	11	time	time	NOUN
fnp-6762	167	12	of	of	ADP
fnp-6762	167	13	5.6	5.6	NUM
fnp-6762	167	14	years	year	NOUN
fnp-6762	167	15	showed	show	VERB
fnp-6762	167	16	that	that	SCONJ
fnp-6762	167	17	the	the	DET
fnp-6762	167	18	appearance	appearance	NOUN
fnp-6762	167	19	of	of	ADP
fnp-6762	167	20	new	new	ADJ
fnp-6762	167	21	prls	prl	NOUN
fnp-6762	167	22	was	be	AUX
fnp-6762	167	23	associated	associate	VERB
fnp-6762	167	24	with	with	ADP
fnp-6762	167	25	increased	increase	VERB
fnp-6762	167	26	rates	rate	NOUN
fnp-6762	167	27	of	of	ADP
fnp-6762	167	28	pira57	pira57	PROPN
fnp-6762	167	29	.	.	PUNCT
fnp-6762	168	1	on	on	ADP
fnp-6762	168	2	the	the	DET
fnp-6762	168	3	other	other	ADJ
fnp-6762	168	4	hand	hand	NOUN
fnp-6762	168	5	,	,	PUNCT
fnp-6762	168	6	prl	prl	PROPN
fnp-6762	168	7	disappearance	disappearance	NOUN
fnp-6762	168	8	was	be	AUX
fnp-6762	168	9	associated	associate	VERB
fnp-6762	168	10	with	with	ADP
fnp-6762	168	11	reduced	reduce	VERB
fnp-6762	168	12	rates	rate	NOUN
fnp-6762	168	13	of	of	ADP
fnp-6762	168	14	confirmed	confirm	VERB
fnp-6762	168	15	disability	disability	NOUN
fnp-6762	168	16	progression	progression	NOUN
fnp-6762	168	17	,	,	PUNCT
fnp-6762	168	18	suggesting	suggest	VERB
fnp-6762	168	19	the	the	DET
fnp-6762	168	20	need	need	NOUN
fnp-6762	168	21	of	of	ADP
fnp-6762	168	22	additional	additional	ADJ
fnp-6762	168	23	studies	study	NOUN
fnp-6762	168	24	to	to	PART
fnp-6762	168	25	understand	understand	VERB
fnp-6762	168	26	the	the	DET
fnp-6762	168	27	predictive	predictive	ADJ
fnp-6762	168	28	value	value	NOUN
fnp-6762	168	29	of	of	ADP
fnp-6762	168	30	these	these	DET
fnp-6762	168	31	dynamic	dynamic	ADJ
fnp-6762	168	32	changes	change	NOUN
fnp-6762	168	33	.	.	PUNCT
fnp-6762	169	1	imaging	imaging	NOUN
fnp-6762	169	2	tools	tool	NOUN
fnp-6762	169	3	to	to	PART
fnp-6762	169	4	assess	assess	VERB
fnp-6762	169	5	neurodegeneration	neurodegeneration	NOUN
fnp-6762	169	6	are	be	AUX
fnp-6762	169	7	another	another	DET
fnp-6762	169	8	approach	approach	NOUN
fnp-6762	169	9	to	to	PART
fnp-6762	169	10	predict	predict	VERB
fnp-6762	169	11	disease	disease	NOUN
fnp-6762	169	12	progression	progression	NOUN
fnp-6762	169	13	.	.	PUNCT
fnp-6762	170	1	higher	high	ADJ
fnp-6762	170	2	baseline	baseline	VERB
fnp-6762	170	3	cortical	cortical	ADJ
fnp-6762	170	4	lesion	lesion	NOUN
fnp-6762	170	5	load	load	NOUN
fnp-6762	170	6	,	,	PUNCT
fnp-6762	170	7	but	but	CCONJ
fnp-6762	170	8	not	not	PART
fnp-6762	170	9	white	white	ADJ
fnp-6762	170	10	matter	matter	NOUN
fnp-6762	170	11	lesion	lesion	NOUN
fnp-6762	170	12	load	load	NOUN
fnp-6762	170	13	or	or	CCONJ
fnp-6762	170	14	new	new	ADJ
fnp-6762	170	15	cortical	cortical	ADJ
fnp-6762	170	16	lesions	lesion	NOUN
fnp-6762	170	17	during	during	ADP
fnp-6762	170	18	the	the	DET
fnp-6762	170	19	observation	observation	NOUN
fnp-6762	170	20	period	period	NOUN
fnp-6762	170	21	of	of	ADP
fnp-6762	170	22	three	three	NUM
fnp-6762	170	23	years	year	NOUN
fnp-6762	170	24	,	,	PUNCT
fnp-6762	170	25	predicted	predict	VERB
fnp-6762	170	26	disability	disability	NOUN
fnp-6762	170	27	worsening	worsen	VERB
fnp-6762	170	28	suggesting	suggest	VERB
fnp-6762	170	29	that	that	SCONJ
fnp-6762	170	30	cortical	cortical	ADJ
fnp-6762	170	31	lesions	lesion	NOUN
fnp-6762	170	32	forming	form	VERB
fnp-6762	170	33	earlier	early	ADV
fnp-6762	170	34	during	during	ADP
fnp-6762	170	35	the	the	DET
fnp-6762	170	36	disease	disease	NOUN
fnp-6762	170	37	course	course	NOUN
fnp-6762	170	38	contribute	contribute	VERB
fnp-6762	170	39	to	to	ADP
fnp-6762	170	40	disability	disability	NOUN
fnp-6762	170	41	progression	progression	NOUN
fnp-6762	170	42	rather	rather	ADV
fnp-6762	170	43	than	than	ADP
fnp-6762	170	44	new	new	ADJ
fnp-6762	170	45	cortical	cortical	ADJ
fnp-6762	170	46	lesions58	lesions58	NOUN
fnp-6762	170	47	.	.	PUNCT
fnp-6762	171	1	however	however	ADV
fnp-6762	171	2	,	,	PUNCT
fnp-6762	171	3	an	an	DET
fnp-6762	171	4	alternative	alternative	ADJ
fnp-6762	171	5	explanation	explanation	NOUN
fnp-6762	171	6	could	could	AUX
fnp-6762	171	7	be	be	AUX
fnp-6762	171	8	that	that	SCONJ
fnp-6762	171	9	the	the	DET
fnp-6762	171	10	detrimental	detrimental	ADJ
fnp-6762	171	11	effects	effect	NOUN
fnp-6762	171	12	of	of	ADP
fnp-6762	171	13	cortical	cortical	ADJ
fnp-6762	171	14	lesions	lesion	NOUN
fnp-6762	171	15	on	on	ADP
fnp-6762	171	16	disease	disease	NOUN
fnp-6762	171	17	progression	progression	NOUN
fnp-6762	171	18	require	require	VERB
fnp-6762	171	19	time	time	NOUN
fnp-6762	171	20	to	to	PART
fnp-6762	171	21	manifest	manifest	VERB
fnp-6762	171	22	clinically	clinically	ADV
fnp-6762	171	23	.	.	PUNCT
fnp-6762	172	1	thalamic	thalamic	ADJ
fnp-6762	172	2	atrophy	atrophy	NOUN
fnp-6762	172	3	is	be	AUX
fnp-6762	172	4	well	well	ADV
fnp-6762	172	5	-	-	PUNCT
fnp-6762	172	6	known	know	VERB
fnp-6762	172	7	to	to	PART
fnp-6762	172	8	be	be	AUX
fnp-6762	172	9	associated	associate	VERB
fnp-6762	172	10	with	with	ADP
fnp-6762	172	11	disease	disease	NOUN
fnp-6762	172	12	progression	progression	NOUN
fnp-6762	172	13	.	.	PUNCT
fnp-6762	173	1	the	the	DET
fnp-6762	173	2	study	study	NOUN
fnp-6762	173	3	by	by	ADP
fnp-6762	173	4	cagol	cagol	NOUN
fnp-6762	173	5	and	and	CCONJ
fnp-6762	173	6	colleagues	colleague	NOUN
fnp-6762	173	7	now	now	ADV
fnp-6762	173	8	provides	provide	VERB
fnp-6762	173	9	further	further	ADJ
fnp-6762	173	10	insight	insight	NOUN
fnp-6762	173	11	into	into	ADP
fnp-6762	173	12	the	the	DET
fnp-6762	173	13	underlying	underlie	VERB
fnp-6762	173	14	mechanisms	mechanism	NOUN
fnp-6762	173	15	of	of	ADP
fnp-6762	173	16	thalamic	thalamic	ADJ
fnp-6762	173	17	atrophy	atrophy	NOUN
fnp-6762	173	18	.	.	PUNCT
fnp-6762	174	1	using	use	VERB
fnp-6762	174	2	advanced	advanced	ADJ
fnp-6762	174	3	quantitative	quantitative	ADJ
fnp-6762	174	4	mri	mri	NOUN
fnp-6762	174	5	,	,	PUNCT
fnp-6762	174	6	they	they	PRON
fnp-6762	174	7	demonstrated	demonstrate	VERB
fnp-6762	174	8	that	that	SCONJ
fnp-6762	174	9	microstructural	microstructural	ADJ
fnp-6762	174	10	thalamic	thalamic	ADJ
fnp-6762	174	11	changes	change	NOUN
fnp-6762	174	12	linked	link	VERB
fnp-6762	174	13	to	to	ADP
fnp-6762	174	14	demyelination	demyelination	NOUN
fnp-6762	174	15	,	,	PUNCT
fnp-6762	174	16	neuroaxonal	neuroaxonal	ADJ
fnp-6762	174	17	loss	loss	NOUN
fnp-6762	174	18	,	,	PUNCT
fnp-6762	174	19	and	and	CCONJ
fnp-6762	174	20	disturbances	disturbance	NOUN
fnp-6762	174	21	in	in	ADP
fnp-6762	174	22	iron	iron	NOUN
fnp-6762	174	23	homeostasis	homeostasis	NOUN
fnp-6762	174	24	correlated	correlate	VERB
fnp-6762	174	25	well	well	ADV
fnp-6762	174	26	with	with	ADP
fnp-6762	174	27	clinical	clinical	ADJ
fnp-6762	174	28	disability	disability	NOUN
fnp-6762	174	29	,	,	PUNCT
fnp-6762	174	30	cognitive	cognitive	ADJ
fnp-6762	174	31	impairment	impairment	NOUN
fnp-6762	174	32	,	,	PUNCT
fnp-6762	174	33	and	and	CCONJ
fnp-6762	174	34	mri	mri	NOUN
fnp-6762	174	35	measures	measure	NOUN
fnp-6762	174	36	of	of	ADP
fnp-6762	174	37	disease	disease	NOUN
fnp-6762	174	38	burden59	burden59	NOUN
fnp-6762	174	39	.	.	PUNCT
fnp-6762	175	1	interestingly	interestingly	ADV
fnp-6762	175	2	,	,	PUNCT
fnp-6762	175	3	a	a	DET
fnp-6762	175	4	recent	recent	ADJ
fnp-6762	175	5	longitudinal	longitudinal	ADJ
fnp-6762	175	6	study	study	NOUN
fnp-6762	175	7	provided	provide	VERB
fnp-6762	175	8	further	further	ADJ
fnp-6762	175	9	evidence	evidence	NOUN
fnp-6762	175	10	about	about	ADP
fnp-6762	175	11	the	the	DET
fnp-6762	175	12	gradual	gradual	ADJ
fnp-6762	175	13	increase	increase	NOUN
fnp-6762	175	14	of	of	ADP
fnp-6762	175	15	choroid	choroid	NOUN
fnp-6762	175	16	plexus	plexus	NOUN
fnp-6762	175	17	volume	volume	NOUN
fnp-6762	175	18	(	(	PUNCT
fnp-6762	175	19	1.4	1.4	NUM
fnp-6762	175	20	 	 	SPACE
fnp-6762	175	21	%	%	NOUN
fnp-6762	175	22	per	per	ADP
fnp-6762	175	23	year	year	NOUN
fnp-6762	175	24	)	)	PUNCT
fnp-6762	175	25	and	and	CCONJ
fnp-6762	175	26	its	its	PRON
fnp-6762	175	27	association	association	NOUN
fnp-6762	175	28	with	with	ADP
fnp-6762	175	29	brain	brain	NOUN
fnp-6762	175	30	atrophy60	atrophy60	NOUN
fnp-6762	175	31	.	.	PUNCT
fnp-6762	176	1	in	in	ADP
fnp-6762	176	2	this	this	DET
fnp-6762	176	3	study	study	NOUN
fnp-6762	176	4	from	from	ADP
fnp-6762	176	5	sydney	sydney	PROPN
fnp-6762	176	6	,	,	PUNCT
fnp-6762	176	7	57	57	NUM
fnp-6762	176	8	patients	patient	NOUN
fnp-6762	176	9	with	with	ADP
fnp-6762	176	10	rrms	rrm	NOUN
fnp-6762	176	11	underwent	undergo	VERB
fnp-6762	176	12	annual	annual	ADJ
fnp-6762	176	13	mri	mri	NOUN
fnp-6762	176	14	scans	scan	NOUN
fnp-6762	176	15	during	during	ADP
fnp-6762	176	16	a	a	DET
fnp-6762	176	17	minimum	minimum	ADJ
fnp-6762	176	18	follow	follow	NOUN
fnp-6762	176	19	-	-	PUNCT
fnp-6762	176	20	up	up	NOUN
fnp-6762	176	21	of	of	ADP
fnp-6762	176	22	four	four	NUM
fnp-6762	176	23	years	year	NOUN
fnp-6762	176	24	.	.	PUNCT
fnp-6762	177	1	interestingly	interestingly	ADV
fnp-6762	177	2	,	,	PUNCT
fnp-6762	177	3	they	they	PRON
fnp-6762	177	4	showed	show	VERB
fnp-6762	177	5	that	that	SCONJ
fnp-6762	177	6	the	the	DET
fnp-6762	177	7	annual	annual	ADJ
fnp-6762	177	8	change	change	NOUN
fnp-6762	177	9	in	in	ADP
fnp-6762	177	10	choroid	choroid	NOUN
fnp-6762	177	11	plexus	plexus	NOUN
fnp-6762	177	12	volume	volume	NOUN
fnp-6762	177	13	correlated	correlate	VERB
fnp-6762	177	14	with	with	ADP
fnp-6762	177	15	chronic	chronic	ADJ
fnp-6762	177	16	lesion	lesion	NOUN
fnp-6762	177	17	expansion	expansion	NOUN
fnp-6762	177	18	(	(	PUNCT
fnp-6762	177	19	r	r	NOUN
fnp-6762	177	20	 	 	SPACE
fnp-6762	177	21	=	=	NOUN
fnp-6762	177	22	 	 	SPACE
fnp-6762	177	23	0.46	0.46	NUM
fnp-6762	177	24	,	,	PUNCT
fnp-6762	177	25	p	p	X
fnp-6762	177	26	 	 	SPACE
fnp-6762	177	27	<	<	X
fnp-6762	177	28	 	 	SPACE
fnp-6762	177	29	0.001	0.001	NUM
fnp-6762	177	30	)	)	PUNCT
fnp-6762	177	31	,	,	PUNCT
fnp-6762	177	32	further	far	ADV
fnp-6762	177	33	supporting	support	VERB
fnp-6762	177	34	the	the	DET
fnp-6762	177	35	notion	notion	NOUN
fnp-6762	177	36	that	that	SCONJ
fnp-6762	177	37	plexus	plexus	NOUN
fnp-6762	177	38	enlargement	enlargement	NOUN
fnp-6762	177	39	is	be	AUX
fnp-6762	177	40	at	at	ADV
fnp-6762	177	41	least	least	ADJ
fnp-6762	177	42	partly	partly	ADV
fnp-6762	177	43	induced	induce	VERB
fnp-6762	177	44	by	by	ADP
fnp-6762	177	45	cellular	cellular	ADJ
fnp-6762	177	46	or	or	CCONJ
fnp-6762	177	47	molecular	molecular	ADJ
fnp-6762	177	48	inflammatory	inflammatory	ADJ
fnp-6762	177	49	mediators	mediator	NOUN
fnp-6762	177	50	.	.	PUNCT
fnp-6762	178	1	an	an	DET
fnp-6762	178	2	association	association	NOUN
fnp-6762	178	3	between	between	ADP
fnp-6762	178	4	choroid	choroid	NOUN
fnp-6762	178	5	plexus	plexus	NOUN
fnp-6762	178	6	volume	volume	NOUN
fnp-6762	178	7	,	,	PUNCT
fnp-6762	178	8	cognitive	cognitive	ADJ
fnp-6762	178	9	impairment	impairment	NOUN
fnp-6762	178	10	,	,	PUNCT
fnp-6762	178	11	and	and	CCONJ
fnp-6762	178	12	fatigue	fatigue	NOUN
fnp-6762	178	13	was	be	AUX
fnp-6762	178	14	also	also	ADV
fnp-6762	178	15	recently	recently	ADV
fnp-6762	178	16	demonstrated61	demonstrated61	NOUN
fnp-6762	178	17	.	.	PUNCT
fnp-6762	179	1	there	there	PRON
fnp-6762	179	2	are	be	VERB
fnp-6762	179	3	also	also	ADV
fnp-6762	179	4	several	several	ADJ
fnp-6762	179	5	other	other	ADJ
fnp-6762	179	6	advanced	advanced	ADJ
fnp-6762	179	7	imaging	imaging	NOUN
fnp-6762	179	8	methods	method	NOUN
fnp-6762	179	9	that	that	PRON
fnp-6762	179	10	have	have	AUX
fnp-6762	179	11	shown	show	VERB
fnp-6762	179	12	promise	promise	NOUN
fnp-6762	179	13	for	for	ADP
fnp-6762	179	14	identification	identification	NOUN
fnp-6762	179	15	of	of	ADP
fnp-6762	179	16	disease	disease	NOUN
fnp-6762	179	17	progression	progression	NOUN
fnp-6762	179	18	,	,	PUNCT
fnp-6762	179	19	such	such	ADJ
fnp-6762	179	20	as	as	ADP
fnp-6762	179	21	the	the	DET
fnp-6762	179	22	diffusion	diffusion	NOUN
fnp-6762	179	23	mri	mri	NOUN
fnp-6762	179	24	based	base	VERB
fnp-6762	179	25	neurite	neurite	PROPN
fnp-6762	179	26	orientation	orientation	NOUN
fnp-6762	179	27	dispersion	dispersion	NOUN
fnp-6762	179	28	and	and	CCONJ
fnp-6762	179	29	density	density	NOUN
fnp-6762	179	30	imaging	imaging	NOUN
fnp-6762	179	31	(	(	PUNCT
fnp-6762	179	32	noddi	noddi	ADJ
fnp-6762	179	33	)	)	PUNCT
fnp-6762	179	34	that	that	PRON
fnp-6762	179	35	provides	provide	VERB
fnp-6762	179	36	specific	specific	ADJ
fnp-6762	179	37	measures	measure	NOUN
fnp-6762	179	38	of	of	ADP
fnp-6762	179	39	tissue	tissue	NOUN
fnp-6762	179	40	microstructure	microstructure	NOUN
fnp-6762	179	41	,	,	PUNCT
fnp-6762	179	42	soma	soma	NOUN
fnp-6762	179	43	and	and	CCONJ
fnp-6762	179	44	neurite	neurite	VERB
fnp-6762	179	45	density	density	NOUN
fnp-6762	179	46	imaging	imaging	NOUN
fnp-6762	179	47	(	(	PUNCT
fnp-6762	179	48	sandi	sandi	PROPN
fnp-6762	179	49	)	)	PUNCT
fnp-6762	179	50	,	,	PUNCT
fnp-6762	179	51	and	and	CCONJ
fnp-6762	179	52	leptomeningeal	leptomeningeal	NOUN
fnp-6762	179	53	enhancement	enhancement	NOUN
fnp-6762	179	54	that	that	PRON
fnp-6762	179	55	can	can	AUX
fnp-6762	179	56	be	be	AUX
fnp-6762	179	57	visualized	visualize	VERB
fnp-6762	179	58	using	use	VERB
fnp-6762	179	59	delayed	delay	VERB
fnp-6762	179	60	post	post	ADJ
fnp-6762	179	61	-	-	ADJ
fnp-6762	179	62	contrast	contrast	ADJ
fnp-6762	179	63	flair	flair	NOUN
fnp-6762	179	64	,	,	PUNCT
fnp-6762	179	65	demonstrating	demonstrate	VERB
fnp-6762	179	66	meningeal	meningeal	NOUN
fnp-6762	179	67	b	b	PROPN
fnp-6762	179	68	cell	cell	NOUN
fnp-6762	179	69	aggregates53	aggregates53	NOUN
fnp-6762	179	70	.	.	PUNCT
fnp-6762	180	1	use	use	NOUN
fnp-6762	180	2	of	of	ADP
fnp-6762	180	3	ai	ai	VERB
fnp-6762	180	4	the	the	DET
fnp-6762	180	5	potential	potential	NOUN
fnp-6762	180	6	of	of	ADP
fnp-6762	180	7	artificial	artificial	ADJ
fnp-6762	180	8	intelligence	intelligence	NOUN
fnp-6762	180	9	(	(	PUNCT
fnp-6762	180	10	ai	ai	NOUN
fnp-6762	180	11	)	)	PUNCT
fnp-6762	180	12	and	and	CCONJ
fnp-6762	180	13	machine	machine	NOUN
fnp-6762	180	14	learning	learning	NOUN
fnp-6762	180	15	continues	continue	VERB
fnp-6762	180	16	to	to	PART
fnp-6762	180	17	be	be	AUX
fnp-6762	180	18	explored	explore	VERB
fnp-6762	180	19	in	in	ADP
fnp-6762	180	20	the	the	DET
fnp-6762	180	21	context	context	NOUN
fnp-6762	180	22	of	of	ADP
fnp-6762	180	23	ms	ms	NOUN
fnp-6762	180	24	as	as	SCONJ
fnp-6762	180	25	reviewed	review	VERB
fnp-6762	180	26	by	by	ADP
fnp-6762	180	27	collorone	collorone	NOUN
fnp-6762	180	28	et	et	NOUN
fnp-6762	180	29	al62	al62	PROPN
fnp-6762	180	30	.	.	PUNCT
fnp-6762	181	1	ai	ai	PROPN
fnp-6762	181	2	has	have	AUX
fnp-6762	181	3	been	be	AUX
fnp-6762	181	4	used	use	VERB
fnp-6762	181	5	in	in	ADP
fnp-6762	181	6	explorative	explorative	ADJ
fnp-6762	181	7	studies	study	NOUN
fnp-6762	181	8	to	to	PART
fnp-6762	181	9	guide	guide	VERB
fnp-6762	181	10	ms	ms	ADJ
fnp-6762	181	11	diagnosis	diagnosis	NOUN
fnp-6762	181	12	,	,	PUNCT
fnp-6762	181	13	prediction	prediction	NOUN
fnp-6762	181	14	,	,	PUNCT
fnp-6762	181	15	lesion	lesion	NOUN
fnp-6762	181	16	segmentation	segmentation	NOUN
fnp-6762	181	17	,	,	PUNCT
fnp-6762	181	18	and	and	CCONJ
fnp-6762	181	19	investigation	investigation	NOUN
fnp-6762	181	20	of	of	ADP
fnp-6762	181	21	disease	disease	NOUN
fnp-6762	181	22	mechanisms	mechanism	NOUN
fnp-6762	181	23	.	.	PUNCT
fnp-6762	182	1	the	the	DET
fnp-6762	182	2	authors	author	NOUN
fnp-6762	182	3	conclude	conclude	VERB
fnp-6762	182	4	that	that	SCONJ
fnp-6762	182	5	although	although	SCONJ
fnp-6762	182	6	there	there	PRON
fnp-6762	182	7	are	be	VERB
fnp-6762	182	8	several	several	ADJ
fnp-6762	182	9	challenges	challenge	NOUN
fnp-6762	182	10	regarding	regard	VERB
fnp-6762	182	11	the	the	DET
fnp-6762	182	12	quality	quality	NOUN
fnp-6762	182	13	of	of	ADP
fnp-6762	182	14	input	input	NOUN
fnp-6762	182	15	data	datum	NOUN
fnp-6762	182	16	and	and	CCONJ
fnp-6762	182	17	ethical	ethical	ADJ
fnp-6762	182	18	issues	issue	NOUN
fnp-6762	182	19	,	,	PUNCT
fnp-6762	182	20	the	the	DET
fnp-6762	182	21	use	use	NOUN
fnp-6762	182	22	of	of	ADP
fnp-6762	182	23	ai	ai	NOUN
fnp-6762	182	24	has	have	AUX
fnp-6762	182	25	made	make	VERB
fnp-6762	182	26	significant	significant	ADJ
fnp-6762	182	27	progress	progress	NOUN
fnp-6762	182	28	in	in	ADP
fnp-6762	182	29	recent	recent	ADJ
fnp-6762	182	30	years	year	NOUN
fnp-6762	182	31	in	in	ADP
fnp-6762	182	32	the	the	DET
fnp-6762	182	33	ms	ms	PROPN
fnp-6762	182	34	field	field	NOUN
fnp-6762	182	35	.	.	PUNCT
fnp-6762	183	1	however	however	ADV
fnp-6762	183	2	,	,	PUNCT
fnp-6762	183	3	the	the	DET
fnp-6762	183	4	reproducibility	reproducibility	NOUN
fnp-6762	183	5	and	and	CCONJ
fnp-6762	183	6	validation	validation	NOUN
fnp-6762	183	7	of	of	ADP
fnp-6762	183	8	the	the	DET
fnp-6762	183	9	results	result	NOUN
fnp-6762	183	10	,	,	PUNCT
fnp-6762	183	11	which	which	PRON
fnp-6762	183	12	is	be	AUX
fnp-6762	183	13	important	important	ADJ
fnp-6762	183	14	for	for	ADP
fnp-6762	183	15	the	the	DET
fnp-6762	183	16	integration	integration	NOUN
fnp-6762	183	17	of	of	ADP
fnp-6762	183	18	ai	ai	PRON
fnp-6762	183	19	based	base	VERB
fnp-6762	183	20	methods	method	NOUN
fnp-6762	183	21	into	into	ADP
fnp-6762	183	22	clinical	clinical	ADJ
fnp-6762	183	23	practice	practice	NOUN
fnp-6762	183	24	,	,	PUNCT
fnp-6762	183	25	warrants	warrant	NOUN
fnp-6762	183	26	further	further	ADJ
fnp-6762	183	27	studies	study	NOUN
fnp-6762	183	28	.	.	PUNCT
fnp-6762	184	1	in	in	ADP
fnp-6762	184	2	2024	2024	NUM
fnp-6762	184	3	,	,	PUNCT
fnp-6762	184	4	noteboom	noteboom	NOUN
fnp-6762	184	5	et	et	NOUN
fnp-6762	184	6	al63	al63	PROPN
fnp-6762	184	7	studied	study	VERB
fnp-6762	184	8	how	how	SCONJ
fnp-6762	184	9	various	various	ADJ
fnp-6762	184	10	machine	machine	NOUN
fnp-6762	184	11	learning	learning	NOUN
fnp-6762	184	12	models	model	NOUN
fnp-6762	184	13	were	be	AUX
fnp-6762	184	14	capable	capable	ADJ
fnp-6762	184	15	of	of	ADP
fnp-6762	184	16	determining	determine	VERB
fnp-6762	184	17	clinical	clinical	ADJ
fnp-6762	184	18	impairment	impairment	NOUN
fnp-6762	184	19	at	at	ADP
fnp-6762	184	20	baseline	baseline	NOUN
fnp-6762	184	21	and	and	CCONJ
fnp-6762	184	22	of	of	ADP
fnp-6762	184	23	predicting	predict	VERB
fnp-6762	184	24	future	future	ADJ
fnp-6762	184	25	clinical	clinical	ADJ
fnp-6762	184	26	worsening	worsening	NOUN
fnp-6762	184	27	in	in	ADP
fnp-6762	184	28	two	two	NUM
fnp-6762	184	29	cohorts	cohort	NOUN
fnp-6762	184	30	(	(	PUNCT
fnp-6762	184	31	n	n	NOUN
fnp-6762	184	32	=	=	SYM
fnp-6762	184	33	123	123	NUM
fnp-6762	184	34	and	and	CCONJ
fnp-6762	184	35	330	330	NUM
fnp-6762	184	36	,	,	PUNCT
fnp-6762	184	37	respectively	respectively	ADV
fnp-6762	184	38	)	)	PUNCT
fnp-6762	184	39	.	.	PUNCT
fnp-6762	185	1	support	support	NOUN
fnp-6762	185	2	vector	vector	NOUN
fnp-6762	185	3	machine	machine	NOUN
fnp-6762	185	4	classifier	classifier	NOUN
fnp-6762	185	5	was	be	AUX
fnp-6762	185	6	the	the	DET
fnp-6762	185	7	best	good	ADJ
fnp-6762	185	8	ai	ai	VERB
fnp-6762	185	9	tool	tool	NOUN
fnp-6762	185	10	to	to	PART
fnp-6762	185	11	identify	identify	VERB
fnp-6762	185	12	higher	high	ADJ
fnp-6762	185	13	disability	disability	NOUN
fnp-6762	185	14	(	(	PUNCT
fnp-6762	185	15	edss	edss	ADV
fnp-6762	185	16	 	 	SPACE
fnp-6762	185	17	≥	≥	PRON
fnp-6762	185	18	 	 	SPACE
fnp-6762	185	19	4	4	NUM
fnp-6762	185	20	)	)	PUNCT
fnp-6762	185	21	and	and	CCONJ
fnp-6762	185	22	impaired	impair	VERB
fnp-6762	185	23	cognition	cognition	NOUN
fnp-6762	185	24	(	(	PUNCT
fnp-6762	185	25	sdmt	sdmt	VERB
fnp-6762	185	26	z	z	NOUN
fnp-6762	185	27	-	-	PUNCT
fnp-6762	185	28	score	score	NOUN
fnp-6762	185	29	 	 	SPACE
fnp-6762	185	30	≤	≤	NOUN
fnp-6762	185	31	 	 	SPACE
fnp-6762	185	32	−1.5	−1.5	PROPN
fnp-6762	185	33	)	)	PUNCT
fnp-6762	185	34	when	when	SCONJ
fnp-6762	185	35	clinical	clinical	ADJ
fnp-6762	185	36	factors	factor	NOUN
fnp-6762	185	37	and	and	CCONJ
fnp-6762	185	38	global	global	ADJ
fnp-6762	185	39	or	or	CCONJ
fnp-6762	185	40	regional	regional	ADJ
fnp-6762	185	41	mri	mri	NOUN
fnp-6762	185	42	volumes	volume	NOUN
fnp-6762	185	43	were	be	AUX
fnp-6762	185	44	used	use	VERB
fnp-6762	185	45	as	as	ADP
fnp-6762	185	46	input	input	NOUN
fnp-6762	185	47	.	.	PUNCT
fnp-6762	186	1	however	however	ADV
fnp-6762	186	2	,	,	PUNCT
fnp-6762	186	3	the	the	DET
fnp-6762	186	4	machine	machine	NOUN
fnp-6762	186	5	learning	learning	NOUN
fnp-6762	186	6	models	model	NOUN
fnp-6762	186	7	were	be	AUX
fnp-6762	186	8	not	not	PART
fnp-6762	186	9	able	able	ADJ
fnp-6762	186	10	to	to	PART
fnp-6762	186	11	predict	predict	VERB
fnp-6762	186	12	clinical	clinical	ADJ
fnp-6762	186	13	worsening	worsening	NOUN
fnp-6762	186	14	after	after	ADP
fnp-6762	186	15	two	two	NUM
fnp-6762	186	16	or	or	CCONJ
fnp-6762	186	17	five	five	NUM
fnp-6762	186	18	years	year	NOUN
fnp-6762	186	19	.	.	PUNCT
fnp-6762	187	1	on	on	ADP
fnp-6762	187	2	the	the	DET
fnp-6762	187	3	other	other	ADJ
fnp-6762	187	4	hand	hand	NOUN
fnp-6762	187	5	,	,	PUNCT
fnp-6762	187	6	andorra	andorra	PROPN
fnp-6762	187	7	et	et	PROPN
fnp-6762	187	8	al	al	PROPN
fnp-6762	187	9	showed	show	VERB
fnp-6762	187	10	that	that	SCONJ
fnp-6762	187	11	random	random	ADJ
fnp-6762	187	12	forest	forest	NOUN
fnp-6762	187	13	algorithms	algorithm	NOUN
fnp-6762	187	14	predicted	predict	VERB
fnp-6762	187	15	neda	neda	PROPN
fnp-6762	187	16	(	(	PUNCT
fnp-6762	187	17	no	no	DET
fnp-6762	187	18	evidence	evidence	NOUN
fnp-6762	187	19	of	of	ADP
fnp-6762	187	20	disease	disease	NOUN
fnp-6762	187	21	activity	activity	NOUN
fnp-6762	187	22	)	)	PUNCT
fnp-6762	187	23	with	with	ADP
fnp-6762	187	24	auc	auc	NOUN
fnp-6762	187	25	0.80	0.80	NUM
fnp-6762	187	26	and	and	CCONJ
fnp-6762	187	27	confirmed	confirm	VERB
fnp-6762	187	28	disability	disability	NOUN
fnp-6762	187	29	accumulation	accumulation	NOUN
fnp-6762	187	30	with	with	ADP
fnp-6762	187	31	aucs	aucs	NOUN
fnp-6762	187	32	0.62	0.62	NUM
fnp-6762	187	33	,	,	PUNCT
fnp-6762	187	34	0,63	0,63	NUM
fnp-6762	187	35	and	and	CCONJ
fnp-6762	187	36	0.61	0.61	NUM
fnp-6762	187	37	for	for	ADP
fnp-6762	187	38	edss	edss	ADV
fnp-6762	187	39	,	,	PUNCT
fnp-6762	187	40	sdmt	sdmt	VERB
fnp-6762	187	41	and	and	CCONJ
fnp-6762	187	42	9hpt	9hpt	PROPN
fnp-6762	187	43	,	,	PUNCT
fnp-6762	187	44	respectively64	respectively64	NOUN
fnp-6762	187	45	.	.	PUNCT
fnp-6762	188	1	algorithms	algorithm	NOUN
fnp-6762	188	2	were	be	AUX
fnp-6762	188	3	first	first	ADV
fnp-6762	188	4	tested	test	VERB
fnp-6762	188	5	using	use	VERB
fnp-6762	188	6	a	a	DET
fnp-6762	188	7	prospective	prospective	ADJ
fnp-6762	188	8	multi	multi	ADJ
fnp-6762	188	9	-	-	ADJ
fnp-6762	188	10	centric	centric	ADJ
fnp-6762	188	11	cohort	cohort	NOUN
fnp-6762	188	12	including	include	VERB
fnp-6762	188	13	322	322	NUM
fnp-6762	188	14	patients	patient	NOUN
fnp-6762	188	15	with	with	ADP
fnp-6762	188	16	ms	ms	PROPN
fnp-6762	188	17	and	and	CCONJ
fnp-6762	188	18	98	98	NUM
fnp-6762	188	19	healthy	healthy	ADJ
fnp-6762	188	20	controls	control	NOUN
fnp-6762	188	21	,	,	PUNCT
fnp-6762	188	22	and	and	CCONJ
fnp-6762	188	23	then	then	ADV
fnp-6762	188	24	using	use	VERB
fnp-6762	188	25	a	a	DET
fnp-6762	188	26	prospective	prospective	ADJ
fnp-6762	188	27	cohort	cohort	NOUN
fnp-6762	188	28	of	of	ADP
fnp-6762	188	29	271	271	NUM
fnp-6762	188	30	patients	patient	NOUN
fnp-6762	188	31	with	with	ADP
fnp-6762	188	32	ms	ms	PROPN
fnp-6762	188	33	.	.	PROPN
fnp-6762	189	1	their	their	PRON
fnp-6762	189	2	findings	finding	NOUN
fnp-6762	189	3	suggest	suggest	VERB
fnp-6762	189	4	,	,	PUNCT
fnp-6762	189	5	that	that	SCONJ
fnp-6762	189	6	combining	combine	VERB
fnp-6762	189	7	clinical	clinical	ADJ
fnp-6762	189	8	,	,	PUNCT
fnp-6762	189	9	and	and	CCONJ
fnp-6762	189	10	imaging	imaging	NOUN
fnp-6762	189	11	and	and	CCONJ
fnp-6762	189	12	in	in	ADP
fnp-6762	189	13	some	some	DET
fnp-6762	189	14	instances	instance	NOUN
fnp-6762	189	15	also	also	ADV
fnp-6762	189	16	omics	omic	VERB
fnp-6762	189	17	data	datum	NOUN
fnp-6762	189	18	with	with	ADP
fnp-6762	189	19	machine	machine	NOUN
fnp-6762	189	20	learning	learning	NOUN
fnp-6762	189	21	may	may	AUX
fnp-6762	189	22	help	help	VERB
fnp-6762	189	23	identifying	identify	VERB
fnp-6762	189	24	ms	ms	ADJ
fnp-6762	189	25	patients	patient	NOUN
fnp-6762	189	26	at	at	ADP
fnp-6762	189	27	risk	risk	NOUN
fnp-6762	189	28	of	of	ADP
fnp-6762	189	29	disability	disability	NOUN
fnp-6762	189	30	worsening	worsen	VERB
fnp-6762	189	31	.	.	PUNCT
fnp-6762	190	1	proper	proper	ADJ
fnp-6762	190	2	identification	identification	NOUN
fnp-6762	190	3	of	of	ADP
fnp-6762	190	4	focal	focal	ADJ
fnp-6762	190	5	ms	ms	ADJ
fnp-6762	190	6	lesions	lesion	NOUN
fnp-6762	190	7	is	be	AUX
fnp-6762	190	8	the	the	DET
fnp-6762	190	9	basis	basis	NOUN
fnp-6762	190	10	for	for	ADP
fnp-6762	190	11	successful	successful	ADJ
fnp-6762	190	12	diagnosis	diagnosis	NOUN
fnp-6762	190	13	,	,	PUNCT
fnp-6762	190	14	treatment	treatment	NOUN
fnp-6762	190	15	and	and	CCONJ
fnp-6762	190	16	disease	disease	NOUN
fnp-6762	190	17	monitoring	monitoring	NOUN
fnp-6762	190	18	.	.	PUNCT
fnp-6762	191	1	furthermore	furthermore	ADV
fnp-6762	191	2	,	,	PUNCT
fnp-6762	191	3	reliable	reliable	ADJ
fnp-6762	191	4	identification	identification	NOUN
fnp-6762	191	5	of	of	ADP
fnp-6762	191	6	chronic	chronic	ADJ
fnp-6762	191	7	active	active	ADJ
fnp-6762	191	8	lesions	lesion	NOUN
fnp-6762	191	9	gives	give	VERB
fnp-6762	191	10	valuable	valuable	ADJ
fnp-6762	191	11	information	information	NOUN
fnp-6762	191	12	on	on	ADP
fnp-6762	191	13	the	the	DET
fnp-6762	191	14	risk	risk	NOUN
fnp-6762	191	15	of	of	ADP
fnp-6762	191	16	later	later	ADJ
fnp-6762	191	17	progression	progression	NOUN
fnp-6762	191	18	as	as	SCONJ
fnp-6762	191	19	described	describe	VERB
fnp-6762	191	20	above	above	ADV
fnp-6762	191	21	.	.	PUNCT
fnp-6762	192	1	manual	manual	ADJ
fnp-6762	192	2	lesion	lesion	NOUN
fnp-6762	192	3	segmentation	segmentation	NOUN
fnp-6762	192	4	is	be	AUX
fnp-6762	192	5	time	time	NOUN
fnp-6762	192	6	-	-	PUNCT
fnp-6762	192	7	consuming	consume	VERB
fnp-6762	192	8	,	,	PUNCT
fnp-6762	192	9	but	but	CCONJ
fnp-6762	192	10	thus	thus	ADV
fnp-6762	192	11	far	far	ADV
fnp-6762	192	12	it	it	PRON
fnp-6762	192	13	has	have	AUX
fnp-6762	192	14	proven	prove	VERB
fnp-6762	192	15	more	more	ADV
fnp-6762	192	16	reliable	reliable	ADJ
fnp-6762	192	17	than	than	ADP
fnp-6762	192	18	existing	exist	VERB
fnp-6762	192	19	automated	automate	VERB
fnp-6762	192	20	lesion	lesion	NOUN
fnp-6762	192	21	segmentation	segmentation	NOUN
fnp-6762	192	22	methods	method	NOUN
fnp-6762	192	23	.	.	PUNCT
fnp-6762	193	1	this	this	PRON
fnp-6762	193	2	is	be	AUX
fnp-6762	193	3	now	now	ADV
fnp-6762	193	4	being	be	AUX
fnp-6762	193	5	challenged	challenge	VERB
fnp-6762	193	6	by	by	ADP
fnp-6762	193	7	recent	recent	ADJ
fnp-6762	193	8	lesion	lesion	NOUN
fnp-6762	193	9	-	-	PUNCT
fnp-6762	193	10	detection	detection	NOUN
fnp-6762	193	11	work	work	NOUN
fnp-6762	193	12	using	use	VERB
fnp-6762	193	13	deep	deep	ADJ
fnp-6762	193	14	learning	learning	NOUN
fnp-6762	193	15	models	model	NOUN
fnp-6762	193	16	.	.	PUNCT
fnp-6762	194	1	pasquale	pasquale	PROPN
fnp-6762	194	2	de	de	PROPN
fnp-6762	194	3	rosa	rosa	PROPN
fnp-6762	194	4	et	et	PROPN
fnp-6762	194	5	al	al	PROPN
fnp-6762	194	6	applied	apply	VERB
fnp-6762	194	7	a	a	DET
fnp-6762	194	8	consensus	consensus	NOUN
fnp-6762	194	9	-	-	PUNCT
fnp-6762	194	10	based	base	VERB
fnp-6762	194	11	framework	framework	NOUN
fnp-6762	194	12	,	,	PUNCT
fnp-6762	194	13	which	which	PRON
fnp-6762	194	14	combines	combine	VERB
fnp-6762	194	15	five	five	NUM
fnp-6762	194	16	publicly	publicly	ADV
fnp-6762	194	17	available	available	ADJ
fnp-6762	194	18	deep	deep	ADJ
fnp-6762	194	19	learning	learning	NOUN
fnp-6762	194	20	models	model	NOUN
fnp-6762	194	21	,	,	PUNCT
fnp-6762	194	22	to	to	PART
fnp-6762	194	23	improve	improve	VERB
fnp-6762	194	24	lesion	lesion	NOUN
fnp-6762	194	25	segmentation65	segmentation65	NOUN
fnp-6762	194	26	.	.	PUNCT
fnp-6762	195	1	they	they	PRON
fnp-6762	195	2	used	use	VERB
fnp-6762	195	3	two	two	NUM
fnp-6762	195	4	datasets	dataset	NOUN
fnp-6762	195	5	,	,	PUNCT
fnp-6762	195	6	including	include	VERB
fnp-6762	195	7	131	131	NUM
fnp-6762	195	8	and	and	CCONJ
fnp-6762	195	9	30	30	NUM
fnp-6762	195	10	patients	patient	NOUN
fnp-6762	195	11	with	with	ADP
fnp-6762	195	12	ms	ms	PROPN
fnp-6762	195	13	to	to	PART
fnp-6762	195	14	compare	compare	VERB
fnp-6762	195	15	it	it	PRON
fnp-6762	195	16	with	with	ADP
fnp-6762	195	17	lesions	lesion	NOUN
fnp-6762	195	18	masks	mask	NOUN
fnp-6762	195	19	segmented	segment	VERB
fnp-6762	195	20	manually	manually	ADV
fnp-6762	195	21	.	.	PUNCT
fnp-6762	196	1	their	their	PRON
fnp-6762	196	2	method	method	NOUN
fnp-6762	196	3	showed	show	VERB
fnp-6762	196	4	good	good	ADJ
fnp-6762	196	5	agreement	agreement	NOUN
fnp-6762	196	6	with	with	ADP
fnp-6762	196	7	the	the	DET
fnp-6762	196	8	volume	volume	NOUN
fnp-6762	196	9	and	and	CCONJ
fnp-6762	196	10	numbers	number	NOUN
fnp-6762	196	11	of	of	ADP
fnp-6762	196	12	lesions	lesion	NOUN
fnp-6762	196	13	identified	identify	VERB
fnp-6762	196	14	through	through	ADP
fnp-6762	196	15	manual	manual	ADJ
fnp-6762	196	16	segmentation	segmentation	NOUN
fnp-6762	196	17	(	(	PUNCT
fnp-6762	196	18	ρ	ρ	NOUN
fnp-6762	196	19	 	 	SPACE
fnp-6762	196	20	=	=	NOUN
fnp-6762	196	21	 	 	SPACE
fnp-6762	196	22	0.92	0.92	NUM
fnp-6762	196	23	and	and	CCONJ
fnp-6762	196	24	ρ	ρ	NOUN
fnp-6762	196	25	 	 	SPACE
fnp-6762	196	26	=	=	NOUN
fnp-6762	196	27	 	 	SPACE
fnp-6762	196	28	0.97	0.97	NUM
fnp-6762	196	29	,	,	PUNCT
fnp-6762	196	30	and	and	CCONJ
fnp-6762	196	31	ρ	ρ	NOUN
fnp-6762	196	32	 	 	SPACE
fnp-6762	196	33	=	=	NOUN
fnp-6762	196	34	 	 	SPACE
fnp-6762	196	35	0.83	0.83	NUM
fnp-6762	196	36	and	and	CCONJ
fnp-6762	196	37	ρ	ρ	NOUN
fnp-6762	196	38	 	 	SPACE
fnp-6762	196	39	=	=	NOUN
fnp-6762	196	40	 	 	SPACE
fnp-6762	196	41	0.94	0.94	NUM
fnp-6762	196	42	for	for	ADP
fnp-6762	196	43	datasets	dataset	NOUN
fnp-6762	196	44	i	i	PRON
fnp-6762	196	45	and	and	CCONJ
fnp-6762	196	46	ii	ii	PROPN
fnp-6762	196	47	,	,	PUNCT
fnp-6762	196	48	respectively	respectively	ADV
fnp-6762	196	49	)	)	PUNCT
fnp-6762	196	50	.	.	PUNCT
fnp-6762	197	1	automated	automate	VERB
fnp-6762	197	2	methods	method	NOUN
fnp-6762	197	3	for	for	ADP
fnp-6762	197	4	prl	prl	PROPN
fnp-6762	197	5	assessment	assessment	NOUN
fnp-6762	197	6	are	be	AUX
fnp-6762	197	7	also	also	ADV
fnp-6762	197	8	urgently	urgently	ADV
fnp-6762	197	9	needed	need	VERB
fnp-6762	197	10	.	.	PUNCT
fnp-6762	198	1	now	now	ADV
fnp-6762	198	2	the	the	DET
fnp-6762	198	3	naims	naim	NOUN
fnp-6762	198	4	cooperative	cooperative	NOUN
fnp-6762	198	5	have	have	AUX
fnp-6762	198	6	tested	test	VERB
fnp-6762	198	7	an	an	DET
fnp-6762	198	8	automated	automate	VERB
fnp-6762	198	9	paramagnetic	paramagnetic	ADJ
fnp-6762	198	10	rim	rim	NOUN
fnp-6762	198	11	lesion	lesion	NOUN
fnp-6762	198	12	(	(	PUNCT
fnp-6762	198	13	aprl	aprl	NOUN
fnp-6762	198	14	)	)	PUNCT
fnp-6762	198	15	algorithm	algorithm	NOUN
fnp-6762	198	16	in	in	ADP
fnp-6762	198	17	a	a	DET
fnp-6762	198	18	multi	multi	ADJ
fnp-6762	198	19	-	-	ADJ
fnp-6762	198	20	center	center	ADJ
fnp-6762	198	21	setting	setting	NOUN
fnp-6762	198	22	and	and	CCONJ
fnp-6762	198	23	reported	report	VERB
fnp-6762	198	24	that	that	SCONJ
fnp-6762	198	25	this	this	DET
fnp-6762	198	26	automated	automate	VERB
fnp-6762	198	27	segmentation	segmentation	NOUN
fnp-6762	198	28	method	method	NOUN
fnp-6762	198	29	successfully	successfully	ADV
fnp-6762	198	30	captured	capture	VERB
fnp-6762	198	31	115	115	NUM
fnp-6762	198	32	(	(	PUNCT
fnp-6762	198	33	78	78	NUM
fnp-6762	198	34	 	 	SPACE
fnp-6762	198	35	%	%	NOUN
fnp-6762	198	36	)	)	PUNCT
fnp-6762	198	37	of	of	ADP
fnp-6762	198	38	manually	manually	ADV
fnp-6762	198	39	identified	identify	VERB
fnp-6762	198	40	prls66	prls66	NOUN
fnp-6762	198	41	.	.	PUNCT
fnp-6762	199	1	this	this	PRON
fnp-6762	199	2	gives	give	VERB
fnp-6762	199	3	promise	promise	NOUN
fnp-6762	199	4	for	for	ADP
fnp-6762	199	5	facilitated	facilitated	ADJ
fnp-6762	199	6	prl	prl	NOUN
fnp-6762	199	7	-	-	PUNCT
fnp-6762	199	8	detection	detection	NOUN
fnp-6762	199	9	in	in	ADP
fnp-6762	199	10	large	large	ADJ
fnp-6762	199	11	datasets	dataset	NOUN
fnp-6762	199	12	;	;	PUNCT
fnp-6762	199	13	an	an	DET
fnp-6762	199	14	improvement	improvement	NOUN
fnp-6762	199	15	that	that	PRON
fnp-6762	199	16	could	could	AUX
fnp-6762	199	17	enable	enable	VERB
fnp-6762	199	18	routine	routine	ADJ
fnp-6762	199	19	prl	prl	PROPN
fnp-6762	199	20	detection	detection	NOUN
fnp-6762	199	21	in	in	ADP
fnp-6762	199	22	clinical	clinical	ADJ
fnp-6762	199	23	settings	setting	NOUN
fnp-6762	199	24	and	and	CCONJ
fnp-6762	199	25	in	in	ADP
fnp-6762	199	26	the	the	DET
fnp-6762	199	27	context	context	NOUN
fnp-6762	199	28	of	of	ADP
fnp-6762	199	29	treatment	treatment	NOUN
fnp-6762	199	30	trials	trial	NOUN
fnp-6762	199	31	.	.	PUNCT
fnp-6762	200	1	rethinking	rethink	VERB
fnp-6762	200	2	ms	ms	ADJ
fnp-6762	200	3	progression	progression	NOUN
fnp-6762	200	4	and	and	CCONJ
fnp-6762	200	5	treatment	treatment	NOUN
fnp-6762	200	6	strategies	strategy	NOUN
fnp-6762	200	7	the	the	DET
fnp-6762	200	8	concept	concept	NOUN
fnp-6762	200	9	of	of	ADP
fnp-6762	200	10	progression	progression	NOUN
fnp-6762	200	11	independent	independent	ADJ
fnp-6762	200	12	from	from	ADP
fnp-6762	200	13	relapse	relapse	NOUN
fnp-6762	200	14	activity	activity	NOUN
fnp-6762	200	15	and	and	CCONJ
fnp-6762	200	16	emerging	emerge	VERB
fnp-6762	200	17	treatments	treatment	NOUN
fnp-6762	200	18	targeting	target	VERB
fnp-6762	200	19	the	the	DET
fnp-6762	200	20	pathophysiology	pathophysiology	NOUN
fnp-6762	200	21	of	of	ADP
fnp-6762	200	22	progression	progression	NOUN
fnp-6762	200	23	while	while	SCONJ
fnp-6762	200	24	it	it	PRON
fnp-6762	200	25	has	have	AUX
fnp-6762	200	26	long	long	ADV
fnp-6762	200	27	been	be	AUX
fnp-6762	200	28	accepted	accept	VERB
fnp-6762	200	29	that	that	SCONJ
fnp-6762	200	30	disability	disability	NOUN
fnp-6762	200	31	accrual	accrual	ADJ
fnp-6762	200	32	in	in	ADP
fnp-6762	200	33	ms	ms	PROPN
fnp-6762	200	34	is	be	AUX
fnp-6762	200	35	primarily	primarily	ADV
fnp-6762	200	36	driven	drive	VERB
fnp-6762	200	37	by	by	ADP
fnp-6762	200	38	focal	focal	ADJ
fnp-6762	200	39	inflammation	inflammation	NOUN
fnp-6762	200	40	as	as	ADP
fnp-6762	200	41	the	the	DET
fnp-6762	200	42	pathophysiological	pathophysiological	ADJ
fnp-6762	200	43	correlate	correlate	NOUN
fnp-6762	200	44	of	of	ADP
fnp-6762	200	45	relapses	relapse	NOUN
fnp-6762	200	46	,	,	PUNCT
fnp-6762	200	47	recent	recent	ADJ
fnp-6762	200	48	research	research	NOUN
fnp-6762	200	49	has	have	AUX
fnp-6762	200	50	identified	identify	VERB
fnp-6762	200	51	significant	significant	ADJ
fnp-6762	200	52	disease	disease	NOUN
fnp-6762	200	53	progression	progression	NOUN
fnp-6762	200	54	independent	independent	ADJ
fnp-6762	200	55	of	of	ADP
fnp-6762	200	56	relapse	relapse	NOUN
fnp-6762	200	57	activity	activity	NOUN
fnp-6762	200	58	,	,	PUNCT
fnp-6762	200	59	termed	term	VERB
fnp-6762	200	60	pira	pira	PROPN
fnp-6762	200	61	.	.	PUNCT
fnp-6762	201	1	identification	identification	NOUN
fnp-6762	201	2	of	of	ADP
fnp-6762	201	3	pira	pira	NOUN
fnp-6762	201	4	became	become	VERB
fnp-6762	201	5	possible	possible	ADJ
fnp-6762	201	6	through	through	ADP
fnp-6762	201	7	careful	careful	ADJ
fnp-6762	201	8	re	re	NOUN
fnp-6762	201	9	-	-	NOUN
fnp-6762	201	10	evaluation	evaluation	NOUN
fnp-6762	201	11	of	of	ADP
fnp-6762	201	12	clinical	clinical	ADJ
fnp-6762	201	13	trial	trial	NOUN
fnp-6762	201	14	data	datum	NOUN
fnp-6762	201	15	from	from	ADP
fnp-6762	201	16	high	high	ADJ
fnp-6762	201	17	-	-	PUNCT
fnp-6762	201	18	efficacy	efficacy	NOUN
fnp-6762	201	19	treatments	treatment	NOUN
fnp-6762	201	20	–	–	PUNCT
fnp-6762	201	21	particularly	particularly	ADV
fnp-6762	201	22	ocrelizumab	ocrelizumab	NOUN
fnp-6762	201	23	–	–	PUNCT
fnp-6762	201	24	where	where	SCONJ
fnp-6762	201	25	progression	progression	NOUN
fnp-6762	201	26	was	be	AUX
fnp-6762	201	27	observed	observe	VERB
fnp-6762	201	28	despite	despite	SCONJ
fnp-6762	201	29	an	an	DET
fnp-6762	201	30	almost	almost	ADV
fnp-6762	201	31	complete	complete	ADJ
fnp-6762	201	32	absence	absence	NOUN
fnp-6762	201	33	of	of	ADP
fnp-6762	201	34	relapses67	relapses67	NOUN
fnp-6762	201	35	.	.	PUNCT
fnp-6762	202	1	in	in	ADP
fnp-6762	202	2	2023	2023	NUM
fnp-6762	202	3	,	,	PUNCT
fnp-6762	202	4	data	datum	NOUN
fnp-6762	202	5	from	from	ADP
fnp-6762	202	6	a	a	DET
fnp-6762	202	7	large	large	ADJ
fnp-6762	202	8	cis	cis	NOUN
fnp-6762	202	9	/	/	PUNCT
fnp-6762	202	10	early	early	ADV
fnp-6762	202	11	ms	ms	PROPN
fnp-6762	202	12	cohort	cohort	NOUN
fnp-6762	202	13	revealed	reveal	VERB
fnp-6762	202	14	that	that	SCONJ
fnp-6762	202	15	pira	pira	PROPN
fnp-6762	202	16	can	can	AUX
fnp-6762	202	17	occur	occur	VERB
fnp-6762	202	18	even	even	ADV
fnp-6762	202	19	in	in	ADP
fnp-6762	202	20	early	early	ADV
fnp-6762	202	21	relapsing	relapse	VERB
fnp-6762	202	22	ms	ms	NOUN
fnp-6762	202	23	and	and	CCONJ
fnp-6762	202	24	is	be	AUX
fnp-6762	202	25	associated	associate	VERB
fnp-6762	202	26	with	with	ADP
fnp-6762	202	27	an	an	DET
fnp-6762	202	28	unfavorable	unfavorable	ADJ
fnp-6762	202	29	long	long	ADJ
fnp-6762	202	30	-	-	PUNCT
fnp-6762	202	31	term	term	NOUN
fnp-6762	202	32	prognosis68	prognosis68	NOUN
fnp-6762	202	33	.	.	PUNCT
fnp-6762	203	1	although	although	SCONJ
fnp-6762	203	2	several	several	ADJ
fnp-6762	203	3	studies	study	NOUN
fnp-6762	203	4	have	have	AUX
fnp-6762	203	5	shown	show	VERB
fnp-6762	203	6	that	that	SCONJ
fnp-6762	203	7	current	current	ADJ
fnp-6762	203	8	treatments	treatment	NOUN
fnp-6762	203	9	partially	partially	ADV
fnp-6762	203	10	influence	influence	VERB
fnp-6762	203	11	pira69	pira69	NOUN
fnp-6762	203	12	,	,	PUNCT
fnp-6762	203	13	none	none	NOUN
fnp-6762	203	14	of	of	ADP
fnp-6762	203	15	the	the	DET
fnp-6762	203	16	approved	approve	VERB
fnp-6762	203	17	therapies	therapy	NOUN
fnp-6762	203	18	are	be	AUX
fnp-6762	203	19	sufficient	sufficient	ADJ
fnp-6762	203	20	to	to	PART
fnp-6762	203	21	control	control	VERB
fnp-6762	203	22	it	it	PRON
fnp-6762	203	23	,	,	PUNCT
fnp-6762	203	24	and	and	CCONJ
fnp-6762	203	25	its	its	PRON
fnp-6762	203	26	exact	exact	ADJ
fnp-6762	203	27	pathophysiology	pathophysiology	NOUN
fnp-6762	203	28	remains	remain	VERB
fnp-6762	203	29	elusive	elusive	ADJ
fnp-6762	203	30	,	,	PUNCT
fnp-6762	203	31	hampering	hamper	VERB
fnp-6762	203	32	the	the	DET
fnp-6762	203	33	development	development	NOUN
fnp-6762	203	34	of	of	ADP
fnp-6762	203	35	targeted	target	VERB
fnp-6762	203	36	treatments	treatment	NOUN
fnp-6762	203	37	.	.	PUNCT
fnp-6762	204	1	in	in	ADP
fnp-6762	204	2	this	this	DET
fnp-6762	204	3	context	context	NOUN
fnp-6762	204	4	,	,	PUNCT
fnp-6762	204	5	a	a	DET
fnp-6762	204	6	novel	novel	ADJ
fnp-6762	204	7	class	class	NOUN
fnp-6762	204	8	of	of	ADP
fnp-6762	204	9	drugs	drug	NOUN
fnp-6762	204	10	–	–	PUNCT
fnp-6762	204	11	bruton	bruton	PROPN
fnp-6762	204	12	’s	’s	PART
fnp-6762	204	13	tyrosine	tyrosine	PROPN
fnp-6762	204	14	kinase	kinase	PROPN
fnp-6762	204	15	(	(	PUNCT
fnp-6762	204	16	btk	btk	PROPN
fnp-6762	204	17	)	)	PUNCT
fnp-6762	204	18	inhibitors	inhibitor	NOUN
fnp-6762	204	19	–	–	PUNCT
fnp-6762	204	20	has	have	AUX
fnp-6762	204	21	gained	gain	VERB
fnp-6762	204	22	attention	attention	NOUN
fnp-6762	204	23	in	in	ADP
fnp-6762	204	24	ms	ms	PROPN
fnp-6762	204	25	treatment	treatment	NOUN
fnp-6762	204	26	.	.	PUNCT
fnp-6762	205	1	btk	btk	NOUN
fnp-6762	205	2	inhibitors	inhibitor	NOUN
fnp-6762	205	3	block	block	VERB
fnp-6762	205	4	btk	btk	PROPN
fnp-6762	205	5	,	,	PUNCT
fnp-6762	205	6	an	an	DET
fnp-6762	205	7	enzyme	enzyme	NOUN
fnp-6762	205	8	essential	essential	ADJ
fnp-6762	205	9	for	for	ADP
fnp-6762	205	10	intracellular	intracellular	NOUN
fnp-6762	205	11	signaling	signal	VERB
fnp-6762	205	12	during	during	ADP
fnp-6762	205	13	b	b	PROPN
fnp-6762	205	14	cell	cell	NOUN
fnp-6762	205	15	receptor	receptor	NOUN
fnp-6762	205	16	activation	activation	NOUN
fnp-6762	205	17	and	and	CCONJ
fnp-6762	205	18	for	for	ADP
fnp-6762	205	19	activating	activate	VERB
fnp-6762	205	20	myeloid	myeloid	ADJ
fnp-6762	205	21	cells	cell	NOUN
fnp-6762	205	22	,	,	PUNCT
fnp-6762	205	23	without	without	ADP
fnp-6762	205	24	directly	directly	ADV
fnp-6762	205	25	affecting	affect	VERB
fnp-6762	205	26	t	t	NOUN
fnp-6762	205	27	cells70	cells70	NOUN
fnp-6762	205	28	.	.	PUNCT
fnp-6762	206	1	several	several	ADJ
fnp-6762	206	2	btk	btk	NOUN
fnp-6762	206	3	inhibitors	inhibitor	NOUN
fnp-6762	206	4	have	have	AUX
fnp-6762	206	5	already	already	ADV
fnp-6762	206	6	been	be	AUX
fnp-6762	206	7	approved	approve	VERB
fnp-6762	206	8	for	for	ADP
fnp-6762	206	9	hematologic	hematologic	NOUN
fnp-6762	206	10	malignancies	malignancy	NOUN
fnp-6762	206	11	such	such	ADJ
fnp-6762	206	12	as	as	ADP
fnp-6762	206	13	chronic	chronic	ADJ
fnp-6762	206	14	lymphocytic	lymphocytic	ADJ
fnp-6762	206	15	leukemia	leukemia	NOUN
fnp-6762	206	16	and	and	CCONJ
fnp-6762	206	17	mantle	mantle	NOUN
fnp-6762	206	18	cell	cell	NOUN
fnp-6762	206	19	lymphoma	lymphoma	NOUN
fnp-6762	206	20	;	;	PUNCT
fnp-6762	206	21	their	their	PRON
fnp-6762	206	22	dual	dual	ADJ
fnp-6762	206	23	action	action	NOUN
fnp-6762	206	24	on	on	ADP
fnp-6762	206	25	b	b	NOUN
fnp-6762	206	26	cells	cell	NOUN
fnp-6762	206	27	and	and	CCONJ
fnp-6762	206	28	myeloid	myeloid	ADJ
fnp-6762	206	29	cells	cell	NOUN
fnp-6762	206	30	has	have	AUX
fnp-6762	206	31	sparked	spark	VERB
fnp-6762	206	32	interest	interest	NOUN
fnp-6762	206	33	for	for	ADP
fnp-6762	206	34	autoimmune	autoimmune	ADJ
fnp-6762	206	35	diseases70	diseases70	NOUN
fnp-6762	206	36	.	.	PUNCT
fnp-6762	207	1	btk	btk	NOUN
fnp-6762	207	2	inhibition	inhibition	NOUN
fnp-6762	207	3	modulates	modulate	NOUN
fnp-6762	207	4	both	both	CCONJ
fnp-6762	207	5	adaptive	adaptive	ADJ
fnp-6762	207	6	and	and	CCONJ
fnp-6762	207	7	innate	innate	ADJ
fnp-6762	207	8	immune	immune	ADJ
fnp-6762	207	9	responses	response	NOUN
fnp-6762	207	10	by	by	ADP
fnp-6762	207	11	suppressing	suppress	VERB
fnp-6762	207	12	proinflammatory	proinflammatory	ADJ
fnp-6762	207	13	cytokine	cytokine	NOUN
fnp-6762	207	14	production	production	NOUN
fnp-6762	207	15	,	,	PUNCT
fnp-6762	207	16	antigen	antigen	ADJ
fnp-6762	207	17	presentation	presentation	NOUN
fnp-6762	207	18	,	,	PUNCT
fnp-6762	207	19	and	and	CCONJ
fnp-6762	207	20	cell	cell	NOUN
fnp-6762	207	21	survival71	survival71	NOUN
fnp-6762	207	22	.	.	PUNCT
fnp-6762	208	1	the	the	DET
fnp-6762	208	2	recognized	recognize	VERB
fnp-6762	208	3	role	role	NOUN
fnp-6762	208	4	of	of	ADP
fnp-6762	208	5	b	b	NOUN
fnp-6762	208	6	cells	cell	NOUN
fnp-6762	208	7	in	in	ADP
fnp-6762	208	8	ms	ms	PROPN
fnp-6762	208	9	pathophysiology	pathophysiology	NOUN
fnp-6762	208	10	,	,	PUNCT
fnp-6762	208	11	along	along	ADP
fnp-6762	208	12	with	with	ADP
fnp-6762	208	13	the	the	DET
fnp-6762	208	14	contribution	contribution	NOUN
fnp-6762	208	15	of	of	ADP
fnp-6762	208	16	myeloid	myeloid	ADJ
fnp-6762	208	17	cells	cell	NOUN
fnp-6762	208	18	to	to	ADP
fnp-6762	208	19	chronic	chronic	ADJ
fnp-6762	208	20	lesion	lesion	NOUN
fnp-6762	208	21	formation	formation	NOUN
fnp-6762	208	22	and	and	CCONJ
fnp-6762	208	23	progression	progression	NOUN
fnp-6762	208	24	,	,	PUNCT
fnp-6762	208	25	has	have	AUX
fnp-6762	208	26	led	lead	VERB
fnp-6762	208	27	to	to	ADP
fnp-6762	208	28	multiple	multiple	ADJ
fnp-6762	208	29	trials	trial	NOUN
fnp-6762	208	30	in	in	ADP
fnp-6762	208	31	both	both	PRON
fnp-6762	208	32	relapsing	relapse	VERB
fnp-6762	208	33	and	and	CCONJ
fnp-6762	208	34	progressive	progressive	ADJ
fnp-6762	208	35	ms70	ms70	PROPN
fnp-6762	208	36	.	.	PUNCT
fnp-6762	209	1	data	datum	NOUN
fnp-6762	209	2	from	from	ADP
fnp-6762	209	3	several	several	ADJ
fnp-6762	209	4	recent	recent	ADJ
fnp-6762	209	5	trials	trial	NOUN
fnp-6762	209	6	investigating	investigate	VERB
fnp-6762	209	7	evobrutinib	evobrutinib	NOUN
fnp-6762	209	8	and	and	CCONJ
fnp-6762	209	9	tolebrutinib	tolebrutinib	NOUN
fnp-6762	209	10	have	have	AUX
fnp-6762	209	11	been	be	AUX
fnp-6762	209	12	presented	present	VERB
fnp-6762	209	13	in	in	ADP
fnp-6762	209	14	2024	2024	NUM
fnp-6762	209	15	.	.	PUNCT
fnp-6762	210	1	notably	notably	ADV
fnp-6762	210	2	,	,	PUNCT
fnp-6762	210	3	evobrutinib	evobrutinib	NOUN
fnp-6762	210	4	failed	fail	VERB
fnp-6762	210	5	to	to	PART
fnp-6762	210	6	demonstrate	demonstrate	VERB
fnp-6762	210	7	superiority	superiority	NOUN
fnp-6762	210	8	over	over	ADP
fnp-6762	210	9	teriflunomide	teriflunomide	NOUN
fnp-6762	210	10	(	(	PUNCT
fnp-6762	210	11	which	which	PRON
fnp-6762	210	12	interferes	interfere	VERB
fnp-6762	210	13	with	with	ADP
fnp-6762	210	14	lymphocyte	lymphocyte	ADJ
fnp-6762	210	15	proliferation	proliferation	NOUN
fnp-6762	210	16	and	and	CCONJ
fnp-6762	210	17	metabolic	metabolic	NOUN
fnp-6762	210	18	activity	activity	NOUN
fnp-6762	210	19	)	)	PUNCT
fnp-6762	210	20	in	in	ADP
fnp-6762	210	21	controlling	control	VERB
fnp-6762	210	22	focal	focal	ADJ
fnp-6762	210	23	inflammatory	inflammatory	ADJ
fnp-6762	210	24	activity	activity	NOUN
fnp-6762	210	25	and	and	CCONJ
fnp-6762	210	26	confirmed	confirm	VERB
fnp-6762	210	27	accumulation	accumulation	NOUN
fnp-6762	210	28	of	of	ADP
fnp-6762	210	29	disability72	disability72	NOUN
fnp-6762	210	30	,	,	PUNCT
fnp-6762	210	31	whereas	whereas	SCONJ
fnp-6762	210	32	tolebrutinib	tolebrutinib	NOUN
fnp-6762	210	33	showed	show	VERB
fnp-6762	210	34	efficacy	efficacy	NOUN
fnp-6762	210	35	in	in	ADP
fnp-6762	210	36	reducing	reduce	VERB
fnp-6762	210	37	confirmed	confirm	VERB
fnp-6762	210	38	disability	disability	NOUN
fnp-6762	210	39	progression	progression	NOUN
fnp-6762	210	40	in	in	ADP
fnp-6762	210	41	three	three	NUM
fnp-6762	210	42	clinical	clinical	ADJ
fnp-6762	210	43	trials	trial	NOUN
fnp-6762	210	44	studying	study	VERB
fnp-6762	210	45	its	its	PRON
fnp-6762	210	46	efficacy	efficacy	NOUN
fnp-6762	210	47	in	in	ADP
fnp-6762	210	48	people	people	NOUN
fnp-6762	210	49	with	with	ADP
fnp-6762	210	50	rrms	rrm	NOUN
fnp-6762	210	51	and	and	CCONJ
fnp-6762	210	52	spms	spm	NOUN
fnp-6762	210	53	(	(	PUNCT
fnp-6762	210	54	gemini	gemini	PROPN
fnp-6762	210	55	i	i	PROPN
fnp-6762	210	56	and	and	CCONJ
fnp-6762	210	57	ii	ii	PROPN
fnp-6762	210	58	and	and	CCONJ
fnp-6762	210	59	hercules	hercules	PROPN
fnp-6762	210	60	trials)73,74	trials)73,74	AUX
fnp-6762	210	61	.	.	PUNCT
fnp-6762	211	1	recently	recently	ADV
fnp-6762	211	2	,	,	PUNCT
fnp-6762	211	3	new	new	ADJ
fnp-6762	211	4	data	datum	NOUN
fnp-6762	211	5	have	have	AUX
fnp-6762	211	6	been	be	AUX
fnp-6762	211	7	presented	present	VERB
fnp-6762	211	8	demonstrating	demonstrate	VERB
fnp-6762	211	9	that	that	SCONJ
fnp-6762	211	10	the	the	DET
fnp-6762	211	11	effect	effect	NOUN
fnp-6762	211	12	of	of	ADP
fnp-6762	211	13	tolebrutinib	tolebrutinib	NOUN
fnp-6762	211	14	on	on	ADP
fnp-6762	211	15	disability	disability	NOUN
fnp-6762	211	16	progression	progression	NOUN
fnp-6762	211	17	was	be	AUX
fnp-6762	211	18	only	only	ADV
fnp-6762	211	19	seen	see	VERB
fnp-6762	211	20	in	in	ADP
fnp-6762	211	21	patients	patient	NOUN
fnp-6762	211	22	with	with	ADP
fnp-6762	211	23	prls	prl	NOUN
fnp-6762	211	24	at	at	ADP
fnp-6762	211	25	baseline75	baseline75	NOUN
fnp-6762	211	26	.	.	PUNCT
fnp-6762	212	1	this	this	PRON
fnp-6762	212	2	is	be	AUX
fnp-6762	212	3	particularly	particularly	ADV
fnp-6762	212	4	remarkable	remarkable	ADJ
fnp-6762	212	5	as	as	SCONJ
fnp-6762	212	6	tolebrutinib	tolebrutinib	NOUN
fnp-6762	212	7	exerted	exert	VERB
fnp-6762	212	8	only	only	ADV
fnp-6762	212	9	modest	modest	ADJ
fnp-6762	212	10	effects	effect	NOUN
fnp-6762	212	11	on	on	ADP
fnp-6762	212	12	markers	marker	NOUN
fnp-6762	212	13	of	of	ADP
fnp-6762	212	14	acute	acute	ADJ
fnp-6762	212	15	focal	focal	ADJ
fnp-6762	212	16	inflammation	inflammation	NOUN
fnp-6762	212	17	,	,	PUNCT
fnp-6762	212	18	therefore	therefore	ADV
fnp-6762	212	19	providing	provide	VERB
fnp-6762	212	20	first	first	ADJ
fnp-6762	212	21	evidence	evidence	NOUN
fnp-6762	212	22	that	that	SCONJ
fnp-6762	212	23	progression	progression	NOUN
fnp-6762	212	24	-	-	PUNCT
fnp-6762	212	25	related	relate	VERB
fnp-6762	212	26	pathology	pathology	NOUN
fnp-6762	212	27	can	can	AUX
fnp-6762	212	28	be	be	AUX
fnp-6762	212	29	modulated	modulate	VERB
fnp-6762	212	30	independently	independently	ADV
fnp-6762	212	31	of	of	ADP
fnp-6762	212	32	acute	acute	ADJ
fnp-6762	212	33	focal	focal	ADJ
fnp-6762	212	34	activity	activity	NOUN
fnp-6762	212	35	and	and	CCONJ
fnp-6762	212	36	this	this	PRON
fnp-6762	212	37	is	be	AUX
fnp-6762	212	38	centered	center	VERB
fnp-6762	212	39	around	around	ADP
fnp-6762	212	40	modulation	modulation	NOUN
fnp-6762	212	41	of	of	ADP
fnp-6762	212	42	b	b	PROPN
fnp-6762	212	43	cells	cell	NOUN
fnp-6762	212	44	and/or	and/or	CCONJ
fnp-6762	212	45	myeloid	myeloid	ADJ
fnp-6762	212	46	cells73,74	cells73,74	NOUN
fnp-6762	212	47	.	.	PUNCT
fnp-6762	213	1	emerging	emerge	VERB
fnp-6762	213	2	cellular	cellular	ADJ
fnp-6762	213	3	therapies	therapy	NOUN
fnp-6762	213	4	–	–	PUNCT
fnp-6762	213	5	car	car	NOUN
fnp-6762	213	6	t	t	NOUN
fnp-6762	213	7	cells	cell	NOUN
fnp-6762	213	8	in	in	ADP
fnp-6762	213	9	other	other	ADJ
fnp-6762	213	10	autoimmune	autoimmune	ADJ
fnp-6762	213	11	diseases	disease	NOUN
fnp-6762	213	12	,	,	PUNCT
fnp-6762	213	13	novel	novel	ADJ
fnp-6762	213	14	cellular	cellular	ADJ
fnp-6762	213	15	therapies	therapy	NOUN
fnp-6762	213	16	are	be	AUX
fnp-6762	213	17	increasingly	increasingly	ADV
fnp-6762	213	18	being	be	AUX
fnp-6762	213	19	explored	explore	VERB
fnp-6762	213	20	for	for	ADP
fnp-6762	213	21	their	their	PRON
fnp-6762	213	22	potential	potential	ADJ
fnp-6762	213	23	applications	application	NOUN
fnp-6762	213	24	.	.	PUNCT
fnp-6762	214	1	one	one	NUM
fnp-6762	214	2	of	of	ADP
fnp-6762	214	3	the	the	DET
fnp-6762	214	4	most	most	ADV
fnp-6762	214	5	promising	promising	ADJ
fnp-6762	214	6	candidates	candidate	NOUN
fnp-6762	214	7	already	already	ADV
fnp-6762	214	8	in	in	ADP
fnp-6762	214	9	clinical	clinical	ADJ
fnp-6762	214	10	use	use	NOUN
fnp-6762	214	11	in	in	ADP
fnp-6762	214	12	oncology	oncology	NOUN
fnp-6762	214	13	are	be	AUX
fnp-6762	214	14	chimeric	chimeric	ADJ
fnp-6762	214	15	antigen	antigen	ADJ
fnp-6762	214	16	receptor	receptor	NOUN
fnp-6762	214	17	(	(	PUNCT
fnp-6762	214	18	car	car	NOUN
fnp-6762	214	19	)	)	PUNCT
fnp-6762	214	20	t	t	PROPN
fnp-6762	214	21	cells76	cells76	PROPN
fnp-6762	214	22	.	.	PUNCT
fnp-6762	215	1	these	these	PRON
fnp-6762	215	2	are	be	AUX
fnp-6762	215	3	t	t	NOUN
fnp-6762	215	4	cells	cell	NOUN
fnp-6762	215	5	that	that	PRON
fnp-6762	215	6	have	have	AUX
fnp-6762	215	7	been	be	AUX
fnp-6762	215	8	genetically	genetically	ADV
fnp-6762	215	9	modified	modify	VERB
fnp-6762	215	10	to	to	PART
fnp-6762	215	11	express	express	VERB
fnp-6762	215	12	a	a	DET
fnp-6762	215	13	construct	construct	NOUN
fnp-6762	215	14	enabling	enable	VERB
fnp-6762	215	15	high	high	ADJ
fnp-6762	215	16	-	-	PUNCT
fnp-6762	215	17	affinity	affinity	NOUN
fnp-6762	215	18	antigen	antigen	NOUN
fnp-6762	215	19	recognition	recognition	NOUN
fnp-6762	215	20	and	and	CCONJ
fnp-6762	215	21	downstream	downstream	ADJ
fnp-6762	215	22	signaling	signal	VERB
fnp-6762	215	23	,	,	PUNCT
fnp-6762	215	24	thereby	thereby	ADV
fnp-6762	215	25	conferring	confer	VERB
fnp-6762	215	26	proliferative	proliferative	ADJ
fnp-6762	215	27	capacity	capacity	NOUN
fnp-6762	215	28	,	,	PUNCT
fnp-6762	215	29	effector	effector	NOUN
fnp-6762	215	30	function	function	NOUN
fnp-6762	215	31	,	,	PUNCT
fnp-6762	215	32	and	and	CCONJ
fnp-6762	215	33	persistence	persistence	NOUN
fnp-6762	215	34	in	in	ADP
fnp-6762	215	35	the	the	DET
fnp-6762	215	36	recipient	recipient	NOUN
fnp-6762	215	37	for	for	ADP
fnp-6762	215	38	a	a	DET
fnp-6762	215	39	durable	durable	ADJ
fnp-6762	215	40	therapeutic	therapeutic	ADJ
fnp-6762	215	41	effect77	effect77	NOUN
fnp-6762	215	42	.	.	PUNCT
fnp-6762	216	1	importantly	importantly	ADV
fnp-6762	216	2	,	,	PUNCT
fnp-6762	216	3	the	the	DET
fnp-6762	216	4	car	car	NOUN
fnp-6762	216	5	t	t	NOUN
fnp-6762	216	6	receptor	receptor	NOUN
fnp-6762	216	7	is	be	AUX
fnp-6762	216	8	not	not	PART
fnp-6762	216	9	restricted	restrict	VERB
fnp-6762	216	10	by	by	ADP
fnp-6762	216	11	mhc	mhc	PROPN
fnp-6762	216	12	for	for	ADP
fnp-6762	216	13	antigen	antigen	ADJ
fnp-6762	216	14	recognition	recognition	NOUN
fnp-6762	216	15	.	.	PUNCT
fnp-6762	217	1	in	in	ADP
fnp-6762	217	2	most	most	ADJ
fnp-6762	217	3	cases	case	NOUN
fnp-6762	217	4	,	,	PUNCT
fnp-6762	217	5	this	this	PRON
fnp-6762	217	6	is	be	AUX
fnp-6762	217	7	done	do	VERB
fnp-6762	217	8	autologously	autologously	ADV
fnp-6762	217	9	–	–	PUNCT
fnp-6762	217	10	t	t	NUM
fnp-6762	217	11	cells	cell	NOUN
fnp-6762	217	12	are	be	AUX
fnp-6762	217	13	obtained	obtain	VERB
fnp-6762	217	14	from	from	ADP
fnp-6762	217	15	the	the	DET
fnp-6762	217	16	patient	patient	NOUN
fnp-6762	217	17	,	,	PUNCT
fnp-6762	217	18	engineered	engineer	VERB
fnp-6762	217	19	ex	ex	PRON
fnp-6762	217	20	vivo	vivo	NOUN
fnp-6762	217	21	with	with	ADP
fnp-6762	217	22	car	car	NOUN
fnp-6762	217	23	constructs	construct	NOUN
fnp-6762	217	24	,	,	PUNCT
fnp-6762	217	25	expanded	expand	VERB
fnp-6762	217	26	,	,	PUNCT
fnp-6762	217	27	and	and	CCONJ
fnp-6762	217	28	then	then	ADV
fnp-6762	217	29	reinfused	reinfuse	VERB
fnp-6762	217	30	.	.	PUNCT
fnp-6762	218	1	the	the	DET
fnp-6762	218	2	concept	concept	NOUN
fnp-6762	218	3	currently	currently	ADV
fnp-6762	218	4	under	under	ADP
fnp-6762	218	5	evaluation	evaluation	NOUN
fnp-6762	218	6	in	in	ADP
fnp-6762	218	7	neuroimmunology	neuroimmunology	NOUN
fnp-6762	218	8	,	,	PUNCT
fnp-6762	218	9	including	include	VERB
fnp-6762	218	10	ms	ms	NOUN
fnp-6762	218	11	,	,	PUNCT
fnp-6762	218	12	involves	involve	VERB
fnp-6762	218	13	car	car	NOUN
fnp-6762	218	14	t	t	NOUN
fnp-6762	218	15	cells	cell	NOUN
fnp-6762	218	16	targeting	target	VERB
fnp-6762	218	17	b	b	PROPN
fnp-6762	218	18	cells	cell	NOUN
fnp-6762	218	19	(	(	PUNCT
fnp-6762	218	20	via	via	ADP
fnp-6762	218	21	cd19	cd19	PROPN
fnp-6762	218	22	or	or	CCONJ
fnp-6762	218	23	bcma	bcma	PROPN
fnp-6762	218	24	)	)	PUNCT
fnp-6762	218	25	to	to	PART
fnp-6762	218	26	achieve	achieve	VERB
fnp-6762	218	27	thorough	thorough	ADJ
fnp-6762	218	28	b	b	NOUN
fnp-6762	218	29	cell	cell	NOUN
fnp-6762	218	30	depletion	depletion	NOUN
fnp-6762	218	31	even	even	ADV
fnp-6762	218	32	in	in	ADP
fnp-6762	218	33	tissues	tissue	NOUN
fnp-6762	218	34	,	,	PUNCT
fnp-6762	218	35	as	as	SCONJ
fnp-6762	218	36	these	these	DET
fnp-6762	218	37	cells	cell	NOUN
fnp-6762	218	38	have	have	AUX
fnp-6762	218	39	demonstrated	demonstrate	VERB
fnp-6762	218	40	good	good	ADJ
fnp-6762	218	41	deep	deep	ADJ
fnp-6762	218	42	tissue	tissue	NOUN
fnp-6762	218	43	penetration	penetration	NOUN
fnp-6762	218	44	,	,	PUNCT
fnp-6762	218	45	including	include	VERB
fnp-6762	218	46	the	the	DET
fnp-6762	218	47	cns78,79	cns78,79	NOUN
fnp-6762	218	48	.	.	PUNCT
fnp-6762	219	1	indeed	indeed	ADV
fnp-6762	219	2	,	,	PUNCT
fnp-6762	219	3	several	several	ADJ
fnp-6762	219	4	case	case	NOUN
fnp-6762	219	5	series	series	NOUN
fnp-6762	219	6	have	have	AUX
fnp-6762	219	7	recently	recently	ADV
fnp-6762	219	8	been	be	AUX
fnp-6762	219	9	published	publish	VERB
fnp-6762	219	10	illustrating	illustrate	VERB
fnp-6762	219	11	profound	profound	ADJ
fnp-6762	219	12	effects	effect	NOUN
fnp-6762	219	13	of	of	ADP
fnp-6762	219	14	this	this	DET
fnp-6762	219	15	therapeutic	therapeutic	ADJ
fnp-6762	219	16	approach	approach	NOUN
fnp-6762	219	17	in	in	ADP
fnp-6762	219	18	several	several	ADJ
fnp-6762	219	19	patients	patient	NOUN
fnp-6762	219	20	with	with	ADP
fnp-6762	219	21	refractory	refractory	NOUN
fnp-6762	219	22	myasthenia	myasthenia	NOUN
fnp-6762	219	23	gravis	gravis	NOUN
fnp-6762	219	24	and	and	CCONJ
fnp-6762	219	25	stiff	stiff	ADJ
fnp-6762	219	26	person	person	NOUN
fnp-6762	219	27	syndrome	syndrome	NOUN
fnp-6762	219	28	,	,	PUNCT
fnp-6762	219	29	however	however	ADV
fnp-6762	219	30	results	result	NOUN
fnp-6762	219	31	from	from	ADP
fnp-6762	219	32	clinical	clinical	ADJ
fnp-6762	219	33	trials	trial	NOUN
fnp-6762	219	34	are	be	AUX
fnp-6762	219	35	not	not	PART
fnp-6762	219	36	yet	yet	ADV
fnp-6762	219	37	available78,80,81	available78,80,81	NUM
fnp-6762	219	38	.	.	PUNCT
fnp-6762	220	1	our	our	PRON
fnp-6762	220	2	current	current	ADJ
fnp-6762	220	3	understanding	understanding	NOUN
fnp-6762	220	4	of	of	ADP
fnp-6762	220	5	ms	ms	ADJ
fnp-6762	220	6	progression	progression	NOUN
fnp-6762	220	7	centers	center	NOUN
fnp-6762	220	8	on	on	ADP
fnp-6762	220	9	a	a	DET
fnp-6762	220	10	compartmentalized	compartmentalized	ADJ
fnp-6762	220	11	inflammatory	inflammatory	ADJ
fnp-6762	220	12	process	process	NOUN
fnp-6762	220	13	that	that	PRON
fnp-6762	220	14	limits	limit	VERB
fnp-6762	220	15	the	the	DET
fnp-6762	220	16	efficacy	efficacy	NOUN
fnp-6762	220	17	of	of	ADP
fnp-6762	220	18	primarily	primarily	ADV
fnp-6762	220	19	peripherally	peripherally	ADV
fnp-6762	220	20	acting	act	VERB
fnp-6762	220	21	dmts	dmts	NOUN
fnp-6762	220	22	and	and	CCONJ
fnp-6762	220	23	car	car	NOUN
fnp-6762	220	24	t	t	NOUN
fnp-6762	220	25	cells	cell	NOUN
fnp-6762	220	26	may	may	AUX
fnp-6762	220	27	represent	represent	VERB
fnp-6762	220	28	an	an	DET
fnp-6762	220	29	emerging	emerge	VERB
fnp-6762	220	30	technology	technology	NOUN
fnp-6762	220	31	to	to	PART
fnp-6762	220	32	tackle	tackle	VERB
fnp-6762	220	33	this	this	DET
fnp-6762	220	34	treatment	treatment	NOUN
fnp-6762	220	35	challenge	challenge	NOUN
fnp-6762	220	36	.	.	PUNCT
fnp-6762	221	1	published	publish	VERB
fnp-6762	221	2	2024	2024	NUM
fnp-6762	221	3	data	datum	NOUN
fnp-6762	221	4	from	from	ADP
fnp-6762	221	5	two	two	NUM
fnp-6762	221	6	progressive	progressive	ADJ
fnp-6762	221	7	ms	ms	NOUN
fnp-6762	221	8	patients	patient	NOUN
fnp-6762	221	9	treated	treat	VERB
fnp-6762	221	10	with	with	ADP
fnp-6762	221	11	a	a	DET
fnp-6762	221	12	single	single	ADJ
fnp-6762	221	13	dose	dose	NOUN
fnp-6762	221	14	of	of	ADP
fnp-6762	221	15	fully	fully	ADV
fnp-6762	221	16	humanized	humanize	VERB
fnp-6762	221	17	second	second	ADJ
fnp-6762	221	18	-	-	PUNCT
fnp-6762	221	19	generation	generation	NOUN
fnp-6762	221	20	cd19	cd19	PROPN
fnp-6762	221	21	car	car	NOUN
fnp-6762	221	22	t	t	NOUN
fnp-6762	221	23	cells	cell	NOUN
fnp-6762	221	24	showed	show	VERB
fnp-6762	221	25	persistence	persistence	NOUN
fnp-6762	221	26	of	of	ADP
fnp-6762	221	27	car	car	NOUN
fnp-6762	221	28	t	t	NOUN
fnp-6762	221	29	cells	cell	NOUN
fnp-6762	221	30	in	in	ADP
fnp-6762	221	31	both	both	CCONJ
fnp-6762	221	32	the	the	DET
fnp-6762	221	33	peripheral	peripheral	ADJ
fnp-6762	221	34	blood	blood	NOUN
fnp-6762	221	35	and	and	CCONJ
fnp-6762	221	36	csf82	csf82	PROPN
fnp-6762	221	37	.	.	PUNCT
fnp-6762	222	1	notably	notably	ADV
fnp-6762	222	2	,	,	PUNCT
fnp-6762	222	3	car	car	NOUN
fnp-6762	222	4	t	t	NOUN
fnp-6762	222	5	cell	cell	NOUN
fnp-6762	222	6	treatment	treatment	NOUN
fnp-6762	222	7	resulted	result	VERB
fnp-6762	222	8	in	in	ADP
fnp-6762	222	9	peripheral	peripheral	ADJ
fnp-6762	222	10	b	b	NOUN
fnp-6762	222	11	cell	cell	NOUN
fnp-6762	222	12	depletion	depletion	NOUN
fnp-6762	222	13	and	and	CCONJ
fnp-6762	222	14	a	a	DET
fnp-6762	222	15	sustained	sustained	ADJ
fnp-6762	222	16	reduction	reduction	NOUN
fnp-6762	222	17	of	of	ADP
fnp-6762	222	18	csf	csf	ADJ
fnp-6762	222	19	oligoclonal	oligoclonal	ADJ
fnp-6762	222	20	bands	band	NOUN
fnp-6762	222	21	in	in	ADP
fnp-6762	222	22	one	one	NUM
fnp-6762	222	23	patient	patient	NOUN
fnp-6762	222	24	,	,	PUNCT
fnp-6762	222	25	providing	provide	VERB
fnp-6762	222	26	indirect	indirect	ADJ
fnp-6762	222	27	evidence	evidence	NOUN
fnp-6762	222	28	of	of	ADP
fnp-6762	222	29	effective	effective	ADJ
fnp-6762	222	30	cns	cns	NOUN
fnp-6762	222	31	plasma	plasma	NOUN
fnp-6762	222	32	cell	cell	NOUN
fnp-6762	222	33	depletion	depletion	NOUN
fnp-6762	222	34	.	.	PUNCT
fnp-6762	223	1	although	although	SCONJ
fnp-6762	223	2	this	this	DET
fnp-6762	223	3	small	small	ADJ
fnp-6762	223	4	case	case	NOUN
fnp-6762	223	5	series	series	NOUN
fnp-6762	223	6	with	with	ADP
fnp-6762	223	7	a	a	DET
fnp-6762	223	8	limited	limited	ADJ
fnp-6762	223	9	observation	observation	NOUN
fnp-6762	223	10	time	time	NOUN
fnp-6762	223	11	precludes	preclude	VERB
fnp-6762	223	12	definitive	definitive	ADJ
fnp-6762	223	13	efficacy	efficacy	NOUN
fnp-6762	223	14	evaluation	evaluation	NOUN
fnp-6762	223	15	,	,	PUNCT
fnp-6762	223	16	the	the	DET
fnp-6762	223	17	treatment	treatment	NOUN
fnp-6762	223	18	was	be	AUX
fnp-6762	223	19	well	well	ADV
fnp-6762	223	20	tolerated	tolerate	VERB
fnp-6762	223	21	,	,	PUNCT
fnp-6762	223	22	with	with	ADP
fnp-6762	223	23	only	only	ADJ
fnp-6762	223	24	mild	mild	ADJ
fnp-6762	223	25	cytokine	cytokine	NOUN
fnp-6762	223	26	release	release	NOUN
fnp-6762	223	27	syndrome	syndrome	NOUN
fnp-6762	223	28	and	and	CCONJ
fnp-6762	223	29	no	no	DET
fnp-6762	223	30	icans	ican	NOUN
fnp-6762	223	31	.	.	PUNCT
fnp-6762	224	1	several	several	ADJ
fnp-6762	224	2	clinical	clinical	ADJ
fnp-6762	224	3	trials	trial	NOUN
fnp-6762	224	4	in	in	ADP
fnp-6762	224	5	relapsing	relapse	VERB
fnp-6762	224	6	and	and	CCONJ
fnp-6762	224	7	progressive	progressive	ADJ
fnp-6762	224	8	ms	ms	NOUN
fnp-6762	224	9	are	be	AUX
fnp-6762	224	10	underway	underway	ADJ
fnp-6762	224	11	to	to	PART
fnp-6762	224	12	further	far	ADV
fnp-6762	224	13	explore	explore	VERB
fnp-6762	224	14	this	this	DET
fnp-6762	224	15	promising	promising	ADJ
fnp-6762	224	16	approach	approach	NOUN
fnp-6762	224	17	and	and	CCONJ
fnp-6762	224	18	assess	assess	VERB
fnp-6762	224	19	potential	potential	ADJ
fnp-6762	224	20	side	side	NOUN
fnp-6762	224	21	effects	effect	NOUN
fnp-6762	224	22	,	,	PUNCT
fnp-6762	224	23	including	include	VERB
fnp-6762	224	24	secondary	secondary	ADJ
fnp-6762	224	25	malignancies	malignancy	NOUN
fnp-6762	224	26	,	,	PUNCT
fnp-6762	224	27	which	which	PRON
fnp-6762	224	28	would	would	AUX
fnp-6762	224	29	strongly	strongly	ADV
fnp-6762	224	30	limit	limit	VERB
fnp-6762	224	31	use	use	NOUN
fnp-6762	224	32	of	of	ADP
fnp-6762	224	33	this	this	DET
fnp-6762	224	34	approach	approach	NOUN
fnp-6762	224	35	in	in	ADP
fnp-6762	224	36	the	the	DET
fnp-6762	224	37	context	context	NOUN
fnp-6762	224	38	of	of	ADP
fnp-6762	224	39	autoimmunity	autoimmunity	NOUN
fnp-6762	224	40	.	.	PUNCT
fnp-6762	225	1	preclinical	preclinical	ADJ
fnp-6762	225	2	studies	study	NOUN
fnp-6762	225	3	the	the	DET
fnp-6762	225	4	search	search	NOUN
fnp-6762	225	5	for	for	ADP
fnp-6762	225	6	neuroprotective	neuroprotective	ADJ
fnp-6762	225	7	and	and	CCONJ
fnp-6762	225	8	remyelination	remyelination	NOUN
fnp-6762	225	9	promoting	promote	VERB
fnp-6762	225	10	therapies	therapy	NOUN
fnp-6762	225	11	continues	continue	VERB
fnp-6762	225	12	,	,	PUNCT
fnp-6762	225	13	but	but	CCONJ
fnp-6762	225	14	is	be	AUX
fnp-6762	225	15	hampered	hamper	VERB
fnp-6762	225	16	by	by	ADP
fnp-6762	225	17	the	the	DET
fnp-6762	225	18	limited	limited	ADJ
fnp-6762	225	19	understanding	understanding	NOUN
fnp-6762	225	20	of	of	ADP
fnp-6762	225	21	the	the	DET
fnp-6762	225	22	molecular	molecular	ADJ
fnp-6762	225	23	and	and	CCONJ
fnp-6762	225	24	cellular	cellular	ADJ
fnp-6762	225	25	mechanisms	mechanism	NOUN
fnp-6762	225	26	driving	drive	VERB
fnp-6762	225	27	neurodegeneration	neurodegeneration	NOUN
fnp-6762	225	28	and	and	CCONJ
fnp-6762	225	29	remyelination	remyelination	NOUN
fnp-6762	225	30	failure	failure	NOUN
fnp-6762	225	31	in	in	ADP
fnp-6762	225	32	ms	ms	PROPN
fnp-6762	225	33	.	.	PROPN
fnp-6762	225	34	oligodendrocytes	oligodendrocytes	PROPN
fnp-6762	225	35	and	and	CCONJ
fnp-6762	225	36	neurons	neuron	NOUN
fnp-6762	225	37	are	be	AUX
fnp-6762	225	38	not	not	PART
fnp-6762	225	39	passive	passive	ADJ
fnp-6762	225	40	targets	target	NOUN
fnp-6762	225	41	of	of	ADP
fnp-6762	225	42	the	the	DET
fnp-6762	225	43	immune	immune	ADJ
fnp-6762	225	44	response	response	NOUN
fnp-6762	225	45	,	,	PUNCT
fnp-6762	225	46	as	as	SCONJ
fnp-6762	225	47	extensive	extensive	ADJ
fnp-6762	225	48	previous	previous	ADJ
fnp-6762	225	49	research	research	NOUN
fnp-6762	225	50	suggest	suggest	VERB
fnp-6762	225	51	that	that	SCONJ
fnp-6762	225	52	oligodendrocytes	oligodendrocyte	NOUN
fnp-6762	225	53	as	as	ADV
fnp-6762	225	54	well	well	ADV
fnp-6762	225	55	as	as	ADP
fnp-6762	225	56	neurons	neuron	NOUN
fnp-6762	225	57	can	can	AUX
fnp-6762	225	58	launch	launch	VERB
fnp-6762	225	59	an	an	DET
fnp-6762	225	60	inflammatory	inflammatory	ADJ
fnp-6762	225	61	response83–87	response83–87	NOUN
fnp-6762	225	62	.	.	PUNCT
fnp-6762	226	1	the	the	DET
fnp-6762	226	2	group	group	NOUN
fnp-6762	226	3	led	lead	VERB
fnp-6762	226	4	by	by	ADP
fnp-6762	226	5	manuel	manuel	PROPN
fnp-6762	226	6	friese	friese	PROPN
fnp-6762	226	7	discovered	discover	VERB
fnp-6762	226	8	,	,	PUNCT
fnp-6762	226	9	in	in	ADP
fnp-6762	226	10	detailed	detailed	ADJ
fnp-6762	226	11	and	and	CCONJ
fnp-6762	226	12	elaborate	elaborate	ADJ
fnp-6762	226	13	in	in	ADP
fnp-6762	226	14	vitro	vitro	X
fnp-6762	226	15	and	and	CCONJ
fnp-6762	226	16	in	in	ADP
fnp-6762	226	17	vivo	vivo	ADJ
fnp-6762	226	18	studies	study	NOUN
fnp-6762	226	19	,	,	PUNCT
fnp-6762	226	20	the	the	DET
fnp-6762	226	21	stimulator	stimulator	NOUN
fnp-6762	226	22	of	of	ADP
fnp-6762	226	23	interferon	interferon	ADJ
fnp-6762	226	24	genes	gene	NOUN
fnp-6762	226	25	(	(	PUNCT
fnp-6762	226	26	sting	sting	ADJ
fnp-6762	226	27	)	)	PUNCT
fnp-6762	226	28	as	as	ADP
fnp-6762	226	29	an	an	DET
fnp-6762	226	30	important	important	ADJ
fnp-6762	226	31	regulator	regulator	NOUN
fnp-6762	226	32	in	in	ADP
fnp-6762	226	33	neurons	neuron	NOUN
fnp-6762	226	34	,	,	PUNCT
fnp-6762	226	35	which	which	PRON
fnp-6762	226	36	is	be	AUX
fnp-6762	226	37	essential	essential	ADJ
fnp-6762	226	38	for	for	ADP
fnp-6762	226	39	the	the	DET
fnp-6762	226	40	homeostasis	homeostasis	NOUN
fnp-6762	226	41	of	of	ADP
fnp-6762	226	42	the	the	DET
fnp-6762	226	43	neuronal	neuronal	ADJ
fnp-6762	226	44	red	red	ADJ
fnp-6762	226	45	-	-	PUNCT
fnp-6762	226	46	ox	ox	NOUN
fnp-6762	226	47	system	system	NOUN
fnp-6762	226	48	and	and	CCONJ
fnp-6762	226	49	inflammation	inflammation	NOUN
fnp-6762	226	50	-	-	PUNCT
fnp-6762	226	51	induced	induce	VERB
fnp-6762	226	52	ferroptosis	ferroptosis	NOUN
fnp-6762	226	53	.	.	PUNCT
fnp-6762	227	1	sting	sting	NOUN
fnp-6762	227	2	is	be	AUX
fnp-6762	227	3	upregulated	upregulate	VERB
fnp-6762	227	4	in	in	ADP
fnp-6762	227	5	neurons	neuron	NOUN
fnp-6762	227	6	in	in	ADP
fnp-6762	227	7	eae	eae	PROPN
fnp-6762	227	8	and	and	CCONJ
fnp-6762	227	9	in	in	ADP
fnp-6762	227	10	people	people	NOUN
fnp-6762	227	11	with	with	ADP
fnp-6762	227	12	ms	ms	PROPN
fnp-6762	227	13	and	and	CCONJ
fnp-6762	227	14	most	most	ADV
fnp-6762	227	15	interesting	interesting	ADJ
fnp-6762	227	16	both	both	PRON
fnp-6762	227	17	,	,	PUNCT
fnp-6762	227	18	pharmacological	pharmacological	ADJ
fnp-6762	227	19	and	and	CCONJ
fnp-6762	227	20	genetic	genetic	ADJ
fnp-6762	227	21	ablation	ablation	NOUN
fnp-6762	227	22	of	of	ADP
fnp-6762	227	23	sting	sting	NOUN
fnp-6762	227	24	protected	protect	VERB
fnp-6762	227	25	against	against	ADP
fnp-6762	227	26	inflammation	inflammation	NOUN
fnp-6762	227	27	-	-	PUNCT
fnp-6762	227	28	induced	induce	VERB
fnp-6762	227	29	neurodegeneration	neurodegeneration	NOUN
fnp-6762	227	30	in	in	ADP
fnp-6762	227	31	eae	eae	PROPN
fnp-6762	227	32	mice	mouse	NOUN
fnp-6762	227	33	.	.	PUNCT
fnp-6762	228	1	sting1	sting1	NOUN
fnp-6762	228	2	-	-	PUNCT
fnp-6762	228	3	cko	cko	PROPN
fnp-6762	228	4	eae	eae	PROPN
fnp-6762	228	5	mice	mouse	NOUN
fnp-6762	228	6	displayed	display	VERB
fnp-6762	228	7	ameliorated	ameliorate	VERB
fnp-6762	228	8	eae	eae	PROPN
fnp-6762	228	9	disease	disease	NOUN
fnp-6762	228	10	course	course	NOUN
fnp-6762	228	11	and	and	CCONJ
fnp-6762	228	12	increased	increase	VERB
fnp-6762	228	13	numbers	number	NOUN
fnp-6762	228	14	of	of	ADP
fnp-6762	228	15	surviving	survive	VERB
fnp-6762	228	16	neurons	neuron	NOUN
fnp-6762	228	17	,	,	PUNCT
fnp-6762	228	18	but	but	CCONJ
fnp-6762	228	19	no	no	DET
fnp-6762	228	20	differences	difference	NOUN
fnp-6762	228	21	in	in	ADP
fnp-6762	228	22	the	the	DET
fnp-6762	228	23	extent	extent	NOUN
fnp-6762	228	24	of	of	ADP
fnp-6762	228	25	inflammatory	inflammatory	ADJ
fnp-6762	228	26	infiltrates	infiltrate	NOUN
fnp-6762	228	27	suggesting	suggest	VERB
fnp-6762	228	28	that	that	SCONJ
fnp-6762	228	29	pharmacological	pharmacological	ADJ
fnp-6762	228	30	targeting	targeting	NOUN
fnp-6762	228	31	of	of	ADP
fnp-6762	228	32	sting	sting	NOUN
fnp-6762	228	33	may	may	AUX
fnp-6762	228	34	represent	represent	VERB
fnp-6762	228	35	a	a	DET
fnp-6762	228	36	direct	direct	ADJ
fnp-6762	228	37	neuroprotective	neuroprotective	ADJ
fnp-6762	228	38	treatment	treatment	NOUN
fnp-6762	228	39	approach88	approach88	NOUN
fnp-6762	228	40	.	.	PUNCT
fnp-6762	229	1	another	another	DET
fnp-6762	229	2	focus	focus	NOUN
fnp-6762	229	3	in	in	ADP
fnp-6762	229	4	preclinical	preclinical	ADJ
fnp-6762	229	5	ms	ms	NOUN
fnp-6762	229	6	research	research	NOUN
fnp-6762	229	7	is	be	AUX
fnp-6762	229	8	to	to	PART
fnp-6762	229	9	unravel	unravel	VERB
fnp-6762	229	10	the	the	DET
fnp-6762	229	11	underlying	underlie	VERB
fnp-6762	229	12	molecular	molecular	ADJ
fnp-6762	229	13	mechanism	mechanism	NOUN
fnp-6762	229	14	for	for	ADP
fnp-6762	229	15	remyelination	remyelination	NOUN
fnp-6762	229	16	failure	failure	NOUN
fnp-6762	229	17	.	.	PUNCT
fnp-6762	230	1	current	current	ADJ
fnp-6762	230	2	concepts	concept	NOUN
fnp-6762	230	3	suggest	suggest	VERB
fnp-6762	230	4	that	that	SCONJ
fnp-6762	230	5	not	not	PART
fnp-6762	230	6	only	only	ADV
fnp-6762	230	7	a	a	DET
fnp-6762	230	8	differentiation	differentiation	NOUN
fnp-6762	230	9	block	block	NOUN
fnp-6762	230	10	of	of	ADP
fnp-6762	230	11	opc	opc	PROPN
fnp-6762	230	12	into	into	ADP
fnp-6762	230	13	mature	mature	ADJ
fnp-6762	230	14	myelinating	myelinate	VERB
fnp-6762	230	15	oligodendrocytes	oligodendrocyte	NOUN
fnp-6762	230	16	but	but	CCONJ
fnp-6762	230	17	also	also	ADV
fnp-6762	230	18	an	an	DET
fnp-6762	230	19	impaired	impaired	ADJ
fnp-6762	230	20	myelin	myelin	NOUN
fnp-6762	230	21	sheath	sheath	NOUN
fnp-6762	230	22	formation	formation	NOUN
fnp-6762	230	23	by	by	ADP
fnp-6762	230	24	mature	mature	ADJ
fnp-6762	230	25	oligodendrocytes	oligodendrocyte	NOUN
fnp-6762	230	26	may	may	AUX
fnp-6762	230	27	contribute	contribute	VERB
fnp-6762	230	28	to	to	ADP
fnp-6762	230	29	remyelination	remyelination	NOUN
fnp-6762	230	30	failure	failure	NOUN
fnp-6762	230	31	in	in	ADP
fnp-6762	230	32	ms89	ms89	PROPN
fnp-6762	230	33	.	.	PUNCT
fnp-6762	231	1	a	a	DET
fnp-6762	231	2	potential	potential	ADJ
fnp-6762	231	3	explanation	explanation	NOUN
fnp-6762	231	4	for	for	ADP
fnp-6762	231	5	the	the	DET
fnp-6762	231	6	latter	latter	ADJ
fnp-6762	231	7	might	might	AUX
fnp-6762	231	8	be	be	AUX
fnp-6762	231	9	that	that	ADV
fnp-6762	231	10	mature	mature	ADJ
fnp-6762	231	11	oligodendrocytes	oligodendrocyte	NOUN
fnp-6762	231	12	are	be	AUX
fnp-6762	231	13	epigenetically	epigenetically	ADV
fnp-6762	231	14	silenced	silence	VERB
fnp-6762	231	15	,	,	PUNCT
fnp-6762	231	16	as	as	SCONJ
fnp-6762	231	17	suggested	suggest	VERB
fnp-6762	231	18	by	by	ADP
fnp-6762	231	19	the	the	DET
fnp-6762	231	20	work	work	NOUN
fnp-6762	231	21	of	of	ADP
fnp-6762	231	22	liu	liu	PROPN
fnp-6762	231	23	and	and	CCONJ
fnp-6762	231	24	colleagues90	colleagues90	NOUN
fnp-6762	231	25	.	.	PUNCT
fnp-6762	232	1	they	they	PRON
fnp-6762	232	2	screened	screen	VERB
fnp-6762	232	3	an	an	DET
fnp-6762	232	4	epigenetic	epigenetic	ADJ
fnp-6762	232	5	compound	compound	NOUN
fnp-6762	232	6	library	library	NOUN
fnp-6762	232	7	and	and	CCONJ
fnp-6762	232	8	identified	identify	VERB
fnp-6762	232	9	the	the	DET
fnp-6762	232	10	small	small	ADJ
fnp-6762	232	11	molecule	molecule	NOUN
fnp-6762	232	12	esi1	esi1	PROPN
fnp-6762	232	13	that	that	PRON
fnp-6762	232	14	promoted	promote	VERB
fnp-6762	232	15	the	the	DET
fnp-6762	232	16	maturation	maturation	NOUN
fnp-6762	232	17	and/or	and/or	CCONJ
fnp-6762	232	18	in	in	ADP
fnp-6762	232	19	vitro	vitro	X
fnp-6762	232	20	myelination	myelination	NOUN
fnp-6762	232	21	of	of	ADP
fnp-6762	232	22	primary	primary	ADJ
fnp-6762	232	23	mouse	mouse	NOUN
fnp-6762	232	24	and	and	CCONJ
fnp-6762	232	25	human	human	PROPN
fnp-6762	232	26	ipsc	ipsc	NOUN
fnp-6762	232	27	derived	derive	VERB
fnp-6762	232	28	oligodendrocytes	oligodendrocyte	NOUN
fnp-6762	232	29	,	,	PUNCT
fnp-6762	232	30	promoted	promote	VERB
fnp-6762	232	31	remyelination	remyelination	NOUN
fnp-6762	232	32	in	in	ADP
fnp-6762	232	33	different	different	ADJ
fnp-6762	232	34	animal	animal	NOUN
fnp-6762	232	35	models	model	NOUN
fnp-6762	232	36	and	and	CCONJ
fnp-6762	232	37	improved	improve	VERB
fnp-6762	232	38	clinical	clinical	ADJ
fnp-6762	232	39	signs	sign	NOUN
fnp-6762	232	40	in	in	ADP
fnp-6762	232	41	the	the	DET
fnp-6762	232	42	eae	eae	PROPN
fnp-6762	232	43	model	model	NOUN
fnp-6762	232	44	.	.	PUNCT
fnp-6762	233	1	in	in	ADP
fnp-6762	233	2	summary	summary	NOUN
fnp-6762	233	3	,	,	PUNCT
fnp-6762	233	4	this	this	DET
fnp-6762	233	5	study	study	NOUN
fnp-6762	233	6	identifies	identify	VERB
fnp-6762	233	7	epigenetic	epigenetic	ADJ
fnp-6762	233	8	silencing	silencing	NOUN
fnp-6762	233	9	of	of	ADP
fnp-6762	233	10	mature	mature	ADJ
fnp-6762	233	11	oligodendrocytes	oligodendrocyte	NOUN
fnp-6762	233	12	as	as	ADP
fnp-6762	233	13	a	a	DET
fnp-6762	233	14	new	new	ADJ
fnp-6762	233	15	pathomechanism	pathomechanism	NOUN
fnp-6762	233	16	contributing	contribute	VERB
fnp-6762	233	17	to	to	ADP
fnp-6762	233	18	remyelination	remyelination	NOUN
fnp-6762	233	19	failure	failure	NOUN
fnp-6762	233	20	in	in	ADP
fnp-6762	233	21	ms	ms	NOUN
fnp-6762	233	22	and	and	CCONJ
fnp-6762	233	23	provides	provide	VERB
fnp-6762	233	24	evidence	evidence	NOUN
fnp-6762	233	25	that	that	SCONJ
fnp-6762	233	26	targeting	target	VERB
fnp-6762	233	27	the	the	DET
fnp-6762	233	28	epigenetic	epigenetic	ADJ
fnp-6762	233	29	machinery	machinery	NOUN
fnp-6762	233	30	might	might	AUX
fnp-6762	233	31	be	be	AUX
fnp-6762	233	32	a	a	DET
fnp-6762	233	33	promising	promising	ADJ
fnp-6762	233	34	new	new	ADJ
fnp-6762	233	35	pharmacological	pharmacological	ADJ
fnp-6762	233	36	target	target	NOUN
fnp-6762	233	37	to	to	PART
fnp-6762	233	38	overcome	overcome	VERB
fnp-6762	233	39	remyelination	remyelination	NOUN
fnp-6762	233	40	failure	failure	NOUN
fnp-6762	233	41	in	in	ADP
fnp-6762	233	42	ms	ms	PROPN
fnp-6762	233	43	.	.	PROPN
fnp-6762	233	44	summary	summary	PROPN
fnp-6762	233	45	conceptually	conceptually	ADV
fnp-6762	233	46	,	,	PUNCT
fnp-6762	233	47	the	the	DET
fnp-6762	233	48	identification	identification	NOUN
fnp-6762	233	49	of	of	ADP
fnp-6762	233	50	the	the	DET
fnp-6762	233	51	first	first	ADJ
fnp-6762	233	52	snp	snp	NOUN
fnp-6762	233	53	associated	associate	VERB
fnp-6762	233	54	with	with	ADP
fnp-6762	233	55	disease	disease	NOUN
fnp-6762	233	56	severity	severity	NOUN
fnp-6762	233	57	represents	represent	VERB
fnp-6762	233	58	a	a	DET
fnp-6762	233	59	major	major	ADJ
fnp-6762	233	60	breakthrough	breakthrough	NOUN
fnp-6762	233	61	,	,	PUNCT
fnp-6762	233	62	since	since	SCONJ
fnp-6762	233	63	it	it	PRON
fnp-6762	233	64	suggests	suggest	VERB
fnp-6762	233	65	a	a	DET
fnp-6762	233	66	genetic	genetic	ADJ
fnp-6762	233	67	component	component	NOUN
fnp-6762	233	68	in	in	ADP
fnp-6762	233	69	the	the	DET
fnp-6762	233	70	pathophysiology	pathophysiology	NOUN
fnp-6762	233	71	of	of	ADP
fnp-6762	233	72	disease	disease	NOUN
fnp-6762	233	73	progression	progression	NOUN
fnp-6762	233	74	independent	independent	ADJ
fnp-6762	233	75	from	from	ADP
fnp-6762	233	76	the	the	DET
fnp-6762	233	77	immune	immune	ADJ
fnp-6762	233	78	system	system	NOUN
fnp-6762	233	79	.	.	PUNCT
fnp-6762	234	1	the	the	DET
fnp-6762	234	2	accumulating	accumulate	VERB
fnp-6762	234	3	evidence	evidence	NOUN
fnp-6762	234	4	of	of	ADP
fnp-6762	234	5	ebv	ebv	NOUN
fnp-6762	234	6	as	as	ADP
fnp-6762	234	7	important	important	ADJ
fnp-6762	234	8	trigger	trigger	NOUN
fnp-6762	234	9	of	of	ADP
fnp-6762	234	10	ms	ms	PROPN
fnp-6762	234	11	disease	disease	NOUN
fnp-6762	234	12	onset	onset	NOUN
fnp-6762	234	13	raises	raise	VERB
fnp-6762	234	14	the	the	DET
fnp-6762	234	15	fascinating	fascinating	ADJ
fnp-6762	234	16	possibility	possibility	NOUN
fnp-6762	234	17	of	of	ADP
fnp-6762	234	18	an	an	DET
fnp-6762	234	19	anti	anti	ADJ
fnp-6762	234	20	-	-	ADJ
fnp-6762	234	21	viral	viral	ADJ
fnp-6762	234	22	treatment	treatment	NOUN
fnp-6762	234	23	which	which	PRON
fnp-6762	234	24	may	may	AUX
fnp-6762	234	25	either	either	CCONJ
fnp-6762	234	26	stop	stop	VERB
fnp-6762	234	27	or	or	CCONJ
fnp-6762	234	28	prevent	prevent	VERB
fnp-6762	234	29	ms	ms	PROPN
fnp-6762	234	30	.	.	PROPN
fnp-6762	235	1	the	the	DET
fnp-6762	235	2	new	new	ADJ
fnp-6762	235	3	diagnostic	diagnostic	ADJ
fnp-6762	235	4	framework	framework	NOUN
fnp-6762	235	5	of	of	ADP
fnp-6762	235	6	ms	ms	PROPN
fnp-6762	235	7	establishes	establish	VERB
fnp-6762	235	8	ms	ms	NOUN
fnp-6762	235	9	as	as	ADP
fnp-6762	235	10	a	a	DET
fnp-6762	235	11	disease	disease	NOUN
fnp-6762	235	12	continuum	continuum	ADJ
fnp-6762	235	13	and	and	CCONJ
fnp-6762	235	14	allows	allow	VERB
fnp-6762	235	15	diagnosis	diagnosis	NOUN
fnp-6762	235	16	based	base	VERB
fnp-6762	235	17	on	on	ADP
fnp-6762	235	18	purely	purely	ADV
fnp-6762	235	19	biologic	biologic	ADJ
fnp-6762	235	20	considerations	consideration	NOUN
fnp-6762	235	21	in	in	ADP
fnp-6762	235	22	the	the	DET
fnp-6762	235	23	absence	absence	NOUN
fnp-6762	235	24	of	of	ADP
fnp-6762	235	25	any	any	DET
fnp-6762	235	26	clinical	clinical	ADJ
fnp-6762	235	27	manifestation	manifestation	NOUN
fnp-6762	235	28	and	and	CCONJ
fnp-6762	235	29	new	new	ADJ
fnp-6762	235	30	imaging	imaging	NOUN
fnp-6762	235	31	and	and	CCONJ
fnp-6762	235	32	biomarkers	biomarker	NOUN
fnp-6762	235	33	as	as	ADV
fnp-6762	235	34	well	well	ADV
fnp-6762	235	35	as	as	ADP
fnp-6762	235	36	ai	ai	PRON
fnp-6762	235	37	approaches	approach	NOUN
fnp-6762	235	38	may	may	AUX
fnp-6762	235	39	facilitate	facilitate	VERB
fnp-6762	235	40	the	the	DET
fnp-6762	235	41	prediction	prediction	NOUN
fnp-6762	235	42	of	of	ADP
fnp-6762	235	43	the	the	DET
fnp-6762	235	44	disease	disease	NOUN
fnp-6762	235	45	course	course	NOUN
fnp-6762	235	46	and	and	CCONJ
fnp-6762	235	47	treatment	treatment	NOUN
fnp-6762	235	48	responses	response	NOUN
fnp-6762	235	49	in	in	ADP
fnp-6762	235	50	individual	individual	ADJ
fnp-6762	235	51	pwms	pwm	NOUN
fnp-6762	235	52	in	in	ADP
fnp-6762	235	53	the	the	DET
fnp-6762	235	54	not	not	PART
fnp-6762	235	55	too	too	ADV
fnp-6762	235	56	far	far	ADJ
fnp-6762	235	57	future	future	NOUN
fnp-6762	235	58	.	.	PUNCT
fnp-6762	236	1	a	a	DET
fnp-6762	236	2	conceptual	conceptual	ADJ
fnp-6762	236	3	game	game	NOUN
fnp-6762	236	4	changer	changer	NOUN
fnp-6762	236	5	from	from	ADP
fnp-6762	236	6	a	a	DET
fnp-6762	236	7	therapeutic	therapeutic	ADJ
fnp-6762	236	8	perspective	perspective	NOUN
fnp-6762	236	9	are	be	AUX
fnp-6762	236	10	the	the	DET
fnp-6762	236	11	results	result	NOUN
fnp-6762	236	12	from	from	ADP
fnp-6762	236	13	the	the	DET
fnp-6762	236	14	tolebrutinib	tolebrutinib	NOUN
fnp-6762	236	15	study	study	NOUN
fnp-6762	236	16	program	program	NOUN
fnp-6762	236	17	,	,	PUNCT
fnp-6762	236	18	as	as	SCONJ
fnp-6762	236	19	they	they	PRON
fnp-6762	236	20	demonstrate	demonstrate	VERB
fnp-6762	236	21	for	for	ADP
fnp-6762	236	22	the	the	DET
fnp-6762	236	23	first	first	ADJ
fnp-6762	236	24	time	time	NOUN
fnp-6762	236	25	that	that	PRON
fnp-6762	236	26	tackling	tackle	VERB
fnp-6762	236	27	clinical	clinical	ADJ
fnp-6762	236	28	outcomes	outcome	NOUN
fnp-6762	236	29	of	of	ADP
fnp-6762	236	30	disease	disease	NOUN
fnp-6762	236	31	progression	progression	NOUN
fnp-6762	236	32	is	be	AUX
fnp-6762	236	33	feasible	feasible	ADJ
fnp-6762	236	34	beyond	beyond	ADP
fnp-6762	236	35	targeting	target	VERB
fnp-6762	236	36	focal	focal	ADJ
fnp-6762	236	37	inflammation	inflammation	NOUN
fnp-6762	236	38	.	.	PUNCT
fnp-6762	237	1	the	the	DET
fnp-6762	237	2	ultimate	ultimate	ADJ
fnp-6762	237	3	challenge	challenge	NOUN
fnp-6762	237	4	for	for	ADP
fnp-6762	237	5	the	the	DET
fnp-6762	237	6	future	future	NOUN
fnp-6762	237	7	will	will	AUX
fnp-6762	237	8	be	be	AUX
fnp-6762	237	9	the	the	DET
fnp-6762	237	10	translation	translation	NOUN
fnp-6762	237	11	of	of	ADP
fnp-6762	237	12	our	our	PRON
fnp-6762	237	13	continuously	continuously	ADV
fnp-6762	237	14	increasing	increase	VERB
fnp-6762	237	15	understanding	understanding	NOUN
fnp-6762	237	16	of	of	ADP
fnp-6762	237	17	ms	ms	PROPN
fnp-6762	237	18	pathophysiology	pathophysiology	NOUN
fnp-6762	237	19	into	into	ADP
fnp-6762	237	20	new	new	ADJ
fnp-6762	237	21	treatment	treatment	NOUN
fnp-6762	237	22	approaches	approach	NOUN
fnp-6762	237	23	to	to	PART
fnp-6762	237	24	successfully	successfully	ADV
fnp-6762	237	25	stop	stop	VERB
fnp-6762	237	26	or	or	CCONJ
fnp-6762	237	27	prevent	prevent	VERB
fnp-6762	237	28	ms	ms	PROPN
fnp-6762	237	29	.	.	PROPN
fnp-6762	237	30	acknowledgements	acknowledgement	NOUN
fnp-6762	237	31	this	this	DET
fnp-6762	237	32	work	work	NOUN
fnp-6762	237	33	was	be	AUX
fnp-6762	237	34	supported	support	VERB
fnp-6762	237	35	by	by	ADP
fnp-6762	237	36	the	the	DET
fnp-6762	237	37	dfg	dfg	PROPN
fnp-6762	237	38	,	,	PUNCT
fnp-6762	237	39	crc	crc	NOUN
fnp-6762	237	40	tr128	tr128	NOUN
fnp-6762	237	41	project	project	NOUN
fnp-6762	237	42	a08	a08	NOUN
fnp-6762	237	43	to	to	ADP
fnp-6762	237	44	lk	lk	NOUN
fnp-6762	237	45	and	and	CCONJ
fnp-6762	237	46	b07	b07	VERB
fnp-6762	237	47	to	to	ADP
fnp-6762	237	48	t.k	t.k	PROPN
fnp-6762	237	49	.	.	PROPN
fnp-6762	237	50	,	,	PUNCT
fnp-6762	237	51	trr332	trr332	PROPN
fnp-6762	237	52	project	project	NOUN
fnp-6762	237	53	b2	b2	NOUN
fnp-6762	237	54	to	to	ADP
fnp-6762	237	55	l.k	l.k	PROPN
fnp-6762	237	56	,	,	PUNCT
fnp-6762	237	57	ku1477/13	ku1477/13	NOUN
fnp-6762	237	58	-	-	PUNCT
fnp-6762	237	59	1	1	NUM
fnp-6762	237	60	to	to	ADP
fnp-6762	237	61	t.k	t.k	PROPN
fnp-6762	237	62	.	.	PROPN
fnp-6762	237	63	,	,	PUNCT
fnp-6762	237	64	by	by	ADP
fnp-6762	237	65	the	the	DET
fnp-6762	237	66	national	national	PROPN
fnp-6762	237	67	ms	ms	PROPN
fnp-6762	237	68	society	society	PROPN
fnp-6762	237	69	(	(	PUNCT
fnp-6762	237	70	rfa180	rfa180	PROPN
fnp-6762	237	71	-	-	PUNCT
fnp-6762	237	72	2202	2202	NUM
fnp-6762	237	73	-	-	PUNCT
fnp-6762	237	74	39141	39141	NUM
fnp-6762	237	75	to	to	ADP
fnp-6762	237	76	lk	lk	NOUN
fnp-6762	237	77	and	and	CCONJ
fnp-6762	237	78	tk	tk	PROPN
fnp-6762	237	79	)	)	PUNCT
fnp-6762	237	80	,	,	PUNCT
fnp-6762	237	81	the	the	DET
fnp-6762	237	82	interdisciplinary	interdisciplinary	ADJ
fnp-6762	237	83	center	center	NOUN
fnp-6762	237	84	for	for	ADP
fnp-6762	237	85	clinical	clinical	ADJ
fnp-6762	237	86	research	research	NOUN
fnp-6762	237	87	(	(	PUNCT
fnp-6762	237	88	kut3/010/24	kut3/010/24	NOUN
fnp-6762	237	89	to	to	ADP
fnp-6762	237	90	t.k	t.k	PROPN
fnp-6762	237	91	.	.	PROPN
fnp-6762	237	92	and	and	CCONJ
fnp-6762	237	93	l.k	l.k	PROPN
fnp-6762	237	94	.	.	PROPN
fnp-6762	237	95	)	)	PUNCT
fnp-6762	237	96	,	,	PUNCT
fnp-6762	237	97	by	by	ADP
fnp-6762	237	98	the	the	DET
fnp-6762	237	99	inflames	inflame	NOUN
fnp-6762	237	100	flagship	flagship	NOUN
fnp-6762	237	101	program	program	NOUN
fnp-6762	237	102	of	of	ADP
fnp-6762	237	103	the	the	DET
fnp-6762	237	104	research	research	NOUN
fnp-6762	237	105	council	council	PROPN
fnp-6762	237	106	of	of	ADP
fnp-6762	237	107	finland	finland	PROPN
fnp-6762	237	108	(	(	PUNCT
fnp-6762	237	109	decision	decision	NOUN
fnp-6762	237	110	numbers	number	NOUN
fnp-6762	237	111	:	:	PUNCT
fnp-6762	237	112	337530	337530	NUM
fnp-6762	237	113	,	,	PUNCT
fnp-6762	237	114	357910	357910	NUM
fnp-6762	237	115	and	and	CCONJ
fnp-6762	237	116	358823	358823	NUM
fnp-6762	237	117	)	)	PUNCT
fnp-6762	237	118	,	,	PUNCT
fnp-6762	237	119	research	research	NOUN
fnp-6762	237	120	council	council	PROPN
fnp-6762	237	121	of	of	ADP
fnp-6762	237	122	finland	finland	PROPN
fnp-6762	237	123	clinical	clinical	ADJ
fnp-6762	237	124	investigator	investigator	NOUN
fnp-6762	237	125	grant	grant	NOUN
fnp-6762	237	126	program	program	NOUN
fnp-6762	237	127	(	(	PUNCT
fnp-6762	237	128	decision	decision	NOUN
fnp-6762	237	129	number	number	NOUN
fnp-6762	237	130	:	:	PUNCT
fnp-6762	237	131	330902	330902	NUM
fnp-6762	237	132	)	)	PUNCT
fnp-6762	237	133	,	,	PUNCT
fnp-6762	237	134	us	us	PROPN
fnp-6762	237	135	national	national	PROPN
fnp-6762	237	136	ms	ms	PROPN
fnp-6762	237	137	society	society	PROPN
fnp-6762	237	138	(	(	PUNCT
fnp-6762	237	139	rfa-2203	rfa-2203	VERB
fnp-6762	237	140	-	-	PUNCT
fnp-6762	237	141	39281	39281	NUM
fnp-6762	237	142	)	)	PUNCT
fnp-6762	237	143	and	and	CCONJ
fnp-6762	237	144	jane	jane	NOUN
fnp-6762	237	145	and	and	CCONJ
fnp-6762	237	146	aatos	aatos	PROPN
fnp-6762	237	147	erkko	erkko	PROPN
fnp-6762	237	148	foundation	foundation	PROPN
fnp-6762	237	149	to	to	ADP
fnp-6762	237	150	l.a	l.a	PROPN
fnp-6762	237	151	.	.	PROPN
fnp-6762	237	152	dr	dr	PROPN
fnp-6762	237	153	.	.	PROPN
fnp-6762	237	154	marjo	marjo	PROPN
fnp-6762	238	1	nylund	nylund	ADV
fnp-6762	238	2	is	be	AUX
fnp-6762	238	3	warmly	warmly	ADV
fnp-6762	238	4	acknowledged	acknowledge	VERB
fnp-6762	238	5	for	for	ADP
fnp-6762	238	6	preparation	preparation	NOUN
fnp-6762	238	7	of	of	ADP
fnp-6762	238	8	the	the	DET
fnp-6762	238	9	pet	pet	ADJ
fnp-6762	238	10	and	and	CCONJ
fnp-6762	238	11	mri	mri	NOUN
fnp-6762	238	12	images	image	NOUN
fnp-6762	238	13	.	.	PUNCT
fnp-6762	239	1	conflict	conflict	NOUN
fnp-6762	239	2	of	of	ADP
fnp-6762	239	3	interest	interest	NOUN
fnp-6762	239	4	and	and	CCONJ
fnp-6762	239	5	funding	funding	NOUN
fnp-6762	239	6	statement	statement	PROPN
fnp-6762	239	7	l.k	l.k	PROPN
fnp-6762	239	8	.	.	PROPN
fnp-6762	239	9	receives	receive	VERB
fnp-6762	239	10	research	research	NOUN
fnp-6762	239	11	support	support	NOUN
fnp-6762	239	12	from	from	ADP
fnp-6762	239	13	the	the	DET
fnp-6762	239	14	german	german	ADJ
fnp-6762	239	15	research	research	NOUN
fnp-6762	239	16	foundation	foundation	NOUN
fnp-6762	239	17	(	(	PUNCT
fnp-6762	239	18	dfg	dfg	PROPN
fnp-6762	239	19	)	)	PUNCT
fnp-6762	239	20	,	,	PUNCT
fnp-6762	239	21	the	the	DET
fnp-6762	239	22	interdisciplinary	interdisciplinary	ADJ
fnp-6762	239	23	center	center	NOUN
fnp-6762	239	24	for	for	ADP
fnp-6762	239	25	clinical	clinical	ADJ
fnp-6762	239	26	research	research	NOUN
fnp-6762	239	27	(	(	PUNCT
fnp-6762	239	28	izkf	izkf	NOUN
fnp-6762	239	29	)	)	PUNCT
fnp-6762	239	30	münster	münster	NOUN
fnp-6762	239	31	,	,	PUNCT
fnp-6762	239	32	national	national	ADJ
fnp-6762	239	33	ms	ms	PROPN
fnp-6762	239	34	society	society	PROPN
fnp-6762	239	35	,	,	PUNCT
fnp-6762	239	36	biogen	biogen	PROPN
fnp-6762	239	37	,	,	PUNCT
fnp-6762	239	38	novartis	novartis	PROPN
fnp-6762	239	39	and	and	CCONJ
fnp-6762	239	40	merck	merck	PROPN
fnp-6762	239	41	serono	serono	PROPN
fnp-6762	239	42	.	.	PUNCT
fnp-6762	240	1	she	she	PRON
fnp-6762	240	2	received	receive	VERB
fnp-6762	240	3	compensation	compensation	NOUN
fnp-6762	240	4	for	for	ADP
fnp-6762	240	5	serving	serve	VERB
fnp-6762	240	6	on	on	ADP
fnp-6762	240	7	scientific	scientific	ADJ
fnp-6762	240	8	advisory	advisory	ADJ
fnp-6762	240	9	boards	board	NOUN
fnp-6762	240	10	and	and	CCONJ
fnp-6762	240	11	speaker	speaker	NOUN
fnp-6762	240	12	honoraria	honorarium	NOUN
fnp-6762	240	13	from	from	ADP
fnp-6762	240	14	alexion	alexion	NOUN
fnp-6762	240	15	,	,	PUNCT
fnp-6762	240	16	amgen	amgen	PROPN
fnp-6762	240	17	,	,	PUNCT
fnp-6762	240	18	argenx	argenx	NOUN
fnp-6762	240	19	,	,	PUNCT
fnp-6762	240	20	bayer	bayer	PROPN
fnp-6762	240	21	,	,	PUNCT
fnp-6762	240	22	biogen	biogen	PROPN
fnp-6762	240	23	,	,	PUNCT
fnp-6762	240	24	bristol	bristol	PROPN
fnp-6762	240	25	-	-	PUNCT
fnp-6762	240	26	myers	myers	PROPN
fnp-6762	240	27	squibb	squibb	PROPN
fnp-6762	240	28	,	,	PUNCT
fnp-6762	240	29	grifols	grifol	NOUN
fnp-6762	240	30	,	,	PUNCT
fnp-6762	240	31	hexal	hexal	NOUN
fnp-6762	240	32	,	,	PUNCT
fnp-6762	240	33	horizon	horizon	PROPN
fnp-6762	240	34	,	,	PUNCT
fnp-6762	240	35	janssen	janssen	PROPN
fnp-6762	240	36	,	,	PUNCT
fnp-6762	240	37	merck	merck	PROPN
fnp-6762	240	38	serono	serono	PROPN
fnp-6762	240	39	,	,	PUNCT
fnp-6762	240	40	novartis	novartis	PROPN
fnp-6762	240	41	,	,	PUNCT
fnp-6762	240	42	roche	roche	PROPN
fnp-6762	240	43	,	,	PUNCT
fnp-6762	240	44	sandoz	sandoz	PROPN
fnp-6762	240	45	,	,	PUNCT
fnp-6762	240	46	sanofi	sanofi	PROPN
fnp-6762	240	47	,	,	PUNCT
fnp-6762	240	48	santhera	santhera	NOUN
fnp-6762	240	49	,	,	PUNCT
fnp-6762	240	50	teva	teva	NOUN
fnp-6762	240	51	and	and	CCONJ
fnp-6762	240	52	viatris	viatris	ADJ
fnp-6762	240	53	.	.	PUNCT
fnp-6762	241	1	l.a	l.a	PROPN
fnp-6762	241	2	.	.	PROPN
fnp-6762	241	3	receives	receive	VERB
fnp-6762	241	4	grants	grant	NOUN
fnp-6762	241	5	from	from	ADP
fnp-6762	241	6	the	the	DET
fnp-6762	241	7	research	research	NOUN
fnp-6762	241	8	council	council	PROPN
fnp-6762	241	9	of	of	ADP
fnp-6762	241	10	finland	finland	PROPN
fnp-6762	241	11	,	,	PUNCT
fnp-6762	241	12	aatos	aatos	NOUN
fnp-6762	241	13	erkko	erkko	PROPN
fnp-6762	241	14	foundation	foundation	PROPN
fnp-6762	241	15	,	,	PUNCT
fnp-6762	241	16	us	us	PROPN
fnp-6762	241	17	national	national	PROPN
fnp-6762	241	18	ms	ms	PROPN
fnp-6762	241	19	society	society	PROPN
fnp-6762	241	20	,	,	PUNCT
fnp-6762	241	21	merckserono	merckserono	NOUN
fnp-6762	241	22	and	and	CCONJ
fnp-6762	241	23	sanofi	sanofi	NOUN
fnp-6762	241	24	.	.	PUNCT
fnp-6762	242	1	she	she	PRON
fnp-6762	242	2	received	receive	VERB
fnp-6762	242	3	speaker	speaker	NOUN
fnp-6762	242	4	and	and	CCONJ
fnp-6762	242	5	advising	advise	VERB
fnp-6762	242	6	honoraria	honorarium	NOUN
fnp-6762	242	7	from	from	ADP
fnp-6762	242	8	sanofi	sanofi	PROPN
fnp-6762	242	9	,	,	PUNCT
fnp-6762	242	10	biogen	biogen	PROPN
fnp-6762	242	11	,	,	PUNCT
fnp-6762	242	12	novartis	novartis	PROPN
fnp-6762	242	13	,	,	PUNCT
fnp-6762	242	14	kiniksa	kiniksa	NOUN
fnp-6762	242	15	,	,	PUNCT
fnp-6762	242	16	continuum	continuum	ADJ
fnp-6762	242	17	therapeutics	therapeutic	NOUN
fnp-6762	242	18	and	and	CCONJ
fnp-6762	242	19	merck	merck	PROPN
fnp-6762	242	20	.	.	PUNCT
fnp-6762	243	1	m.s	m.s	PROPN
fnp-6762	243	2	.	.	PROPN
fnp-6762	243	3	declares	declare	VERB
fnp-6762	243	4	no	no	DET
fnp-6762	243	5	conflicts	conflict	NOUN
fnp-6762	243	6	of	of	ADP
fnp-6762	243	7	interest	interest	NOUN
fnp-6762	243	8	.	.	PUNCT
fnp-6762	244	1	t.k	t.k	AUX
fnp-6762	244	2	.	.	PROPN
fnp-6762	244	3	receives	receive	VERB
fnp-6762	244	4	research	research	NOUN
fnp-6762	244	5	funding	funding	NOUN
fnp-6762	244	6	from	from	ADP
fnp-6762	244	7	the	the	DET
fnp-6762	244	8	german	german	ADJ
fnp-6762	244	9	research	research	NOUN
fnp-6762	244	10	foundation	foundation	PROPN
fnp-6762	244	11	,	,	PUNCT
fnp-6762	244	12	interdisciplinary	interdisciplinary	ADJ
fnp-6762	244	13	center	center	NOUN
fnp-6762	244	14	for	for	ADP
fnp-6762	244	15	clinical	clinical	ADJ
fnp-6762	244	16	research	research	NOUN
fnp-6762	244	17	(	(	PUNCT
fnp-6762	244	18	izkf	izkf	NOUN
fnp-6762	244	19	)	)	PUNCT
fnp-6762	244	20	münster	münster	NOUN
fnp-6762	244	21	,	,	PUNCT
fnp-6762	244	22	national	national	ADJ
fnp-6762	244	23	ms	ms	PROPN
fnp-6762	244	24	society	society	PROPN
fnp-6762	244	25	,	,	PUNCT
fnp-6762	244	26	german	german	ADJ
fnp-6762	244	27	ms	ms	PROPN
fnp-6762	244	28	society	society	NOUN
fnp-6762	244	29	and	and	CCONJ
fnp-6762	244	30	novartis	novartis	NOUN
fnp-6762	244	31	.	.	PUNCT
fnp-6762	245	1	she	she	PRON
fnp-6762	245	2	received	receive	VERB
fnp-6762	245	3	compensation	compensation	NOUN
fnp-6762	245	4	for	for	ADP
fnp-6762	245	5	serving	serve	VERB
fnp-6762	245	6	on	on	ADP
fnp-6762	245	7	scientific	scientific	ADJ
fnp-6762	245	8	advisory	advisory	ADJ
fnp-6762	245	9	boards	board	NOUN
fnp-6762	245	10	from	from	ADP
fnp-6762	245	11	novartis	novartis	PROPN
fnp-6762	245	12	,	,	PUNCT
fnp-6762	245	13	sanofi	sanofi	PROPN
fnp-6762	245	14	and	and	CCONJ
fnp-6762	245	15	merck	merck	PROPN
fnp-6762	245	16	and	and	CCONJ
fnp-6762	245	17	speaker	speaker	NOUN
fnp-6762	245	18	honoraria	honorarium	NOUN
fnp-6762	245	19	from	from	ADP
fnp-6762	245	20	novartis	novartis	PROPN
fnp-6762	245	21	,	,	PUNCT
fnp-6762	245	22	biogen	biogen	PROPN
fnp-6762	245	23	,	,	PUNCT
fnp-6762	245	24	sanofi	sanofi	PROPN
fnp-6762	245	25	and	and	CCONJ
fnp-6762	245	26	roche	roche	PROPN
fnp-6762	245	27	.	.	PUNCT
fnp-6762	246	1	references	reference	NOUN
fnp-6762	246	2	1	1	NUM
fnp-6762	246	3	.	.	PUNCT
fnp-6762	246	4	international	international	ADJ
fnp-6762	246	5	multiple	multiple	ADJ
fnp-6762	246	6	sclerosis	sclerosis	NOUN
fnp-6762	246	7	genetics	genetic	NOUN
fnp-6762	246	8	,	,	PUNCT
fnp-6762	246	9	c.	c.	PROPN
fnp-6762	246	10	multiple	multiple	ADJ
fnp-6762	246	11	sclerosis	sclerosis	NOUN
fnp-6762	246	12	genomic	genomic	NOUN
fnp-6762	246	13	map	map	NOUN
fnp-6762	246	14	implicates	implicate	VERB
fnp-6762	246	15	peripheral	peripheral	ADJ
fnp-6762	246	16	immune	immune	ADJ
fnp-6762	246	17	cells	cell	NOUN
fnp-6762	246	18	and	and	CCONJ
fnp-6762	246	19	microglia	microglia	NOUN
fnp-6762	246	20	in	in	ADP
fnp-6762	246	21	susceptibility	susceptibility	NOUN
fnp-6762	246	22	.	.	PUNCT
fnp-6762	247	1	science	science	PROPN
fnp-6762	247	2	365(2019	365(2019	NUM
fnp-6762	247	3	)	)	PUNCT
fnp-6762	247	4	.	.	PUNCT
fnp-6762	248	1	https://doi.org/10.1126/science.aav7188	https://doi.org/10.1126/science.aav7188	NOUN
fnp-6762	248	2	2	2	X
fnp-6762	248	3	.	.	X
fnp-6762	248	4	international	international	ADJ
fnp-6762	248	5	multiple	multiple	ADJ
fnp-6762	248	6	sclerosis	sclerosis	NOUN
fnp-6762	248	7	genetics	genetic	NOUN
fnp-6762	248	8	,	,	PUNCT
fnp-6762	248	9	c.	c.	PROPN
fnp-6762	248	10	&	&	CCONJ
fnp-6762	248	11	multiple	multiple	ADJ
fnp-6762	248	12	,	,	PUNCT
fnp-6762	248	13	m.s.c	m.s.c	ADJ
fnp-6762	248	14	.	.	PUNCT
fnp-6762	248	15	locus	locus	NOUN
fnp-6762	248	16	for	for	ADP
fnp-6762	248	17	severity	severity	NOUN
fnp-6762	248	18	implicates	implicate	VERB
fnp-6762	248	19	cns	cns	NOUN
fnp-6762	248	20	resilience	resilience	NOUN
fnp-6762	248	21	in	in	ADP
fnp-6762	248	22	progression	progression	NOUN
fnp-6762	248	23	of	of	ADP
fnp-6762	248	24	multiple	multiple	ADJ
fnp-6762	248	25	sclerosis	sclerosis	NOUN
fnp-6762	248	26	.	.	PUNCT
fnp-6762	249	1	nature	nature	NOUN
fnp-6762	249	2	619	619	NUM
fnp-6762	249	3	,	,	PUNCT
fnp-6762	249	4	323	323	NUM
fnp-6762	249	5	-	-	SYM
fnp-6762	249	6	331	331	NUM
fnp-6762	249	7	(	(	PUNCT
fnp-6762	249	8	2023	2023	NUM
fnp-6762	249	9	)	)	PUNCT
fnp-6762	249	10	.	.	PUNCT
fnp-6762	250	1	https://doi.org/10.1038/s41586-023-06250-x	https://doi.org/10.1038/s41586-023-06250-x	PROPN
fnp-6762	250	2	3	3	NUM
fnp-6762	250	3	.	.	PUNCT
fnp-6762	250	4	bjornevik	bjornevik	PROPN
fnp-6762	250	5	,	,	PUNCT
fnp-6762	250	6	k.	k.	PROPN
fnp-6762	250	7	,	,	PUNCT
fnp-6762	250	8	et	et	PROPN
fnp-6762	250	9	al	al	PROPN
fnp-6762	250	10	.	.	PUNCT
fnp-6762	251	1	longitudinal	longitudinal	ADJ
fnp-6762	251	2	analysis	analysis	NOUN
fnp-6762	251	3	reveals	reveal	VERB
fnp-6762	251	4	high	high	ADJ
fnp-6762	251	5	prevalence	prevalence	NOUN
fnp-6762	251	6	of	of	ADP
fnp-6762	251	7	epstein	epstein	PROPN
fnp-6762	251	8	-	-	PUNCT
fnp-6762	251	9	barr	barr	PROPN
fnp-6762	251	10	virus	virus	NOUN
fnp-6762	251	11	associated	associate	VERB
fnp-6762	251	12	with	with	ADP
fnp-6762	251	13	multiple	multiple	ADJ
fnp-6762	251	14	sclerosis	sclerosis	NOUN
fnp-6762	251	15	.	.	PUNCT
fnp-6762	252	1	science	science	NOUN
fnp-6762	252	2	375	375	NUM
fnp-6762	252	3	,	,	PUNCT
fnp-6762	252	4	296	296	NUM
fnp-6762	252	5	-	-	SYM
fnp-6762	252	6	301	301	NUM
fnp-6762	252	7	(	(	PUNCT
fnp-6762	252	8	2022	2022	NUM
fnp-6762	252	9	)	)	PUNCT
fnp-6762	252	10	.	.	PUNCT
fnp-6762	253	1	https://doi.org/10.1126/science.abj8222	https://doi.org/10.1126/science.abj8222	PROPN
fnp-6762	253	2	4	4	NUM
fnp-6762	253	3	.	.	PUNCT
fnp-6762	253	4	barrie	barrie	PROPN
fnp-6762	253	5	,	,	PUNCT
fnp-6762	253	6	w.	w.	PROPN
fnp-6762	253	7	,	,	PUNCT
fnp-6762	253	8	et	et	PROPN
fnp-6762	253	9	al	al	PROPN
fnp-6762	253	10	.	.	PROPN
fnp-6762	253	11	elevated	elevate	VERB
fnp-6762	253	12	genetic	genetic	ADJ
fnp-6762	253	13	risk	risk	NOUN
fnp-6762	253	14	for	for	ADP
fnp-6762	253	15	multiple	multiple	ADJ
fnp-6762	253	16	sclerosis	sclerosis	NOUN
fnp-6762	253	17	emerged	emerge	VERB
fnp-6762	253	18	in	in	ADP
fnp-6762	253	19	steppe	steppe	NOUN
fnp-6762	253	20	pastoralist	pastoralist	NOUN
fnp-6762	253	21	populations	population	NOUN
fnp-6762	253	22	.	.	PUNCT
fnp-6762	254	1	nature	nature	NOUN
fnp-6762	254	2	625	625	NUM
fnp-6762	254	3	,	,	PUNCT
fnp-6762	254	4	321	321	NUM
fnp-6762	254	5	-	-	SYM
fnp-6762	254	6	328	328	NUM
fnp-6762	254	7	(	(	PUNCT
fnp-6762	254	8	2024	2024	NUM
fnp-6762	254	9	)	)	PUNCT
fnp-6762	254	10	.	.	PUNCT
fnp-6762	255	1	https://doi.org/10.1038/s41586-023-06618-z	https://doi.org/10.1038/s41586-023-06618-z	PROPN
fnp-6762	255	2	5	5	NUM
fnp-6762	255	3	.	.	PUNCT
fnp-6762	255	4	meruvu	meruvu	NOUN
fnp-6762	255	5	,	,	PUNCT
fnp-6762	255	6	s.	s.	PROPN
fnp-6762	255	7	,	,	PUNCT
fnp-6762	255	8	hugendubler	hugendubler	NOUN
fnp-6762	255	9	,	,	PUNCT
fnp-6762	255	10	l.	l.	PROPN
fnp-6762	255	11	&	&	CCONJ
fnp-6762	255	12	mueller	mueller	PROPN
fnp-6762	255	13	,	,	PUNCT
fnp-6762	255	14	e.	e.	PROPN
fnp-6762	255	15	regulation	regulation	PROPN
fnp-6762	255	16	of	of	ADP
fnp-6762	255	17	adipocyte	adipocyte	ADJ
fnp-6762	255	18	differentiation	differentiation	NOUN
fnp-6762	255	19	by	by	ADP
fnp-6762	255	20	the	the	DET
fnp-6762	255	21	zinc	zinc	NOUN
fnp-6762	255	22	finger	finger	NOUN
fnp-6762	255	23	protein	protein	NOUN
fnp-6762	255	24	znf638	znf638	PROPN
fnp-6762	255	25	.	.	PUNCT
fnp-6762	256	1	j	j	PROPN
fnp-6762	256	2	biol	biol	PROPN
fnp-6762	256	3	chem	chem	NOUN
fnp-6762	256	4	286	286	NUM
fnp-6762	256	5	,	,	PUNCT
fnp-6762	256	6	26516	26516	NUM
fnp-6762	256	7	-	-	SYM
fnp-6762	256	8	26523	26523	NUM
fnp-6762	256	9	(	(	PUNCT
fnp-6762	256	10	2011	2011	NUM
fnp-6762	256	11	)	)	PUNCT
fnp-6762	256	12	.	.	PUNCT
fnp-6762	257	1	https://doi.org/10.1074/jbc.m110.212506	https://doi.org/10.1074/jbc.m110.212506	NOUN
fnp-6762	257	2	6	6	NUM
fnp-6762	257	3	.	.	PUNCT
fnp-6762	258	1	gasperi	gasperi	PROPN
fnp-6762	258	2	,	,	PUNCT
fnp-6762	258	3	c.	c.	PROPN
fnp-6762	258	4	,	,	PUNCT
fnp-6762	258	5	et	et	PROPN
fnp-6762	258	6	al	al	PROPN
fnp-6762	258	7	.	.	PUNCT
fnp-6762	259	1	a	a	DET
fnp-6762	259	2	genetic	genetic	ADJ
fnp-6762	259	3	risk	risk	NOUN
fnp-6762	259	4	variant	variant	NOUN
fnp-6762	259	5	for	for	ADP
fnp-6762	259	6	multiple	multiple	ADJ
fnp-6762	259	7	sclerosis	sclerosis	NOUN
fnp-6762	259	8	severity	severity	NOUN
fnp-6762	259	9	is	be	AUX
fnp-6762	259	10	associated	associate	VERB
fnp-6762	259	11	with	with	ADP
fnp-6762	259	12	brain	brain	NOUN
fnp-6762	259	13	atrophy	atrophy	NOUN
fnp-6762	259	14	.	.	PUNCT
fnp-6762	260	1	ann	ann	PROPN
fnp-6762	260	2	neurol	neurol	PROPN
fnp-6762	260	3	94	94	NUM
fnp-6762	260	4	,	,	PUNCT
fnp-6762	260	5	1080	1080	NUM
fnp-6762	260	6	-	-	SYM
fnp-6762	260	7	1085	1085	NUM
fnp-6762	260	8	(	(	PUNCT
fnp-6762	260	9	2023	2023	NUM
fnp-6762	260	10	)	)	PUNCT
fnp-6762	260	11	.	.	PUNCT
fnp-6762	261	1	https://doi.org/10.1002/ana.26807	https://doi.org/10.1002/ana.26807	PROPN
fnp-6762	261	2	7	7	NUM
fnp-6762	261	3	.	.	PUNCT
fnp-6762	261	4	campagna	campagna	PROPN
fnp-6762	261	5	,	,	PUNCT
fnp-6762	261	6	m.p	m.p	PROPN
fnp-6762	261	7	.	.	PROPN
fnp-6762	261	8	,	,	PUNCT
fnp-6762	261	9	et	et	PROPN
fnp-6762	261	10	al	al	PROPN
fnp-6762	261	11	.	.	PUNCT
fnp-6762	262	1	no	no	DET
fnp-6762	262	2	evidence	evidence	NOUN
fnp-6762	262	3	for	for	ADP
fnp-6762	262	4	association	association	NOUN
fnp-6762	262	5	between	between	ADP
fnp-6762	262	6	rs10191329	rs10191329	NOUN
fnp-6762	262	7	severity	severity	NOUN
fnp-6762	262	8	locus	locus	NOUN
fnp-6762	262	9	and	and	CCONJ
fnp-6762	262	10	longitudinal	longitudinal	ADJ
fnp-6762	262	11	disease	disease	NOUN
fnp-6762	262	12	severity	severity	NOUN
fnp-6762	262	13	in	in	ADP
fnp-6762	262	14	1813	1813	NUM
fnp-6762	262	15	relapse	relapse	NOUN
fnp-6762	262	16	-	-	PUNCT
fnp-6762	262	17	onset	onset	VERB
fnp-6762	262	18	multiple	multiple	ADJ
fnp-6762	262	19	sclerosis	sclerosis	NOUN
fnp-6762	262	20	patients	patient	NOUN
fnp-6762	262	21	from	from	ADP
fnp-6762	262	22	the	the	DET
fnp-6762	262	23	msbase	msbase	NOUN
fnp-6762	262	24	registry	registry	NOUN
fnp-6762	262	25	.	.	PUNCT
fnp-6762	263	1	mult	mult	PROPN
fnp-6762	263	2	scler	scler	PROPN
fnp-6762	263	3	30	30	NUM
fnp-6762	263	4	,	,	PUNCT
fnp-6762	263	5	1216	1216	NUM
fnp-6762	263	6	-	-	SYM
fnp-6762	263	7	1220	1220	NUM
fnp-6762	263	8	(	(	PUNCT
fnp-6762	263	9	2024	2024	NUM
fnp-6762	263	10	)	)	PUNCT
fnp-6762	263	11	.	.	PUNCT
fnp-6762	264	1	https://doi.org/10.1177/13524585241240406	https://doi.org/10.1177/13524585241240406	ADJ
fnp-6762	264	2	8	8	NUM
fnp-6762	264	3	.	.	PUNCT
fnp-6762	264	4	kreft	kreft	PROPN
fnp-6762	264	5	,	,	PUNCT
fnp-6762	264	6	k.l	k.l	PROPN
fnp-6762	264	7	.	.	PROPN
fnp-6762	264	8	,	,	PUNCT
fnp-6762	264	9	et	et	PROPN
fnp-6762	264	10	al	al	PROPN
fnp-6762	264	11	.	.	PUNCT
fnp-6762	264	12	relevance	relevance	NOUN
fnp-6762	264	13	of	of	ADP
fnp-6762	264	14	multiple	multiple	ADJ
fnp-6762	264	15	sclerosis	sclerosis	NOUN
fnp-6762	264	16	severity	severity	NOUN
fnp-6762	264	17	genotype	genotype	NOUN
fnp-6762	264	18	in	in	ADP
fnp-6762	264	19	predicting	predict	VERB
fnp-6762	264	20	disease	disease	NOUN
fnp-6762	264	21	course	course	NOUN
fnp-6762	264	22	:	:	PUNCT
fnp-6762	264	23	a	a	DET
fnp-6762	264	24	real	real	ADJ
fnp-6762	264	25	-	-	PUNCT
fnp-6762	264	26	world	world	NOUN
fnp-6762	264	27	cohort	cohort	NOUN
fnp-6762	264	28	.	.	PUNCT
fnp-6762	265	1	ann	ann	PROPN
fnp-6762	265	2	neurol	neurol	PROPN
fnp-6762	265	3	95	95	NUM
fnp-6762	265	4	,	,	PUNCT
fnp-6762	265	5	459	459	NUM
fnp-6762	265	6	-	-	SYM
fnp-6762	265	7	470	470	NUM
fnp-6762	265	8	(	(	PUNCT
fnp-6762	265	9	2024	2024	NUM
fnp-6762	265	10	)	)	PUNCT
fnp-6762	265	11	.	.	PUNCT
fnp-6762	266	1	https://doi.org/10.1002/ana.26831	https://doi.org/10.1002/ana.26831	PROPN
fnp-6762	266	2	9	9	NUM
fnp-6762	266	3	.	.	PUNCT
fnp-6762	266	4	bjornevik	bjornevik	PROPN
fnp-6762	266	5	,	,	PUNCT
fnp-6762	266	6	k.	k.	PROPN
fnp-6762	266	7	,	,	PUNCT
fnp-6762	266	8	munz	munz	NOUN
fnp-6762	266	9	,	,	PUNCT
fnp-6762	266	10	c.	c.	PROPN
fnp-6762	266	11	,	,	PUNCT
fnp-6762	266	12	cohen	cohen	PROPN
fnp-6762	266	13	,	,	PUNCT
fnp-6762	266	14	j.i	j.i	PROPN
fnp-6762	266	15	.	.	PROPN
fnp-6762	266	16	&	&	CCONJ
fnp-6762	266	17	ascherio	ascherio	PROPN
fnp-6762	266	18	,	,	PUNCT
fnp-6762	266	19	a.	a.	PROPN
fnp-6762	266	20	epstein	epstein	PROPN
fnp-6762	266	21	-	-	PUNCT
fnp-6762	266	22	barr	barr	PROPN
fnp-6762	266	23	virus	virus	PROPN
fnp-6762	266	24	as	as	ADP
fnp-6762	266	25	a	a	DET
fnp-6762	266	26	leading	lead	VERB
fnp-6762	266	27	cause	cause	NOUN
fnp-6762	266	28	of	of	ADP
fnp-6762	266	29	multiple	multiple	ADJ
fnp-6762	266	30	sclerosis	sclerosis	NOUN
fnp-6762	266	31	:	:	PUNCT
fnp-6762	266	32	mechanisms	mechanism	NOUN
fnp-6762	266	33	and	and	CCONJ
fnp-6762	266	34	implications	implication	NOUN
fnp-6762	266	35	.	.	PUNCT
fnp-6762	267	1	nat	nat	PROPN
fnp-6762	267	2	rev	rev	VERB
fnp-6762	267	3	neurol	neurol	PROPN
fnp-6762	267	4	19	19	NUM
fnp-6762	267	5	,	,	PUNCT
fnp-6762	267	6	160	160	NUM
fnp-6762	267	7	-	-	SYM
fnp-6762	267	8	171	171	NUM
fnp-6762	267	9	(	(	PUNCT
fnp-6762	267	10	2023	2023	NUM
fnp-6762	267	11	)	)	PUNCT
fnp-6762	267	12	.	.	PUNCT
fnp-6762	268	1	https://doi.org/10.1038/s41582-023-00775-5	https://doi.org/10.1038/s41582-023-00775-5	X
fnp-6762	268	2	10	10	NUM
fnp-6762	268	3	.	.	PUNCT
fnp-6762	269	1	giovannoni	giovannoni	NOUN
fnp-6762	269	2	,	,	PUNCT
fnp-6762	269	3	g.	g.	PROPN
fnp-6762	269	4	targeting	target	VERB
fnp-6762	269	5	epstein	epstein	PROPN
fnp-6762	269	6	-	-	PUNCT
fnp-6762	269	7	barr	barr	PROPN
fnp-6762	269	8	virus	virus	PROPN
fnp-6762	269	9	in	in	ADP
fnp-6762	269	10	multiple	multiple	ADJ
fnp-6762	269	11	sclerosis	sclerosis	NOUN
fnp-6762	269	12	:	:	PUNCT
fnp-6762	269	13	when	when	SCONJ
fnp-6762	269	14	and	and	CCONJ
fnp-6762	269	15	how	how	SCONJ
fnp-6762	269	16	?	?	PUNCT
fnp-6762	270	1	curr	curr	PROPN
fnp-6762	270	2	opin	opin	PROPN
fnp-6762	270	3	neurol	neurol	NOUN
fnp-6762	270	4	37	37	NUM
fnp-6762	270	5	,	,	PUNCT
fnp-6762	270	6	228	228	NUM
fnp-6762	270	7	-	-	SYM
fnp-6762	270	8	236	236	NUM
fnp-6762	270	9	(	(	PUNCT
fnp-6762	270	10	2024	2024	NUM
fnp-6762	270	11	)	)	PUNCT
fnp-6762	270	12	.	.	PUNCT
fnp-6762	271	1	https://doi.org/10.1097/wco.0000000000001266	https://doi.org/10.1097/wco.0000000000001266	NOUN
fnp-6762	271	2	11	11	NUM
fnp-6762	271	3	.	.	PUNCT
fnp-6762	272	1	banwell	banwell	NOUN
fnp-6762	272	2	,	,	PUNCT
fnp-6762	272	3	b.	b.	PROPN
fnp-6762	272	4	,	,	PUNCT
fnp-6762	272	5	et	et	PROPN
fnp-6762	272	6	al	al	PROPN
fnp-6762	272	7	.	.	PROPN
fnp-6762	273	1	clinical	clinical	ADJ
fnp-6762	273	2	,	,	PUNCT
fnp-6762	273	3	environmental	environmental	ADJ
fnp-6762	273	4	,	,	PUNCT
fnp-6762	273	5	and	and	CCONJ
fnp-6762	273	6	genetic	genetic	ADJ
fnp-6762	273	7	determinants	determinant	NOUN
fnp-6762	273	8	of	of	ADP
fnp-6762	273	9	multiple	multiple	ADJ
fnp-6762	273	10	sclerosis	sclerosis	NOUN
fnp-6762	273	11	in	in	ADP
fnp-6762	273	12	children	child	NOUN
fnp-6762	273	13	with	with	ADP
fnp-6762	273	14	acute	acute	ADJ
fnp-6762	273	15	demyelination	demyelination	NOUN
fnp-6762	273	16	:	:	PUNCT
fnp-6762	273	17	a	a	DET
fnp-6762	273	18	prospective	prospective	ADJ
fnp-6762	273	19	national	national	ADJ
fnp-6762	273	20	cohort	cohort	NOUN
fnp-6762	273	21	study	study	NOUN
fnp-6762	273	22	.	.	PUNCT
fnp-6762	274	1	lancet	lancet	PROPN
fnp-6762	274	2	neurol	neurol	PROPN
fnp-6762	274	3	10	10	NUM
fnp-6762	274	4	,	,	PUNCT
fnp-6762	274	5	436	436	NUM
fnp-6762	274	6	-	-	SYM
fnp-6762	274	7	445	445	NUM
fnp-6762	274	8	(	(	PUNCT
fnp-6762	274	9	2011	2011	NUM
fnp-6762	274	10	)	)	PUNCT
fnp-6762	274	11	.	.	PUNCT
fnp-6762	275	1	https://doi.org/10.1016/s1474-4422(11)70045-x	https://doi.org/10.1016/s1474-4422(11)70045-x	VERB
fnp-6762	275	2	12	12	NUM
fnp-6762	275	3	.	.	PUNCT
fnp-6762	276	1	fadda	fadda	PROPN
fnp-6762	276	2	,	,	PUNCT
fnp-6762	276	3	g.	g.	PROPN
fnp-6762	276	4	,	,	PUNCT
fnp-6762	276	5	et	et	PROPN
fnp-6762	276	6	al	al	PROPN
fnp-6762	276	7	.	.	PROPN
fnp-6762	276	8	epstein	epstein	PROPN
fnp-6762	276	9	-	-	PUNCT
fnp-6762	276	10	barr	barr	PROPN
fnp-6762	276	11	virus	virus	PROPN
fnp-6762	276	12	strongly	strongly	ADV
fnp-6762	276	13	associates	associate	VERB
fnp-6762	276	14	with	with	ADP
fnp-6762	276	15	pediatric	pediatric	ADJ
fnp-6762	276	16	multiple	multiple	ADJ
fnp-6762	276	17	sclerosis	sclerosis	NOUN
fnp-6762	276	18	,	,	PUNCT
fnp-6762	276	19	but	but	CCONJ
fnp-6762	276	20	not	not	PART
fnp-6762	276	21	myelin	myelin	NOUN
fnp-6762	276	22	oligodendrocyte	oligodendrocyte	NOUN
fnp-6762	276	23	glycoprotein	glycoprotein	NOUN
fnp-6762	276	24	-	-	PUNCT
fnp-6762	276	25	antibody	antibody	NOUN
fnp-6762	276	26	-	-	PUNCT
fnp-6762	276	27	associated	associate	VERB
fnp-6762	276	28	disease	disease	NOUN
fnp-6762	276	29	.	.	PUNCT
fnp-6762	277	1	ann	ann	PROPN
fnp-6762	277	2	neurol	neurol	PROPN
fnp-6762	277	3	95	95	NUM
fnp-6762	277	4	,	,	PUNCT
fnp-6762	277	5	700	700	NUM
fnp-6762	277	6	-	-	SYM
fnp-6762	277	7	705	705	NUM
fnp-6762	277	8	(	(	PUNCT
fnp-6762	277	9	2024	2024	NUM
fnp-6762	277	10	)	)	PUNCT
fnp-6762	277	11	.	.	PUNCT
fnp-6762	278	1	https://doi.org/10.1002/ana.26890	https://doi.org/10.1002/ana.26890	ADJ
fnp-6762	278	2	13	13	NUM
fnp-6762	278	3	.	.	PUNCT
fnp-6762	279	1	munger	munger	PROPN
fnp-6762	279	2	,	,	PUNCT
fnp-6762	279	3	k.l	k.l	PROPN
fnp-6762	279	4	.	.	PROPN
fnp-6762	279	5	,	,	PUNCT
fnp-6762	279	6	levin	levin	PROPN
fnp-6762	279	7	,	,	PUNCT
fnp-6762	279	8	l.i	l.i	PROPN
fnp-6762	279	9	.	.	PROPN
fnp-6762	279	10	,	,	PUNCT
fnp-6762	279	11	o'reilly	o'reilly	PROPN
fnp-6762	279	12	,	,	PUNCT
fnp-6762	279	13	e.j	e.j	PROPN
fnp-6762	279	14	.	.	PROPN
fnp-6762	279	15	,	,	PUNCT
fnp-6762	279	16	falk	falk	NOUN
fnp-6762	279	17	,	,	PUNCT
fnp-6762	279	18	k.i	k.i	PROPN
fnp-6762	279	19	.	.	PROPN
fnp-6762	279	20	&	&	CCONJ
fnp-6762	279	21	ascherio	ascherio	PROPN
fnp-6762	279	22	,	,	PUNCT
fnp-6762	279	23	a.	a.	NOUN
fnp-6762	279	24	anti	anti	PROPN
fnp-6762	279	25	-	-	ADJ
fnp-6762	279	26	epstein	epstein	ADJ
fnp-6762	279	27	-	-	PUNCT
fnp-6762	279	28	barr	barr	PROPN
fnp-6762	279	29	virus	virus	PROPN
fnp-6762	279	30	antibodies	antibodie	VERB
fnp-6762	279	31	as	as	ADP
fnp-6762	279	32	serological	serological	ADJ
fnp-6762	279	33	markers	marker	NOUN
fnp-6762	279	34	of	of	ADP
fnp-6762	279	35	multiple	multiple	ADJ
fnp-6762	279	36	sclerosis	sclerosis	NOUN
fnp-6762	279	37	:	:	PUNCT
fnp-6762	279	38	a	a	DET
fnp-6762	279	39	prospective	prospective	ADJ
fnp-6762	279	40	study	study	NOUN
fnp-6762	279	41	among	among	ADP
fnp-6762	279	42	united	united	PROPN
fnp-6762	279	43	states	states	PROPN
fnp-6762	279	44	military	military	ADJ
fnp-6762	279	45	personnel	personnel	NOUN
fnp-6762	279	46	.	.	PUNCT
fnp-6762	280	1	mult	mult	PROPN
fnp-6762	280	2	scler	scler	PROPN
fnp-6762	280	3	17	17	NUM
fnp-6762	280	4	,	,	PUNCT
fnp-6762	280	5	1185	1185	NUM
fnp-6762	280	6	-	-	SYM
fnp-6762	280	7	1193	1193	NUM
fnp-6762	280	8	(	(	PUNCT
fnp-6762	280	9	2011	2011	NUM
fnp-6762	280	10	)	)	PUNCT
fnp-6762	280	11	.	.	PUNCT
fnp-6762	281	1	https://doi.org/10.1177/1352458511408991	https://doi.org/10.1177/1352458511408991	ADV
fnp-6762	281	2	14	14	NUM
fnp-6762	281	3	.	.	PUNCT
fnp-6762	282	1	delorenze	delorenze	PROPN
fnp-6762	282	2	,	,	PUNCT
fnp-6762	282	3	g.n	g.n	PROPN
fnp-6762	282	4	.	.	PROPN
fnp-6762	282	5	,	,	PUNCT
fnp-6762	282	6	et	et	PROPN
fnp-6762	282	7	al	al	PROPN
fnp-6762	282	8	.	.	PROPN
fnp-6762	282	9	epstein	epstein	PROPN
fnp-6762	282	10	-	-	PUNCT
fnp-6762	282	11	barr	barr	PROPN
fnp-6762	282	12	virus	virus	NOUN
fnp-6762	282	13	and	and	CCONJ
fnp-6762	282	14	multiple	multiple	ADJ
fnp-6762	282	15	sclerosis	sclerosis	NOUN
fnp-6762	282	16	:	:	PUNCT
fnp-6762	282	17	evidence	evidence	NOUN
fnp-6762	282	18	of	of	ADP
fnp-6762	282	19	association	association	NOUN
fnp-6762	282	20	from	from	ADP
fnp-6762	282	21	a	a	DET
fnp-6762	282	22	prospective	prospective	ADJ
fnp-6762	282	23	study	study	NOUN
fnp-6762	282	24	with	with	ADP
fnp-6762	282	25	long	long	ADJ
fnp-6762	282	26	-	-	PUNCT
fnp-6762	282	27	term	term	NOUN
fnp-6762	282	28	follow	follow	NOUN
fnp-6762	282	29	-	-	PUNCT
fnp-6762	282	30	up	up	NOUN
fnp-6762	282	31	.	.	PUNCT
fnp-6762	283	1	arch	arch	ADJ
fnp-6762	283	2	neurol	neurol	PROPN
fnp-6762	283	3	63	63	NUM
fnp-6762	283	4	,	,	PUNCT
fnp-6762	283	5	839	839	NUM
fnp-6762	283	6	-	-	SYM
fnp-6762	283	7	844	844	NUM
fnp-6762	283	8	(	(	PUNCT
fnp-6762	283	9	2006	2006	NUM
fnp-6762	283	10	)	)	PUNCT
fnp-6762	283	11	.	.	PUNCT
fnp-6762	284	1	https://doi.org/10.1001/archneur.63.6.noc50328	https://doi.org/10.1001/archneur.63.6.noc50328	PROPN
fnp-6762	284	2	15	15	NUM
fnp-6762	284	3	.	.	PUNCT
fnp-6762	285	1	thomas	thomas	PROPN
fnp-6762	285	2	,	,	PUNCT
fnp-6762	285	3	o.g	o.g	PROPN
fnp-6762	285	4	.	.	PROPN
fnp-6762	285	5	,	,	PUNCT
fnp-6762	285	6	et	et	PROPN
fnp-6762	285	7	al	al	PROPN
fnp-6762	285	8	.	.	PROPN
fnp-6762	285	9	heightened	heightened	PROPN
fnp-6762	285	10	epstein	epstein	PROPN
fnp-6762	285	11	-	-	PUNCT
fnp-6762	285	12	barr	barr	PROPN
fnp-6762	285	13	virus	virus	PROPN
fnp-6762	285	14	immunity	immunity	NOUN
fnp-6762	285	15	and	and	CCONJ
fnp-6762	285	16	potential	potential	ADJ
fnp-6762	285	17	cross	cross	NOUN
fnp-6762	285	18	-	-	NOUN
fnp-6762	285	19	reactivities	reactivity	NOUN
fnp-6762	285	20	in	in	ADP
fnp-6762	285	21	multiple	multiple	ADJ
fnp-6762	285	22	sclerosis	sclerosis	NOUN
fnp-6762	285	23	.	.	PUNCT
fnp-6762	286	1	plos	plos	PROPN
fnp-6762	286	2	pathog	pathog	VERB
fnp-6762	286	3	20	20	NUM
fnp-6762	286	4	,	,	PUNCT
fnp-6762	286	5	e1012177	e1012177	PROPN
fnp-6762	286	6	(	(	PUNCT
fnp-6762	286	7	2024	2024	NUM
fnp-6762	286	8	)	)	PUNCT
fnp-6762	286	9	.	.	PUNCT
fnp-6762	287	1	https://doi.org/10.1371/journal.ppat.1012177	https://doi.org/10.1371/journal.ppat.1012177	NOUN
fnp-6762	287	2	16	16	NUM
fnp-6762	287	3	.	.	PUNCT
fnp-6762	288	1	schneider	schneider	NOUN
fnp-6762	288	2	-	-	PUNCT
fnp-6762	288	3	hohendorf	hohendorf	PROPN
fnp-6762	288	4	,	,	PUNCT
fnp-6762	288	5	t.	t.	PROPN
fnp-6762	288	6	,	,	PUNCT
fnp-6762	288	7	et	et	PROPN
fnp-6762	288	8	al	al	PROPN
fnp-6762	288	9	.	.	PUNCT
fnp-6762	289	1	broader	broad	ADJ
fnp-6762	289	2	anti	anti	ADJ
fnp-6762	289	3	-	-	ADJ
fnp-6762	289	4	ebv	ebv	ADJ
fnp-6762	289	5	tcr	tcr	NOUN
fnp-6762	289	6	repertoire	repertoire	NOUN
fnp-6762	289	7	in	in	ADP
fnp-6762	289	8	multiple	multiple	ADJ
fnp-6762	289	9	sclerosis	sclerosis	NOUN
fnp-6762	289	10	:	:	PUNCT
fnp-6762	289	11	disease	disease	NOUN
fnp-6762	289	12	specificity	specificity	NOUN
fnp-6762	289	13	and	and	CCONJ
fnp-6762	289	14	treatment	treatment	NOUN
fnp-6762	289	15	modulation	modulation	NOUN
fnp-6762	289	16	.	.	PUNCT
fnp-6762	290	1	brain	brain	NOUN
fnp-6762	290	2	148	148	NUM
fnp-6762	290	3	,	,	PUNCT
fnp-6762	290	4	933	933	NUM
fnp-6762	290	5	-	-	SYM
fnp-6762	290	6	940	940	NUM
fnp-6762	290	7	(	(	PUNCT
fnp-6762	290	8	2025	2025	NUM
fnp-6762	290	9	)	)	PUNCT
fnp-6762	290	10	.	.	PUNCT
fnp-6762	291	1	https://doi.org/10.1093/brain/awae244	https://doi.org/10.1093/brain/awae244	PROPN
fnp-6762	292	1	17	17	NUM
fnp-6762	292	2	.	.	PUNCT
fnp-6762	293	1	ingelfinger	ingelfinger	PROPN
fnp-6762	293	2	,	,	PUNCT
fnp-6762	293	3	f.	f.	PROPN
fnp-6762	293	4	,	,	PUNCT
fnp-6762	293	5	et	et	PROPN
fnp-6762	293	6	al	al	PROPN
fnp-6762	293	7	.	.	PROPN
fnp-6762	294	1	twin	twin	PROPN
fnp-6762	294	2	study	study	NOUN
fnp-6762	294	3	dissects	dissect	VERB
fnp-6762	294	4	cxcr3(+	cxcr3(+	NOUN
fnp-6762	294	5	)	)	PUNCT
fnp-6762	294	6	memory	memory	NOUN
fnp-6762	294	7	b	b	PROPN
fnp-6762	294	8	cells	cell	NOUN
fnp-6762	294	9	as	as	ADP
fnp-6762	294	10	non	non	ADJ
fnp-6762	294	11	-	-	ADJ
fnp-6762	294	12	heritable	heritable	ADJ
fnp-6762	294	13	feature	feature	NOUN
fnp-6762	294	14	in	in	ADP
fnp-6762	294	15	multiple	multiple	ADJ
fnp-6762	294	16	sclerosis	sclerosis	NOUN
fnp-6762	294	17	.	.	PUNCT
fnp-6762	295	1	med	med	PROPN
fnp-6762	295	2	5	5	NUM
fnp-6762	295	3	,	,	PUNCT
fnp-6762	295	4	368	368	NUM
fnp-6762	295	5	-	-	SYM
fnp-6762	295	6	373	373	NUM
fnp-6762	295	7	e363	e363	PROPN
fnp-6762	295	8	(	(	PUNCT
fnp-6762	295	9	2024	2024	NUM
fnp-6762	295	10	)	)	PUNCT
fnp-6762	295	11	.	.	PUNCT
fnp-6762	296	1	https://doi.org/10.1016/j.medj.2024.02.013	https://doi.org/10.1016/j.medj.2024.02.013	PROPN
fnp-6762	296	2	18	18	NUM
fnp-6762	296	3	.	.	PUNCT
fnp-6762	297	1	soldan	soldan	PROPN
fnp-6762	297	2	,	,	PUNCT
fnp-6762	297	3	s.s	s.s	PROPN
fnp-6762	297	4	.	.	PROPN
fnp-6762	297	5	,	,	PUNCT
fnp-6762	297	6	et	et	PROPN
fnp-6762	297	7	al	al	PROPN
fnp-6762	297	8	.	.	PROPN
fnp-6762	297	9	multiple	multiple	ADJ
fnp-6762	297	10	sclerosis	sclerosis	NOUN
fnp-6762	297	11	patient	patient	NOUN
fnp-6762	297	12	-	-	PUNCT
fnp-6762	297	13	derived	derive	VERB
fnp-6762	297	14	spontaneous	spontaneous	ADJ
fnp-6762	297	15	b	b	PROPN
fnp-6762	297	16	cells	cell	NOUN
fnp-6762	297	17	have	have	VERB
fnp-6762	297	18	distinct	distinct	ADJ
fnp-6762	297	19	ebv	ebv	NOUN
fnp-6762	297	20	and	and	CCONJ
fnp-6762	297	21	host	host	NOUN
fnp-6762	297	22	gene	gene	NOUN
fnp-6762	297	23	expression	expression	NOUN
fnp-6762	297	24	profiles	profile	NOUN
fnp-6762	297	25	in	in	ADP
fnp-6762	297	26	active	active	ADJ
fnp-6762	297	27	disease	disease	NOUN
fnp-6762	297	28	.	.	PUNCT
fnp-6762	298	1	nat	nat	PROPN
fnp-6762	298	2	microbiol	microbiol	PROPN
fnp-6762	298	3	9	9	NUM
fnp-6762	298	4	,	,	PUNCT
fnp-6762	298	5	1540	1540	NUM
fnp-6762	298	6	-	-	SYM
fnp-6762	298	7	1554	1554	NUM
fnp-6762	298	8	(	(	PUNCT
fnp-6762	298	9	2024	2024	NUM
fnp-6762	298	10	)	)	PUNCT
fnp-6762	298	11	.	.	PUNCT
fnp-6762	299	1	https://doi.org/10.1038/s41564-024-01699-6	https://doi.org/10.1038/s41564-024-01699-6	NUM
fnp-6762	299	2	19	19	NUM
fnp-6762	299	3	.	.	PUNCT
fnp-6762	300	1	van	van	PROPN
fnp-6762	300	2	de	de	PROPN
fnp-6762	300	3	waterweg	waterweg	PROPN
fnp-6762	300	4	berends	berend	NOUN
fnp-6762	300	5	,	,	PUNCT
fnp-6762	300	6	a.	a.	PROPN
fnp-6762	300	7	,	,	PUNCT
fnp-6762	300	8	broux	broux	PROPN
fnp-6762	300	9	,	,	PUNCT
fnp-6762	300	10	b.	b.	PROPN
fnp-6762	300	11	,	,	PUNCT
fnp-6762	300	12	machiels	machiels	PROPN
fnp-6762	300	13	,	,	PUNCT
fnp-6762	300	14	b.	b.	PROPN
fnp-6762	300	15	,	,	PUNCT
fnp-6762	300	16	gillet	gillet	PROPN
fnp-6762	300	17	,	,	PUNCT
fnp-6762	300	18	l.	l.	PROPN
fnp-6762	300	19	&	&	CCONJ
fnp-6762	300	20	hellings	hellings	PROPN
fnp-6762	300	21	,	,	PUNCT
fnp-6762	300	22	n.	n.	VERB
fnp-6762	300	23	the	the	DET
fnp-6762	300	24	ebv	ebv	NOUN
fnp-6762	300	25	-	-	PUNCT
fnp-6762	300	26	ms	ms	NOUN
fnp-6762	300	27	connection	connection	NOUN
fnp-6762	300	28	:	:	PUNCT
fnp-6762	300	29	the	the	DET
fnp-6762	300	30	enigma	enigma	NOUN
fnp-6762	300	31	remains	remain	VERB
fnp-6762	300	32	.	.	PUNCT
fnp-6762	301	1	front	front	ADJ
fnp-6762	301	2	immunol	immunol	NOUN
fnp-6762	301	3	15	15	NUM
fnp-6762	301	4	,	,	PUNCT
fnp-6762	301	5	1466339	1466339	NUM
fnp-6762	301	6	(	(	PUNCT
fnp-6762	301	7	2024	2024	NUM
fnp-6762	301	8	)	)	PUNCT
fnp-6762	301	9	.	.	PUNCT
fnp-6762	302	1	https://doi.org/10.3389/fimmu.2024.1466339	https://doi.org/10.3389/fimmu.2024.1466339	PROPN
fnp-6762	302	2	20	20	NUM
fnp-6762	302	3	.	.	PUNCT
fnp-6762	303	1	lerma	lerma	PROPN
fnp-6762	303	2	-	-	PUNCT
fnp-6762	303	3	martin	martin	PROPN
fnp-6762	303	4	,	,	PUNCT
fnp-6762	303	5	c.	c.	PROPN
fnp-6762	303	6	,	,	PUNCT
fnp-6762	303	7	et	et	PROPN
fnp-6762	303	8	al	al	PROPN
fnp-6762	303	9	.	.	PROPN
fnp-6762	303	10	cell	cell	NOUN
fnp-6762	303	11	type	type	NOUN
fnp-6762	303	12	mapping	mapping	NOUN
fnp-6762	303	13	reveals	reveal	VERB
fnp-6762	303	14	tissue	tissue	NOUN
fnp-6762	303	15	niches	niche	NOUN
fnp-6762	303	16	and	and	CCONJ
fnp-6762	303	17	interactions	interaction	NOUN
fnp-6762	303	18	in	in	ADP
fnp-6762	303	19	subcortical	subcortical	ADJ
fnp-6762	303	20	multiple	multiple	ADJ
fnp-6762	303	21	sclerosis	sclerosis	NOUN
fnp-6762	303	22	lesions	lesion	NOUN
fnp-6762	303	23	.	.	PUNCT
fnp-6762	304	1	nat	nat	PROPN
fnp-6762	304	2	neurosci	neurosci	PROPN
fnp-6762	304	3	27	27	NUM
fnp-6762	304	4	,	,	PUNCT
fnp-6762	304	5	2354	2354	NUM
fnp-6762	304	6	-	-	SYM
fnp-6762	304	7	2365	2365	NUM
fnp-6762	304	8	(	(	PUNCT
fnp-6762	304	9	2024	2024	NUM
fnp-6762	304	10	)	)	PUNCT
fnp-6762	304	11	.	.	PUNCT
fnp-6762	305	1	https://doi.org/10.1038/s41593-024-01796-z	https://doi.org/10.1038/s41593-024-01796-z	PROPN
fnp-6762	305	2	21	21	NUM
fnp-6762	305	3	.	.	PUNCT
fnp-6762	306	1	alsema	alsema	PROPN
fnp-6762	306	2	,	,	PUNCT
fnp-6762	306	3	a.m.	a.m.	ADV
fnp-6762	306	4	,	,	PUNCT
fnp-6762	306	5	et	et	PROPN
fnp-6762	306	6	al	al	PROPN
fnp-6762	306	7	.	.	PROPN
fnp-6762	306	8	spatially	spatially	ADV
fnp-6762	306	9	resolved	resolve	VERB
fnp-6762	306	10	gene	gene	NOUN
fnp-6762	306	11	signatures	signature	NOUN
fnp-6762	306	12	of	of	ADP
fnp-6762	306	13	white	white	ADJ
fnp-6762	306	14	matter	matter	NOUN
fnp-6762	306	15	lesion	lesion	NOUN
fnp-6762	306	16	progression	progression	NOUN
fnp-6762	306	17	in	in	ADP
fnp-6762	306	18	multiple	multiple	ADJ
fnp-6762	306	19	sclerosis	sclerosis	NOUN
fnp-6762	306	20	.	.	PUNCT
fnp-6762	307	1	nat	nat	PROPN
fnp-6762	307	2	neurosci	neurosci	PROPN
fnp-6762	307	3	(	(	PUNCT
fnp-6762	307	4	2024	2024	NUM
fnp-6762	307	5	)	)	PUNCT
fnp-6762	307	6	.	.	PUNCT
fnp-6762	308	1	https://doi.org/10.1038/s41593-024-01765-6	https://doi.org/10.1038/s41593-024-01765-6	PROPN
fnp-6762	308	2	22	22	NUM
fnp-6762	308	3	.	.	PUNCT
fnp-6762	309	1	macnair	macnair	PROPN
fnp-6762	309	2	,	,	PUNCT
fnp-6762	309	3	w.	w.	PROPN
fnp-6762	309	4	,	,	PUNCT
fnp-6762	309	5	et	et	PROPN
fnp-6762	309	6	al	al	PROPN
fnp-6762	309	7	.	.	PROPN
fnp-6762	309	8	snrna	snrna	ADJ
fnp-6762	309	9	-	-	PUNCT
fnp-6762	309	10	seq	seq	NOUN
fnp-6762	309	11	stratifies	stratify	VERB
fnp-6762	309	12	multiple	multiple	ADJ
fnp-6762	309	13	sclerosis	sclerosis	NOUN
fnp-6762	309	14	patients	patient	NOUN
fnp-6762	309	15	into	into	ADP
fnp-6762	309	16	distinct	distinct	ADJ
fnp-6762	309	17	white	white	ADJ
fnp-6762	309	18	matter	matter	NOUN
fnp-6762	309	19	glial	glial	ADJ
fnp-6762	309	20	responses	response	NOUN
fnp-6762	309	21	.	.	PUNCT
fnp-6762	310	1	neuron	neuron	PROPN
fnp-6762	310	2	113	113	NUM
fnp-6762	310	3	,	,	PUNCT
fnp-6762	310	4	396	396	NUM
fnp-6762	310	5	-	-	SYM
fnp-6762	310	6	410	410	NUM
fnp-6762	310	7	e399	e399	PROPN
fnp-6762	310	8	(	(	PUNCT
fnp-6762	310	9	2025	2025	NUM
fnp-6762	310	10	)	)	PUNCT
fnp-6762	310	11	.	.	PUNCT
fnp-6762	311	1	https://doi.org/10.1016/j.neuron.2024.11.016	https://doi.org/10.1016/j.neuron.2024.11.016	PRON
fnp-6762	311	2	23	23	NUM
fnp-6762	311	3	.	.	PUNCT
fnp-6762	312	1	tonietto	tonietto	NOUN
fnp-6762	312	2	,	,	PUNCT
fnp-6762	312	3	m.	m.	NOUN
fnp-6762	312	4	,	,	PUNCT
fnp-6762	312	5	et	et	PROPN
fnp-6762	312	6	al	al	PROPN
fnp-6762	312	7	.	.	PUNCT
fnp-6762	313	1	periventricular	periventricular	ADJ
fnp-6762	313	2	remyelination	remyelination	NOUN
fnp-6762	313	3	failure	failure	NOUN
fnp-6762	313	4	in	in	ADP
fnp-6762	313	5	multiple	multiple	ADJ
fnp-6762	313	6	sclerosis	sclerosis	NOUN
fnp-6762	313	7	:	:	PUNCT
fnp-6762	313	8	a	a	DET
fnp-6762	313	9	substrate	substrate	NOUN
fnp-6762	313	10	for	for	ADP
fnp-6762	313	11	neurodegeneration	neurodegeneration	NOUN
fnp-6762	313	12	.	.	PUNCT
fnp-6762	314	1	brain	brain	NOUN
fnp-6762	314	2	146	146	NUM
fnp-6762	314	3	,	,	PUNCT
fnp-6762	314	4	182	182	NUM
fnp-6762	314	5	-	-	SYM
fnp-6762	314	6	194	194	NUM
fnp-6762	314	7	(	(	PUNCT
fnp-6762	314	8	2023	2023	NUM
fnp-6762	314	9	)	)	PUNCT
fnp-6762	314	10	.	.	PUNCT
fnp-6762	315	1	https://doi.org/10.1093/brain/awac334	https://doi.org/10.1093/brain/awac334	PROPN
fnp-6762	316	1	24	24	NUM
fnp-6762	316	2	.	.	PUNCT
fnp-6762	317	1	kessler	kessler	PROPN
fnp-6762	317	2	,	,	PUNCT
fnp-6762	317	3	w.	w.	PROPN
fnp-6762	317	4	,	,	PUNCT
fnp-6762	317	5	thomas	thomas	PROPN
fnp-6762	317	6	,	,	PUNCT
fnp-6762	317	7	c.	c.	PROPN
fnp-6762	317	8	&	&	CCONJ
fnp-6762	317	9	kuhlmann	kuhlmann	PROPN
fnp-6762	317	10	,	,	PUNCT
fnp-6762	317	11	t.	t.	NOUN
fnp-6762	317	12	microglia	microglia	ADJ
fnp-6762	317	13	activation	activation	NOUN
fnp-6762	317	14	in	in	ADP
fnp-6762	317	15	periplaque	periplaque	ADJ
fnp-6762	317	16	white	white	ADJ
fnp-6762	317	17	matter	matter	NOUN
fnp-6762	317	18	in	in	ADP
fnp-6762	317	19	multiple	multiple	ADJ
fnp-6762	317	20	sclerosis	sclerosis	NOUN
fnp-6762	317	21	depends	depend	VERB
fnp-6762	317	22	on	on	ADP
fnp-6762	317	23	age	age	NOUN
fnp-6762	317	24	and	and	CCONJ
fnp-6762	317	25	lesion	lesion	NOUN
fnp-6762	317	26	type	type	NOUN
fnp-6762	317	27	,	,	PUNCT
fnp-6762	317	28	but	but	CCONJ
fnp-6762	317	29	does	do	AUX
fnp-6762	317	30	not	not	PART
fnp-6762	317	31	correlate	correlate	VERB
fnp-6762	317	32	with	with	ADP
fnp-6762	317	33	oligodendroglial	oligodendroglial	ADJ
fnp-6762	317	34	loss	loss	NOUN
fnp-6762	317	35	.	.	PUNCT
fnp-6762	318	1	acta	acta	PROPN
fnp-6762	318	2	neuropathol	neuropathol	PROPN
fnp-6762	318	3	146	146	NUM
fnp-6762	318	4	,	,	PUNCT
fnp-6762	318	5	817	817	NUM
fnp-6762	318	6	-	-	SYM
fnp-6762	318	7	828	828	NUM
fnp-6762	318	8	(	(	PUNCT
fnp-6762	318	9	2023	2023	NUM
fnp-6762	318	10	)	)	PUNCT
fnp-6762	318	11	.	.	PUNCT
fnp-6762	319	1	https://doi.org/10.1007/s00401-023-02645-2	https://doi.org/10.1007/s00401-023-02645-2	NUM
fnp-6762	319	2	25	25	NUM
fnp-6762	319	3	.	.	PUNCT
fnp-6762	320	1	bodini	bodini	PROPN
fnp-6762	320	2	,	,	PUNCT
fnp-6762	320	3	b.	b.	PROPN
fnp-6762	320	4	,	,	PUNCT
fnp-6762	320	5	et	et	PROPN
fnp-6762	320	6	al	al	PROPN
fnp-6762	320	7	.	.	PUNCT
fnp-6762	320	8	individual	individual	ADJ
fnp-6762	320	9	mapping	mapping	NOUN
fnp-6762	320	10	of	of	ADP
fnp-6762	320	11	innate	innate	ADJ
fnp-6762	320	12	immune	immune	ADJ
fnp-6762	320	13	cell	cell	NOUN
fnp-6762	320	14	activation	activation	NOUN
fnp-6762	320	15	is	be	AUX
fnp-6762	320	16	a	a	DET
fnp-6762	320	17	candidate	candidate	NOUN
fnp-6762	320	18	marker	marker	NOUN
fnp-6762	320	19	of	of	ADP
fnp-6762	320	20	patient	patient	NOUN
fnp-6762	320	21	-	-	PUNCT
fnp-6762	320	22	specific	specific	ADJ
fnp-6762	320	23	trajectories	trajectory	NOUN
fnp-6762	320	24	of	of	ADP
fnp-6762	320	25	worsening	worsen	VERB
fnp-6762	320	26	disability	disability	NOUN
fnp-6762	320	27	in	in	ADP
fnp-6762	320	28	multiple	multiple	ADJ
fnp-6762	320	29	sclerosis	sclerosis	NOUN
fnp-6762	320	30	.	.	PUNCT
fnp-6762	321	1	j	j	PROPN
fnp-6762	321	2	nucl	nucl	PROPN
fnp-6762	321	3	med	me	VERB
fnp-6762	321	4	61	61	NUM
fnp-6762	321	5	,	,	PUNCT
fnp-6762	321	6	1043	1043	NUM
fnp-6762	321	7	-	-	SYM
fnp-6762	321	8	1049	1049	NUM
fnp-6762	321	9	(	(	PUNCT
fnp-6762	321	10	2020	2020	NUM
fnp-6762	321	11	)	)	PUNCT
fnp-6762	321	12	.	.	PUNCT
fnp-6762	322	1	https://doi.org/10.2967/jnumed.119.231340	https://doi.org/10.2967/jnumed.119.231340	PROPN
fnp-6762	322	2	26	26	NUM
fnp-6762	322	3	.	.	PUNCT
fnp-6762	323	1	kukanja	kukanja	NOUN
fnp-6762	323	2	,	,	PUNCT
fnp-6762	323	3	p.	p.	PROPN
fnp-6762	323	4	,	,	PUNCT
fnp-6762	323	5	et	et	PROPN
fnp-6762	323	6	al	al	PROPN
fnp-6762	323	7	.	.	PUNCT
fnp-6762	323	8	cellular	cellular	ADJ
fnp-6762	323	9	architecture	architecture	NOUN
fnp-6762	323	10	of	of	ADP
fnp-6762	323	11	evolving	evolve	VERB
fnp-6762	323	12	neuroinflammatory	neuroinflammatory	ADJ
fnp-6762	323	13	lesions	lesion	NOUN
fnp-6762	323	14	and	and	CCONJ
fnp-6762	323	15	multiple	multiple	ADJ
fnp-6762	323	16	sclerosis	sclerosis	NOUN
fnp-6762	323	17	pathology	pathology	NOUN
fnp-6762	323	18	.	.	PUNCT
fnp-6762	324	1	cell	cell	NOUN
fnp-6762	324	2	187	187	NUM
fnp-6762	324	3	,	,	PUNCT
fnp-6762	324	4	1990	1990	NUM
fnp-6762	324	5	-	-	SYM
fnp-6762	324	6	2009	2009	NUM
fnp-6762	324	7	e1919	e1919	NOUN
fnp-6762	324	8	(	(	PUNCT
fnp-6762	324	9	2024	2024	NUM
fnp-6762	324	10	)	)	PUNCT
fnp-6762	324	11	.	.	PUNCT
fnp-6762	325	1	https://doi.org/10.1016/j.cell.2024.02.030	https://doi.org/10.1016/j.cell.2024.02.030	PROPN
fnp-6762	325	2	27	27	NUM
fnp-6762	325	3	.	.	PUNCT
fnp-6762	326	1	oliveira	oliveira	PROPN
fnp-6762	326	2	,	,	PUNCT
fnp-6762	326	3	m.f	m.f	PROPN
fnp-6762	326	4	.	.	PROPN
fnp-6762	326	5	,	,	PUNCT
fnp-6762	326	6	et	et	PROPN
fnp-6762	326	7	al	al	PROPN
fnp-6762	326	8	.	.	PUNCT
fnp-6762	326	9	characterization	characterization	NOUN
fnp-6762	326	10	of	of	ADP
fnp-6762	326	11	immune	immune	ADJ
fnp-6762	326	12	cell	cell	NOUN
fnp-6762	326	13	populations	population	NOUN
fnp-6762	326	14	in	in	ADP
fnp-6762	326	15	the	the	DET
fnp-6762	326	16	tumor	tumor	NOUN
fnp-6762	326	17	microenvironment	microenvironment	NOUN
fnp-6762	326	18	of	of	ADP
fnp-6762	326	19	colorectal	colorectal	ADJ
fnp-6762	326	20	cancer	cancer	NOUN
fnp-6762	326	21	using	use	VERB
fnp-6762	326	22	high	high	ADJ
fnp-6762	326	23	definition	definition	NOUN
fnp-6762	326	24	spatial	spatial	ADJ
fnp-6762	326	25	profiling	profiling	NOUN
fnp-6762	326	26	.	.	PUNCT
fnp-6762	327	1	biorxiv	biorxiv	NOUN
fnp-6762	327	2	,	,	PUNCT
fnp-6762	327	3	2024.2006.2004.597233	2024.2006.2004.597233	NUM
fnp-6762	327	4	(	(	PUNCT
fnp-6762	327	5	2024	2024	NUM
fnp-6762	327	6	)	)	PUNCT
fnp-6762	327	7	.	.	PUNCT
fnp-6762	328	1	https://doi.org/10.1101/2024.06.04.597233	https://doi.org/10.1101/2024.06.04.597233	NUM
fnp-6762	328	2	28	28	NUM
fnp-6762	328	3	.	.	PUNCT
fnp-6762	329	1	okuda	okuda	PROPN
fnp-6762	329	2	,	,	PUNCT
fnp-6762	329	3	d.t	d.t	PROPN
fnp-6762	329	4	.	.	PROPN
fnp-6762	329	5	,	,	PUNCT
fnp-6762	329	6	et	et	PROPN
fnp-6762	329	7	al	al	PROPN
fnp-6762	329	8	.	.	PROPN
fnp-6762	330	1	incidental	incidental	ADJ
fnp-6762	330	2	mri	mri	NOUN
fnp-6762	330	3	anomalies	anomaly	NOUN
fnp-6762	330	4	suggestive	suggestive	ADJ
fnp-6762	330	5	of	of	ADP
fnp-6762	330	6	multiple	multiple	ADJ
fnp-6762	330	7	sclerosis	sclerosis	NOUN
fnp-6762	330	8	:	:	PUNCT
fnp-6762	330	9	the	the	DET
fnp-6762	330	10	radiologically	radiologically	ADV
fnp-6762	330	11	isolated	isolate	VERB
fnp-6762	330	12	syndrome	syndrome	NOUN
fnp-6762	330	13	.	.	PUNCT
fnp-6762	331	1	neurology	neurology	NOUN
fnp-6762	331	2	72	72	NUM
fnp-6762	331	3	,	,	PUNCT
fnp-6762	331	4	800	800	NUM
fnp-6762	331	5	-	-	SYM
fnp-6762	331	6	805	805	NUM
fnp-6762	331	7	(	(	PUNCT
fnp-6762	331	8	2009	2009	NUM
fnp-6762	331	9	)	)	PUNCT
fnp-6762	331	10	.	.	PUNCT
fnp-6762	332	1	https://doi.org/10.1212/01.wnl.0000335764.14513.1a	https://doi.org/10.1212/01.wnl.0000335764.14513.1a	VERB
fnp-6762	332	2	29	29	NUM
fnp-6762	332	3	.	.	PUNCT
fnp-6762	333	1	lebrun	lebrun	NOUN
fnp-6762	333	2	-	-	PUNCT
fnp-6762	333	3	frenay	frenay	PROPN
fnp-6762	333	4	,	,	PUNCT
fnp-6762	333	5	c.	c.	PROPN
fnp-6762	333	6	,	,	PUNCT
fnp-6762	333	7	et	et	PROPN
fnp-6762	333	8	al	al	PROPN
fnp-6762	333	9	.	.	PUNCT
fnp-6762	334	1	the	the	DET
fnp-6762	334	2	radiologically	radiologically	ADV
fnp-6762	334	3	isolated	isolate	VERB
fnp-6762	334	4	syndrome	syndrome	NOUN
fnp-6762	334	5	:	:	PUNCT
fnp-6762	334	6	revised	revise	VERB
fnp-6762	334	7	diagnostic	diagnostic	ADJ
fnp-6762	334	8	criteria	criterion	NOUN
fnp-6762	334	9	.	.	PUNCT
fnp-6762	335	1	brain	brain	NOUN
fnp-6762	335	2	146	146	NUM
fnp-6762	335	3	,	,	PUNCT
fnp-6762	335	4	3431	3431	NUM
fnp-6762	335	5	-	-	SYM
fnp-6762	335	6	3443	3443	NUM
fnp-6762	335	7	(	(	PUNCT
fnp-6762	335	8	2023	2023	NUM
fnp-6762	335	9	)	)	PUNCT
fnp-6762	335	10	.	.	PUNCT
fnp-6762	336	1	https://doi.org/10.1093/brain/awad073	https://doi.org/10.1093/brain/awad073	NOUN
fnp-6762	336	2	30	30	NUM
fnp-6762	336	3	.	.	PUNCT
fnp-6762	337	1	lebrun	lebrun	NOUN
fnp-6762	337	2	-	-	PUNCT
fnp-6762	337	3	frenay	frenay	PROPN
fnp-6762	337	4	,	,	PUNCT
fnp-6762	337	5	c.	c.	PROPN
fnp-6762	337	6	,	,	PUNCT
fnp-6762	337	7	et	et	PROPN
fnp-6762	337	8	al	al	PROPN
fnp-6762	337	9	.	.	PROPN
fnp-6762	337	10	teriflunomide	teriflunomide	PROPN
fnp-6762	337	11	and	and	CCONJ
fnp-6762	337	12	time	time	NOUN
fnp-6762	337	13	to	to	ADP
fnp-6762	337	14	clinical	clinical	ADJ
fnp-6762	337	15	multiple	multiple	ADJ
fnp-6762	337	16	sclerosis	sclerosis	NOUN
fnp-6762	337	17	in	in	ADP
fnp-6762	337	18	patients	patient	NOUN
fnp-6762	337	19	with	with	ADP
fnp-6762	337	20	radiologically	radiologically	ADV
fnp-6762	337	21	isolated	isolate	VERB
fnp-6762	337	22	syndrome	syndrome	NOUN
fnp-6762	337	23	:	:	PUNCT
fnp-6762	337	24	the	the	DET
fnp-6762	337	25	teris	teris	NOUN
fnp-6762	337	26	randomized	randomize	VERB
fnp-6762	337	27	clinical	clinical	ADJ
fnp-6762	337	28	trial	trial	NOUN
fnp-6762	337	29	.	.	PUNCT
fnp-6762	338	1	jama	jama	PROPN
fnp-6762	338	2	neurol	neurol	PROPN
fnp-6762	338	3	80	80	NUM
fnp-6762	338	4	,	,	PUNCT
fnp-6762	338	5	1080	1080	NUM
fnp-6762	338	6	-	-	SYM
fnp-6762	338	7	1088	1088	NUM
fnp-6762	338	8	(	(	PUNCT
fnp-6762	338	9	2023	2023	NUM
fnp-6762	338	10	)	)	PUNCT
fnp-6762	338	11	.	.	PUNCT
fnp-6762	339	1	https://doi.org/10.1001/jamaneurol.2023.2815	https://doi.org/10.1001/jamaneurol.2023.2815	PROPN
fnp-6762	339	2	31	31	NUM
fnp-6762	339	3	.	.	PUNCT
fnp-6762	339	4	epstein	epstein	PROPN
fnp-6762	339	5	,	,	PUNCT
fnp-6762	339	6	s.e	s.e	PROPN
fnp-6762	339	7	.	.	PROPN
fnp-6762	339	8	&	&	CCONJ
fnp-6762	339	9	longbrake	longbrake	PROPN
fnp-6762	339	10	,	,	PUNCT
fnp-6762	339	11	e.e	e.e	PROPN
fnp-6762	339	12	.	.	PROPN
fnp-6762	339	13	shifting	shift	VERB
fnp-6762	339	14	our	our	PRON
fnp-6762	339	15	attention	attention	NOUN
fnp-6762	339	16	earlier	early	ADV
fnp-6762	339	17	in	in	ADP
fnp-6762	339	18	the	the	DET
fnp-6762	339	19	multiple	multiple	ADJ
fnp-6762	339	20	sclerosis	sclerosis	NOUN
fnp-6762	339	21	disease	disease	NOUN
fnp-6762	339	22	course	course	NOUN
fnp-6762	339	23	.	.	PUNCT
fnp-6762	340	1	curr	curr	PROPN
fnp-6762	340	2	opin	opin	PROPN
fnp-6762	340	3	neurol	neurol	NOUN
fnp-6762	340	4	37	37	NUM
fnp-6762	340	5	,	,	PUNCT
fnp-6762	340	6	212	212	NUM
fnp-6762	340	7	-	-	SYM
fnp-6762	340	8	219	219	NUM
fnp-6762	340	9	(	(	PUNCT
fnp-6762	340	10	2024	2024	NUM
fnp-6762	340	11	)	)	PUNCT
fnp-6762	340	12	.	.	PUNCT
fnp-6762	341	1	https://doi.org/10.1097/wco.0000000000001268	https://doi.org/10.1097/wco.0000000000001268	PROPN
fnp-6762	341	2	32	32	NUM
fnp-6762	341	3	.	.	PUNCT
fnp-6762	342	1	britze	britze	PROPN
fnp-6762	342	2	,	,	PUNCT
fnp-6762	342	3	j.	j.	PROPN
fnp-6762	342	4	,	,	PUNCT
fnp-6762	342	5	et	et	PROPN
fnp-6762	342	6	al	al	PROPN
fnp-6762	342	7	.	.	PUNCT
fnp-6762	342	8	temporal	temporal	ADJ
fnp-6762	342	9	dynamics	dynamic	NOUN
fnp-6762	342	10	of	of	ADP
fnp-6762	342	11	plasma	plasma	NOUN
fnp-6762	342	12	neurofilament	neurofilament	NOUN
fnp-6762	342	13	light	light	NOUN
fnp-6762	342	14	in	in	ADP
fnp-6762	342	15	blood	blood	NOUN
fnp-6762	342	16	donors	donor	NOUN
fnp-6762	342	17	with	with	ADP
fnp-6762	342	18	preclinical	preclinical	ADJ
fnp-6762	342	19	multiple	multiple	ADJ
fnp-6762	342	20	sclerosis	sclerosis	NOUN
fnp-6762	342	21	.	.	PUNCT
fnp-6762	343	1	neurol	neurol	PROPN
fnp-6762	343	2	neuroimmunol	neuroimmunol	PROPN
fnp-6762	343	3	neuroinflamm	neuroinflamm	PROPN
fnp-6762	343	4	12	12	NUM
fnp-6762	343	5	,	,	PUNCT
fnp-6762	343	6	e200335	e200335	NUM
fnp-6762	343	7	(	(	PUNCT
fnp-6762	343	8	2025	2025	NUM
fnp-6762	343	9	)	)	PUNCT
fnp-6762	343	10	.	.	PUNCT
fnp-6762	344	1	https://doi.org/10.1212/nxi.0000000000200335	https://doi.org/10.1212/nxi.0000000000200335	PROPN
fnp-6762	344	2	33	33	NUM
fnp-6762	344	3	.	.	PUNCT
fnp-6762	345	1	guinebretiere	guinebretiere	INTJ
fnp-6762	345	2	,	,	PUNCT
fnp-6762	345	3	o.	o.	PROPN
fnp-6762	345	4	,	,	PUNCT
fnp-6762	345	5	et	et	PROPN
fnp-6762	345	6	al	al	PROPN
fnp-6762	345	7	.	.	PROPN
fnp-6762	345	8	association	association	PROPN
fnp-6762	345	9	between	between	ADP
fnp-6762	345	10	diseases	disease	NOUN
fnp-6762	345	11	and	and	CCONJ
fnp-6762	345	12	symptoms	symptom	NOUN
fnp-6762	345	13	diagnosed	diagnose	VERB
fnp-6762	345	14	in	in	ADP
fnp-6762	345	15	primary	primary	ADJ
fnp-6762	345	16	care	care	NOUN
fnp-6762	345	17	and	and	CCONJ
fnp-6762	345	18	the	the	DET
fnp-6762	345	19	subsequent	subsequent	ADJ
fnp-6762	345	20	specific	specific	ADJ
fnp-6762	345	21	risk	risk	NOUN
fnp-6762	345	22	of	of	ADP
fnp-6762	345	23	multiple	multiple	ADJ
fnp-6762	345	24	sclerosis	sclerosis	NOUN
fnp-6762	345	25	.	.	PUNCT
fnp-6762	346	1	neurology	neurology	NOUN
fnp-6762	346	2	101	101	NUM
fnp-6762	346	3	,	,	PUNCT
fnp-6762	346	4	e2497	e2497	NOUN
fnp-6762	346	5	-	-	PUNCT
fnp-6762	346	6	e2508	e2508	NOUN
fnp-6762	346	7	(	(	PUNCT
fnp-6762	346	8	2023	2023	NUM
fnp-6762	346	9	)	)	PUNCT
fnp-6762	346	10	.	.	PUNCT
fnp-6762	347	1	https://doi.org/10.1212/wnl.0000000000207981	https://doi.org/10.1212/wnl.0000000000207981	PROPN
fnp-6762	347	2	34	34	NUM
fnp-6762	347	3	.	.	PUNCT
fnp-6762	347	4	akmatov	akmatov	PROPN
fnp-6762	347	5	,	,	PUNCT
fnp-6762	347	6	m.k	m.k	PROPN
fnp-6762	347	7	.	.	PROPN
fnp-6762	347	8	,	,	PUNCT
fnp-6762	347	9	et	et	PROPN
fnp-6762	347	10	al	al	PROPN
fnp-6762	347	11	.	.	PROPN
fnp-6762	347	12	symptoms	symptom	NOUN
fnp-6762	347	13	prior	prior	ADV
fnp-6762	347	14	to	to	ADP
fnp-6762	347	15	diagnosis	diagnosis	NOUN
fnp-6762	347	16	of	of	ADP
fnp-6762	347	17	multiple	multiple	ADJ
fnp-6762	347	18	sclerosis	sclerosis	NOUN
fnp-6762	347	19	in	in	ADP
fnp-6762	347	20	individuals	individual	NOUN
fnp-6762	347	21	younger	young	ADJ
fnp-6762	347	22	than	than	ADP
fnp-6762	347	23	18	18	NUM
fnp-6762	347	24	years	year	NOUN
fnp-6762	347	25	.	.	PUNCT
fnp-6762	348	1	jama	jama	PROPN
fnp-6762	348	2	netw	netw	PROPN
fnp-6762	348	3	open	open	ADJ
fnp-6762	348	4	7	7	NUM
fnp-6762	348	5	,	,	PUNCT
fnp-6762	348	6	e2452652	e2452652	PROPN
fnp-6762	348	7	(	(	PUNCT
fnp-6762	348	8	2024	2024	NUM
fnp-6762	348	9	)	)	PUNCT
fnp-6762	348	10	.	.	PUNCT
fnp-6762	349	1	https://doi.org/10.1001/jamanetworkopen.2024.52652	https://doi.org/10.1001/jamanetworkopen.2024.52652	PROPN
fnp-6762	349	2	35	35	NUM
fnp-6762	349	3	.	.	PUNCT
fnp-6762	350	1	thompson	thompson	PROPN
fnp-6762	350	2	,	,	PUNCT
fnp-6762	350	3	a.j	a.j	PROPN
fnp-6762	350	4	.	.	PROPN
fnp-6762	350	5	,	,	PUNCT
fnp-6762	350	6	et	et	PROPN
fnp-6762	350	7	al	al	PROPN
fnp-6762	350	8	.	.	PUNCT
fnp-6762	350	9	diagnosis	diagnosis	NOUN
fnp-6762	350	10	of	of	ADP
fnp-6762	350	11	multiple	multiple	ADJ
fnp-6762	350	12	sclerosis	sclerosis	NOUN
fnp-6762	350	13	:	:	PUNCT
fnp-6762	350	14	2017	2017	NUM
fnp-6762	350	15	revisions	revision	NOUN
fnp-6762	350	16	of	of	ADP
fnp-6762	350	17	the	the	DET
fnp-6762	350	18	mcdonald	mcdonald	PROPN
fnp-6762	350	19	criteria	criterion	NOUN
fnp-6762	350	20	.	.	PUNCT
fnp-6762	351	1	lancet	lancet	PROPN
fnp-6762	351	2	neurol	neurol	PROPN
fnp-6762	351	3	17	17	NUM
fnp-6762	351	4	,	,	PUNCT
fnp-6762	351	5	162	162	NUM
fnp-6762	351	6	-	-	SYM
fnp-6762	351	7	173	173	NUM
fnp-6762	351	8	(	(	PUNCT
fnp-6762	351	9	2018	2018	NUM
fnp-6762	351	10	)	)	PUNCT
fnp-6762	351	11	.	.	PUNCT
fnp-6762	352	1	https://doi.org/10.1016/s1474-4422(17)30470-2	https://doi.org/10.1016/s1474-4422(17)30470-2	PROPN
fnp-6762	352	2	36	36	NUM
fnp-6762	352	3	.	.	PUNCT
fnp-6762	352	4	montalban	montalban	PROPN
fnp-6762	352	5	,	,	PUNCT
fnp-6762	352	6	x.	x.	NOUN
fnp-6762	352	7	ectrims	ectrim	VERB
fnp-6762	352	8	2024	2024	NUM
fnp-6762	352	9	oral	oral	ADJ
fnp-6762	352	10	presentations	presentation	NOUN
fnp-6762	352	11	.	.	PUNCT
fnp-6762	353	1	multiple	multiple	ADJ
fnp-6762	353	2	sclerosis	sclerosis	NOUN
fnp-6762	353	3	journal	journal	PROPN
fnp-6762	353	4	30	30	NUM
fnp-6762	353	5	,	,	PUNCT
fnp-6762	353	6	4	4	NUM
fnp-6762	353	7	-	-	SYM
fnp-6762	353	8	124	124	NUM
fnp-6762	353	9	(	(	PUNCT
fnp-6762	353	10	2024	2024	NUM
fnp-6762	353	11	)	)	PUNCT
fnp-6762	353	12	.	.	PUNCT
fnp-6762	354	1	https://doi.org/10.1177/13524585241269218	https://doi.org/10.1177/13524585241269218	NOUN
fnp-6762	354	2	37	37	NUM
fnp-6762	354	3	.	.	PUNCT
fnp-6762	355	1	levraut	levraut	PROPN
fnp-6762	355	2	,	,	PUNCT
fnp-6762	355	3	m.	m.	NOUN
fnp-6762	355	4	,	,	PUNCT
fnp-6762	355	5	landes	lande	NOUN
fnp-6762	355	6	-	-	PUNCT
fnp-6762	355	7	chateau	chateau	NOUN
fnp-6762	355	8	,	,	PUNCT
fnp-6762	355	9	c.	c.	NOUN
fnp-6762	355	10	,	,	PUNCT
fnp-6762	355	11	mondot	mondot	PROPN
fnp-6762	355	12	,	,	PUNCT
fnp-6762	355	13	l.	l.	PROPN
fnp-6762	355	14	,	,	PUNCT
fnp-6762	355	15	cohen	cohen	PROPN
fnp-6762	355	16	,	,	PUNCT
fnp-6762	355	17	m.	m.	NOUN
fnp-6762	355	18	&	&	CCONJ
fnp-6762	355	19	lebrun	lebrun	PROPN
fnp-6762	355	20	-	-	PUNCT
fnp-6762	355	21	frenay	frenay	NOUN
fnp-6762	355	22	,	,	PUNCT
fnp-6762	355	23	c.	c.	PROPN
fnp-6762	355	24	the	the	DET
fnp-6762	355	25	kappa	kappa	PROPN
fnp-6762	355	26	free	free	ADJ
fnp-6762	355	27	light	light	ADJ
fnp-6762	355	28	chains	chain	NOUN
fnp-6762	355	29	index	index	NOUN
fnp-6762	355	30	and	and	CCONJ
fnp-6762	355	31	central	central	ADJ
fnp-6762	355	32	vein	vein	ADJ
fnp-6762	355	33	sign	sign	NOUN
fnp-6762	355	34	:	:	PUNCT
fnp-6762	355	35	two	two	NUM
fnp-6762	355	36	new	new	ADJ
fnp-6762	355	37	biomarkers	biomarker	NOUN
fnp-6762	355	38	for	for	ADP
fnp-6762	355	39	multiple	multiple	ADJ
fnp-6762	355	40	sclerosis	sclerosis	NOUN
fnp-6762	355	41	diagnosis	diagnosis	NOUN
fnp-6762	355	42	.	.	PUNCT
fnp-6762	356	1	neurol	neurol	NOUN
fnp-6762	356	2	ther	ther	PROPN
fnp-6762	356	3	14	14	NUM
fnp-6762	356	4	,	,	PUNCT
fnp-6762	356	5	711	711	NOUN
fnp-6762	356	6	-	-	SYM
fnp-6762	356	7	731	731	NUM
fnp-6762	356	8	(	(	PUNCT
fnp-6762	356	9	2025	2025	NUM
fnp-6762	356	10	)	)	PUNCT
fnp-6762	356	11	.	.	PUNCT
fnp-6762	357	1	https://doi.org/10.1007/s40120-025-00737-7	https://doi.org/10.1007/s40120-025-00737-7	NUM
fnp-6762	358	1	38	38	NUM
fnp-6762	358	2	.	.	PUNCT
fnp-6762	359	1	borrelli	borrelli	PROPN
fnp-6762	359	2	,	,	PUNCT
fnp-6762	359	3	s.	s.	PROPN
fnp-6762	359	4	,	,	PUNCT
fnp-6762	359	5	et	et	PROPN
fnp-6762	359	6	al	al	PROPN
fnp-6762	359	7	.	.	PROPN
fnp-6762	359	8	central	central	PROPN
fnp-6762	359	9	vein	vein	ADJ
fnp-6762	359	10	sign	sign	NOUN
fnp-6762	359	11	,	,	PUNCT
fnp-6762	359	12	cortical	cortical	ADJ
fnp-6762	359	13	lesions	lesion	NOUN
fnp-6762	359	14	,	,	PUNCT
fnp-6762	359	15	and	and	CCONJ
fnp-6762	359	16	paramagnetic	paramagnetic	ADJ
fnp-6762	359	17	rim	rim	NOUN
fnp-6762	359	18	lesions	lesion	NOUN
fnp-6762	359	19	for	for	ADP
fnp-6762	359	20	the	the	DET
fnp-6762	359	21	diagnostic	diagnostic	ADJ
fnp-6762	359	22	and	and	CCONJ
fnp-6762	359	23	prognostic	prognostic	ADJ
fnp-6762	359	24	workup	workup	NOUN
fnp-6762	359	25	of	of	ADP
fnp-6762	359	26	multiple	multiple	ADJ
fnp-6762	359	27	sclerosis	sclerosis	NOUN
fnp-6762	359	28	.	.	PUNCT
fnp-6762	360	1	neurol	neurol	PROPN
fnp-6762	360	2	neuroimmunol	neuroimmunol	PROPN
fnp-6762	360	3	neuroinflamm	neuroinflamm	PROPN
fnp-6762	360	4	11	11	NUM
fnp-6762	360	5	,	,	PUNCT
fnp-6762	360	6	e200253	e200253	VERB
fnp-6762	360	7	(	(	PUNCT
fnp-6762	360	8	2024	2024	NUM
fnp-6762	360	9	)	)	PUNCT
fnp-6762	360	10	.	.	PUNCT
fnp-6762	361	1	https://doi.org/10.1212/nxi.0000000000200253	https://doi.org/10.1212/nxi.0000000000200253	PROPN
fnp-6762	361	2	39	39	NUM
fnp-6762	361	3	.	.	PUNCT
fnp-6762	362	1	vecchio	vecchio	PROPN
fnp-6762	362	2	,	,	PUNCT
fnp-6762	362	3	d.	d.	PROPN
fnp-6762	362	4	,	,	PUNCT
fnp-6762	362	5	et	et	PROPN
fnp-6762	362	6	al	al	PROPN
fnp-6762	362	7	.	.	PROPN
fnp-6762	362	8	kappa	kappa	PROPN
fnp-6762	362	9	index	index	PROPN
fnp-6762	362	10	for	for	ADP
fnp-6762	362	11	multiple	multiple	ADJ
fnp-6762	362	12	sclerosis	sclerosis	NOUN
fnp-6762	362	13	diagnosis	diagnosis	NOUN
fnp-6762	362	14	:	:	PUNCT
fnp-6762	362	15	an	an	DET
fnp-6762	362	16	accurate	accurate	ADJ
fnp-6762	362	17	biomarker	biomarker	NOUN
fnp-6762	362	18	of	of	ADP
fnp-6762	362	19	intrathecal	intrathecal	ADJ
fnp-6762	362	20	synthesis	synthesis	NOUN
fnp-6762	362	21	.	.	PUNCT
fnp-6762	363	1	j	j	PROPN
fnp-6762	363	2	neurol	neurol	PROPN
fnp-6762	363	3	272	272	NUM
fnp-6762	363	4	,	,	PUNCT
fnp-6762	363	5	30	30	NUM
fnp-6762	363	6	(	(	PUNCT
fnp-6762	363	7	2024	2024	NUM
fnp-6762	363	8	)	)	PUNCT
fnp-6762	363	9	.	.	PUNCT
fnp-6762	364	1	https://doi.org/10.1007/s00415-024-12826-y	https://doi.org/10.1007/s00415-024-12826-y	NOUN
fnp-6762	364	2	40	40	NUM
fnp-6762	364	3	.	.	PUNCT
fnp-6762	365	1	lebrun	lebrun	NOUN
fnp-6762	365	2	-	-	PUNCT
fnp-6762	365	3	frenay	frenay	PROPN
fnp-6762	365	4	,	,	PUNCT
fnp-6762	365	5	c.	c.	PROPN
fnp-6762	365	6	,	,	PUNCT
fnp-6762	365	7	et	et	PROPN
fnp-6762	365	8	al	al	PROPN
fnp-6762	365	9	.	.	PROPN
fnp-6762	365	10	radiologically	radiologically	ADV
fnp-6762	365	11	isolated	isolate	VERB
fnp-6762	365	12	syndrome	syndrome	NOUN
fnp-6762	365	13	.	.	PUNCT
fnp-6762	366	1	lancet	lancet	PROPN
fnp-6762	366	2	neurol	neurol	PROPN
fnp-6762	366	3	22	22	NUM
fnp-6762	366	4	,	,	PUNCT
fnp-6762	366	5	1075	1075	NUM
fnp-6762	366	6	-	-	SYM
fnp-6762	366	7	1086	1086	NUM
fnp-6762	366	8	(	(	PUNCT
fnp-6762	366	9	2023	2023	NUM
fnp-6762	366	10	)	)	PUNCT
fnp-6762	366	11	.	.	PUNCT
fnp-6762	367	1	https://doi.org/10.1016/s1474-4422(23)00281-8	https://doi.org/10.1016/s1474-4422(23)00281-8	PROPN
fnp-6762	367	2	41	41	NUM
fnp-6762	367	3	.	.	PUNCT
fnp-6762	367	4	bittner	bittner	PROPN
fnp-6762	367	5	,	,	PUNCT
fnp-6762	367	6	s.	s.	PROPN
fnp-6762	367	7	,	,	PUNCT
fnp-6762	367	8	oh	oh	INTJ
fnp-6762	367	9	,	,	PUNCT
fnp-6762	367	10	j.	j.	PROPN
fnp-6762	367	11	,	,	PUNCT
fnp-6762	367	12	havrdova	havrdova	PROPN
fnp-6762	367	13	,	,	PUNCT
fnp-6762	367	14	e.k	e.k	PROPN
fnp-6762	367	15	.	.	PROPN
fnp-6762	367	16	,	,	PUNCT
fnp-6762	367	17	tintore	tintore	NOUN
fnp-6762	367	18	,	,	PUNCT
fnp-6762	367	19	m.	m.	NOUN
fnp-6762	367	20	&	&	CCONJ
fnp-6762	367	21	zipp	zipp	PROPN
fnp-6762	367	22	,	,	PUNCT
fnp-6762	367	23	f.	f.	PROPN
fnp-6762	367	24	the	the	DET
fnp-6762	367	25	potential	potential	NOUN
fnp-6762	367	26	of	of	ADP
fnp-6762	367	27	serum	serum	NOUN
fnp-6762	367	28	neurofilament	neurofilament	NOUN
fnp-6762	367	29	as	as	ADP
fnp-6762	367	30	biomarker	biomarker	NOUN
fnp-6762	367	31	for	for	ADP
fnp-6762	367	32	multiple	multiple	ADJ
fnp-6762	367	33	sclerosis	sclerosis	NOUN
fnp-6762	367	34	.	.	PUNCT
fnp-6762	368	1	brain	brain	NOUN
fnp-6762	368	2	144	144	NUM
fnp-6762	368	3	,	,	PUNCT
fnp-6762	368	4	2954	2954	NUM
fnp-6762	368	5	-	-	SYM
fnp-6762	368	6	2963	2963	NUM
fnp-6762	368	7	(	(	PUNCT
fnp-6762	368	8	2021	2021	NUM
fnp-6762	368	9	)	)	PUNCT
fnp-6762	368	10	.	.	PUNCT
fnp-6762	369	1	https://doi.org/10.1093/brain/awab241	https://doi.org/10.1093/brain/awab241	VERB
fnp-6762	370	1	42	42	NUM
fnp-6762	370	2	.	.	PUNCT
fnp-6762	370	3	benkert	benkert	PROPN
fnp-6762	370	4	,	,	PUNCT
fnp-6762	370	5	p.	p.	PROPN
fnp-6762	370	6	,	,	PUNCT
fnp-6762	370	7	et	et	PROPN
fnp-6762	370	8	al	al	PROPN
fnp-6762	370	9	.	.	PROPN
fnp-6762	370	10	serum	serum	PROPN
fnp-6762	370	11	glial	glial	ADJ
fnp-6762	370	12	fibrillary	fibrillary	ADJ
fnp-6762	370	13	acidic	acidic	ADJ
fnp-6762	370	14	protein	protein	NOUN
fnp-6762	370	15	and	and	CCONJ
fnp-6762	370	16	neurofilament	neurofilament	ADJ
fnp-6762	370	17	light	light	ADJ
fnp-6762	370	18	chain	chain	NOUN
fnp-6762	370	19	levels	level	NOUN
fnp-6762	370	20	reflect	reflect	VERB
fnp-6762	370	21	different	different	ADJ
fnp-6762	370	22	mechanisms	mechanism	NOUN
fnp-6762	370	23	of	of	ADP
fnp-6762	370	24	disease	disease	NOUN
fnp-6762	370	25	progression	progression	NOUN
fnp-6762	370	26	under	under	ADP
fnp-6762	370	27	b	b	NOUN
fnp-6762	370	28	-	-	PUNCT
fnp-6762	370	29	cell	cell	NOUN
fnp-6762	370	30	depleting	deplete	VERB
fnp-6762	370	31	treatment	treatment	NOUN
fnp-6762	370	32	in	in	ADP
fnp-6762	370	33	multiple	multiple	ADJ
fnp-6762	370	34	sclerosis	sclerosis	NOUN
fnp-6762	370	35	.	.	PUNCT
fnp-6762	371	1	ann	ann	PROPN
fnp-6762	371	2	neurol	neurol	PROPN
fnp-6762	371	3	97	97	NUM
fnp-6762	371	4	,	,	PUNCT
fnp-6762	371	5	104	104	NUM
fnp-6762	371	6	-	-	SYM
fnp-6762	371	7	115	115	NUM
fnp-6762	371	8	(	(	PUNCT
fnp-6762	371	9	2024	2024	NUM
fnp-6762	371	10	)	)	PUNCT
fnp-6762	371	11	.	.	PUNCT
fnp-6762	372	1	https://doi.org/10.1002/ana.27096	https://doi.org/10.1002/ana.27096	PROPN
fnp-6762	372	2	43	43	NUM
fnp-6762	372	3	.	.	PUNCT
fnp-6762	373	1	monreal	monreal	PROPN
fnp-6762	373	2	,	,	PUNCT
fnp-6762	373	3	e.	e.	PROPN
fnp-6762	373	4	,	,	PUNCT
fnp-6762	373	5	et	et	PROPN
fnp-6762	373	6	al	al	PROPN
fnp-6762	373	7	.	.	PROPN
fnp-6762	373	8	association	association	PROPN
fnp-6762	373	9	of	of	ADP
fnp-6762	373	10	serum	serum	PROPN
fnp-6762	373	11	neurofilament	neurofilament	PROPN
fnp-6762	373	12	light	light	ADJ
fnp-6762	373	13	chain	chain	NOUN
fnp-6762	373	14	levels	level	NOUN
fnp-6762	373	15	at	at	ADP
fnp-6762	373	16	disease	disease	NOUN
fnp-6762	373	17	onset	onset	VERB
fnp-6762	373	18	with	with	ADP
fnp-6762	373	19	disability	disability	NOUN
fnp-6762	373	20	worsening	worsen	VERB
fnp-6762	373	21	in	in	ADP
fnp-6762	373	22	patients	patient	NOUN
fnp-6762	373	23	with	with	ADP
fnp-6762	373	24	a	a	DET
fnp-6762	373	25	first	first	ADJ
fnp-6762	373	26	demyelinating	demyelinate	VERB
fnp-6762	373	27	multiple	multiple	ADJ
fnp-6762	373	28	sclerosis	sclerosis	NOUN
fnp-6762	373	29	event	event	NOUN
fnp-6762	373	30	not	not	PART
fnp-6762	373	31	treated	treat	VERB
fnp-6762	373	32	with	with	ADP
fnp-6762	373	33	high	high	ADJ
fnp-6762	373	34	-	-	PUNCT
fnp-6762	373	35	efficacy	efficacy	NOUN
fnp-6762	373	36	drugs	drug	NOUN
fnp-6762	373	37	.	.	PUNCT
fnp-6762	374	1	jama	jama	PROPN
fnp-6762	374	2	neurol	neurol	PROPN
fnp-6762	374	3	80	80	NUM
fnp-6762	374	4	,	,	PUNCT
fnp-6762	374	5	397	397	NUM
fnp-6762	374	6	-	-	SYM
fnp-6762	374	7	403	403	NUM
fnp-6762	374	8	(	(	PUNCT
fnp-6762	374	9	2023	2023	NUM
fnp-6762	374	10	)	)	PUNCT
fnp-6762	374	11	.	.	PUNCT
fnp-6762	375	1	https://doi.org/10.1001/jamaneurol.2023.0010	https://doi.org/10.1001/jamaneurol.2023.0010	PROPN
fnp-6762	375	2	44	44	NUM
fnp-6762	375	3	.	.	PUNCT
fnp-6762	376	1	meier	meier	PROPN
fnp-6762	376	2	,	,	PUNCT
fnp-6762	376	3	s.	s.	PROPN
fnp-6762	376	4	,	,	PUNCT
fnp-6762	377	1	et	et	PROPN
fnp-6762	377	2	al	al	PROPN
fnp-6762	377	3	.	.	PROPN
fnp-6762	377	4	serum	serum	PROPN
fnp-6762	377	5	glial	glial	ADJ
fnp-6762	377	6	fibrillary	fibrillary	ADJ
fnp-6762	377	7	acidic	acidic	ADJ
fnp-6762	377	8	protein	protein	NOUN
fnp-6762	377	9	compared	compare	VERB
fnp-6762	377	10	with	with	ADP
fnp-6762	377	11	neurofilament	neurofilament	ADJ
fnp-6762	377	12	light	light	NOUN
fnp-6762	377	13	chain	chain	NOUN
fnp-6762	377	14	as	as	ADP
fnp-6762	377	15	a	a	DET
fnp-6762	377	16	biomarker	biomarker	NOUN
fnp-6762	377	17	for	for	ADP
fnp-6762	377	18	disease	disease	NOUN
fnp-6762	377	19	progression	progression	NOUN
fnp-6762	377	20	in	in	ADP
fnp-6762	377	21	multiple	multiple	ADJ
fnp-6762	377	22	sclerosis	sclerosis	NOUN
fnp-6762	377	23	.	.	PUNCT
fnp-6762	378	1	jama	jama	PROPN
fnp-6762	378	2	neurol	neurol	PROPN
fnp-6762	378	3	80	80	NUM
fnp-6762	378	4	,	,	PUNCT
fnp-6762	378	5	287	287	NUM
fnp-6762	378	6	-	-	SYM
fnp-6762	378	7	297	297	NUM
fnp-6762	378	8	(	(	PUNCT
fnp-6762	378	9	2023	2023	NUM
fnp-6762	378	10	)	)	PUNCT
fnp-6762	378	11	.	.	PUNCT
fnp-6762	379	1	https://doi.org/10.1001/jamaneurol.2022.5250	https://doi.org/10.1001/jamaneurol.2022.5250	PROPN
fnp-6762	379	2	45	45	NUM
fnp-6762	379	3	.	.	PUNCT
fnp-6762	379	4	monreal	monreal	PROPN
fnp-6762	379	5	,	,	PUNCT
fnp-6762	379	6	e.	e.	PROPN
fnp-6762	379	7	,	,	PUNCT
fnp-6762	379	8	et	et	PROPN
fnp-6762	379	9	al	al	PROPN
fnp-6762	379	10	.	.	PROPN
fnp-6762	379	11	serum	serum	PROPN
fnp-6762	379	12	biomarkers	biomarker	NOUN
fnp-6762	379	13	at	at	ADP
fnp-6762	379	14	disease	disease	NOUN
fnp-6762	379	15	onset	onset	VERB
fnp-6762	379	16	for	for	ADP
fnp-6762	379	17	personalized	personalized	ADJ
fnp-6762	379	18	therapy	therapy	NOUN
fnp-6762	379	19	in	in	ADP
fnp-6762	379	20	multiple	multiple	ADJ
fnp-6762	379	21	sclerosis	sclerosis	NOUN
fnp-6762	379	22	.	.	PUNCT
fnp-6762	380	1	brain	brain	NOUN
fnp-6762	380	2	147	147	NUM
fnp-6762	380	3	,	,	PUNCT
fnp-6762	380	4	4084	4084	NUM
fnp-6762	380	5	-	-	SYM
fnp-6762	380	6	4093	4093	NUM
fnp-6762	380	7	(	(	PUNCT
fnp-6762	380	8	2024	2024	NUM
fnp-6762	380	9	)	)	PUNCT
fnp-6762	380	10	.	.	PUNCT
fnp-6762	381	1	https://doi.org/10.1093/brain/awae260	https://doi.org/10.1093/brain/awae260	PROPN
fnp-6762	381	2	46	46	NUM
fnp-6762	381	3	.	.	PUNCT
fnp-6762	382	1	loginovic	loginovic	PROPN
fnp-6762	382	2	,	,	PUNCT
fnp-6762	382	3	p.	p.	PROPN
fnp-6762	382	4	,	,	PUNCT
fnp-6762	382	5	et	et	PROPN
fnp-6762	382	6	al	al	PROPN
fnp-6762	382	7	.	.	PUNCT
fnp-6762	383	1	applying	apply	VERB
fnp-6762	383	2	a	a	DET
fnp-6762	383	3	genetic	genetic	ADJ
fnp-6762	383	4	risk	risk	NOUN
fnp-6762	383	5	score	score	NOUN
fnp-6762	383	6	model	model	NOUN
fnp-6762	383	7	to	to	PART
fnp-6762	383	8	enhance	enhance	VERB
fnp-6762	383	9	prediction	prediction	NOUN
fnp-6762	383	10	of	of	ADP
fnp-6762	383	11	future	future	ADJ
fnp-6762	383	12	multiple	multiple	ADJ
fnp-6762	383	13	sclerosis	sclerosis	NOUN
fnp-6762	383	14	diagnosis	diagnosis	NOUN
fnp-6762	383	15	at	at	ADP
fnp-6762	383	16	first	first	ADJ
fnp-6762	383	17	presentation	presentation	NOUN
fnp-6762	383	18	with	with	ADP
fnp-6762	383	19	optic	optic	ADJ
fnp-6762	383	20	neuritis	neuritis	NOUN
fnp-6762	383	21	.	.	PUNCT
fnp-6762	384	1	nat	nat	PROPN
fnp-6762	384	2	commun	commun	PROPN
fnp-6762	384	3	15	15	NUM
fnp-6762	384	4	,	,	PUNCT
fnp-6762	384	5	1415	1415	NUM
fnp-6762	384	6	(	(	PUNCT
fnp-6762	384	7	2024	2024	NUM
fnp-6762	384	8	)	)	PUNCT
fnp-6762	384	9	.	.	PUNCT
fnp-6762	385	1	https://doi.org/10.1038/s41467-024-44917-9	https://doi.org/10.1038/s41467-024-44917-9	NOUN
fnp-6762	385	2	47	47	NUM
fnp-6762	385	3	.	.	PUNCT
fnp-6762	386	1	zamecnik	zamecnik	NOUN
fnp-6762	386	2	,	,	PUNCT
fnp-6762	386	3	c.r	c.r	PROPN
fnp-6762	386	4	.	.	PROPN
fnp-6762	386	5	,	,	PUNCT
fnp-6762	386	6	et	et	PROPN
fnp-6762	386	7	al	al	PROPN
fnp-6762	386	8	.	.	PUNCT
fnp-6762	387	1	an	an	DET
fnp-6762	387	2	autoantibody	autoantibody	ADJ
fnp-6762	387	3	signature	signature	NOUN
fnp-6762	387	4	predictive	predictive	NOUN
fnp-6762	387	5	for	for	ADP
fnp-6762	387	6	multiple	multiple	ADJ
fnp-6762	387	7	sclerosis	sclerosis	NOUN
fnp-6762	387	8	.	.	PUNCT
fnp-6762	388	1	nat	nat	PROPN
fnp-6762	388	2	med	me	VERB
fnp-6762	388	3	30	30	NUM
fnp-6762	388	4	,	,	PUNCT
fnp-6762	388	5	1300	1300	NUM
fnp-6762	388	6	-	-	SYM
fnp-6762	388	7	1308	1308	NUM
fnp-6762	388	8	(	(	PUNCT
fnp-6762	388	9	2024	2024	NUM
fnp-6762	388	10	)	)	PUNCT
fnp-6762	388	11	.	.	PUNCT
fnp-6762	389	1	https://doi.org/10.1038/s41591-024-02938-3	https://doi.org/10.1038/s41591-024-02938-3	NUM
fnp-6762	389	2	48	48	NUM
fnp-6762	389	3	.	.	PUNCT
fnp-6762	390	1	comi	comi	PROPN
fnp-6762	390	2	,	,	PUNCT
fnp-6762	390	3	g.	g.	PROPN
fnp-6762	390	4	,	,	PUNCT
fnp-6762	390	5	et	et	PROPN
fnp-6762	390	6	al	al	PROPN
fnp-6762	390	7	.	.	PUNCT
fnp-6762	391	1	assessing	assess	VERB
fnp-6762	391	2	disease	disease	NOUN
fnp-6762	391	3	progression	progression	NOUN
fnp-6762	391	4	and	and	CCONJ
fnp-6762	391	5	treatment	treatment	NOUN
fnp-6762	391	6	response	response	NOUN
fnp-6762	391	7	in	in	ADP
fnp-6762	391	8	progressive	progressive	ADJ
fnp-6762	391	9	multiple	multiple	ADJ
fnp-6762	391	10	sclerosis	sclerosis	NOUN
fnp-6762	391	11	.	.	PUNCT
fnp-6762	392	1	nat	nat	PROPN
fnp-6762	392	2	rev	rev	VERB
fnp-6762	392	3	neurol	neurol	PROPN
fnp-6762	392	4	20	20	NUM
fnp-6762	392	5	,	,	PUNCT
fnp-6762	392	6	573	573	NUM
fnp-6762	392	7	-	-	SYM
fnp-6762	392	8	586	586	NUM
fnp-6762	392	9	(	(	PUNCT
fnp-6762	392	10	2024	2024	NUM
fnp-6762	392	11	)	)	PUNCT
fnp-6762	392	12	.	.	PUNCT
fnp-6762	393	1	https://doi.org/10.1038/s41582-024-01006-1	https://doi.org/10.1038/s41582-024-01006-1	NUM
fnp-6762	393	2	49	49	NUM
fnp-6762	393	3	.	.	PUNCT
fnp-6762	394	1	rocca	rocca	PROPN
fnp-6762	394	2	,	,	PUNCT
fnp-6762	394	3	m.a	m.a	PROPN
fnp-6762	394	4	.	.	PROPN
fnp-6762	394	5	,	,	PUNCT
fnp-6762	394	6	et	et	PROPN
fnp-6762	394	7	al	al	PROPN
fnp-6762	394	8	.	.	PROPN
fnp-6762	395	1	current	current	ADJ
fnp-6762	395	2	and	and	CCONJ
fnp-6762	395	3	future	future	ADJ
fnp-6762	395	4	role	role	NOUN
fnp-6762	395	5	of	of	ADP
fnp-6762	395	6	mri	mri	NOUN
fnp-6762	395	7	in	in	ADP
fnp-6762	395	8	the	the	DET
fnp-6762	395	9	diagnosis	diagnosis	NOUN
fnp-6762	395	10	and	and	CCONJ
fnp-6762	395	11	prognosis	prognosis	NOUN
fnp-6762	395	12	of	of	ADP
fnp-6762	395	13	multiple	multiple	ADJ
fnp-6762	395	14	sclerosis	sclerosis	NOUN
fnp-6762	395	15	.	.	PUNCT
fnp-6762	396	1	lancet	lancet	PROPN
fnp-6762	396	2	reg	reg	PROPN
fnp-6762	396	3	health	health	NOUN
fnp-6762	396	4	eur	eur	PROPN
fnp-6762	396	5	44	44	NUM
fnp-6762	396	6	,	,	PUNCT
fnp-6762	396	7	100978	100978	NUM
fnp-6762	396	8	(	(	PUNCT
fnp-6762	396	9	2024	2024	NUM
fnp-6762	396	10	)	)	PUNCT
fnp-6762	396	11	.	.	PUNCT
fnp-6762	397	1	https://doi.org/10.1016/j.lanepe.2024.100978	https://doi.org/10.1016/j.lanepe.2024.100978	PROPN
fnp-6762	397	2	50	50	NUM
fnp-6762	397	3	.	.	PUNCT
fnp-6762	397	4	dal	dal	NOUN
fnp-6762	397	5	-	-	PUNCT
fnp-6762	397	6	bianco	bianco	PROPN
fnp-6762	397	7	,	,	PUNCT
fnp-6762	397	8	a.	a.	NOUN
fnp-6762	397	9	,	,	PUNCT
fnp-6762	397	10	oh	oh	INTJ
fnp-6762	397	11	,	,	PUNCT
fnp-6762	397	12	j.	j.	PROPN
fnp-6762	397	13	,	,	PUNCT
fnp-6762	397	14	sati	sati	PROPN
fnp-6762	397	15	,	,	PUNCT
fnp-6762	397	16	p.	p.	PROPN
fnp-6762	397	17	&	&	CCONJ
fnp-6762	397	18	absinta	absinta	PROPN
fnp-6762	397	19	,	,	PUNCT
fnp-6762	397	20	m.	m.	NOUN
fnp-6762	397	21	chronic	chronic	ADJ
fnp-6762	397	22	active	active	ADJ
fnp-6762	397	23	lesions	lesion	NOUN
fnp-6762	397	24	in	in	ADP
fnp-6762	397	25	multiple	multiple	ADJ
fnp-6762	397	26	sclerosis	sclerosis	NOUN
fnp-6762	397	27	:	:	PUNCT
fnp-6762	397	28	classification	classification	NOUN
fnp-6762	397	29	,	,	PUNCT
fnp-6762	397	30	terminology	terminology	NOUN
fnp-6762	397	31	,	,	PUNCT
fnp-6762	397	32	and	and	CCONJ
fnp-6762	397	33	clinical	clinical	ADJ
fnp-6762	397	34	significance	significance	NOUN
fnp-6762	397	35	.	.	PUNCT
fnp-6762	398	1	ther	ther	VERB
fnp-6762	398	2	adv	adv	PROPN
fnp-6762	399	1	neurol	neurol	PROPN
fnp-6762	399	2	disord	disord	PROPN
fnp-6762	399	3	17	17	NUM
fnp-6762	399	4	,	,	PUNCT
fnp-6762	399	5	17562864241306684	17562864241306684	NUM
fnp-6762	399	6	(	(	PUNCT
fnp-6762	399	7	2024	2024	NUM
fnp-6762	399	8	)	)	PUNCT
fnp-6762	399	9	.	.	PUNCT
fnp-6762	400	1	https://doi.org/10.1177/17562864241306684	https://doi.org/10.1177/17562864241306684	ADP
fnp-6762	400	2	51	51	NUM
fnp-6762	400	3	.	.	X
fnp-6762	400	4	bagnato	bagnato	PROPN
fnp-6762	400	5	,	,	PUNCT
fnp-6762	400	6	f.	f.	PROPN
fnp-6762	400	7	,	,	PUNCT
fnp-6762	401	1	et	et	PROPN
fnp-6762	401	2	al	al	PROPN
fnp-6762	401	3	.	.	PUNCT
fnp-6762	401	4	imaging	imaging	PROPN
fnp-6762	401	5	chronic	chronic	ADJ
fnp-6762	401	6	active	active	ADJ
fnp-6762	401	7	lesions	lesion	NOUN
fnp-6762	401	8	in	in	ADP
fnp-6762	401	9	multiple	multiple	ADJ
fnp-6762	401	10	sclerosis	sclerosis	NOUN
fnp-6762	401	11	:	:	PUNCT
fnp-6762	401	12	a	a	DET
fnp-6762	401	13	consensus	consensus	NOUN
fnp-6762	401	14	statement	statement	NOUN
fnp-6762	401	15	.	.	PUNCT
fnp-6762	402	1	brain	brain	NOUN
fnp-6762	402	2	147	147	NUM
fnp-6762	402	3	,	,	PUNCT
fnp-6762	402	4	2913	2913	NUM
fnp-6762	402	5	-	-	SYM
fnp-6762	402	6	2933	2933	NUM
fnp-6762	402	7	(	(	PUNCT
fnp-6762	402	8	2024	2024	NUM
fnp-6762	402	9	)	)	PUNCT
fnp-6762	402	10	.	.	PUNCT
fnp-6762	403	1	https://doi.org/10.1093/brain/awae013	https://doi.org/10.1093/brain/awae013	X
fnp-6762	404	1	52	52	NUM
fnp-6762	404	2	.	.	PUNCT
fnp-6762	405	1	scalfari	scalfari	PROPN
fnp-6762	405	2	,	,	PUNCT
fnp-6762	405	3	a.	a.	PROPN
fnp-6762	405	4	,	,	PUNCT
fnp-6762	405	5	et	et	PROPN
fnp-6762	405	6	al	al	PROPN
fnp-6762	405	7	.	.	PUNCT
fnp-6762	405	8	smouldering	smoulder	VERB
fnp-6762	405	9	-	-	PUNCT
fnp-6762	405	10	associated	associate	VERB
fnp-6762	405	11	worsening	worsen	VERB
fnp-6762	405	12	in	in	ADP
fnp-6762	405	13	multiple	multiple	ADJ
fnp-6762	405	14	sclerosis	sclerosis	NOUN
fnp-6762	405	15	:	:	PUNCT
fnp-6762	405	16	an	an	DET
fnp-6762	405	17	international	international	ADJ
fnp-6762	405	18	consensus	consensus	NOUN
fnp-6762	405	19	statement	statement	NOUN
fnp-6762	405	20	on	on	ADP
fnp-6762	405	21	definition	definition	NOUN
fnp-6762	405	22	,	,	PUNCT
fnp-6762	405	23	biology	biology	NOUN
fnp-6762	405	24	,	,	PUNCT
fnp-6762	405	25	clinical	clinical	ADJ
fnp-6762	405	26	implications	implication	NOUN
fnp-6762	405	27	,	,	PUNCT
fnp-6762	405	28	and	and	CCONJ
fnp-6762	405	29	future	future	ADJ
fnp-6762	405	30	directions	direction	NOUN
fnp-6762	405	31	.	.	PUNCT
fnp-6762	406	1	ann	ann	PROPN
fnp-6762	406	2	neurol	neurol	PROPN
fnp-6762	406	3	96	96	NUM
fnp-6762	406	4	,	,	PUNCT
fnp-6762	406	5	826	826	NUM
fnp-6762	406	6	-	-	SYM
fnp-6762	406	7	845	845	NUM
fnp-6762	406	8	(	(	PUNCT
fnp-6762	406	9	2024	2024	NUM
fnp-6762	406	10	)	)	PUNCT
fnp-6762	406	11	.	.	PUNCT
fnp-6762	407	1	https://doi.org/10.1002/ana.27034	https://doi.org/10.1002/ana.27034	PROPN
fnp-6762	407	2	53	53	NUM
fnp-6762	407	3	.	.	PUNCT
fnp-6762	407	4	calabrese	calabrese	PROPN
fnp-6762	407	5	,	,	PUNCT
fnp-6762	407	6	m.	m.	NOUN
fnp-6762	407	7	,	,	PUNCT
fnp-6762	407	8	et	et	PROPN
fnp-6762	407	9	al	al	PROPN
fnp-6762	407	10	.	.	PUNCT
fnp-6762	407	11	determinants	determinant	NOUN
fnp-6762	407	12	and	and	CCONJ
fnp-6762	407	13	biomarkers	biomarker	NOUN
fnp-6762	407	14	of	of	ADP
fnp-6762	407	15	progression	progression	NOUN
fnp-6762	407	16	independent	independent	ADJ
fnp-6762	407	17	of	of	ADP
fnp-6762	407	18	relapses	relapse	NOUN
fnp-6762	407	19	in	in	ADP
fnp-6762	407	20	multiple	multiple	ADJ
fnp-6762	407	21	sclerosis	sclerosis	NOUN
fnp-6762	407	22	.	.	PUNCT
fnp-6762	408	1	ann	ann	PROPN
fnp-6762	408	2	neurol	neurol	PROPN
fnp-6762	408	3	96	96	NUM
fnp-6762	408	4	,	,	PUNCT
fnp-6762	408	5	1	1	NUM
fnp-6762	408	6	-	-	SYM
fnp-6762	408	7	20	20	NUM
fnp-6762	408	8	(	(	PUNCT
fnp-6762	408	9	2024	2024	NUM
fnp-6762	408	10	)	)	PUNCT
fnp-6762	408	11	.	.	PUNCT
fnp-6762	409	1	https://doi.org/10.1002/ana.26913	https://doi.org/10.1002/ana.26913	PROPN
fnp-6762	409	2	54	54	NUM
fnp-6762	409	3	.	.	PUNCT
fnp-6762	410	1	calvi	calvi	PROPN
fnp-6762	410	2	,	,	PUNCT
fnp-6762	410	3	a.	a.	PROPN
fnp-6762	410	4	,	,	PUNCT
fnp-6762	410	5	et	et	PROPN
fnp-6762	410	6	al	al	PROPN
fnp-6762	410	7	.	.	PROPN
fnp-6762	410	8	relationship	relationship	NOUN
fnp-6762	410	9	between	between	ADP
fnp-6762	410	10	paramagnetic	paramagnetic	ADJ
fnp-6762	410	11	rim	rim	NOUN
fnp-6762	410	12	lesions	lesion	NOUN
fnp-6762	410	13	and	and	CCONJ
fnp-6762	410	14	slowly	slowly	ADV
fnp-6762	410	15	expanding	expand	VERB
fnp-6762	410	16	lesions	lesion	NOUN
fnp-6762	410	17	in	in	ADP
fnp-6762	410	18	multiple	multiple	ADJ
fnp-6762	410	19	sclerosis	sclerosis	NOUN
fnp-6762	410	20	.	.	PUNCT
fnp-6762	411	1	mult	mult	PROPN
fnp-6762	411	2	scler	scler	PROPN
fnp-6762	411	3	29	29	NUM
fnp-6762	411	4	,	,	PUNCT
fnp-6762	411	5	352	352	NUM
fnp-6762	411	6	-	-	SYM
fnp-6762	411	7	362	362	NUM
fnp-6762	411	8	(	(	PUNCT
fnp-6762	411	9	2023	2023	NUM
fnp-6762	411	10	)	)	PUNCT
fnp-6762	411	11	.	.	PUNCT
fnp-6762	412	1	https://doi.org/10.1177/13524585221141964	https://doi.org/10.1177/13524585221141964	X
fnp-6762	413	1	55	55	NUM
fnp-6762	413	2	.	.	PUNCT
fnp-6762	414	1	treaba	treaba	PROPN
fnp-6762	414	2	,	,	PUNCT
fnp-6762	414	3	c.a	c.a	PROPN
fnp-6762	414	4	.	.	PROPN
fnp-6762	414	5	,	,	PUNCT
fnp-6762	414	6	et	et	PROPN
fnp-6762	414	7	al	al	PROPN
fnp-6762	414	8	.	.	PUNCT
fnp-6762	415	1	phenotyping	phenotype	VERB
fnp-6762	415	2	in	in	ADP
fnp-6762	415	3	vivo	vivo	ADJ
fnp-6762	415	4	chronic	chronic	ADJ
fnp-6762	415	5	inflammation	inflammation	NOUN
fnp-6762	415	6	in	in	ADP
fnp-6762	415	7	multiple	multiple	ADJ
fnp-6762	415	8	sclerosis	sclerosis	NOUN
fnp-6762	415	9	by	by	ADP
fnp-6762	415	10	combined	combine	VERB
fnp-6762	415	11	(	(	PUNCT
fnp-6762	415	12	11)c	11)c	NUM
fnp-6762	415	13	-	-	PUNCT
fnp-6762	415	14	pbr28	pbr28	NOUN
fnp-6762	415	15	mr	mr	NOUN
fnp-6762	415	16	-	-	PUNCT
fnp-6762	415	17	pet	pet	NOUN
fnp-6762	415	18	and	and	CCONJ
fnp-6762	415	19	7	7	NUM
fnp-6762	415	20	t	t	NOUN
fnp-6762	415	21	susceptibility	susceptibility	NOUN
fnp-6762	415	22	-	-	PUNCT
fnp-6762	415	23	weighted	weight	VERB
fnp-6762	415	24	imaging	imaging	NOUN
fnp-6762	415	25	.	.	PUNCT
fnp-6762	416	1	mult	mult	PROPN
fnp-6762	416	2	scler	scler	PROPN
fnp-6762	416	3	30	30	NUM
fnp-6762	416	4	,	,	PUNCT
fnp-6762	416	5	1755	1755	NUM
fnp-6762	416	6	-	-	SYM
fnp-6762	416	7	1764	1764	NUM
fnp-6762	416	8	(	(	PUNCT
fnp-6762	416	9	2024	2024	NUM
fnp-6762	416	10	)	)	PUNCT
fnp-6762	416	11	.	.	PUNCT
fnp-6762	417	1	https://doi.org/10.1177/13524585241284157	https://doi.org/10.1177/13524585241284157	PROPN
fnp-6762	418	1	56	56	NUM
fnp-6762	418	2	.	.	PUNCT
fnp-6762	418	3	cagol	cagol	PROPN
fnp-6762	418	4	,	,	PUNCT
fnp-6762	418	5	a.	a.	PROPN
fnp-6762	418	6	,	,	PUNCT
fnp-6762	418	7	et	et	PROPN
fnp-6762	418	8	al	al	PROPN
fnp-6762	418	9	.	.	PROPN
fnp-6762	418	10	association	association	PROPN
fnp-6762	418	11	of	of	ADP
fnp-6762	418	12	spinal	spinal	ADJ
fnp-6762	418	13	cord	cord	NOUN
fnp-6762	418	14	atrophy	atrophy	NOUN
fnp-6762	418	15	and	and	CCONJ
fnp-6762	418	16	brain	brain	NOUN
fnp-6762	418	17	paramagnetic	paramagnetic	ADJ
fnp-6762	418	18	rim	rim	NOUN
fnp-6762	418	19	lesions	lesion	NOUN
fnp-6762	418	20	with	with	ADP
fnp-6762	418	21	progression	progression	NOUN
fnp-6762	418	22	independent	independent	ADJ
fnp-6762	418	23	of	of	ADP
fnp-6762	418	24	relapse	relapse	NOUN
fnp-6762	418	25	activity	activity	NOUN
fnp-6762	418	26	in	in	ADP
fnp-6762	418	27	people	people	NOUN
fnp-6762	418	28	with	with	ADP
fnp-6762	418	29	ms	ms	PROPN
fnp-6762	418	30	.	.	PROPN
fnp-6762	418	31	neurology	neurology	PROPN
fnp-6762	418	32	102	102	NUM
fnp-6762	418	33	,	,	PUNCT
fnp-6762	418	34	e207768	e207768	NOUN
fnp-6762	418	35	(	(	PUNCT
fnp-6762	418	36	2024	2024	NUM
fnp-6762	418	37	)	)	PUNCT
fnp-6762	418	38	.	.	PUNCT
fnp-6762	419	1	https://doi.org/10.1212/wnl.0000000000207768	https://doi.org/10.1212/wnl.0000000000207768	NOUN
fnp-6762	419	2	57	57	NUM
fnp-6762	419	3	.	.	PUNCT
fnp-6762	420	1	reeves	reeves	PROPN
fnp-6762	420	2	,	,	PUNCT
fnp-6762	420	3	j.a	j.a	PROPN
fnp-6762	420	4	.	.	PROPN
fnp-6762	420	5	,	,	PUNCT
fnp-6762	420	6	et	et	PROPN
fnp-6762	420	7	al	al	PROPN
fnp-6762	420	8	.	.	PROPN
fnp-6762	420	9	associations	association	NOUN
fnp-6762	420	10	between	between	ADP
fnp-6762	420	11	paramagnetic	paramagnetic	ADJ
fnp-6762	420	12	rim	rim	NOUN
fnp-6762	420	13	lesion	lesion	NOUN
fnp-6762	420	14	evolution	evolution	NOUN
fnp-6762	420	15	and	and	CCONJ
fnp-6762	420	16	clinical	clinical	ADJ
fnp-6762	420	17	and	and	CCONJ
fnp-6762	420	18	radiologic	radiologic	ADJ
fnp-6762	420	19	disease	disease	NOUN
fnp-6762	420	20	progression	progression	NOUN
fnp-6762	420	21	in	in	ADP
fnp-6762	420	22	persons	person	NOUN
fnp-6762	420	23	with	with	ADP
fnp-6762	420	24	multiple	multiple	ADJ
fnp-6762	420	25	sclerosis	sclerosis	NOUN
fnp-6762	420	26	.	.	PUNCT
fnp-6762	421	1	neurology	neurology	NOUN
fnp-6762	421	2	103	103	NUM
fnp-6762	421	3	,	,	PUNCT
fnp-6762	421	4	e210004	e210004	NOUN
fnp-6762	421	5	(	(	PUNCT
fnp-6762	421	6	2024	2024	NUM
fnp-6762	421	7	)	)	PUNCT
fnp-6762	421	8	.	.	PUNCT
fnp-6762	422	1	https://doi.org/10.1212/wnl.0000000000210004	https://doi.org/10.1212/wnl.0000000000210004	NOUN
fnp-6762	422	2	58	58	NUM
fnp-6762	422	3	.	.	PUNCT
fnp-6762	423	1	beck	beck	PROPN
fnp-6762	423	2	,	,	PUNCT
fnp-6762	423	3	e.s	e.s	PROPN
fnp-6762	423	4	.	.	PROPN
fnp-6762	423	5	,	,	PUNCT
fnp-6762	423	6	et	et	PROPN
fnp-6762	423	7	al	al	PROPN
fnp-6762	423	8	.	.	PROPN
fnp-6762	423	9	contribution	contribution	NOUN
fnp-6762	423	10	of	of	ADP
fnp-6762	423	11	new	new	ADJ
fnp-6762	423	12	and	and	CCONJ
fnp-6762	423	13	chronic	chronic	ADJ
fnp-6762	423	14	cortical	cortical	ADJ
fnp-6762	423	15	lesions	lesion	NOUN
fnp-6762	423	16	to	to	ADP
fnp-6762	423	17	disability	disability	NOUN
fnp-6762	423	18	accrual	accrual	ADJ
fnp-6762	423	19	in	in	ADP
fnp-6762	423	20	multiple	multiple	ADJ
fnp-6762	423	21	sclerosis	sclerosis	NOUN
fnp-6762	423	22	.	.	PUNCT
fnp-6762	424	1	brain	brain	PROPN
fnp-6762	424	2	commun	commun	PROPN
fnp-6762	424	3	6	6	NUM
fnp-6762	424	4	,	,	PUNCT
fnp-6762	424	5	fcae158	fcae158	PROPN
fnp-6762	424	6	(	(	PUNCT
fnp-6762	424	7	2024	2024	NUM
fnp-6762	424	8	)	)	PUNCT
fnp-6762	424	9	.	.	PUNCT
fnp-6762	425	1	https://doi.org/10.1093/braincomms/fcae158	https://doi.org/10.1093/braincomms/fcae158	X
fnp-6762	425	2	59	59	NUM
fnp-6762	425	3	.	.	PUNCT
fnp-6762	425	4	cagol	cagol	PROPN
fnp-6762	425	5	,	,	PUNCT
fnp-6762	425	6	a.	a.	PROPN
fnp-6762	425	7	,	,	PUNCT
fnp-6762	425	8	et	et	PROPN
fnp-6762	425	9	al	al	PROPN
fnp-6762	425	10	.	.	PROPN
fnp-6762	426	1	advanced	advanced	ADJ
fnp-6762	426	2	quantitative	quantitative	ADJ
fnp-6762	426	3	mri	mri	NOUN
fnp-6762	426	4	unveils	unveil	VERB
fnp-6762	426	5	microstructural	microstructural	ADJ
fnp-6762	426	6	thalamic	thalamic	ADJ
fnp-6762	426	7	changes	change	NOUN
fnp-6762	426	8	reflecting	reflect	VERB
fnp-6762	426	9	disease	disease	NOUN
fnp-6762	426	10	progression	progression	NOUN
fnp-6762	426	11	in	in	ADP
fnp-6762	426	12	multiple	multiple	ADJ
fnp-6762	426	13	sclerosis	sclerosis	NOUN
fnp-6762	426	14	.	.	PUNCT
fnp-6762	427	1	neurol	neurol	PROPN
fnp-6762	427	2	neuroimmunol	neuroimmunol	PROPN
fnp-6762	427	3	neuroinflamm	neuroinflamm	PROPN
fnp-6762	427	4	11	11	NUM
fnp-6762	427	5	,	,	PUNCT
fnp-6762	427	6	e200299	e200299	X
fnp-6762	427	7	(	(	PUNCT
fnp-6762	427	8	2024	2024	NUM
fnp-6762	427	9	)	)	PUNCT
fnp-6762	427	10	.	.	PUNCT
fnp-6762	428	1	https://doi.org/10.1212/nxi.0000000000200299	https://doi.org/10.1212/nxi.0000000000200299	VERB
fnp-6762	428	2	60	60	NUM
fnp-6762	428	3	.	.	PUNCT
fnp-6762	429	1	klistorner	klistorner	PROPN
fnp-6762	429	2	,	,	PUNCT
fnp-6762	429	3	s.	s.	PROPN
fnp-6762	429	4	,	,	PUNCT
fnp-6762	429	5	et	et	PROPN
fnp-6762	429	6	al	al	PROPN
fnp-6762	429	7	.	.	PUNCT
fnp-6762	430	1	longitudinal	longitudinal	ADJ
fnp-6762	430	2	enlargement	enlargement	NOUN
fnp-6762	430	3	of	of	ADP
fnp-6762	430	4	choroid	choroid	NOUN
fnp-6762	430	5	plexus	plexus	NOUN
fnp-6762	430	6	is	be	AUX
fnp-6762	430	7	associated	associate	VERB
fnp-6762	430	8	with	with	ADP
fnp-6762	430	9	chronic	chronic	ADJ
fnp-6762	430	10	lesion	lesion	NOUN
fnp-6762	430	11	expansion	expansion	NOUN
fnp-6762	430	12	and	and	CCONJ
fnp-6762	430	13	neurodegeneration	neurodegeneration	NOUN
fnp-6762	430	14	in	in	ADP
fnp-6762	430	15	rrms	rrm	NOUN
fnp-6762	430	16	patients	patient	NOUN
fnp-6762	430	17	.	.	PUNCT
fnp-6762	431	1	mult	mult	PROPN
fnp-6762	431	2	scler	scler	PROPN
fnp-6762	431	3	30	30	NUM
fnp-6762	431	4	,	,	PUNCT
fnp-6762	431	5	496	496	NUM
fnp-6762	431	6	-	-	SYM
fnp-6762	431	7	504	504	NUM
fnp-6762	431	8	(	(	PUNCT
fnp-6762	431	9	2024	2024	NUM
fnp-6762	431	10	)	)	PUNCT
fnp-6762	431	11	.	.	PUNCT
fnp-6762	432	1	https://doi.org/10.1177/13524585241228423	https://doi.org/10.1177/13524585241228423	X
fnp-6762	432	2	61	61	NUM
fnp-6762	432	3	.	.	PUNCT
fnp-6762	433	1	preziosa	preziosa	PROPN
fnp-6762	433	2	,	,	PUNCT
fnp-6762	433	3	p.	p.	PROPN
fnp-6762	433	4	,	,	PUNCT
fnp-6762	433	5	et	et	PROPN
fnp-6762	433	6	al	al	PROPN
fnp-6762	433	7	.	.	PROPN
fnp-6762	433	8	chronic	chronic	ADJ
fnp-6762	433	9	active	active	ADJ
fnp-6762	433	10	lesions	lesion	NOUN
fnp-6762	433	11	and	and	CCONJ
fnp-6762	433	12	larger	large	ADJ
fnp-6762	433	13	choroid	choroid	NOUN
fnp-6762	433	14	plexus	plexus	NOUN
fnp-6762	433	15	explain	explain	VERB
fnp-6762	433	16	cognition	cognition	NOUN
fnp-6762	433	17	and	and	CCONJ
fnp-6762	433	18	fatigue	fatigue	NOUN
fnp-6762	433	19	in	in	ADP
fnp-6762	433	20	multiple	multiple	ADJ
fnp-6762	433	21	sclerosis	sclerosis	NOUN
fnp-6762	433	22	.	.	PUNCT
fnp-6762	434	1	neurol	neurol	PROPN
fnp-6762	434	2	neuroimmunol	neuroimmunol	PROPN
fnp-6762	434	3	neuroinflamm	neuroinflamm	PROPN
fnp-6762	434	4	11	11	NUM
fnp-6762	434	5	,	,	PUNCT
fnp-6762	434	6	e200205	e200205	NOUN
fnp-6762	434	7	(	(	PUNCT
fnp-6762	434	8	2024	2024	NUM
fnp-6762	434	9	)	)	PUNCT
fnp-6762	434	10	.	.	PUNCT
fnp-6762	435	1	https://doi.org/10.1212/nxi.0000000000200205	https://doi.org/10.1212/nxi.0000000000200205	PROPN
fnp-6762	435	2	62	62	NUM
fnp-6762	435	3	.	.	PUNCT
fnp-6762	436	1	collorone	collorone	PROPN
fnp-6762	436	2	,	,	PUNCT
fnp-6762	436	3	s.	s.	PROPN
fnp-6762	436	4	,	,	PUNCT
fnp-6762	436	5	et	et	PROPN
fnp-6762	436	6	al	al	PROPN
fnp-6762	436	7	.	.	PUNCT
fnp-6762	437	1	artificial	artificial	ADJ
fnp-6762	437	2	intelligence	intelligence	NOUN
fnp-6762	437	3	applied	apply	VERB
fnp-6762	437	4	to	to	ADP
fnp-6762	437	5	mri	mri	NOUN
fnp-6762	437	6	data	datum	NOUN
fnp-6762	437	7	to	to	PART
fnp-6762	437	8	tackle	tackle	VERB
fnp-6762	437	9	key	key	ADJ
fnp-6762	437	10	challenges	challenge	NOUN
fnp-6762	437	11	in	in	ADP
fnp-6762	437	12	multiple	multiple	ADJ
fnp-6762	437	13	sclerosis	sclerosis	NOUN
fnp-6762	437	14	.	.	PUNCT
fnp-6762	438	1	mult	mult	PROPN
fnp-6762	438	2	scler	scler	PROPN
fnp-6762	438	3	30	30	NUM
fnp-6762	438	4	,	,	PUNCT
fnp-6762	438	5	767	767	NUM
fnp-6762	438	6	-	-	SYM
fnp-6762	438	7	784	784	NUM
fnp-6762	438	8	(	(	PUNCT
fnp-6762	438	9	2024	2024	NUM
fnp-6762	438	10	)	)	PUNCT
fnp-6762	438	11	.	.	PUNCT
fnp-6762	439	1	https://doi.org/10.1177/13524585241249422	https://doi.org/10.1177/13524585241249422	NOUN
fnp-6762	439	2	63	63	NUM
fnp-6762	439	3	.	.	PUNCT
fnp-6762	440	1	noteboom	noteboom	PROPN
fnp-6762	440	2	,	,	PUNCT
fnp-6762	440	3	s.	s.	PROPN
fnp-6762	440	4	,	,	PUNCT
fnp-6762	440	5	et	et	PROPN
fnp-6762	440	6	al	al	PROPN
fnp-6762	440	7	.	.	PUNCT
fnp-6762	440	8	evaluation	evaluation	NOUN
fnp-6762	440	9	of	of	ADP
fnp-6762	440	10	machine	machine	NOUN
fnp-6762	440	11	learning	learning	NOUN
fnp-6762	440	12	-	-	PUNCT
fnp-6762	440	13	based	base	VERB
fnp-6762	440	14	classification	classification	NOUN
fnp-6762	440	15	of	of	ADP
fnp-6762	440	16	clinical	clinical	ADJ
fnp-6762	440	17	impairment	impairment	NOUN
fnp-6762	440	18	and	and	CCONJ
fnp-6762	440	19	prediction	prediction	NOUN
fnp-6762	440	20	of	of	ADP
fnp-6762	440	21	clinical	clinical	ADJ
fnp-6762	440	22	worsening	worsening	NOUN
fnp-6762	440	23	in	in	ADP
fnp-6762	440	24	multiple	multiple	ADJ
fnp-6762	440	25	sclerosis	sclerosis	NOUN
fnp-6762	440	26	.	.	PUNCT
fnp-6762	441	1	j	j	PROPN
fnp-6762	441	2	neurol	neurol	NOUN
fnp-6762	441	3	271	271	NUM
fnp-6762	441	4	,	,	PUNCT
fnp-6762	441	5	5577	5577	NUM
fnp-6762	441	6	-	-	SYM
fnp-6762	441	7	5589	5589	NUM
fnp-6762	441	8	(	(	PUNCT
fnp-6762	441	9	2024	2024	NUM
fnp-6762	441	10	)	)	PUNCT
fnp-6762	441	11	.	.	PUNCT
fnp-6762	442	1	https://doi.org/10.1007/s00415-024-12507-w	https://doi.org/10.1007/s00415-024-12507-w	NOUN
fnp-6762	442	2	64	64	NUM
fnp-6762	442	3	.	.	PUNCT
fnp-6762	443	1	andorra	andorra	PROPN
fnp-6762	443	2	,	,	PUNCT
fnp-6762	443	3	m.	m.	NOUN
fnp-6762	443	4	,	,	PUNCT
fnp-6762	443	5	et	et	PROPN
fnp-6762	443	6	al	al	PROPN
fnp-6762	443	7	.	.	PROPN
fnp-6762	443	8	predicting	predict	VERB
fnp-6762	443	9	disease	disease	NOUN
fnp-6762	443	10	severity	severity	NOUN
fnp-6762	443	11	in	in	ADP
fnp-6762	443	12	multiple	multiple	ADJ
fnp-6762	443	13	sclerosis	sclerosis	NOUN
fnp-6762	443	14	using	use	VERB
fnp-6762	443	15	multimodal	multimodal	NOUN
fnp-6762	443	16	data	datum	NOUN
fnp-6762	443	17	and	and	CCONJ
fnp-6762	443	18	machine	machine	NOUN
fnp-6762	443	19	learning	learning	NOUN
fnp-6762	443	20	.	.	PUNCT
fnp-6762	444	1	j	j	PROPN
fnp-6762	444	2	neurol	neurol	NOUN
fnp-6762	444	3	271	271	NUM
fnp-6762	444	4	,	,	PUNCT
fnp-6762	444	5	1133	1133	NUM
fnp-6762	444	6	-	-	SYM
fnp-6762	444	7	1149	1149	NUM
fnp-6762	444	8	(	(	PUNCT
fnp-6762	444	9	2024	2024	NUM
fnp-6762	444	10	)	)	PUNCT
fnp-6762	444	11	.	.	PUNCT
fnp-6762	445	1	https://doi.org/10.1007/s00415-023-12132-z	https://doi.org/10.1007/s00415-023-12132-z	PRON
fnp-6762	445	2	65	65	NUM
fnp-6762	445	3	.	.	PUNCT
fnp-6762	446	1	de	de	PROPN
fnp-6762	446	2	rosa	rosa	PROPN
fnp-6762	446	3	,	,	PUNCT
fnp-6762	446	4	a.p	a.p	PROPN
fnp-6762	446	5	.	.	PROPN
fnp-6762	446	6	,	,	PUNCT
fnp-6762	446	7	et	et	PROPN
fnp-6762	446	8	al	al	PROPN
fnp-6762	446	9	.	.	PUNCT
fnp-6762	446	10	consensus	consensus	NOUN
fnp-6762	446	11	of	of	ADP
fnp-6762	446	12	algorithms	algorithm	NOUN
fnp-6762	446	13	for	for	ADP
fnp-6762	446	14	lesion	lesion	NOUN
fnp-6762	446	15	segmentation	segmentation	NOUN
fnp-6762	446	16	in	in	ADP
fnp-6762	446	17	brain	brain	NOUN
fnp-6762	446	18	mri	mri	NOUN
fnp-6762	446	19	studies	study	NOUN
fnp-6762	446	20	of	of	ADP
fnp-6762	446	21	multiple	multiple	ADJ
fnp-6762	446	22	sclerosis	sclerosis	NOUN
fnp-6762	446	23	.	.	PUNCT
fnp-6762	447	1	sci	sci	PROPN
fnp-6762	447	2	rep	rep	PROPN
fnp-6762	447	3	14	14	NUM
fnp-6762	447	4	,	,	PUNCT
fnp-6762	447	5	21348	21348	NUM
fnp-6762	447	6	(	(	PUNCT
fnp-6762	447	7	2024	2024	NUM
fnp-6762	447	8	)	)	PUNCT
fnp-6762	447	9	.	.	PUNCT
fnp-6762	448	1	https://doi.org/10.1038/s41598-024-72649-9	https://doi.org/10.1038/s41598-024-72649-9	NUM
fnp-6762	448	2	66	66	NUM
fnp-6762	448	3	.	.	PUNCT
fnp-6762	449	1	chen	chen	PROPN
fnp-6762	449	2	,	,	PUNCT
fnp-6762	449	3	l.	l.	PROPN
fnp-6762	449	4	,	,	PUNCT
fnp-6762	449	5	et	et	PROPN
fnp-6762	449	6	al	al	PROPN
fnp-6762	449	7	.	.	PUNCT
fnp-6762	450	1	multicenter	multicenter	NOUN
fnp-6762	450	2	validation	validation	NOUN
fnp-6762	450	3	of	of	ADP
fnp-6762	450	4	automated	automate	VERB
fnp-6762	450	5	detection	detection	NOUN
fnp-6762	450	6	of	of	ADP
fnp-6762	450	7	paramagnetic	paramagnetic	ADJ
fnp-6762	450	8	rim	rim	NOUN
fnp-6762	450	9	lesions	lesion	NOUN
fnp-6762	450	10	on	on	ADP
fnp-6762	450	11	brain	brain	NOUN
fnp-6762	450	12	mri	mri	NOUN
fnp-6762	450	13	in	in	ADP
fnp-6762	450	14	multiple	multiple	ADJ
fnp-6762	450	15	sclerosis	sclerosis	NOUN
fnp-6762	450	16	.	.	PUNCT
fnp-6762	451	1	j	j	PROPN
fnp-6762	451	2	neuroimaging	neuroimage	VERB
fnp-6762	451	3	34	34	NUM
fnp-6762	451	4	,	,	PUNCT
fnp-6762	451	5	750	750	NUM
fnp-6762	451	6	-	-	SYM
fnp-6762	451	7	757	757	NUM
fnp-6762	451	8	(	(	PUNCT
fnp-6762	451	9	2024	2024	NUM
fnp-6762	451	10	)	)	PUNCT
fnp-6762	451	11	.	.	PUNCT
fnp-6762	452	1	https://doi.org/10.1111/jon.13242	https://doi.org/10.1111/jon.13242	PROPN
fnp-6762	452	2	67	67	NUM
fnp-6762	452	3	.	.	PUNCT
fnp-6762	453	1	kappos	kappos	PROPN
fnp-6762	453	2	,	,	PUNCT
fnp-6762	453	3	l.	l.	PROPN
fnp-6762	453	4	,	,	PUNCT
fnp-6762	453	5	et	et	PROPN
fnp-6762	453	6	al	al	PROPN
fnp-6762	453	7	.	.	PROPN
fnp-6762	453	8	contribution	contribution	NOUN
fnp-6762	453	9	of	of	ADP
fnp-6762	453	10	relapse	relapse	NOUN
fnp-6762	453	11	-	-	PUNCT
fnp-6762	453	12	independent	independent	ADJ
fnp-6762	453	13	progression	progression	NOUN
fnp-6762	453	14	vs	vs	ADP
fnp-6762	453	15	relapse	relapse	NOUN
fnp-6762	453	16	-	-	PUNCT
fnp-6762	453	17	associated	associate	VERB
fnp-6762	453	18	worsening	worsen	VERB
fnp-6762	453	19	to	to	ADP
fnp-6762	453	20	overall	overall	ADJ
fnp-6762	453	21	confirmed	confirm	VERB
fnp-6762	453	22	disability	disability	NOUN
fnp-6762	453	23	accumulation	accumulation	NOUN
fnp-6762	453	24	in	in	ADP
fnp-6762	453	25	typical	typical	ADJ
fnp-6762	453	26	relapsing	relapse	VERB
fnp-6762	453	27	multiple	multiple	ADJ
fnp-6762	453	28	sclerosis	sclerosis	NOUN
fnp-6762	453	29	in	in	ADP
fnp-6762	453	30	a	a	DET
fnp-6762	453	31	pooled	pooled	ADJ
fnp-6762	453	32	analysis	analysis	NOUN
fnp-6762	453	33	of	of	ADP
fnp-6762	453	34	2	2	NUM
fnp-6762	453	35	randomized	randomize	VERB
fnp-6762	453	36	clinical	clinical	ADJ
fnp-6762	453	37	trials	trial	NOUN
fnp-6762	453	38	.	.	PUNCT
fnp-6762	454	1	jama	jama	PROPN
fnp-6762	454	2	neurol	neurol	PROPN
fnp-6762	454	3	77	77	NUM
fnp-6762	454	4	,	,	PUNCT
fnp-6762	454	5	1132	1132	NUM
fnp-6762	454	6	-	-	SYM
fnp-6762	454	7	1140	1140	NUM
fnp-6762	454	8	(	(	PUNCT
fnp-6762	454	9	2020	2020	NUM
fnp-6762	454	10	)	)	PUNCT
fnp-6762	454	11	.	.	PUNCT
fnp-6762	455	1	https://doi.org/10.1001/jamaneurol.2020.1568	https://doi.org/10.1001/jamaneurol.2020.1568	PROPN
fnp-6762	455	2	68	68	NUM
fnp-6762	455	3	.	.	PUNCT
fnp-6762	456	1	tur	tur	PROPN
fnp-6762	456	2	,	,	PUNCT
fnp-6762	456	3	c.	c.	PROPN
fnp-6762	456	4	,	,	PUNCT
fnp-6762	456	5	et	et	PROPN
fnp-6762	456	6	al	al	PROPN
fnp-6762	456	7	.	.	PROPN
fnp-6762	456	8	association	association	PROPN
fnp-6762	456	9	of	of	ADP
fnp-6762	456	10	early	early	ADJ
fnp-6762	456	11	progression	progression	NOUN
fnp-6762	456	12	independent	independent	ADJ
fnp-6762	456	13	of	of	ADP
fnp-6762	456	14	relapse	relapse	NOUN
fnp-6762	456	15	activity	activity	NOUN
fnp-6762	456	16	with	with	ADP
fnp-6762	456	17	long	long	ADJ
fnp-6762	456	18	-	-	PUNCT
fnp-6762	456	19	term	term	NOUN
fnp-6762	456	20	disability	disability	NOUN
fnp-6762	456	21	after	after	ADP
fnp-6762	456	22	a	a	DET
fnp-6762	456	23	first	first	ADJ
fnp-6762	456	24	demyelinating	demyelinate	VERB
fnp-6762	456	25	event	event	NOUN
fnp-6762	456	26	in	in	ADP
fnp-6762	456	27	multiple	multiple	ADJ
fnp-6762	456	28	sclerosis	sclerosis	NOUN
fnp-6762	456	29	.	.	PUNCT
fnp-6762	457	1	jama	jama	PROPN
fnp-6762	457	2	neurol	neurol	PROPN
fnp-6762	457	3	(	(	PUNCT
fnp-6762	457	4	2022	2022	NUM
fnp-6762	457	5	)	)	PUNCT
fnp-6762	457	6	.	.	PUNCT
fnp-6762	458	1	https://doi.org/10.1001/jamaneurol.2022.4655	https://doi.org/10.1001/jamaneurol.2022.4655	NOUN
fnp-6762	458	2	69	69	NUM
fnp-6762	458	3	.	.	PUNCT
fnp-6762	459	1	portaccio	portaccio	PROPN
fnp-6762	459	2	,	,	PUNCT
fnp-6762	459	3	e.	e.	PROPN
fnp-6762	459	4	,	,	PUNCT
fnp-6762	459	5	et	et	PROPN
fnp-6762	459	6	al	al	PROPN
fnp-6762	459	7	.	.	PROPN
fnp-6762	459	8	progression	progression	NOUN
fnp-6762	459	9	is	be	AUX
fnp-6762	459	10	independent	independent	ADJ
fnp-6762	459	11	of	of	ADP
fnp-6762	459	12	relapse	relapse	NOUN
fnp-6762	459	13	activity	activity	NOUN
fnp-6762	459	14	in	in	ADP
fnp-6762	459	15	early	early	ADJ
fnp-6762	459	16	multiple	multiple	ADJ
fnp-6762	459	17	sclerosis	sclerosis	NOUN
fnp-6762	459	18	:	:	PUNCT
fnp-6762	459	19	a	a	DET
fnp-6762	459	20	real	real	ADJ
fnp-6762	459	21	-	-	PUNCT
fnp-6762	459	22	life	life	NOUN
fnp-6762	459	23	cohort	cohort	NOUN
fnp-6762	459	24	study	study	NOUN
fnp-6762	459	25	.	.	PUNCT
fnp-6762	460	1	brain	brain	NOUN
fnp-6762	460	2	145	145	NUM
fnp-6762	460	3	,	,	PUNCT
fnp-6762	460	4	2796	2796	NUM
fnp-6762	460	5	-	-	SYM
fnp-6762	460	6	2805	2805	NUM
fnp-6762	460	7	(	(	PUNCT
fnp-6762	460	8	2022	2022	NUM
fnp-6762	460	9	)	)	PUNCT
fnp-6762	460	10	.	.	PUNCT
fnp-6762	461	1	https://doi.org/10.1093/brain/awac111	https://doi.org/10.1093/brain/awac111	PROPN
fnp-6762	461	2	70	70	NUM
fnp-6762	461	3	.	.	PUNCT
fnp-6762	462	1	kramer	kramer	PROPN
fnp-6762	462	2	,	,	PUNCT
fnp-6762	462	3	j.	j.	PROPN
fnp-6762	462	4	,	,	PUNCT
fnp-6762	462	5	bar	bar	NOUN
fnp-6762	462	6	-	-	PUNCT
fnp-6762	462	7	or	or	CCONJ
fnp-6762	462	8	,	,	PUNCT
fnp-6762	462	9	a.	a.	PROPN
fnp-6762	462	10	,	,	PUNCT
fnp-6762	462	11	turner	turner	PROPN
fnp-6762	462	12	,	,	PUNCT
fnp-6762	462	13	t.j	t.j	PROPN
fnp-6762	462	14	.	.	PROPN
fnp-6762	462	15	&	&	CCONJ
fnp-6762	462	16	wiendl	wiendl	PROPN
fnp-6762	462	17	,	,	PUNCT
fnp-6762	462	18	h.	h.	PROPN
fnp-6762	462	19	bruton	bruton	PROPN
fnp-6762	462	20	tyrosine	tyrosine	PROPN
fnp-6762	462	21	kinase	kinase	PROPN
fnp-6762	462	22	inhibitors	inhibitor	NOUN
fnp-6762	462	23	for	for	ADP
fnp-6762	462	24	multiple	multiple	ADJ
fnp-6762	462	25	sclerosis	sclerosis	NOUN
fnp-6762	462	26	.	.	PUNCT
fnp-6762	463	1	nat	nat	PROPN
fnp-6762	463	2	rev	rev	VERB
fnp-6762	463	3	neurol	neurol	PROPN
fnp-6762	463	4	19	19	NUM
fnp-6762	463	5	,	,	PUNCT
fnp-6762	463	6	289	289	NUM
fnp-6762	463	7	-	-	SYM
fnp-6762	463	8	304	304	NUM
fnp-6762	463	9	(	(	PUNCT
fnp-6762	463	10	2023	2023	NUM
fnp-6762	463	11	)	)	PUNCT
fnp-6762	463	12	.	.	PUNCT
fnp-6762	464	1	https://doi.org/10.1038/s41582-023-00800-7	https://doi.org/10.1038/s41582-023-00800-7	NUM
fnp-6762	464	2	71	71	NUM
fnp-6762	464	3	.	.	PUNCT
fnp-6762	464	4	de	de	PROPN
fnp-6762	464	5	bondt	bondt	PROPN
fnp-6762	464	6	,	,	PUNCT
fnp-6762	464	7	m.	m.	NOUN
fnp-6762	464	8	,	,	PUNCT
fnp-6762	464	9	renders	render	VERB
fnp-6762	464	10	,	,	PUNCT
fnp-6762	464	11	j.	j.	PROPN
fnp-6762	464	12	,	,	PUNCT
fnp-6762	464	13	struyf	struyf	PROPN
fnp-6762	464	14	,	,	PUNCT
fnp-6762	464	15	s.	s.	PROPN
fnp-6762	464	16	&	&	CCONJ
fnp-6762	464	17	hellings	hellings	PROPN
fnp-6762	464	18	,	,	PUNCT
fnp-6762	464	19	n.	n.	NOUN
fnp-6762	464	20	inhibitors	inhibitor	NOUN
fnp-6762	464	21	of	of	ADP
fnp-6762	464	22	bruton	bruton	PROPN
fnp-6762	464	23	's	's	PART
fnp-6762	464	24	tyrosine	tyrosine	NOUN
fnp-6762	464	25	kinase	kinase	NOUN
fnp-6762	464	26	as	as	ADP
fnp-6762	464	27	emerging	emerge	VERB
fnp-6762	464	28	therapeutic	therapeutic	ADJ
fnp-6762	464	29	strategy	strategy	NOUN
fnp-6762	464	30	in	in	ADP
fnp-6762	464	31	autoimmune	autoimmune	ADJ
fnp-6762	464	32	diseases	disease	NOUN
fnp-6762	464	33	.	.	PUNCT
fnp-6762	465	1	autoimmun	autoimmun	PROPN
fnp-6762	465	2	rev	rev	VERB
fnp-6762	465	3	23	23	NUM
fnp-6762	465	4	,	,	PUNCT
fnp-6762	465	5	103532	103532	NUM
fnp-6762	465	6	(	(	PUNCT
fnp-6762	465	7	2024	2024	NUM
fnp-6762	465	8	)	)	PUNCT
fnp-6762	465	9	.	.	PUNCT
fnp-6762	466	1	https://doi.org/10.1016/j.autrev.2024.103532	https://doi.org/10.1016/j.autrev.2024.103532	NOUN
fnp-6762	466	2	72	72	NUM
fnp-6762	466	3	.	.	PUNCT
fnp-6762	466	4	montalban	montalban	PROPN
fnp-6762	466	5	,	,	PUNCT
fnp-6762	466	6	x.	x.	PROPN
fnp-6762	466	7	,	,	PUNCT
fnp-6762	466	8	et	et	PROPN
fnp-6762	466	9	al	al	PROPN
fnp-6762	466	10	.	.	PROPN
fnp-6762	466	11	safety	safety	NOUN
fnp-6762	466	12	and	and	CCONJ
fnp-6762	466	13	efficacy	efficacy	NOUN
fnp-6762	466	14	of	of	ADP
fnp-6762	466	15	evobrutinib	evobrutinib	NOUN
fnp-6762	466	16	in	in	ADP
fnp-6762	466	17	relapsing	relapse	VERB
fnp-6762	466	18	multiple	multiple	ADJ
fnp-6762	466	19	sclerosis	sclerosis	NOUN
fnp-6762	466	20	(	(	PUNCT
fnp-6762	466	21	evolutionrms1	evolutionrms1	NOUN
fnp-6762	466	22	and	and	CCONJ
fnp-6762	466	23	evolutionrms2	evolutionrms2	PROPN
fnp-6762	466	24	):	):	PUNCT
fnp-6762	466	25	two	two	NUM
fnp-6762	466	26	multicentre	multicentre	NOUN
fnp-6762	466	27	,	,	PUNCT
fnp-6762	466	28	randomised	randomise	VERB
fnp-6762	466	29	,	,	PUNCT
fnp-6762	466	30	double	double	ADJ
fnp-6762	466	31	-	-	PUNCT
fnp-6762	466	32	blind	blind	ADJ
fnp-6762	466	33	,	,	PUNCT
fnp-6762	466	34	active	active	ADJ
fnp-6762	466	35	-	-	PUNCT
fnp-6762	466	36	controlled	control	VERB
fnp-6762	466	37	,	,	PUNCT
fnp-6762	466	38	phase	phase	NOUN
fnp-6762	466	39	3	3	NUM
fnp-6762	466	40	trials	trial	NOUN
fnp-6762	466	41	.	.	PUNCT
fnp-6762	467	1	lancet	lancet	PROPN
fnp-6762	467	2	neurol	neurol	PROPN
fnp-6762	467	3	23	23	NUM
fnp-6762	467	4	,	,	PUNCT
fnp-6762	467	5	1119	1119	NUM
fnp-6762	467	6	-	-	SYM
fnp-6762	467	7	1132	1132	NUM
fnp-6762	467	8	(	(	PUNCT
fnp-6762	467	9	2024	2024	NUM
fnp-6762	467	10	)	)	PUNCT
fnp-6762	467	11	.	.	PUNCT
fnp-6762	468	1	https://doi.org/10.1016/s1474-4422(24)00328-4	https://doi.org/10.1016/s1474-4422(24)00328-4	PROPN
fnp-6762	468	2	73	73	NUM
fnp-6762	468	3	.	.	PUNCT
fnp-6762	469	1	fox	fox	PROPN
fnp-6762	469	2	,	,	PUNCT
fnp-6762	469	3	r.j	r.j	PROPN
fnp-6762	469	4	.	.	PROPN
fnp-6762	469	5	,	,	PUNCT
fnp-6762	469	6	et	et	PROPN
fnp-6762	469	7	al	al	PROPN
fnp-6762	469	8	.	.	PROPN
fnp-6762	469	9	tolebrutinib	tolebrutinib	PROPN
fnp-6762	469	10	in	in	ADP
fnp-6762	469	11	nonrelapsing	nonrelapse	VERB
fnp-6762	469	12	secondary	secondary	ADJ
fnp-6762	469	13	progressive	progressive	ADJ
fnp-6762	469	14	multiple	multiple	ADJ
fnp-6762	469	15	sclerosis	sclerosis	NOUN
fnp-6762	469	16	.	.	PUNCT
fnp-6762	470	1	n	n	PROPN
fnp-6762	470	2	engl	engl	PROPN
fnp-6762	470	3	j	j	PROPN
fnp-6762	470	4	med	med	PROPN
fnp-6762	470	5	392	392	NUM
fnp-6762	470	6	,	,	PUNCT
fnp-6762	470	7	1883	1883	NUM
fnp-6762	470	8	-	-	SYM
fnp-6762	470	9	1892	1892	NUM
fnp-6762	470	10	(	(	PUNCT
fnp-6762	470	11	2025	2025	NUM
fnp-6762	470	12	)	)	PUNCT
fnp-6762	470	13	.	.	PUNCT
fnp-6762	471	1	https://doi.org/10.1056/nejmoa2415988	https://doi.org/10.1056/nejmoa2415988	PROPN
fnp-6762	471	2	74	74	NUM
fnp-6762	471	3	.	.	PUNCT
fnp-6762	472	1	oh	oh	INTJ
fnp-6762	472	2	,	,	PUNCT
fnp-6762	472	3	j.	j.	PROPN
fnp-6762	472	4	,	,	PUNCT
fnp-6762	472	5	et	et	PROPN
fnp-6762	472	6	al	al	PROPN
fnp-6762	472	7	.	.	PROPN
fnp-6762	472	8	tolebrutinib	tolebrutinib	NOUN
fnp-6762	472	9	versus	versus	ADP
fnp-6762	472	10	teriflunomide	teriflunomide	ADV
fnp-6762	472	11	in	in	ADP
fnp-6762	472	12	relapsing	relapse	VERB
fnp-6762	472	13	multiple	multiple	ADJ
fnp-6762	472	14	sclerosis	sclerosis	NOUN
fnp-6762	472	15	.	.	PUNCT
fnp-6762	473	1	n	n	PROPN
fnp-6762	473	2	engl	engl	PROPN
fnp-6762	473	3	j	j	PROPN
fnp-6762	473	4	med	med	PROPN
fnp-6762	473	5	392	392	NUM
fnp-6762	473	6	,	,	PUNCT
fnp-6762	473	7	1893	1893	NUM
fnp-6762	473	8	-	-	SYM
fnp-6762	473	9	1904	1904	NUM
fnp-6762	473	10	(	(	PUNCT
fnp-6762	473	11	2025	2025	NUM
fnp-6762	473	12	)	)	PUNCT
fnp-6762	473	13	.	.	PUNCT
fnp-6762	474	1	https://doi.org/10.1056/nejmoa2415985	https://doi.org/10.1056/nejmoa2415985	X
fnp-6762	474	2	75	75	NUM
fnp-6762	474	3	.	.	PUNCT
fnp-6762	475	1	oh	oh	INTJ
fnp-6762	475	2	,	,	PUNCT
fnp-6762	475	3	j.	j.	PROPN
fnp-6762	475	4	,	,	PUNCT
fnp-6762	475	5	et	et	PROPN
fnp-6762	475	6	al	al	PROPN
fnp-6762	475	7	.	.	PUNCT
fnp-6762	476	1	paramagnetic	paramagnetic	ADJ
fnp-6762	476	2	rim	rim	PROPN
fnp-6762	476	3	lesions	lesion	NOUN
fnp-6762	476	4	as	as	ADP
fnp-6762	476	5	a	a	DET
fnp-6762	476	6	prognostic	prognostic	ADJ
fnp-6762	476	7	and	and	CCONJ
fnp-6762	476	8	predictive	predictive	ADJ
fnp-6762	476	9	biomarker	biomarker	NOUN
fnp-6762	476	10	in	in	ADP
fnp-6762	476	11	the	the	DET
fnp-6762	476	12	tolebrutinib	tolebrutinib	NOUN
fnp-6762	476	13	phase	phase	NOUN
fnp-6762	476	14	3	3	NUM
fnp-6762	476	15	trials	trial	NOUN
fnp-6762	476	16	for	for	ADP
fnp-6762	476	17	disability	disability	NOUN
fnp-6762	476	18	outcomes	outcome	NOUN
fnp-6762	476	19	.	.	PUNCT
fnp-6762	477	1	actrims	actrims	ADP
fnp-6762	477	2	forum	forum	NOUN
fnp-6762	477	3	2025	2025	NUM
fnp-6762	477	4	platform	platform	NOUN
fnp-6762	477	5	and	and	CCONJ
fnp-6762	477	6	invited	invite	VERB
fnp-6762	477	7	.	.	PUNCT
fnp-6762	478	1	multiple	multiple	ADJ
fnp-6762	478	2	sclerosis	sclerosis	NOUN
fnp-6762	478	3	journal	journal	NOUN
fnp-6762	478	4	.	.	PUNCT
fnp-6762	479	1	31	31	NUM
fnp-6762	479	2	,	,	PUNCT
fnp-6762	479	3	3	3	NUM
fnp-6762	479	4	-	-	SYM
fnp-6762	479	5	23	23	NUM
fnp-6762	479	6	(	(	PUNCT
fnp-6762	479	7	2025	2025	NUM
fnp-6762	479	8	)	)	PUNCT
fnp-6762	479	9	.	.	PUNCT
fnp-6762	480	1	https://doi.org/10.1177/1352458525133322	https://doi.org/10.1177/1352458525133322	PROPN
fnp-6762	481	1	76	76	NUM
fnp-6762	481	2	.	.	PUNCT
fnp-6762	482	1	mougiakakos	mougiakakos	PROPN
fnp-6762	482	2	,	,	PUNCT
fnp-6762	482	3	d.	d.	PROPN
fnp-6762	482	4	,	,	PUNCT
fnp-6762	482	5	meyer	meyer	PROPN
fnp-6762	482	6	,	,	PUNCT
fnp-6762	482	7	e.	e.	PROPN
fnp-6762	482	8	&	&	CCONJ
fnp-6762	482	9	schett	schett	PROPN
fnp-6762	482	10	,	,	PUNCT
fnp-6762	482	11	g.	g.	PROPN
fnp-6762	482	12	car	car	PROPN
fnp-6762	482	13	t	t	PROPN
fnp-6762	482	14	-	-	PUNCT
fnp-6762	482	15	cells	cell	NOUN
fnp-6762	482	16	in	in	ADP
fnp-6762	482	17	autoimmunity	autoimmunity	NOUN
fnp-6762	482	18	:	:	PUNCT
fnp-6762	482	19	game	game	NOUN
fnp-6762	482	20	changer	changer	NOUN
fnp-6762	482	21	or	or	CCONJ
fnp-6762	482	22	stepping	stepping	ADJ
fnp-6762	482	23	stone	stone	NOUN
fnp-6762	482	24	?	?	PUNCT
fnp-6762	483	1	blood	blood	NOUN
fnp-6762	483	2	(	(	PUNCT
fnp-6762	483	3	2024	2024	NUM
fnp-6762	483	4	)	)	PUNCT
fnp-6762	483	5	.	.	PUNCT
fnp-6762	484	1	https://doi.org/10.1182/blood.2024025413	https://doi.org/10.1182/blood.2024025413	ADJ
fnp-6762	484	2	77	77	NUM
fnp-6762	484	3	.	.	PUNCT
fnp-6762	485	1	ransohoff	ransohoff	PROPN
fnp-6762	485	2	,	,	PUNCT
fnp-6762	485	3	r.m	r.m	PROPN
fnp-6762	485	4	.	.	PROPN
fnp-6762	485	5	selected	select	VERB
fnp-6762	485	6	aspects	aspect	NOUN
fnp-6762	485	7	of	of	ADP
fnp-6762	485	8	the	the	DET
fnp-6762	485	9	neuroimmunology	neuroimmunology	NOUN
fnp-6762	485	10	of	of	ADP
fnp-6762	485	11	cell	cell	NOUN
fnp-6762	485	12	therapies	therapy	NOUN
fnp-6762	485	13	for	for	ADP
fnp-6762	485	14	neurologic	neurologic	ADJ
fnp-6762	485	15	disease	disease	NOUN
fnp-6762	485	16	:	:	PUNCT
fnp-6762	485	17	perspective	perspective	NOUN
fnp-6762	485	18	.	.	PUNCT
fnp-6762	486	1	neurol	neurol	PROPN
fnp-6762	486	2	neuroimmunol	neuroimmunol	PROPN
fnp-6762	486	3	neuroinflamm	neuroinflamm	PROPN
fnp-6762	486	4	12	12	NUM
fnp-6762	486	5	,	,	PUNCT
fnp-6762	486	6	e200352	e200352	PROPN
fnp-6762	486	7	(	(	PUNCT
fnp-6762	486	8	2025	2025	NUM
fnp-6762	486	9	)	)	PUNCT
fnp-6762	486	10	.	.	PUNCT
fnp-6762	487	1	https://doi.org/10.1212/nxi.0000000000200352	https://doi.org/10.1212/nxi.0000000000200352	NOUN
fnp-6762	487	2	78	78	NUM
fnp-6762	487	3	.	.	PUNCT
fnp-6762	488	1	mougiakakos	mougiakakos	PROPN
fnp-6762	488	2	,	,	PUNCT
fnp-6762	488	3	d.	d.	PROPN
fnp-6762	488	4	,	,	PUNCT
fnp-6762	488	5	et	et	PROPN
fnp-6762	488	6	al	al	PROPN
fnp-6762	488	7	.	.	PUNCT
fnp-6762	489	1	successful	successful	ADJ
fnp-6762	489	2	generation	generation	NOUN
fnp-6762	489	3	of	of	ADP
fnp-6762	489	4	fully	fully	ADV
fnp-6762	489	5	human	human	ADJ
fnp-6762	489	6	,	,	PUNCT
fnp-6762	489	7	second	second	ADJ
fnp-6762	489	8	generation	generation	NOUN
fnp-6762	489	9	,	,	PUNCT
fnp-6762	489	10	anti	anti	ADJ
fnp-6762	489	11	-	-	ADJ
fnp-6762	489	12	cd19	cd19	ADJ
fnp-6762	489	13	car	car	NOUN
fnp-6762	489	14	t	t	NOUN
fnp-6762	489	15	cells	cell	NOUN
fnp-6762	489	16	for	for	ADP
fnp-6762	489	17	clinical	clinical	ADJ
fnp-6762	489	18	use	use	NOUN
fnp-6762	489	19	in	in	ADP
fnp-6762	489	20	patients	patient	NOUN
fnp-6762	489	21	with	with	ADP
fnp-6762	489	22	diverse	diverse	ADJ
fnp-6762	489	23	autoimmune	autoimmune	ADJ
fnp-6762	489	24	disorders	disorder	NOUN
fnp-6762	489	25	.	.	PUNCT
fnp-6762	490	1	cytotherapy	cytotherapy	NOUN
fnp-6762	490	2	27	27	NUM
fnp-6762	490	3	,	,	PUNCT
fnp-6762	490	4	236	236	NUM
fnp-6762	490	5	-	-	SYM
fnp-6762	490	6	246	246	NUM
fnp-6762	490	7	(	(	PUNCT
fnp-6762	490	8	2025	2025	NUM
fnp-6762	490	9	)	)	PUNCT
fnp-6762	490	10	.	.	PUNCT
fnp-6762	491	1	https://doi.org/10.1016/j.jcyt.2024.09.008	https://doi.org/10.1016/j.jcyt.2024.09.008	NOUN
fnp-6762	491	2	79	79	NUM
fnp-6762	491	3	.	.	PUNCT
fnp-6762	492	1	tur	tur	INTJ
fnp-6762	492	2	,	,	PUNCT
fnp-6762	492	3	c.	c.	PROPN
fnp-6762	492	4	,	,	PUNCT
fnp-6762	492	5	et	et	PROPN
fnp-6762	492	6	al	al	PROPN
fnp-6762	492	7	.	.	PUNCT
fnp-6762	493	1	cd19	cd19	PROPN
fnp-6762	493	2	-	-	PUNCT
fnp-6762	493	3	car	car	NOUN
fnp-6762	493	4	t	t	NOUN
fnp-6762	493	5	-	-	PUNCT
fnp-6762	493	6	cell	cell	NOUN
fnp-6762	493	7	therapy	therapy	NOUN
fnp-6762	493	8	induces	induce	VERB
fnp-6762	493	9	deep	deep	ADJ
fnp-6762	493	10	tissue	tissue	NOUN
fnp-6762	493	11	depletion	depletion	NOUN
fnp-6762	493	12	of	of	ADP
fnp-6762	493	13	b	b	NOUN
fnp-6762	493	14	cells	cell	NOUN
fnp-6762	493	15	.	.	PUNCT
fnp-6762	494	1	ann	ann	PROPN
fnp-6762	494	2	rheum	rheum	PROPN
fnp-6762	494	3	dis	dis	PROPN
fnp-6762	494	4	84	84	NUM
fnp-6762	494	5	,	,	PUNCT
fnp-6762	494	6	106	106	NUM
fnp-6762	494	7	-	-	SYM
fnp-6762	494	8	114	114	NUM
fnp-6762	494	9	(	(	PUNCT
fnp-6762	494	10	2025	2025	NUM
fnp-6762	494	11	)	)	PUNCT
fnp-6762	494	12	.	.	PUNCT
fnp-6762	495	1	https://doi.org/10.1136/ard-2024-226142	https://doi.org/10.1136/ard-2024-226142	NOUN
fnp-6762	495	2	80	80	NUM
fnp-6762	495	3	.	.	PUNCT
fnp-6762	496	1	faissner	faissner	PROPN
fnp-6762	496	2	,	,	PUNCT
fnp-6762	496	3	s.	s.	PROPN
fnp-6762	496	4	,	,	PUNCT
fnp-6762	496	5	et	et	PROPN
fnp-6762	496	6	al	al	PROPN
fnp-6762	496	7	.	.	PROPN
fnp-6762	497	1	successful	successful	ADJ
fnp-6762	497	2	use	use	NOUN
fnp-6762	497	3	of	of	ADP
fnp-6762	497	4	anti	anti	ADJ
fnp-6762	497	5	-	-	ADJ
fnp-6762	497	6	cd19	cd19	ADJ
fnp-6762	497	7	car	car	NOUN
fnp-6762	497	8	t	t	NOUN
fnp-6762	497	9	cells	cell	NOUN
fnp-6762	497	10	in	in	ADP
fnp-6762	497	11	severe	severe	ADJ
fnp-6762	497	12	treatment	treatment	NOUN
fnp-6762	497	13	-	-	PUNCT
fnp-6762	497	14	refractory	refractory	NOUN
fnp-6762	497	15	stiff	stiff	ADJ
fnp-6762	497	16	-	-	PUNCT
fnp-6762	497	17	person	person	NOUN
fnp-6762	497	18	syndrome	syndrome	NOUN
fnp-6762	497	19	.	.	PUNCT
fnp-6762	498	1	proc	proc	PROPN
fnp-6762	498	2	natl	natl	PROPN
fnp-6762	498	3	acad	acad	PROPN
fnp-6762	498	4	sci	sci	PROPN
fnp-6762	498	5	u	u	PROPN
fnp-6762	498	6	s	s	PROPN
fnp-6762	498	7	a	a	DET
fnp-6762	498	8	121	121	NUM
fnp-6762	498	9	,	,	PUNCT
fnp-6762	498	10	e2403227121	e2403227121	NUM
fnp-6762	498	11	(	(	PUNCT
fnp-6762	498	12	2024	2024	NUM
fnp-6762	498	13	)	)	PUNCT
fnp-6762	498	14	.	.	PUNCT
fnp-6762	499	1	https://doi.org/10.1073/pnas.2403227121	https://doi.org/10.1073/pnas.2403227121	PUNCT
fnp-6762	499	2	81	81	NUM
fnp-6762	499	3	.	.	PUNCT
fnp-6762	500	1	haghikia	haghikia	NOUN
fnp-6762	500	2	,	,	PUNCT
fnp-6762	500	3	a.	a.	NOUN
fnp-6762	500	4	,	,	PUNCT
fnp-6762	500	5	et	et	PROPN
fnp-6762	500	6	al	al	PROPN
fnp-6762	500	7	.	.	PUNCT
fnp-6762	501	1	anti	anti	ADJ
fnp-6762	501	2	-	-	ADJ
fnp-6762	501	3	cd19	cd19	PROPN
fnp-6762	501	4	car	car	NOUN
fnp-6762	501	5	t	t	NOUN
fnp-6762	501	6	cells	cell	NOUN
fnp-6762	501	7	for	for	ADP
fnp-6762	501	8	refractory	refractory	NOUN
fnp-6762	501	9	myasthenia	myasthenia	NOUN
fnp-6762	501	10	gravis	gravis	PROPN
fnp-6762	501	11	.	.	PUNCT
fnp-6762	502	1	lancet	lancet	PROPN
fnp-6762	502	2	neurol	neurol	PROPN
fnp-6762	502	3	22	22	NUM
fnp-6762	502	4	,	,	PUNCT
fnp-6762	502	5	1104	1104	NUM
fnp-6762	502	6	-	-	SYM
fnp-6762	502	7	1105	1105	NUM
fnp-6762	502	8	(	(	PUNCT
fnp-6762	502	9	2023	2023	NUM
fnp-6762	502	10	)	)	PUNCT
fnp-6762	502	11	.	.	PUNCT
fnp-6762	503	1	https://doi.org/10.1016/s1474-4422(23)00375-7	https://doi.org/10.1016/s1474-4422(23)00375-7	PROPN
fnp-6762	503	2	82	82	NUM
fnp-6762	503	3	.	.	PUNCT
fnp-6762	504	1	fischbach	fischbach	PROPN
fnp-6762	504	2	,	,	PUNCT
fnp-6762	504	3	f.	f.	PROPN
fnp-6762	504	4	,	,	PUNCT
fnp-6762	504	5	et	et	PROPN
fnp-6762	504	6	al	al	PROPN
fnp-6762	504	7	.	.	PUNCT
fnp-6762	505	1	cd19	cd19	PROPN
fnp-6762	505	2	-	-	PUNCT
fnp-6762	505	3	targeted	target	VERB
fnp-6762	505	4	chimeric	chimeric	ADJ
fnp-6762	505	5	antigen	antigen	ADJ
fnp-6762	505	6	receptor	receptor	NOUN
fnp-6762	505	7	t	t	NOUN
fnp-6762	505	8	cell	cell	NOUN
fnp-6762	505	9	therapy	therapy	NOUN
fnp-6762	505	10	in	in	ADP
fnp-6762	505	11	two	two	NUM
fnp-6762	505	12	patients	patient	NOUN
fnp-6762	505	13	with	with	ADP
fnp-6762	505	14	multiple	multiple	ADJ
fnp-6762	505	15	sclerosis	sclerosis	NOUN
fnp-6762	505	16	.	.	PUNCT
fnp-6762	506	1	med	med	PROPN
fnp-6762	506	2	5	5	NUM
fnp-6762	506	3	,	,	PUNCT
fnp-6762	506	4	550	550	NUM
fnp-6762	506	5	-	-	SYM
fnp-6762	506	6	558	558	NUM
fnp-6762	506	7	e552	e552	NUM
fnp-6762	506	8	(	(	PUNCT
fnp-6762	506	9	2024	2024	NUM
fnp-6762	506	10	)	)	PUNCT
fnp-6762	506	11	.	.	PUNCT
fnp-6762	507	1	https://doi.org/10.1016/j.medj.2024.03.002	https://doi.org/10.1016/j.medj.2024.03.002	DET
fnp-6762	507	2	83	83	NUM
fnp-6762	507	3	.	.	PUNCT
fnp-6762	508	1	jakel	jakel	PROPN
fnp-6762	508	2	,	,	PUNCT
fnp-6762	508	3	s.	s.	PROPN
fnp-6762	508	4	,	,	PUNCT
fnp-6762	508	5	et	et	PROPN
fnp-6762	508	6	al	al	PROPN
fnp-6762	508	7	.	.	PROPN
fnp-6762	508	8	altered	alter	VERB
fnp-6762	508	9	human	human	ADJ
fnp-6762	508	10	oligodendrocyte	oligodendrocyte	PROPN
fnp-6762	508	11	heterogeneity	heterogeneity	NOUN
fnp-6762	508	12	in	in	ADP
fnp-6762	508	13	multiple	multiple	ADJ
fnp-6762	508	14	sclerosis	sclerosis	NOUN
fnp-6762	508	15	.	.	PUNCT
fnp-6762	509	1	nature	nature	NOUN
fnp-6762	509	2	566	566	NUM
fnp-6762	509	3	,	,	PUNCT
fnp-6762	509	4	543	543	NUM
fnp-6762	509	5	-	-	SYM
fnp-6762	509	6	547	547	NUM
fnp-6762	509	7	(	(	PUNCT
fnp-6762	509	8	2019	2019	NUM
fnp-6762	509	9	)	)	PUNCT
fnp-6762	509	10	.	.	PUNCT
fnp-6762	510	1	https://doi.org/10.1038/s41586-019-0903-2	https://doi.org/10.1038/s41586-019-0903-2	NOUN
fnp-6762	511	1	84	84	NUM
fnp-6762	511	2	.	.	PUNCT
fnp-6762	512	1	kirby	kirby	PROPN
fnp-6762	512	2	,	,	PUNCT
fnp-6762	512	3	l.	l.	PROPN
fnp-6762	512	4	,	,	PUNCT
fnp-6762	512	5	et	et	PROPN
fnp-6762	512	6	al	al	PROPN
fnp-6762	512	7	.	.	PROPN
fnp-6762	512	8	oligodendrocyte	oligodendrocyte	ADJ
fnp-6762	512	9	precursor	precursor	NOUN
fnp-6762	512	10	cells	cell	NOUN
fnp-6762	512	11	present	present	VERB
fnp-6762	512	12	antigen	antigen	ADV
fnp-6762	512	13	and	and	CCONJ
fnp-6762	512	14	are	be	AUX
fnp-6762	512	15	cytotoxic	cytotoxic	ADJ
fnp-6762	512	16	targets	target	NOUN
fnp-6762	512	17	in	in	ADP
fnp-6762	512	18	inflammatory	inflammatory	ADJ
fnp-6762	512	19	demyelination	demyelination	NOUN
fnp-6762	512	20	.	.	PUNCT
fnp-6762	513	1	nat	nat	PROPN
fnp-6762	513	2	commun	commun	PROPN
fnp-6762	513	3	10	10	NUM
fnp-6762	513	4	,	,	PUNCT
fnp-6762	513	5	3887	3887	NUM
fnp-6762	513	6	(	(	PUNCT
fnp-6762	513	7	2019	2019	NUM
fnp-6762	513	8	)	)	PUNCT
fnp-6762	513	9	.	.	PUNCT
fnp-6762	514	1	https://doi.org/10.1038/s41467-019-11638-3	https://doi.org/10.1038/s41467-019-11638-3	NUM
fnp-6762	514	2	85	85	NUM
fnp-6762	514	3	.	.	PUNCT
fnp-6762	514	4	di	di	PROPN
fnp-6762	514	5	liberto	liberto	PROPN
fnp-6762	514	6	,	,	PUNCT
fnp-6762	514	7	g.	g.	PROPN
fnp-6762	514	8	,	,	PUNCT
fnp-6762	514	9	et	et	PROPN
fnp-6762	514	10	al	al	PROPN
fnp-6762	514	11	.	.	PUNCT
fnp-6762	514	12	neurons	neuron	NOUN
fnp-6762	514	13	under	under	ADP
fnp-6762	514	14	t	t	PROPN
fnp-6762	514	15	cell	cell	NOUN
fnp-6762	514	16	attack	attack	NOUN
fnp-6762	514	17	coordinate	coordinate	NOUN
fnp-6762	514	18	phagocyte	phagocyte	NOUN
fnp-6762	514	19	-	-	PUNCT
fnp-6762	514	20	mediated	mediate	VERB
fnp-6762	514	21	synaptic	synaptic	ADJ
fnp-6762	514	22	stripping	stripping	NOUN
fnp-6762	514	23	.	.	PUNCT
fnp-6762	515	1	cell	cell	NOUN
fnp-6762	515	2	175	175	NUM
fnp-6762	515	3	,	,	PUNCT
fnp-6762	515	4	458	458	NUM
fnp-6762	515	5	-	-	SYM
fnp-6762	515	6	471	471	NUM
fnp-6762	515	7	e419	e419	PROPN
fnp-6762	515	8	(	(	PUNCT
fnp-6762	515	9	2018	2018	NUM
fnp-6762	515	10	)	)	PUNCT
fnp-6762	515	11	.	.	PUNCT
fnp-6762	516	1	https://doi.org/10.1016/j.cell.2018.07.049	https://doi.org/10.1016/j.cell.2018.07.049	PROPN
fnp-6762	516	2	86	86	NUM
fnp-6762	516	3	.	.	PUNCT
fnp-6762	517	1	andreadou	andreadou	NOUN
fnp-6762	517	2	,	,	PUNCT
fnp-6762	517	3	m.	m.	NOUN
fnp-6762	517	4	,	,	PUNCT
fnp-6762	517	5	et	et	PROPN
fnp-6762	517	6	al	al	PROPN
fnp-6762	517	7	.	.	PROPN
fnp-6762	518	1	il-12	il-12	VERB
fnp-6762	518	2	sensing	sense	VERB
fnp-6762	518	3	in	in	ADP
fnp-6762	518	4	neurons	neuron	NOUN
fnp-6762	518	5	induces	induce	VERB
fnp-6762	518	6	neuroprotective	neuroprotective	ADJ
fnp-6762	518	7	cns	cns	NOUN
fnp-6762	518	8	tissue	tissue	NOUN
fnp-6762	518	9	adaptation	adaptation	NOUN
fnp-6762	518	10	and	and	CCONJ
fnp-6762	518	11	attenuates	attenuate	VERB
fnp-6762	518	12	neuroinflammation	neuroinflammation	NOUN
fnp-6762	518	13	in	in	ADP
fnp-6762	518	14	mice	mouse	NOUN
fnp-6762	518	15	.	.	PUNCT
fnp-6762	519	1	nat	nat	PROPN
fnp-6762	519	2	neurosci	neurosci	PROPN
fnp-6762	519	3	26	26	NUM
fnp-6762	519	4	,	,	PUNCT
fnp-6762	519	5	1701	1701	NUM
fnp-6762	519	6	-	-	SYM
fnp-6762	519	7	1712	1712	NUM
fnp-6762	519	8	(	(	PUNCT
fnp-6762	519	9	2023	2023	NUM
fnp-6762	519	10	)	)	PUNCT
fnp-6762	519	11	.	.	PUNCT
fnp-6762	520	1	https://doi.org/10.1038/s41593-023-01435-z	https://doi.org/10.1038/s41593-023-01435-z	VERB
fnp-6762	520	2	87	87	NUM
fnp-6762	520	3	.	.	PUNCT
fnp-6762	521	1	alves	alves	PROPN
fnp-6762	521	2	de	de	X
fnp-6762	521	3	lima	lima	PROPN
fnp-6762	521	4	,	,	PUNCT
fnp-6762	521	5	k.	k.	PROPN
fnp-6762	521	6	,	,	PUNCT
fnp-6762	521	7	et	et	PROPN
fnp-6762	521	8	al	al	PROPN
fnp-6762	521	9	.	.	PROPN
fnp-6762	522	1	meningeal	meningeal	PROPN
fnp-6762	522	2	gammadelta	gammadelta	PROPN
fnp-6762	522	3	t	t	PROPN
fnp-6762	522	4	cells	cell	NOUN
fnp-6762	522	5	regulate	regulate	VERB
fnp-6762	522	6	anxiety	anxiety	NOUN
fnp-6762	522	7	-	-	PUNCT
fnp-6762	522	8	like	like	ADJ
fnp-6762	522	9	behavior	behavior	NOUN
fnp-6762	522	10	via	via	ADP
fnp-6762	522	11	il-17a	il-17a	PROPN
fnp-6762	522	12	signaling	signal	VERB
fnp-6762	522	13	in	in	ADP
fnp-6762	522	14	neurons	neuron	NOUN
fnp-6762	522	15	.	.	PUNCT
fnp-6762	523	1	nat	nat	PROPN
fnp-6762	523	2	immunol	immunol	NOUN
fnp-6762	523	3	21	21	NUM
fnp-6762	523	4	,	,	PUNCT
fnp-6762	523	5	1421	1421	NUM
fnp-6762	523	6	-	-	SYM
fnp-6762	523	7	1429	1429	NUM
fnp-6762	523	8	(	(	PUNCT
fnp-6762	523	9	2020	2020	NUM
fnp-6762	523	10	)	)	PUNCT
fnp-6762	523	11	.	.	PUNCT
fnp-6762	524	1	https://doi.org/10.1038/s41590-020-0776-4	https://doi.org/10.1038/s41590-020-0776-4	NUM
fnp-6762	524	2	88	88	NUM
fnp-6762	524	3	.	.	PUNCT
fnp-6762	525	1	woo	woo	PROPN
fnp-6762	525	2	,	,	PUNCT
fnp-6762	525	3	m.s	m.s	PROPN
fnp-6762	525	4	.	.	PROPN
fnp-6762	525	5	,	,	PUNCT
fnp-6762	525	6	et	et	PROPN
fnp-6762	525	7	al	al	PROPN
fnp-6762	525	8	.	.	PROPN
fnp-6762	525	9	sting	sting	PROPN
fnp-6762	525	10	orchestrates	orchestrate	VERB
fnp-6762	525	11	the	the	DET
fnp-6762	525	12	neuronal	neuronal	ADJ
fnp-6762	525	13	inflammatory	inflammatory	ADJ
fnp-6762	525	14	stress	stress	NOUN
fnp-6762	525	15	response	response	NOUN
fnp-6762	525	16	in	in	ADP
fnp-6762	525	17	multiple	multiple	ADJ
fnp-6762	525	18	sclerosis	sclerosis	NOUN
fnp-6762	525	19	.	.	PUNCT
fnp-6762	526	1	cell	cell	NOUN
fnp-6762	526	2	187	187	NUM
fnp-6762	526	3	,	,	PUNCT
fnp-6762	526	4	4043	4043	NUM
fnp-6762	526	5	-	-	SYM
fnp-6762	526	6	4060	4060	NUM
fnp-6762	526	7	e4030	e4030	PROPN
fnp-6762	526	8	(	(	PUNCT
fnp-6762	526	9	2024	2024	NUM
fnp-6762	526	10	)	)	PUNCT
fnp-6762	526	11	.	.	PUNCT
fnp-6762	527	1	https://doi.org/10.1016/j.cell.2024.05.031	https://doi.org/10.1016/j.cell.2024.05.031	NOUN
fnp-6762	527	2	89	89	NUM
fnp-6762	527	3	.	.	PUNCT
fnp-6762	528	1	klotz	klotz	PROPN
fnp-6762	528	2	,	,	PUNCT
fnp-6762	528	3	l.	l.	PROPN
fnp-6762	528	4	,	,	PUNCT
fnp-6762	528	5	antel	antel	PROPN
fnp-6762	528	6	,	,	PUNCT
fnp-6762	528	7	j.	j.	PROPN
fnp-6762	528	8	&	&	CCONJ
fnp-6762	528	9	kuhlmann	kuhlmann	PROPN
fnp-6762	528	10	,	,	PUNCT
fnp-6762	528	11	t.	t.	NOUN
fnp-6762	528	12	inflammation	inflammation	NOUN
fnp-6762	528	13	in	in	ADP
fnp-6762	528	14	multiple	multiple	ADJ
fnp-6762	528	15	sclerosis	sclerosis	NOUN
fnp-6762	528	16	:	:	PUNCT
fnp-6762	528	17	consequences	consequence	NOUN
fnp-6762	528	18	for	for	ADP
fnp-6762	528	19	remyelination	remyelination	NOUN
fnp-6762	528	20	and	and	CCONJ
fnp-6762	528	21	disease	disease	NOUN
fnp-6762	528	22	progression	progression	NOUN
fnp-6762	528	23	.	.	PUNCT
fnp-6762	529	1	nat	nat	PROPN
fnp-6762	529	2	rev	rev	VERB
fnp-6762	529	3	neurol	neurol	PROPN
fnp-6762	529	4	19	19	NUM
fnp-6762	529	5	,	,	PUNCT
fnp-6762	529	6	305	305	NUM
fnp-6762	529	7	-	-	SYM
fnp-6762	529	8	320	320	NUM
fnp-6762	529	9	(	(	PUNCT
fnp-6762	529	10	2023	2023	NUM
fnp-6762	529	11	)	)	PUNCT
fnp-6762	529	12	.	.	PUNCT
fnp-6762	530	1	https://doi.org/10.1038/s41582-023-00801-6	https://doi.org/10.1038/s41582-023-00801-6	NUM
fnp-6762	531	1	90	90	NUM
fnp-6762	531	2	.	.	PUNCT
fnp-6762	532	1	liu	liu	PROPN
fnp-6762	532	2	,	,	PUNCT
fnp-6762	532	3	x.	x.	PROPN
fnp-6762	532	4	,	,	PUNCT
fnp-6762	532	5	et	et	PROPN
fnp-6762	532	6	al	al	PROPN
fnp-6762	532	7	.	.	PUNCT
fnp-6762	532	8	small	small	ADJ
fnp-6762	532	9	-	-	PUNCT
fnp-6762	532	10	molecule	molecule	NOUN
fnp-6762	532	11	-	-	PUNCT
fnp-6762	532	12	induced	induce	VERB
fnp-6762	532	13	epigenetic	epigenetic	ADJ
fnp-6762	532	14	rejuvenation	rejuvenation	NOUN
fnp-6762	532	15	promotes	promote	VERB
fnp-6762	532	16	srebp	srebp	ADJ
fnp-6762	532	17	condensation	condensation	NOUN
fnp-6762	532	18	and	and	CCONJ
fnp-6762	532	19	overcomes	overcome	VERB
fnp-6762	532	20	barriers	barrier	NOUN
fnp-6762	532	21	to	to	ADP
fnp-6762	532	22	cns	cns	VERB
fnp-6762	532	23	myelin	myelin	ADJ
fnp-6762	532	24	regeneration	regeneration	NOUN
fnp-6762	532	25	.	.	PUNCT
fnp-6762	533	1	cell	cell	NOUN
fnp-6762	533	2	187	187	NUM
fnp-6762	533	3	,	,	PUNCT
fnp-6762	533	4	2465	2465	NUM
fnp-6762	533	5	-	-	SYM
fnp-6762	533	6	2484	2484	NUM
fnp-6762	533	7	e2422	e2422	PROPN
fnp-6762	533	8	(	(	PUNCT
fnp-6762	533	9	2024	2024	NUM
fnp-6762	533	10	)	)	PUNCT
fnp-6762	533	11	.	.	PUNCT
fnp-6762	534	1	https://doi.org/10.1016/j.cell.2024.04.005	https://doi.org/10.1016/j.cell.2024.04.005	VERB
fnp-6762	534	2	copyright	copyright	NOUN
fnp-6762	534	3	:	:	PUNCT
fnp-6762	534	4	©	©	PROPN
fnp-6762	534	5	2025	2025	NUM
fnp-6762	534	6	the	the	DET
fnp-6762	534	7	author(s	author(s	NOUN
fnp-6762	534	8	)	)	PUNCT
fnp-6762	534	9	.	.	PUNCT
fnp-6762	535	1	this	this	PRON
fnp-6762	535	2	is	be	AUX
fnp-6762	535	3	an	an	DET
fnp-6762	535	4	open	open	ADJ
fnp-6762	535	5	access	access	NOUN
fnp-6762	535	6	article	article	NOUN
fnp-6762	535	7	distributed	distribute	VERB
fnp-6762	535	8	under	under	ADP
fnp-6762	535	9	the	the	DET
fnp-6762	535	10	terms	term	NOUN
fnp-6762	535	11	of	of	ADP
fnp-6762	535	12	the	the	DET
fnp-6762	535	13	creative	creative	ADJ
fnp-6762	535	14	commons	common	NOUN
fnp-6762	535	15	attribution	attribution	NOUN
fnp-6762	535	16	4.0	4.0	NUM
fnp-6762	535	17	international	international	ADJ
fnp-6762	535	18	license	license	NOUN
fnp-6762	535	19	(	(	PUNCT
fnp-6762	535	20	https://creativecommons.org/licenses/by/4.0/	https://creativecommons.org/licenses/by/4.0/	PROPN
fnp-6762	535	21	)	)	PUNCT
fnp-6762	535	22	,	,	PUNCT
fnp-6762	535	23	which	which	PRON
fnp-6762	535	24	permits	permit	VERB
fnp-6762	535	25	unrestricted	unrestricted	ADJ
fnp-6762	535	26	use	use	NOUN
fnp-6762	535	27	,	,	PUNCT
fnp-6762	535	28	distribution	distribution	NOUN
fnp-6762	535	29	,	,	PUNCT
fnp-6762	535	30	and	and	CCONJ
fnp-6762	535	31	reproduction	reproduction	NOUN
fnp-6762	535	32	in	in	ADP
fnp-6762	535	33	any	any	DET
fnp-6762	535	34	medium	medium	NOUN
fnp-6762	535	35	,	,	PUNCT
fnp-6762	535	36	provided	provide	VERB
fnp-6762	535	37	the	the	DET
fnp-6762	535	38	original	original	ADJ
fnp-6762	535	39	author	author	NOUN
fnp-6762	535	40	and	and	CCONJ
fnp-6762	535	41	source	source	NOUN
fnp-6762	535	42	are	be	AUX
fnp-6762	535	43	credited	credit	VERB
fnp-6762	535	44	,	,	PUNCT
fnp-6762	535	45	a	a	DET
fnp-6762	535	46	link	link	NOUN
fnp-6762	535	47	to	to	ADP
fnp-6762	535	48	the	the	DET
fnp-6762	535	49	creative	creative	ADJ
fnp-6762	535	50	commons	common	NOUN
fnp-6762	535	51	license	license	NOUN
fnp-6762	535	52	is	be	AUX
fnp-6762	535	53	provided	provide	VERB
fnp-6762	535	54	,	,	PUNCT
fnp-6762	535	55	and	and	CCONJ
fnp-6762	535	56	any	any	DET
fnp-6762	535	57	changes	change	NOUN
fnp-6762	535	58	are	be	AUX
fnp-6762	535	59	indicated	indicate	VERB
fnp-6762	535	60	.	.	PUNCT
fnp-6762	536	1	the	the	DET
fnp-6762	536	2	creative	creative	ADJ
fnp-6762	536	3	commons	common	NOUN
fnp-6762	536	4	public	public	ADJ
fnp-6762	536	5	domain	domain	NOUN
fnp-6762	536	6	dedication	dedication	NOUN
fnp-6762	536	7	waiver	waiver	NOUN
fnp-6762	536	8	(	(	PUNCT
fnp-6762	536	9	https://creativecommons.org/publicdomain/zero/1.0/	https://creativecommons.org/publicdomain/zero/1.0/	PROPN
fnp-6762	536	10	)	)	PUNCT
fnp-6762	536	11	applies	apply	VERB
fnp-6762	536	12	to	to	ADP
fnp-6762	536	13	the	the	DET
fnp-6762	536	14	data	datum	NOUN
fnp-6762	536	15	made	make	VERB
fnp-6762	536	16	available	available	ADJ
fnp-6762	536	17	in	in	ADP
fnp-6762	536	18	this	this	DET
fnp-6762	536	19	article	article	NOUN
fnp-6762	536	20	,	,	PUNCT
fnp-6762	536	21	unless	unless	SCONJ
fnp-6762	536	22	otherwise	otherwise	ADV
fnp-6762	536	23	stated	state	VERB
fnp-6762	536	24	.	.	PUNCT